(19)
(11)EP 3 157 549 B1

(12)EUROPEAN PATENT SPECIFICATION

(45)Mention of the grant of the patent:
29.04.2020 Bulletin 2020/18

(21)Application number: 15730135.9

(22)Date of filing:  17.06.2015
(51)International Patent Classification (IPC): 
A61K 39/00(2006.01)
C07K 16/00(2006.01)
A61P 35/00(2006.01)
C12N 5/0783(2010.01)
A61K 35/17(2015.01)
A61K 47/50(2017.01)
C07K 7/06(2006.01)
A61K 48/00(2006.01)
A61K 38/00(2006.01)
(86)International application number:
PCT/EP2015/063566
(87)International publication number:
WO 2015/193359 (23.12.2015 Gazette  2015/51)

(54)

NOVEL IMMUNOTHERAPY AGAINST SEVERAL TUMORS OF THE BLOOD, IN PARTICULAR CHRONIC LYMPHOID LEUKEMIA (CLL)

NEUARTIGE IMMUNTHERAPIE GEGEN VERSCHIEDENE TUMOREN DES BLUTES, INSBESONDERE CHRONISCHER LYMPHOIDER LEUKÄMIE (CLL)

NOUVELLE IMMUNOTHÉRAPIE DIRIGÉE CONTRE PLUSIEURS TUMEURS DU SANG, EN PARTICULIER LA LEUCÉMIE LYMPHOÏDE CHRONIQUE (LLC)


(84)Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30)Priority: 20.06.2014 US 201462014849 P
20.06.2014 GB 201411037

(43)Date of publication of application:
26.04.2017 Bulletin 2017/17

(73)Proprietor: immatics biotechnologies GmbH
72076 Tübingen (DE)

(72)Inventors:
  • STICKEL, Juliane
    72076 Tübingen (DE)
  • KOWALEWSKI, Daniel
    72074 Tübingen (DE)
  • RAMMENSEE, Hans-Georg
    72070 Tübingen (DE)
  • STEVANOVIC, Stefan
    72074 Tübingen (DE)

(74)Representative: Michalski Hüttermann & Partner Patentanwälte mbB 
Speditionstraße 21
40221 Düsseldorf
40221 Düsseldorf (DE)


(56)References cited: : 
WO-A2-2005/114221
WO-A2-2005/114221
WO-A2-2007/150077
WO-A2-2008/070047
WO-A2-2008/070047
WO-A2-2005/114221
WO-A2-2007/150077
WO-A2-2007/150077
WO-A2-2008/070047
  
  • C BERLIN ET AL: "Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy", LEUKEMIA, vol. 29, no. 3, 5 August 2014 (2014-08-05) , pages 647-659, XP055207425, ISSN: 0887-6924, DOI: 10.1038/leu.2014.233
  • ETIENNE CARON ET AL: "An open-source computational and data resource to analyze digital maps of immunopeptidomes", ELIFE, vol. 4, 8 July 2015 (2015-07-08), XP055207421, DOI: 10.7554/eLife.07661
  • DANIEL J. KOWALEWSKI ET AL: "HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 2, 13 January 2015 (2015-01-13), pages E166-E175, XP055207429, ISSN: 0027-8424, DOI: 10.1073/pnas.1416389112
  • KOWALEWSKI DANIEL JOHANNES; SCHUSTER HEIKO; BERLIN CLAUDIA; KANZ LOTHAR; SALIH HELMUT R; RAMMENSEE HANS-GEORG; STEVANOVIC STEFAN;: "Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis - New Targets for Peptide Based Immunotherapy", BLOOD, vol. 120, no. 21, suppl., 1 December 2012 (2012-12-01), page 4119, XP055207460, 56TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2014 ISSN: 0006-4971
  • C BERLIN ET AL: "Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy", LEUKEMIA, vol. 29, no. 3, 5 August 2014 (2014-08-05) , pages 647-659, XP055207425, ISSN: 0887-6924, DOI: 10.1038/leu.2014.233
  • ETIENNE CARON ET AL: "An open-source computational and data resource to analyze digital maps of immunopeptidomes", ELIFE, vol. 4, 8 July 2015 (2015-07-08), XP055207421, DOI: 10.7554/eLife.07661
  • DANIEL J. KOWALEWSKI ET AL: "HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 2, 13 January 2015 (2015-01-13), pages E166-E175, XP055207429, ISSN: 0027-8424, DOI: 10.1073/pnas.1416389112
  • KOWALEWSKI DANIEL JOHANNES; SCHUSTER HEIKO; BERLIN CLAUDIA; KANZ LOTHAR; SALIH HELMUT R; RAMMENSEE HANS-GEORG; STEVANOVIC STEFAN;: "Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis - New Targets for Peptide Based Immunotherapy", BLOOD, vol. 120, no. 21, suppl., 1 December 2012 (2012-12-01), page 4119, XP055207460, US ISSN: 0006-4971
  • C BERLIN ET AL: "Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy", LEUKEMIA, vol. 29, no. 3, 5 August 2014 (2014-08-05) , pages 647-659, XP055207425, ISSN: 0887-6924, DOI: 10.1038/leu.2014.233
  • ETIENNE CARON ET AL: "An open-source computational and data resource to analyze digital maps of immunopeptidomes", ELIFE, vol. 4, 8 July 2015 (2015-07-08), XP055207421, DOI: 10.7554/eLife.07661
  • DANIEL J. KOWALEWSKI ET AL: "HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 112, no. 2, 13 January 2015 (2015-01-13), pages E166-E175, XP055207429, ISSN: 0027-8424, DOI: 10.1073/pnas.1416389112
  • KOWALEWSKI DANIEL JOHANNES; SCHUSTER HEIKO; BERLIN CLAUDIA; KANZ LOTHAR; SALIH HELMUT R; RAMMENSEE HANS-GEORG; STEVANOVIC STEFAN;: "Identification of Novel Tumor-Associated Antigens for Chronic Lymphocytic Leukemia (CLL) Based On HLA Ligandome Analysis - New Targets for Peptide Based Immunotherapy", BLOOD, vol. 120, no. 21, suppl., 1 December 2012 (2012-12-01), page 4119, XP055207460, 56TH ANNUAL MEETING OF THE AMERICAN-SOCIETY-OF-HEMATOLOGY; SAN FRANCISCO, CA, USA; DECEMBER 06 -09, 2014 ISSN: 0006-4971
  
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).


Description


[0001] The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several peptide sequences derived from HLA class I molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.

Background of the invention



[0002] B-cell chronic lymphocytic leukemia (B-CLL), also known as chronic lymphoid leukemia (CLL), is the most common type of leukemia.

[0003] Leukemias are cancers of the white blood cells (leukocytes). CLL affects B cell lymphocytes. B cells originate in the bone marrow, develop in the lymph nodes, and normally fight infection by producing antibodies. In CLL, B cells grow out of control and accumulate in the bone marrow and blood, where they crowd out healthy blood cells. CLL is a stage of small lymphocytic lymphoma (SLL), a type of B-cell lymphoma, which presents primarily in the lymph nodes. CLL and SLL are considered the same underlying disease, just with different appearances.

[0004] CLL is a disease of adults, but, in rare cases, it can occur in teenagers and occasionally in children (inherited). Most (>75%) people newly diagnosed with CLL are over the age of 50, and the majority are men, with a median age of 70 years at the time of diagnosis. Though less common, CLL sometimes affects people between 30 and 39 years of age. The incidence of CLL increases very quickly with increasing age.

[0005] In the United States, during 2012 about 16,060 new cases are expected to be diagnosed, and 4,580 patients are expected to die from CLL.

[0006] CLL is very rare in Asian countries, such as Japan and China, and may account for as few as 10 percent of all leukemias in those regions.

[0007] In view of the above, there remains a need for new efficacious and safe treatment option for cancers, in particular chronic lymphoid leukemia (CLL) and other cancers of the blood of different phenotypes which improve the well-being of the patients by not using excessive chemotherapeutic agents or other agents that may lead to severe side effects.

[0008] The present invention employs peptides that stimulate the immune system of the patient and act as anti-tumor-agents in a non-invasive fashion.

Summary of the invention



[0009] In a first aspect of the present invention, the present invention relates to a peptide of between 10 and 30 amino acids in length, comprising an amino acid sequence consisting of SEQ ID NO: 167, or a pharmaceutically acceptable salt thereof
The following tables show the peptides according to the present invention, its respective SEQ ID NO:, and the prospective source (underlying) proteins for these peptides. All peptides in Table 1a and 1b bind to HLA A HLA B or HLA C alleles, peptides in Table 2 bind to HLA-DR alleles (MHC class II). The peptides in table 3 are further useful in the diagnosis and/or treatment of CLL, Acute myelogenous leukemia (AML), and other hematological malignancies, which involve an over-expression or over-presentaion of the respective underlying polypeptide.
Table 1a: Preferred 49 HLA class I ligandome derived tumor associated antigens (LiTAAs) found represented in ≥20% of CLL patient ligandomes (n=30) and the 225 representing HLA ligands (LiTAPs) annotated with respective HLA restriction. SEQ ID NO: 167 is according to the invention.
SEQ ID NO:Underlying source protein/ HLA ligandsNumber of positive CLLs (frequency [%])HLA
  APOBEC3D apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3D 13 (43.3)  
1  AEHPNVTLTI 1 B*40
2  FLAEHPNVTL 8 A*02
3  ILYGRSYTW 1 A*32
4  EVAEFLARH 2 A*26
5  RHSNVNLTI 1 C*07
  CDK14 cyclin-dependent kinase 14 12 (40.0)  
6  HPDNVKLFL 1 B*35
7  ISDTGELKL 1 C*05
8  KVNGKLVALK 1 A*03
9  NRLSAQAAL 1 B*39
10  TPFTAIREA 1 B*55
11  FGLARAKSV 6 B*08
12  KIADFGLAR 1 A*03
  RASGRF1 Ras protein-specific guanine nucleotide-releasing factor 1 12 (40.0) B*35
13  AAANIIRTL 8 A*02, B*13, B*51
14  GRFKNLREAL 1 B*27
15  MSPFSKATL 2 C*14
16  QEDPGDNQITL 1 B*40
17  SPFSKATL 2 B*08, B*07
  CDCA7L cell division cycle associated 7-like 11 (36.7)  
18  DALLKRTM 1 B*08
19  GEDVRSALL 3 B*40
20  KFAEEFYSF 2 A*24
21  YGYDNVKEY 7 C*03, C*12
  CELSR1 cadherin, EGF LAG seven-pass G-type receptor 1 11 (36.7)  
22  LEVEERTKPV 1 B*44
23  RDSPINANLRY 1 B*40
24  RPFVIVTA 1 B*55
25  RPIINTPMV 1 B*55
26  SPTSSRTSSL 7 B*07
27  ATSAPLVSR 1 A*11
  AKAP2 A kinase (PRKA) anchor protein 2 11 (36.7)  
28  AELRSTASLL 1 B*40
29  APASSHERASM 2 B*07
30  ASRQAPPHI 1 A*30
31  AVKKNPGIAA 2 A*02
32  EEHLESHKKY 2 B*44
33  GEFTSARAV 1 B*49
34  GQSTPRLFSI 1 B*13
35  LVDDPLEY 1 A*01
36  RPKNLMQTL 3 B*07
37  RQAPPHIEL 2 B*13
38  SEAAELRSTA 1 B*50
  CTDP1 CTD phosphatase, subunit 1 11 (36.7)  
39  AAVRIGSVL 2 A*02, B*13
40  ERAGVVREL 1 C*07
41  GAAVRIGSVL 1 A*02
42  KLYELHVFTF 1 A*32
43  LYELHVFTF 2 A*24, A*23
44  YLNKEIEEA 6 A*02
  DNMBP dynamin binding protein 10 [33.3]  
45  DELPKFHQY 2 B*18
46  DVTGQFPSSF 1 A*26
47  EHSRVLQQL 2 B*39:01
48  IKVSKQLL 1 B*08
49  KPRQSSPQL 3 B*07
50  KQLLAALEI 1 B*13
51  RRKDLVLKY 2 B*27
52  RTRDYASLPPK 1 A*03
  TAGAP T-cell activation RhoGTPase activating protein 10 (33.3)  
53  APGSVLPRAL 3 B*07
54  DIKEHPLL 1 B*08
55  DSAGPQDAR 1 A*68
56  FQYAKESYI 1 B*13
57  KVLSWPFLM 1 A*32
58  LENDQSLSF 1 B*44
59  SPSRQPQV 1 B*07
60  SRHQSFTTK 3 B*27
61  SSHNASKTL 2 C*12
  ABCA6 ATP-binding cassette, sub-family A (ABC1), member 6 10 (33.3)  
62  EEIDTTMRW 1 B*44
63  ILDEKPVII 5 A*02
64  LPQEPRTSL 2 B*07
65  LTYKLPVA 1 B*57
66  NEMELAHSSF 2 B*18
67  REFPEANFEL 1 B*40
68  THHIPDAKL 1 B*38
69  TVKENLSLF 1 A*26
70  VLLKKAVL 1 B*08
  DMXL1 Dmx-like 1 10 (33.3)  
71  HLKSIPVSL 2 B*08, B*07
72  KVWYNVENW 1 A*32
73  LPAYRAQLL 1 B*07
74  LSEQTSVPL 1 A*02
75  SLNQWLVSF 1 A*32
76  SMTSLAQKI 1 A*02
77  SSSGLHPPK 2 A*03, A*11, A*68
  PARP3 poly (ADP-ribose) polymerase family, member 3 10 (33.3)  
78  DLDVKKMPL 4 B*08
79  FYTVIPHNF 3 A*24
80  HHINTDNPSL 2 B*39
81  RVGEVGQSK 2 A*03
  TP53I11 tumor protein p53 inducible protein 11 8 (26.7)  
82  AVFDGAQVTSK 7 A*03, A*11
83  SQTDL VSRL 1 B*15
  B4GALT1 UDP-Gal:betaGlcNAc beta 1,4-galactosyltransferase, polypeptide 1 8 (26.7)  
84  VPVPHTTAL 7 B*07
85  YQVLDVQRY 1 B*15
  IRF9 interferon regulatory factor 9 8 (26.7)  
86  APFQGDQRSL 2 B*07
87  DVAEPYKVY 1 A*26
88  IVSGQPGTQK 3 A*03
89  TPEQQAAIL 1 B*35
90  VELFRTAYF 1 B*37
  KDM2B lysine (K)-specific demethylase 2B 8 (26.7)  
91  EHADDDPSL 1 B*38
92  SEESVKSTTL 2 B*40
93  SPRPPLGSSL 4 B*07
94  SPWWRSSL 1 B*07
95  VYTPVDSLVF 1 A*24
  TBC1D22A TBC1 domain family, member 22A 8 (26.7)  
96  APLQRSQSL 6 B*07, B*08
97  DEVHQDTY 1 B*18
98  LPHSATVTL 1 B*07
  ZNF296 zinc finger protein 296 8 (26.7)  
99  SEAPEAPLL 1 B*40
100  SPRASGSGL 6 B*07
101  WGPAAEAK 2 A*03
  BACH2 BTB and CNC homology 1, basic leucine zipper transcription factor 2 8 (26.7)  
102  FSITKSVEL 4 A*02
103  GQTKNDLW 1 B*13
104  LSQEVCRD 2 n.a.
105  RDIQSPEQI 1 B*40
106  REDNSSNSL 1 B*40
107  TEHQEPGL 2 B*40
108  TKNDLVVSL 1 B*39
  PRR12 proline rich 12 8 (26.7)  
109  AEEAGGTRL 1 B*40
110  ENVNKKDY 1 A*26
111  GLDPNKPPEL 4 A*02
112  RPAGEPYNRKTL 2 B*07
  ZFAND5 zinc finger, AN1-type domain 5 7 (23.3)  
113  SASVQRADTSL 5 C*03
114  YGNPRTNGM 2 B*08
  ATP5G1 ATP synthase, H+ transporting, mitochondrial Fo complex, subunit C1 7 (23.3)  
115  LIRPVSASF 3 B*07
116  SPVNSSKQPSY 3 B*35
117  QLFSYAILGF 1 A*32
  DMD dystrophin 7 (23.3)  
118  DEHLLIQHY 2 B*18
119  KQVASSTGF 1 B*15
120  RDFGPASQHFL 1 B*40
121  RQLGEVASF 2 A*32
122  TEAETTANVL 1 B*40
123  GYLPVQTVL 1 A*24
  ARID5B AT rich interactive domain 5B (MRF1-like) 7 (23.3)  
124  GQKEALLKY 1 B*15
125  KPSEERKTI 1 B*07
126  KQTPKVLVV 1 B*13
127  SVIQHVQSF 1 A*26
128  TPIERIPYL 3 B*51
  ZNF638 zinc finger protein 638 7 (23.3)  
129  AEVEKNETV 1 B*40
130  EVKEEIPLV 1 B*08
131  KPTSARSGL 2 B*07
132  KYIETTPLTI 1 A*24
133  SEIKTSIEV 1 B*40
134  SVKPTSATK 4 A*03
135  YPNKGVGQA 1 B*55
  DDX46 DEAD (Asp-Glu-Ala-Asp) box polypeptide 46 7 (23.3)  
136  ISMKILNSL 2 A*02
137  KTIAFLLPMF 1 A*32
138  RDSIINDF 2 B*37
139  SVKGGGGNEK 1 A*03
140  GIAKTGSGK 1 A*03
  RRM2B ribonucleotide reductase M2 B (TP53 inducible) 7 (23.3)  
141  AETTDNVFTL 1 B*40
142  SEYQRFAVM 3 B*37, B*40, B*49
143  TFGERVVAF 1 A*24
144  NENLVERF 2 B*18
  BLNK B-cell linker 7 (23.3)  
145  KITVPASQK 1 A*03
146  KITVPASQKL 7 A*02
147  VPASQKLRQL 2 B*07
  HSH2D hematopoietic SH2 domain containing 7 (23.3)  
148  HVGYTLSYK 1 A*03
149  KLPLPLPPRL 3 C*14
150  KPIEPRREL 1 B*07
151  SHSHVGYTL 3 B*38, B*39
  ERP44 endoplasmic reticulum protein 44 7 (23.3)  
152  APSEYRYTL 1 B*07
153  APSEYRYTLL 3 B*07
154  EIFQNEVAR 1 A*68
155  KDVLIPGKL 1 B*40
156  VPLVREITF 2 B*08
  METTL7A methyltransferase like 7A 7 (23.3)  
157  DPNPNFEKF 1 B*35
158  IQAPLSWEL 1 B*13
159  VIYNEQMASK 3 A*03
160  VLRPGGAFY 2 B*15
  ELP3 elongator acetyltransferase complex subunit 3 7 (23.3)  
161  EDPDQDILI 1 B*18
162  HGNLRELAL 3 B*08
163  KLYPTLVIR 4 A*03
164  SEETFRFEL 1 B*40
  NLRP2 NLR family, pyrin domain containing 2 6 (20.0)  
165  ELNKLLEEI 3 A*02
166  IPFSNPRVL 2 B*07
167  LLDEGAKLLY 2 A*01
168  SPADAHRNL 1 B*07
  ZC3H12D zinc finger CCCH-type containing 12D 6 (20.0)  
169  AELERQAVL 1 B*37
170  GRVPGPLSL 1 B*27
171  SDLARLILL 1 B*27
172  TPIREQHVL 3 B*35
  NELFE negative elongation factor complex member E 6 (20.0)  
173  APRKGNTL 1 B*07
174  EEEEALQKKF 1 B*44
175  KENLVDGF 2 B*37
176  VYKENLVDGF 2 A*23, A*24
  ATP6V1C1 ATPase, H+ transporting, lysosomal 42kDa, V1 subunit C1 6 (20.0)  
177  TLLVVVPKL 6 A*02
  HLA-DMA major histocompatibility complex, class II, DM alpha 6 (20.0)  
178  HEIDRYTAI 1 B*40
179  VFTLKPLEF 3 A*23, A*24
180  YWVPRNAL 2 B*08
  TUFM Tu translation elongation factor, mitochondrial 6 (20.0)  
181  IGVEHVVVY 5 C*12
182  RDKPHVNV 1 B*37
  EIF6 eukaryotic translation initiation factor 6 6 (20.0)  
183  ADVLKVEVF 2 B*37
184  IPVVHASI 1 B*51
185  RDSLIDSLT 1 B*40
186  TVADQVLVGSY 2 A*26
  CKAP4 cytoskeleton-associated protein 4 6 (20.0)  
187  AADTERLAL 1 A*02
188  DMKAKVASL 2 B*08
189  HVLEEVQQV 2 B*13
190  KEAADTERL 1 B*40
191  RISEVLQKL 1 A*02
192  TEVRELVSL 2 B*40
  COBLL1 cordon-bleu WH2 repeat protein-like 1 6 (20.0)  
193  AIRSGEAAAK 2 A*03
194  APNPAPKEL 4 B*07
195  RQSLLTAI 1 B*13
196  SPEQTLSPL 1 B*35
197  TEHQVPSSV 1 B*40
198  TTYKIVPPK 1 A*03
  TMED4 transmembrane emp24 protein    
  transport domain containing 4 6 (20.0)  
199  QLLDQVEQI 4 A*02
200  DETMVIGNY 1 B*18
201  RQYGSEGRFTF 1 B*37
  TNFRSF13C tumor necrosis factor receptor superfamily, member 13C 6 (20.0)  
202  SPAPRTAL 6 B*07
  UBL7 ubiquitin-like 7 6 (20.0)  
203  GPRPITQSEL 6 B*07
204  KPEPVDKVA 1 B*07
205  TPSSRPASL 4 B*07
  CXorf21 chromosome X open reading frame 21 6 (20.0)  
206  DETQVRSLY 2 B*18
207  KEEETNSVATL 1 B*40
208  LEQKVVELY 2 B*18
209  NPISNAVLNEY 1 B*35
210  SIKEKSSL 1 B*08
211  TEITEISTPSL 1 B*40
  ASUN asunder spermatogenesis regulator 6 (20.0)  
212  GRLNSVNNR 1 B*27
213  SILEDPPSI 3 A*02
214  TPRTNNIEL 2 B*07
  RSL24D1 ribosomal L24 domain containing 1 6 (20.0)  
215  DAMKRVEEI 3 B*08
216  DIKEVKQNI 3 B*08
217  GPIYPGHGM 1 B*07
  Q9UII5, ZNF107 zinc finger protein 107 6 (20.0)  
218  GDYGRAFNL 2 B*37
219  TRHKIVHTK 2 B*27
220  RIHTGEKPYK 1 A*03
221  KAFNWFSTL 1 A*32
  TRAF3IP3 TRAF3 interacting protein 3 6 (20.0)  
222  QSTQRSLAL 2 B*08
223  RDLQMNQALRF 1 B*40
224  RELESQLHVL 2 B*40
225  SEAEKLTLV 1 B*40
Table 1b: Additional peptides for CLL - MHC class I
SEQ ID NO:Amino acid sequenceHLA
226 AAAKPVATK A*03, A*11
227 ATYHGSFSTK A*03, A*11
228 FMYDRPLRL A*02
229 FRVGNVQEL A*03, A*11,
230 GVAPFTIAR A*68
231 KMKPLDGSALY A*30
232 KPAPAKPVA B*55
233 KPVAAKPAA n.a.
234 KQFGVAPFTI B*13
235 QEELVKISL B*40:01
236 RQLGTVQQVI B*13
237 RQLINALQI B*13, A*32
238 RVIGGLLAGQTY B*15:01
239 SENAFYLSP n.a.
240 SQAPVLDAI B*13
241 STRYPPPAV A*30
242 TEDTLKVYL B*40:01, B*52
243 VAAKPVATK A*03
244 VQRWESL B*08
245 VRNPSVVVK B*27
246 GESEVAIKI B*49, B*52
247 LIYSVGLLLA A*02
248 SAYPHQLSF A*32
249 SVIGVFITK A*03, A*11, A*68
250 AELGNSVQLI B*49
251 ANMTVTRI n.a
252 ARISNVEFY C*07
253 AVFIGNQQF B*15:01
254 DIELQAENI A*02
255 DSYTVRVSV B*51
256 DVKIFVNTI B*51
257 EIIPKYGSI A*25
258 EQSKIFIHR n.a
259 FVDVGLYQY A*03
260 GHTSTISTL B*39
261 GRIEYVEVF C*07
262 GTSIIPFQK A*11
263 HPFLRGIGY B*35
264 IPVEIHTA B*55
265 KIFVNTIAY B*15:01
266 LPEDKVRIAY B*35
267 LPFSEGLTV B*51
268 LPWANKVTI B*51
269 PWANKVTI n.a.
270 QAYNRAVTI B*51
271 RSFPQKMAY B*15:01
272 RYPIHWHLL C*07
273 SPQNLRLML B*07
274 SYFSSPTQR B*27
275 VQIKSSLI B*13
276 VYIGHTSTI C*07
277 YHVPGTGESY C*07
278 ATNGDLASR A*31
279 GLHAEVTGVGY B*15:01
280 HVSSTSSSF A*32
281 LQADLQNGL B*13
282 SELPVSEVA B*45
283 SQTKSVFEI B*13
284 THIFTSDGL B*39
285 VIYFPPLQK A*11
286 YPFSSEQKW B*35
287 GQYFGELAL B*13
288 RIIVKNNAK n.a.
289 RRIIVKNNAK B*27
290 SFGELALMY n.a.
291 AFNAPVINR B*27
292 IMKRNIATY B*15:01
293 KVVDVIGTK A*11
294 LPFLKSLEF B*07, B*35
295 RLKVVDVIGTK A*03 B*07, B*51,
296 TPRAATITA B*55
297 KPSEKIQVL B*07
298 VPYPVTTTV B*35
299 ASFPPFVEK B*15
300 AFIHISTAY A*29
301 ATFEKIPFER A*11
302 KLFEKVKEV A*02
303 SQMPKLEAF B*15:01
304 AVLGQHHNY A*03
305 GPPAHKPR n.a.
306 RVYDVLVLK A*03, A*11
307 LPRPQGITV B*07
308 VLYVGSKTK A*03
309 KTKEQVTNV A*11
310 MPVDPDNEAY B*35
311 AEKTKQGVA B*40
312 DIADFFTTR A*68
313 HSYLQRQSV C*12
314 KEVTLIEEL B*40:01
315 REDGPGVAL B*40:01
316 REDPLPPGL B*40:01
317 SLFGGSQGLRK A*03
318 AEFQRLKQA B*50
319 EVIDGVPGKW A*25
320 IPKAPGKII B*07, B*08, B*55
321 SHNGSAIRY A*32
322 TEVTVVGDKL B*40:01
323 YASVVVKRY A*28
324 ATDLALYIK A*11
325 AYHNWRHAF C*07
326 EPLNIKDAY B*35
327 KIAATIISF B*15:01
328 KIFLHIHGL B*71
329 LEVILKKI n.a.
330 SEHPLAQLY B*44
331 VPSAQTLKI B*51
332 AEYRSYVA B*45
333 ALAPGRGTLY A*24
334 GPRGTQAAL B*07
335 IEDPGTLHI B*49
336 IEDPGTLHIW B*44
337 RPIPIAVKY B*35
338 VEKLLTNW n.a.
339 FLDPDIGGVAV A*02
340 HTAPPENKTW A*30
341 LLDTPVKTQY A*01
342 NAVKDFTSF A*03, A*11
343 SGLLQIKKL n.a.
344 YHDKNIVLL B*39
345 SVDPKNYPK A*11, A*03
346 AVGLVLPAK A*11
347 AVGLVLPAKL n.a.
348 ALLEVLSQK A*03
349 HEKQDTLVA B*45
350 KELELQIGM B*40:01, B*52
351 MYSDVWKQL A*24
352 RELQDEKAEL B*40:01
353 RITDVLDQK A*11
354 EVIKITGLK A*68
355 HHVDITKKL B*39
356 LPFNVKVSV B*51
357 TLPRVLEI B*51
358 TVDLPKSPK A*11
359 AEHGLLLTA B*45
360 AQAGALLQV B*13
361 DGGFVLKV B*51
362 IVYPSGKVY B*15:01
363 KLDNQVSKV A*02
364 SENVKLFSA B*45
365 VQKLQNII  
366 FSTPHGLEV B*51
367 KRFHQKSDM B*27
368 KTFGHAVSL A*32
369 SSNLITHSR A*31
370 GVIDGHIYAV A*02
371 IEPAKETTTNV B*40:01, B*44
372 NAPPSEVLL n.a.
373 SIEPAKETTTNV A*02
374 AQSQHNQSL B*13
375 AQSRTNPQV B*13
376 KMHDKVFAY A*03
377 TAKAPLSTV B*51
378 IPTRTVAI B*51
379 NHDRKHAV B*39
380 NNHDRKHAV B*08
381 TPGGTRIIY B*35
382 EHWPSPETF A*68
383 EIITNTLSF A*25
384 EVRGALMSAF A*25
385 IPRPILVLL B*07
386 LPNKNRDEL B*07
387 QRIPAGAVL B*27
388 AEGPAGGFMW B*49
389 AYYRDAEAY C*07
390 QVNRPLTMR A*03
391 RHSPVFQVY A*32
392 SLPVPNSAY B*15:01
393 TLGPPGTAHLY B*15:01
394 IEPAKETTTNV B*40:01, B*44
395 NAPPSEVLL n.a.
396 SIEPAKETTTNV A*02
397 DLYSGLNQR A*68
398 KAKAKPVTR A*31
399 AVLDKAMKAK A*03
400 LELSTPLKI B*49
401 LPLNLDTKY B*35
402 TVIYRIQAL A*02
403 DAHIYLNHI B*51
404 NHIEPLKIQL B*39
405 AYRPAVHPR B*27
406 LRAPLEHEL n.a.
407 RLFMVLLLK A*03
408 RSPDVLKDF B*15:01
409 ETAPGVHKR A*68
410 LYHGYIYTY A*24
411 GQHVATQHF B*15:01
412 LNGQLPNL n.a.
413 LPFPDETHERY B*35
414 LPHNTHRW B*51
415 VVFDSPRNR A*03
416 YPLGRILI B*51
417 KEFAEFVTS B*50
418 VMLDVPIRL A*02
419 VPMTPLRTV B*51
420 QIDYKTLVL B*13
421 VEDPTIVRI B*40:01, B*44, B*52
422 IPYQDLPHL B*07
423 DTPFLTGHGR A*68
424 EFYRALYI  
425 RYYPQILTNK  
426 KAYERHVL B*08
427 LPSPEFHDY B*35
428 SLYAHPIEH A*03
429 LVREPGSQA B*08
430 RLAGPGSEKY B*15:01
431 SPGAGRNSVL B*07
432 SVQSDQGYISR A*11
433 GVRPPAPSL B*13
434 IFSEKPVFV n.a.
435 KASNLLLGF B*58
436 KRYIFADAY n.a.
437 RNLQLSLPR A*31
438 EASEPVALR A*68
439 RPKVPDQSV B*07, B*08, B*35
440 VLYENALKL A*02
441 EVLDKSQTNY A*25
442 MPSPIPAKY B*35
443 YGIENFTSV B*51
444 ARAAQVFFL B*27
445 EHIVPNAEL B*39
446 EAFEFVKQR A*68
447 NHFEGHYQY n.a.
448 DAYPKNPHL B*51
449 DVNIKSTER A*68
450 HINSIKSVF A*31
451 YESEKVGVA B*50
452 ENAPTTVSR A*68
453 RFPHLLAHTY C*14
454 TLDGSLHAV A*02
455 RTVLKNLSLLK A*03
456 FEAKVQAI B*49
457 FFEAKVQAI C*12
458 KELQSTFK n.a.
459 NVSSRFEEEI A*02
460 EVWNNLGTTK A*68
461 MIFRSGSLI n.a.
462 NHALPLPGF B*39
463 ASVFGTMPLK A*11
464 REFPDRLVGY B*44
465 SVFGTMPLK A*11
466 DEMRFVTQI n.a.
467 ETVHFATTQW A*25
468 LPPPATQI B*51
469 LARDLYAF C*03, C*12
470 LPGIGLSTSL B*53
471 MEVILPML n.a.
472 AILDYILAK A*03
473 KIASQLSKL A*02
474 KVTSTTTVK A*03, A*11
475 YNTLLPYTF n.a.
476 FLDPRPLTV A*02
477 SAFADRPAF C*03
478 AAVPVIISR A*68
479 EEIGKVAAA B*45
480 FLKDLVASV A*02
481 VIISRALEL C*03
482 APRTTGTPRTSL B*07
483 ESVGGSPQTK A*68
484 IPKDKAIL B*08
485 LPAYGRTTL B*07
486 HQAAIVSKI B*13
487 QAAIVSKI B*51
488 RQKMPEDGL B*13
489 SVQKSSGVK A*11
490 DSIGSTVSSER A*68
491 LPYNNKDRDAL B*07
492 IYDEIQQEM C*14
493 AQAKGLIQV B*13
494 EVSSEIYQW A*25
495 KWNPVPLSY A*29
496 NRLLAQQSL B*27
497 APRPVAVAV B*07
498 FYRETVQVGR A*33
499 LLAPRPVAV A*02
500 GLAALVILK A*03
501 KIQEVFSSY B*15:01
502 ASLDKFLSH A*11
503 ALYATKTLR A*03
504 MEYVISRI n.a.
505 VPVGRQPII B*51
506 KLLIGVIAAV A*02
507 LPSLIKLD n.a. B*51!!)
508 PSLIKLDL n.a.
509 ARNKELIGK B*27
510 AVKSNAAAY B*15:01
511 EVIIPHSGW A*25
512 SVKEQEAQF B*15:01
513 APRGLEPIAI B*07
514 GRFGGVITI B*27
515 PVAGFFINT A*68
516 TPKTPSRDA B*08, B*55
517 VLFGGKVSGA A*02
518 AEHIESRTL B*40, B*44
519 DQYPYLKSV C*12
520 IARNLTQQL B*07
521 IESRTLAIA B*50
522 MTSALPIIQK A*11
523 SLLTSSKGQLQK A*03
524 TSALPIIQK A*11, A*03
525 VRLGSLSTK B*27
526 RINEFSISSF B*15
527 DEKQQHIVY B*18
528 DEVYQVTVY B*18
529 GEISEKAKL B*40
530 YTMKEVLFY A*03
531 SQLTTLSFY B*15
532 LEKQLIEL B*44
533 ELTLGEFLK A*68, A*33
534 LTLGEFLK A*68
535 LTLGEFLKL A*02
536 TLGEFLKL A*02
537 ITARPVLW B*58
538 KLMSPKLYVW A*32
539 KVSAVTLAY A*03
540 VEGSGELFRW B*44
541 RPKSNIVL B*07
542 RPKSNIVLL B*07
Table 1c: Additional peptides for CLL - MHC class II
SEQ ID NO:Amino acid sequenceMHC
543 GEPLSYTRFSLARQ class II
544 GEPLSYTRFSLARQVD class II
545 GEPLSYTRFSLARQVDG class II
546 GGEPLSYTRFSLARQVD class II
547 GGEPLSYTRFSLARQVDG class II
548 NPGGYVAYSKAATVTG class II
549 NPGGYVAYSKAATVTGK class II
550 NPGGYVAYSKAATVTGKL class II
551 NSVIIVDKNGRL class II
552 NSVIIVDKNGRLV class II
553 NSVIIVDKNGRLVY class II
554 RVEYHFLSPYVSPK class II
555 RVEYHFLSPYVSPKE class II
556 RVEYHFLSPYVSPKESPF class II
557 SPFRHVFWGSGSHTL class II
558 SVIIVDKNGRLV class II
559 VEYHFLSPYVSPK class II
560 VEYHFLSPYVSPKE class II
561 LPSQAFEYILYNKG class II
562 LPSQAFEYILYNKGI class II
563 LPSQAFEYILYNKGIM class II
564 LPSQAFEYILYNKGIMG class II
565 MNGYFLIERGKNM class II
566 NGYFLIERGKNM class II
567 PSQAFEYILYNKG class II
568 PSQAFEYILYNKGI class II
569 PSQAFEYILYNKGIM class II
570 EGVQYSYSLFHLM class II
571 EGVQYSYSLFHLML class II
572 GVQYSYSLFHLM class II
573 GVQYSYSLFHLML class II
574 SIISIHPKIQEHQPR class II
575 SSIRTSTNSQVDK class II
576 VLVGYKAVYRIS class II
577 YSSIRTSTNSQVDK class II
578 GGGYGSGGGSGGYGSRRF class II
579 GGSFGGRSSGSP class II
580 KGGSFGGRSSGSP class II
581 SGQQQSNYGPMKGGSFGGRSSGSPY class II
582 SGSPYGGGYGSGGGSGGYGSRRF class II
583 SPYGGGYGSGGGSGGYGSRRF class II
584 YGGGYGSGGGSGGYGSRRF class II
585 GNRINEFSISSF class II
586 HGNQITSDKVGRKV class II
587 IPPVNTNLENLYLQ class II
588 LQVLRLDGNEIKR class II
589 LQVLRLDGNEIKRS class II
590 LQVLRLDGNEIKRSA class II
591 LRELHLDHNQISRVPN class II
592 LYVRLSHNSLTNNG class II
593 VPSRMKYVYFQNNQ class II
594 VPSRMKYVYFQNNQIT class II
595 VPSRMKYVYFQNNQITS class II
596 WIALHGNQITSD class II
597 WIALHGNQITSDK class II
598 ADDNVSFRWEALGNT class II
599 ADDNVSFRWEALGNTL class II
600 DADDNVSFRWEALGNTL class II
601 DDNVSFRWEALGNT class II
602 DDNVSFRWEALGNTL class II
603 DNVSFRWEALGNT class II
604 DNVSFRWEALGNTL class II
605 DNVSFRWEALGNTLS class II
606 DTGSYRAQISTKTSAK class II
607 DTGSYRAQISTKTSAKL class II
608 DTITIYSTINHSK class II
609 EDTGSYRAQISTKTSAK class II
610 ENDTITIYSTINHSK class II
611 ENDTITIYSTINHSKESKPT class II
612 GSYRAQISTKTSAK class II
613 NDTITIYSTINH class II
614 NDTITIYSTINHS class II
615 NDTITIYSTINHSK class II
616 NVSFRWEALGNTL class II
617 SPTNNTVYASVTHSNRET class II
618 TGSYRAQISTKTSAK class II
619 TPRENDTITIYSTINHSK class II
620 TPRENDTITIYSTINHSKESKPT class II
621 VSFRWEALGNTL class II
622 APIHFTIEKLELNEK class II
623 DAQFEVIKGQTIE class II
624 DAQFEVIKGQTIEVR class II
625 ESYFIPEVRIYDSGT class II
626 IPEVRIYDSGTY class II
627 KDKAIVAHNRHGNK class II
628 KDKAIVAHNRHGNKA class II
629 NFVILEFPVEEQDR class II
630 SQPRISYDAQFEVIK class II
631 SQPRISYDAQFEVIKG class II
632 YDAQFEVIKGQTIE class II
633 GNPAYRSFSNSLSQ class II
634 GPPGEAGYKAFSSLLA class II
635 GPPGEAGYKAFSSLLASS class II
636 GPPGEAGYKAFSSLLASSA class II
637 GPPGEAGYKAFSSLLASSAVSPE class II
638 GPPGEAGYKAFSSLLASSAVSPEK class II
639 GYKAFSSLLASSAVSP class II
640 GYKAFSSLLASSAVSPE class II
641 KAFSSLLASSAVSPE class II
642 NPAYRSFSNSLSQ class II
643 SRDDFQEGREGIVAR class II
644 SSSSFHPAPGNAQ class II
645 VARLTESLFLDL class II
646 VARLTESLFLDLLG class II
647 VIAGNPAYRSFSN class II
648 VPQPEPETWEQILRRNVLQ class II
649 YKAFSSLLASSAVS class II
650 YKAFSSLLASSAVSP class II
651 YKAFSSLLASSAVSPE class II
652 GNQVFSYTANKEIRTDD class II
653 IEEIVLVDDASERD class II
654 IEEIVLVDDASERDF class II
655 LENIYPDSQIPRH class II
656 LENIYPDSQIPRHY class II
657 NQVFSYTANKEIR class II
658 NQVFSYTANKEIRT class II
659 NQVFSYTANKEIRTDD class II
660 VHSVINRSPRHMIEE class II
661 EYVSLYHQPAAM class II
662 IKAEYKGRVTLKQYPR class II
663 LNVHSEYEPSWEEQP class II
664 LPYLFQMPAYASSS class II
665 LPYLFQMPAYASSSK class II
666 NFIKAEYKGRVT class II
667 TNFIKAEYKGRVT class II
668 TTNFIKAEYKGRVT class II
669 VTLNVHSEYEPSWEEQP class II
670 YPRKNLFLVEVTQLTESDS class II
671 YPRKNLFLVEVTQLTESDSG class II
672 ADLSSFKSQELN class II
673 ADLSSFKSQELNER class II
674 ADLSSFKSQELNERN class II
675 ADLSSFKSQELNERNE class II
676 ADLSSFKSQELNERNEA class II
677 AEQQRLKSQDLELSWNLNG class II
678 EQQRLKSQDLELSWN class II
679 ISQELEELRAEQQR class II
680 ISQELEELRAEQQRLK class II
681 KGTKQWVHARYA class II
682 QADLSSFKSQELNER class II
683 SWNLNGLQADLSSFK class II
684 TGSWIGLRNLDLKG class II
685 FGNYNNQSSNFGPMKGGNFGGRS class II
686 FGPMKGGNFGGRSSGPYGGGGQY class II
687 GPMKGGNFGGRSSGP class II
688 GPYGGGGQYFAKP class II
689 KGGNFGGRSSGP class II
690 NDFGNYNNQSSNFGP class II
691 SGPYGGGGQYFAKP class II
692 DAGSYKAQINQRNFE class II
693 DAGSYKAQINQRNFEVT class II
694 DGELIRTQPQRLPQ class II
695 GELIRTQPQRLPQ class II
696 NPSDGELIRTQPQRLP class II
697 NPSDGELIRTQPQRLPQ class II
698 NPSDGELIRTQPQRLPQL class II
699 ASNDMYHSRALQVVR class II
700 ASNDMYHSRALQVVRA class II
701 EGVRRALDFAVGEYN class II
702 EGVRRALDFAVGEYNK class II
703 SNDMYHSRALQVVR class II
704 VGEYNKASNDMYH class II
705 VRARKQIVAGVNY class II
706 VRRALDFAVGEYNKASND class II
707 VVRARKQIVAGVN class II
708 WRARKQIVAGVNY class II
709 APLEGARFALVRED class II
710 APVELILSDETLPAPE class II
711 ELILSDETLPAPE class II
712 LAPLEGARFALVRE class II
713 LAPLEGARFALVRED class II
714 RGEKELLVPRSSTSPD class II
715 ASKTFTTQETITNAET class II
716 DQHFRTTPLEKNAPV class II
717 NTPILVDGKDVMPE class II
718 NTPILVDGKDVMPEV class II
719 NTPILVDGKDVMPEVN class II
720 SNTPILVDGKDVMPE class II
721 SNTPILVDGKDVMPEVN class II
722 TPILVDGKDVMP class II
723 TPILVDGKDVMPE class II
724 TPILVDGKDVMPEV class II
725 TPILVDGKDVMPEVN class II
726 GPLKFLHQDIDSGQG class II
727 GPLKFLHQDIDSGQGIR class II
728 LGDIYFKLFRASG class II
729 TGHLFDLSSLSGRAG class II
730 VPSPVDCQVTDLAGNE class II
731 DGLNSLTYQVLDVQRYPL class II
732 HPVLQRQQLDYGIY class II
733 LNSLTYQVLDVQR class II
734 LNSLTYQVLDVQRYP class II
735 LNSLTYQVLDVQRYPL class II
736 LPQLVGVSTPLQG class II
737 LPQLVGVSTPLQGG class II
738 LPQLVGVSTPLQGGS class II
739 RLPQLVGVSTPLQGGS class II
740 SPHKVAIIIPFRNR class II
741 SPHKVAIIIPFRNRQE class II
742 SPHKVAIIIPFRNRQEH class II
743 AIVQAVSAHRHR class II
744 ARNFERNKAIKVI class II
745 ARNFERNKAIKVIIA class II
746 NFERNKAIKVII class II
747 NFERNKAIKVIIA class II
748 VAIVQAVSAHRH class II
749 VAIVQAVSAHRHR class II
750 VAIVQAVSAHRHRA class II
751 VAIVQAVSAHRHRAR class II
752 EEVITLIRSNQQLE class II
753 EEVITLIRSNQQLEN class II
754 IPADTFAALKNPNAML class II
755 LKQLLSDKQQKRQSG class II
756 LKQLLSDKQQKRQSGQ class II
757 TPSYVAFTDTER class II
758 TPSYVAFTDTERL class II
759 EGLYSRTLAGSIT class II
760 EGLYSRTLAGSITTPP class II
761 EKWYIPDPTGKFN class II
762 GAIAAINSIQHNTR class II
763 LPILVPSAKKAI class II
764 LPILVPSAKKAIY class II
765 LPILVPSAKKAIYM class II
766 LPILVPSAKKAIYMD class II
767 LPILVPSAKKAIYMDD class II
768 VEEGLYSRTLAGSIT class II
769 WEKWYIPDPTGKFN class II
770 YKIVNFDPKLLE class II
771 YKIVNFDPKLLEG class II
772 YKIVNFDPKLLEGKV class II
773 LPEFYKTVSPAL class II
774 VGQFIQDVKNSRST class II
775 VGQFIQDVKNSRSTD class II
776 VVGQFIQDVKNSRS class II
777 VVGQFIQDVKNSRST class II
778 VVGQFIQDVKNSRSTD class II
779 VVGQFIQDVKNSRSTDS class II
780 DNGHLYREDQTSPAPG class II
781 DNGHLYREDQTSPAPGLR class II
782 EVQVFAPANALPARSE class II
783 GHLYREDQTSPAPG class II
784 LPARSEAAAVQPVIG class II
785 NGHLYREDQTSPAPG class II
786 NGHLYREDQTSPAPGL class II
787 NGHLYREDQTSPAPGLR class II
788 VFAPANALPARSEAA class II
789 VQVFAPANALPARSE class II
790 AIVVSDRDGVPVIK class II
791 GLHAIVVSDRDGVPV class II
792 GLHAIVVSDRDGVPVIK class II
793 HAIVVSDRDGVPV class II
794 KLPSVEGLHAIVVSDRDG class II
795 LHAIVVSDRDGVPV class II
796 LHAIVVSDRDGVPVI class II
797 LHAIVVSDRDGVPVIK class II
798 LPSVEGLHAIVVSDR class II
799 VPVIKVANDNAPE class II
800 YNTYQVVQFNRLP class II
801 YNTYQVVQFNRLPL class II
802 YNTYQVVQFNRLPLV class II
803 YNTYQVVQFNRLPLVV class II
804 YYNTYQVVQFNRLP class II
805 YYNTYQVVQFNRLPL class II
806 YYNTYQVVQFNRLPLV class II
807 DKIYFMAGSSRKE class II
808 DVGTDEEEETAKESTAEKDE class II
809 EVTFKSILFVPTSAP class II
810 KSEKFAFQAEVNR class II
811 LPEFDGKRFQNVAK class II
812 DGSYRIFSKGASE class II
813 GSYRIFSKGASE class II
814 SDGSYRIFSKGASE class II
815 SVKKMMKDNNLVRH class II
816 VKKMMKDNNLVRH class II
817 NNMRIFGEAAEKN class II
818 VDKVLERDQKLSE class II
819 VDKVLERDQKLSELD class II
820 VDKVLERDQKLSELDD class II
821 VDKVLERDQKLSELDDR class II
822 VLERDQKLSELDDR class II
823 ATRSIQVDGKTIKAQ class II
824 ATRSIQVDGKTIKAQI class II
825 IGVEFATRSIQVDGK class II
826 RSIQVDGKTIKA class II
827 RSIQVDGKTIKAQ class II
828 RSIQVDGKTIKAQI class II
829 TRSIQVDGKTIKAQ class II
830 DIMRVNVDKVLERDQK class II
831 DIMRVNVDKVLERDQKL class II
832 IMRVNVDKVLERDQK class II
833 VDKVLERDQKLSE class II
834 VDKVLERDQKLSELD class II
835 VDKVLERDQKLSELDD class II
836 VDKVLERDQKLSELDDR class II
837 VLERDQKLSELDDR class II
838 ATRSIQVDGKTIKAQ class II
839 ATRSIQVDGKTIKAQI class II
840 IGVEFATRSIQVDGK class II
841 RSIQVDGKTIKA class II
842 RSIQVDGKTIKAQ class II
843 RSIQVDGKTIKAQI class II
844 TRSIQVDGKTIKAQ class II
845 GIRVAPVPLYNS class II
846 GIRVAPVPLYNSFH class II
847 NPNGIRVAPVPLYNSFH class II
848 DDPAIDVCKKLLGKYPN class II
849 DKQPYSKLPGVSLLKP class II
850 DKQPYSKLPGVSLLKPL class II
851 HPRYYISANVTGFK class II
852 SHPRYYISANVTG class II
853 SHPRYYISANVTGFK class II
854 TSHPRYYISANVTG class II
855 TSHPRYYISANVTGFK class II
856 ADIFVDPVLHTA class II
857 ADIFVDPVLHTACA class II
858 DPGADYRIDRALNEA class II
859 IAQDYKVSYSLA class II
860 IAQDYKVSYSLAK class II
861 ISRDWKLDPVLYRK class II
862 LIAQDYKVSYSLA class II
863 RQKLIAQDYKVSYS class II
864 RQKLIAQDYKVSYSL class II
865 RQKLIAQDYKVSYSLA class II
866 RQKLIAQDYKVSYSLAK class II
867 SALDYRLDPQLQLH class II
868 SKADIFVDPVLHTA class II
869 SPSKNYILSVISGSI class II
870 ETTQLTADSHPSYHTDG class II
871 SGESLYHVLGLDKNATSDD class II
872 TTQLTADSHPSYHT class II
873 TTQLTADSHPSYHTD class II
874 TTQLTADSHPSYHTDG class II
875 SVEEFLSEKLERI class II
876 VEEFLSEKLERI class II
877 DLSSSILAQSRERVA class II
878 EKGVRTLTAAAVSGAQ class II
879 EKGVRTLTAAAVSGAQP class II
880 EKGVRTLTAAAVSGAQPI class II
881 KGVRTLTAAAVSGA class II
882 KGVRTLTAAAVSGAQ class II
883 VGPFAPGITEKAPEEKK class II
884 DPPLIALDKDAPLR class II
885 EIITPDVPFTVDKDG class II
886 IITPDVPFTVDKDG class II
887 PPLIALDKDAPLR class II
888 TNVKKSHKATVHIQ class II
889 DDNIKTYSDHPE class II
890 DDNIKTYSDHPEK class II
891 DSAVFFEQGTTRIG class II
892 GDKVYVHLKNLASRPY class II
893 GDKVYVHLKNLASRPYT class II
894 VHLKNLASRPYT class II
895 VYVHLKNLASRPY class II
896 VYVHLKNLASRPYT class II
897 VYVHLKNLASRPYTFH class II
898 YVHLKNLASRPY class II
899 YVHLKNLASRPYT class II
900 YVHLKNLASRPYTFH class II
901 SNLIKLAQKVPTAD class II
902 YDTRTSALSAKS class II
903 ALMTDPKLITWSPV class II
904 NDVAWNFEKFLVGPDG class II
905 QSVYAFSARPLAG class II
906 QSVYAFSARPLAGGEPV class II
907 WNFEKFLVGPDG class II
908 DVGMFVALTKLGQPD class II
909 VGMFVALTKLGQPD class II
910 AGVFHVEKNGRY class II
911 FAGVFHVEKNGRYS class II
912 GPITITIVNRDGTR class II
913 NGRYSISRTEAADL class II
914 RKSRQGSLAMEELK class II
915 RRKSRQGSLAMEELK class II
916 EEFKKLTSIKIQNDK class II
917 INRRMADDNKLFR class II
918 TATIVMVTNLKERKE class II
919 ELFYKGIRPAINVG class II
920 GQKRSTVAQLVKR class II
921 SDLDAATQQLLSRGV class II
922 FDFSQNTRVPRLPE class II
923 GDAPAILFDKEF class II
924 VTHEIDRYTAIAY class II
925 GQGYLIKDGKLIKNNA class II
926 IDTTSKFGHGRFQTM class II
927 IDVIGVTKGKGYKGVTSRW class II
928 MGPLKKDRIAKEEGA class II
929 AAKYQLDPTASISA class II
930 IAAKYQLDPTASISA class II
931 IAAKYQLDPTASISAK class II
932 AGLGRAYALAFAERG class II
933 DAFGRIDVVVNNAG class II
934 GLGRAYALAFAER class II
935 GLGRAYALAFAERG class II
936 AKFALNGEEFMNFDL class II
937 AKFALNGEEFMNFDLK class II
938 ALNGEEFMNFDLK class II
939 KFALNGEEFMNFDL class II
940 SDGSFHASSSLTVK class II
941 EERNLLSVAYKNVVGAR class II
942 ERNLLSVAYKNVVGAR class II
943 IAELDTLSEESYKD class II
944 IAELDTLSEESYKDS class II
945 ADSYLDEGFLLDKKIG class II
946 DSYLDEGFLLDKK class II
947 DSYLDEGFLLDKKIG class II
948 VDNIIKAAPRKRVPD class II
949 SPPQFRVNGAISN class II
950 SPPQFRVNGAISNFE class II
951 SPPQFRVNGAISNFEE class II
952 SPPQFRVNGAISNFEEF class II
953 VGKMFVDVYFQEDKK class II
954 VGKMFVDVYFQEDKKE class II
955 DPKRTIAQDYGVLKADE class II
956 DPKRTIAQDYGVLKADEG class II
957 PKRTIAQDYGVLKADEG class II
958 GLFIIDDKGILRQ class II
959 GLFIIDDKGILRQIT class II
960 RGLFIIDDKGILR class II
961 RGLFIIDDKGILRQ class II
962 RGLFIIDDKGILRQIT class II
963 GNTVIHLDQALARMR class II
964 NTVIHLDQALARMR class II
965 NTVIHLDQALARMRE class II
966 ENNEIISNIRDSVIN class II
967 NNEIISNIRDSVIN class II
968 SPTVQVFSASGKPV class II
969 SSPTVQVFSASGKPVE class II
970 AEPNYHSLPSARTDEQ class II
971 SSILAKTASNIIDVS class II
972 LEARATAPPAPSAPN class II
973 ADDLEGEAFLPL class II
974 ADDLEGEAFLPLR class II
975 ADDLEGEAFLPLRE class II
976 GADDLEGEAFLPLR class II
977 AGREINLVDAHLKSE class II
978 AGREINLVDAHLKSEQT class II
979 GREINLVDAHLKSE class II
980 KPGIVYASLNHSVIG class II
981 NKPGIVYASLNHSVIG class II
982 TTLYVTDVKSASERPS class II
983 APSTYAHLSPAKTPPP class II
984 APSTYAHLSPAKTPPPP class II
985 APSTYAHLSPAKTPPPPA class II
986 RDDLYDQDDSRDFPR class II
987 TRPYHSLPSEAVFA class II
988 TRPYHSLPSEAVFAN class II
989 VAVFTFHNHGRT class II
990 VAVFTFHNHGRTA class II
991 VAVFTFHNHGRTANL class II
992 EDDYIKSWEDNQQGDE class II
993 ELERIQIQEAAKKKPG class II
994 ERIQIQEAAKKKP class II
995 ERIQIQEAAKKKPG class II
996 ERIQIQEAAKKKPGI class II
997 LERIQIQEAAKKKPG class II
998 LSSISQYSGKIK class II
999 SPAKDSLSFEDF class II
1000 SPAKDSLSFEDFLDL class II
1001 INSRFPIPSATDPD class II
1002 VQHYELLNGQSVFG class II
1003 DNQYAVLENQKSSH class II
1004 GPPEIYSDTQFPS class II
1005 GPPEIYSDTQFPSLQ class II
1006 TPQGPPEIYSDTQFPS class II
1007 TPQGPPEIYSDTQFPSLQ class II
1008 TPQGPPEIYSDTQFPSLQST class II
1009 ANLQRAYSLAKEQR class II
1010 NLQRAYSLAKEQR class II
1011 TPSGITYDRKDIEEH class II
1012 VSTLNSEDFVLVSR class II
1013 VSTLNSEDFVLVSRQ class II
1014 VSTLNSEDFVLVSRQG class II
1015 GSSFFGELFNQNPE class II
1016 SGSSFFGELFNQNPE class II
Table 2: Peptides suitable for the (combined) treatment of CLL and/or AML
SEQ ID NO:Amino acid sequence
710 APVELILSDETLPAPE
878 EKGVRTLTAAAVSGAQ
879 EKGVRTLTAAAVSGAQP
533 ELTLGEFLK
476 FLDPRPLTV
892 GDKVYVHLKNLASRPY
111 GLDPNKPPEL
178 HEIDRYTAI
181 IGVEHVVVY
184 IPVVHASI
882 KGVRTLTAAAVSGAQ
363 KLDNQVSKV
42 KLYELHVFTF
163 KLYPTLVIR
137 KTIAFLLPMF
713 LAPLEGARFALVRED
532 LEKQLIEL
734 LNSLTYQVLDVQRYP
736 LPQLVGVSTPLQG
737 LPQLVGVSTPLQGG
738 LPQLVGVSTPLQGGS
534 LTLGEFLK
535 LTLGEFLKL
914 RKSRQGSLAMEELK
739 RLPQLVGVSTPLQGGS
477 SAFADRPAF
164 SEETFRFEL
364 SENVKLFSA
531 SQLTTLSFY
536 TLGEFLKL
186 TVADQVLVGSY
179 VFTLKPLEF
159 VIYNEQMASK
365 VQKLQNII
895 VYVHLKNLASRPY
44 YLNKEIEEA
180 YWVPRNAL


[0010] Disclosed is at least one peptide selected from the group consisting of SEQ ID NO: 710, 878, 879, 533, 476, 892, 111, 178, 181, 184, 882, 363, 42, 163, 137, 713, 532, 734, 736, 737, 738, 534, 535, 914, 739, 477, 164, 364, 531, 536, 186, 179, 159, 365, 895, 44, and 180, and the use thereof in the treatment of AML and/or CML as described herein.

[0011] The present invention furthermore relates to the peptides according to the present invention for use in the treatment of CLL/AML As shown in the following table 3, many of the peptides as disclosed can also be used in other cancerous and proliferative indications.
Table 3: Peptides as disclosed and their specific uses in other proliferative diseases, optionally in other organs. SEQ ID NO: 167 is according to the invention.
Seq IDSequenceTissue and disease
1 AEHPNVTLTI colon or rectum, spleen, non-Hodgkin's lymphoma
2 FLAEHPNVTL colon or rectum, spleen, non-Hodgkin's lymphoma
3 ILYGRSYTW stomach, adenocarcinoma, skin, squamous cell carcinoma
4 EVAEFLARH colon or rectum, spleen, non-Hodgkin's lymphoma lymphoma
5 RHSNVNLTI colon or rectum, spleen, non-Hodgkin's lymphoma
6 HPDNVKLFL pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
7 ISDTGELKL pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
8 KVNGKLVALK pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
9 NRLSAQAAL pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
10 TPFTAIREA pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
11 FGLARAKSV kidney, clear cell renal cell carcinoma,
12 KIADFGLAR brain, glioblastoma, liver, hepatocellular carcinoma
13 AAANIIRTL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma
14 GRFKNLREAL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma
15 MSPFSKATL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma
16 QEDPGDNQITL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma
17 SPFSKATL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma
18 DALLKRTM stomach, metastatic, skin, basal cell carcinoma
19 GEDVRSALL stomach, metastatic, skin, basal cell carcinoma
20 KFAEEFYSF stomach, metastatic, skin, basal cell carcinoma
21 YGYDNVKEY stomach, metastatic, skin, basal cell carcinoma
22 LEVEERTKPV lung, non-small cell lung carcinoma, breast, carcinoma
23 RDSPINANLRY lung, non-small cell lung carcinoma, breast, carcinoma
24 RPFVIVTA lung, non-small cell lung carcinoma, breast, carcinoma
25 RPIINTPMV lung, non-small cell lung carcinoma, breast, carcinoma
26 SPTSSRTSSL lung, non-small cell lung carcinoma, breast, carcinoma
27 ATSAPLVSR stomach, metastatic, lung, neuroendocrine carcinoma (non-small cell type)
28 AELRSTASLL lipoma
29 APASSHERASM lipoma
30 ASRQAPPHI lipoma
31 AVKKNPGIAA lipoma
32 EEHLESHKKY lipoma
33 GEFTSARAV lipoma
34 GQSTPRLFSI lipoma
35 LVDDPLEY lipoma
36 RPKNLMQTL lipoma
37 RQAPPHIEL lipoma
38 SEAAELRSTA lipoma
39 AAVRIGSVL colon, adenoma
40 ERAGVVREL colon, adenoma
41 GAAVRIGSVL colon, adenoma
42 KLYELHVFTF colon, adenoma
43 LYELHVFTF colon, adenoma
44 YLNKEIEEA colon, adenoma
45 DELPKFHQY stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
46 DVTGQFPSSF stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
47 EHSRVLQQL stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
48 IKVSKQLL stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
49 KPRQSSPQL stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
50 KQLLAALEI stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
51 RRKDLVLKY stomach, adenocarcinoma, liver, focal nodular hyperplasia
52 RTRDYASLPPK stomach, adenocarcinoma, white blood cell s, chronic lymphocytic leukemia
53 APGSVLPRAL stomach, adenocarcinoma, lymph node, Hodgkin's disease
54 DIKEHPLL stomach, adenocarcinoma, lymph node, Hodgkin's disease
55 DSAGPQDAR stomach, adenocarcinoma, lymph node, Hodgkin's disease
56 FQYAKESYI stomach, adenocarcinoma, lymph node, Hodgkin's disease
57 KVLSWPFLM stomach, adenocarcinoma, lymph node, Hodgkin's disease
58 LENDQSLSF stomach, adenocarcinoma, lymph node, Hodgkin's disease
59 SPSRQPQV stomach, adenocarcinoma, lymph node, Hodgkin's disease
60 SRHQSFTTK stomach, adenocarcinoma, lymph node, Hodgkin's disease
61 SSHNASKTL stomach, adenocarcinoma, lymph node, Hodgkin's disease
62 EEIDTTMRW liver, hepatocellular carcinoma, lipoma
63 ILDEKPVII liver, hepatocellular carcinoma, lipoma
64 LPQEPRTSL liver, hepatocellular carcinoma, lipoma
65 LTYKLPVA liver, hepatocellular carcinoma, lipoma
66 NEMELAHSSF liver, hepatocellular carcinoma, lipoma
67 REFPEANFEL liver, hepatocellular carcinoma, lipoma
68 THHIPDAKL liver, hepatocellular carcinoma, lipoma
69 TVKENLSLF liver, hepatocellular carcinoma, lipoma
70 VLLKKAVL liver, hepatocellular carcinoma, lipoma
71 HLKSIPVSL kidney, clear cell renal cell carcinoma
72 KVWYNVENW kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
73 LPAYRAQLL kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
74 LSEQTSVPL kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
75 SLNQWLVSF kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
76 SMTSLAQKI kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
77 SSSGLHPPK kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
78 DLDVKKMPL stomach, metastatic, kidney, carcinoma
79 FYTVIPHNF stomach, metastatic, kidney, carcinoma
80 HHINTDNPSL stomach, metastatic, kidney, carcinoma
81 RVGEVGQSK stomach, metastatic, kidney, carcinoma
82 AVFDGAQVTSK lung, non-small cell lung carcinoma, kidney, oncocytoma
83 SQTDLVSRL lung, non-small cell lung carcinoma, kidney, oncocytoma
84 VPVPHTTAL kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
85 YQVLDVQRY kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
86 APFQGDQRSL colon or rectum, breast, mucinous carcinoma
87 DVAEPYKVY colon or rectum, breast, mucinous carcinoma
88 IVSGQPGTQK colon or rectum, breast, mucinous carcinoma
89 TPEQQAAIL colon or rectum, breast, mucinous carcinoma
90 VELFRTAYF colon or rectum, breast, mucinous carcinoma
91 EHADDDPSL brain, cancer, kidney, Wilm's tumor
92 SEESVKSTTL brain, cancer, kidney, Wilm's tumor
93 SPRPPLGSSL brain, cancer, kidney, Wilm's tumor
94 SPWWRSSL brain, cancer, kidney, Wilm's tumor
95 VYTPVDSLVF brain, cancer, kidney, Wilm's tumor pancreas, adenocarcinoma, kidney, renal
96 APLQRSQSL cell carcinoma
97 DEVHQDTY pancreas, adenocarcinoma, kidney, renal cell carcinoma
98 LPHSATVTL pancreas, adenocarcinoma, kidney, renal cell carcinoma
99 SEAPEAPLL testis, seminoma
100 SPRASGSGL testis, seminoma
101 VVGPAAEAK testis, seminoma
102 FSITKSVEL non-Hodgkin's lymphoma, small lymphocytic type
103 GQTKNDLVV non-Hodgkin's lymphoma, small lymphocytic type
104 LSQEVCRD non-Hodgkin's lymphoma, small lymphocytic type
105 RDIQSPEQI non-Hodgkin's lymphoma, small lymphocytic type
106 REDNSSNSL non-Hodgkin's lymphoma, small lymphocytic type
107 TEHQEPGL non-Hodgkin's lymphoma, small lymphocytic type
108 TKNDLVVSL non-Hodgkin's lymphoma, small lymphocytic type
109 AEEAGGTRL breast, carcinoma
110 ENVNKKDY breast, carcinoma
111 GLDPNKPPEL breast, carcinoma
112 RPAGEPYNRKTL breast, carcinoma
113 SASVQRADTSL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical adenoma
114 YGNPRTNGM stomach, metastatic, breast, carcinoma
115 LIRPVSASF esophagus, adenocarcinoma
116 SPVNSSKQPSY esophagus, adenocarcinoma
117 QLFSYAILGF liver, hepatocellular carcinoma, colon, non-Hodgkin's lymphoma
118 DEHLLIQHY liver, hepatocellular carcinoma, parotid gland, pleomorphic adenoma
119 KQVASSTGF liver, hepatocellular carcinoma, parotid gland, pleomorphic adenoma
120 RDFGPASQHFL liver, hepatocellular carcinoma, parotid gland, pleomorphic adenoma
121 RQLGEVASF liver, hepatocellular carcinoma, parotid gland, pleomorphic adenoma
122 TEAETTANVL liver, hepatocellular carcinoma, parotid gland, pleomorphic adenoma
123 GYLPVQTVL kidney, clear cell renal cell carcinoma, parotid gland, pleomorphic adenoma
124 GQKEALLKY liver, hepatocellular carcinoma, synovial sarcoma
125 KPSEERKTI liver, hepatocellular carcinoma, synovial sarcoma
126 KQTPKVLVV liver, hepatocellular carcinoma, synovial sarcoma
127 SVIQHVQSF liver, hepatocellular carcinoma, synovial sarcoma
128 TPIERIPYL liver, hepatocellular carcinoma, synovial sarcoma
129 AEVEKNETV kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
130 EVKEEIPLV kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
131 KPTSARSGL kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
132 KYIETTPLTI kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
133 SEIKTSIEV kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
134 SVKPTSATK kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
135 YPNKGVGQA kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma
136 ISMKILNSL lung, non-small cell lung carcinoma, thymus, thymoma, benign
137 KTIAFLLPMF lung, non-small cell lung carcinoma, thymus, thymoma, benign
138 RDSIINDF lung, non-small cell lung carcinoma, thymus, thymoma, benign
139 SVKGGGGNEK lung, non-small cell lung carcinoma, thymus, thymoma, benign
140 GIAKTGSGK lung, non-small cell lung carcinoma, thymus, thymoma, benign
141 AETTDNVFTL kidney, clear cell renal cell carcinoma, thyroid gland, follicular adenoma
142 SEYQRFAVM kidney, clear cell renal cell carcinoma, thyroid gland, follicular adenoma
143 TFGERVVAF kidney, clear cell renal cell carcinoma, thyroid gland, follicular adenoma
144 NENLVERF stomach, adenocarcinoma, colon, adenocarcinoma
145 KITVPASQK stomach, adenocarcinoma, colon, non-Hodgkin's lymphoma
146 KITVPASQKL stomach, adenocarcinoma, colon, non-Hodgkin's lymphoma
147 VPASQKLRQL stomach, adenocarcinoma, colon, non-Hodgkin's lymphoma
148 HVGYTLSYK stomach, adenocarcinoma
149 KLPLPLPPRL stomach, adenocarcinoma
150 KPIEPRREL stomach, adenocarcinoma
151 SHSHVGYTL stomach, adenocarcinoma
152 APSEYRYTL colon or rectum, stomach, mucinous adenocarcinoma
153 APSEYRYTLL colon or rectum, stomach, mucinous adenocarcinoma
154 EIFQNEVAR colon or rectum, stomach, mucinous adenocarcinoma
155 KDVLIPGKL colon or rectum, stomach, mucinous adenocarcinoma
156 VPLVREITF colon or rectum, stomach, mucinous adenocarcinoma
157 DPNPNFEKF liver, hepatocellular carcinoma, cancer, liver, focal nodular hyperplasia
158 IQAPLSWEL liver, hepatocellular carcinoma, cancer, liver, focal nodular hyperplasia
159 VIYNEQMASK liver, hepatocellular carcinoma, cancer, liver, focal nodular hyperplasia
160 VLRPGGAFY liver, hepatocellular carcinoma, cancer, liver, focal nodular hyperplasia
161 EDPDQDILI stomach, adenocarcinoma, endometrium, adenocarcinoma, endometrioid
162 HGNLRELAL stomach, adenocarcinoma, endometrium, adenocarcinoma, endometrioid
163 KLYPTLVIR stomach, adenocarcinoma, endometrium, adenocarcinoma, endometrioid
164 SEETFRFEL stomach, adenocarcinoma, endometrium, adenocarcinoma, endometrioid
165 ELNKLLEEI stomach, adenocarcinoma, ovary, adenocarcinoma, endometrioid
166 IPFSNPRVL stomach, adenocarcinoma, ovary, adenocarcinoma, endometrioid
167 LLDEGAKLLY stomach, adenocarcinoma, ovary, adenocarcinoma, endometrioid
168 SPADAHRNL stomach, adenocarcinoma, ovary, adenocarcinoma, endometrioid
173 APRKGNTL stomach, metastatic, endometrium, Mullerian mixed tumor
174 EEEEALQKKF stomach, metastatic, endometrium, Mullerian mixed tumor
175 KENLVDGF stomach, metastatic, endometrium, Mullerian mixed tumor
176 VYKENLVDGF stomach, metastatic, endometrium, Mullerian mixed tumor
177 TLLVVVPKL stomach, adenocarcinoma, bone, giant cell tumor of bone
178 HEIDRYTAI kidney, clear cell renal cell carcinoma, non-Hodgkin's lymphoma
179 VFTLKPLEF kidney, clear cell renal cell carcinoma, non-Hodgkin's lymphoma
180 YWVPRNAL kidney, clear cell renal cell carcinoma, non-Hodgkin's lymphoma
181 IGVEHVVVY brain, cancer, kidney, oncocytoma
182 RDKPHVNV brain, cancer, omentum, leiomyosarcoma
183 ADVLKVEVF stomach, adenocarcinoma, colon, adenocarcinoma
184 IPVVHASI stomach, adenocarcinoma, colon, adenocarcinoma
185 RDSLIDSLT stomach, adenocarcinoma, colon, adenocarcinoma
186 TVADQVLVGSY stomach, adenocarcinoma, colon, adenocarcinoma
187 AADTERLAL lung, non-small cell lung carcinoma, chondrosarcoma
188 DMKAKVASL lung, non-small cell lung carcinoma, chondrosarcoma
189 HVLEEVQQV lung, non-small cell lung carcinoma, chondrosarcoma
190 KEAADTERL lung, non-small cell lung carcinoma, chondrosarcoma
191 RISEVLQKL lung, non-small cell lung carcinoma, chondrosarcoma
192 TEVRELVSL lung, non-small cell lung carcinoma, chondrosarcoma
193 AIRSGEAAAK liver, hepatocellular carcinoma, pleura, malignant mesothelioma
194 APNPAPKEL liver, hepatocellular carcinoma, pleura, malignant mesothelioma
195 RQSLLTAI liver, hepatocellular carcinoma, liver, hepatocellular carcinoma, cancer, pleura, malignant mesothelioma
196 SPEQTLSPL liver, hepatocellular carcinoma, pleura, malignant mesothelioma
197 TEHQVPSSV liver, hepatocellular carcinoma, liver, hepatocellular carcinoma, cancer, pleura, malignant mesothelioma
198 TTYKIVPPK liver, hepatocellular carcinoma, liver, hepatocellular carcinoma, cancer, pleura, malignant mesothelioma
199 QLLDQVEQI stomach, metastatic thyroid gland, papillary carcinoma
200 DETMVIGNY stomach, metastatic, rectum, adenocarcinoma
201 RQYGSEGRFTF kidney, clear cell renal cell carcinoma, rectum, adenocarcinoma
203 GPRPITQSEL stomach, metastatic, lymph node, non-Hodgkin's lymphoma
204 KPEPVDKVA stomach, metastatic, lymph node, non-Hodgkin's lymphoma
205 TPSSRPASL stomach, metastatic, lymph node, non-Hodgkin's lymphoma
212 GRLNSVNNR kidney, clear cell renal cell carcinoma, leiomyosarcoma
213 SILEDPPSI kidney, clear cell renal cell carcinoma, leiomyosarcoma
214 TPRTNNIEL kidney, clear cell renal cell carcinoma, leiomyosarcoma
215 DAMKRVEEI stomach, adenocarcinoma, ovary, thecoma-fibroma
216 DIKEVKQNI stomach, adenocarcinoma, ovary, thecoma-fibroma
217 GPIYPGHGM stomach, adenocarcinoma, ovary, thecoma-fibroma
218 GDYGRAFNL stomach, metastatic, lymph node, non-Hodgkin's lymphoma
219 TRHKIVHTK stomach, metastatic, lymph node, non-Hodgkin's lymphoma
220 RIHTGEKPYK colon or rectum, thyroid gland, nodular hyperplasia
221 KAFNWFSTL stomach, metastatic, lymph node, non-Hodgkin's lymphoma
222 QSTQRSLAL liver, hepatocellular carcinoma, uterin cervix, squamous cell carcinoma
223 RDLQMNQALRF liver, hepatocellular carcinoma, uterin cervix, squamous cell carcinoma
224 RELESQLHVL liver, hepatocellular carcinoma, uterin cervix, squamous cell carcinoma
225 SEAEKLTLV liver, hepatocellular carcinoma, uterin cervix, squamous cell carcinoma
226 AAAKPVATK pancreas, adenocarcinoma, fibromatosis
227 ATYHGSFSTK pancreas, adenocarcinoma, fibromatosis
228 FMYDRPLRL pancreas, adenocarcinoma, fibromatosis
229 FRVGNVQEL pancreas, adenocarcinoma, fibromatosis
230 GVAPFTIAR pancreas, adenocarcinoma, fibromatosis
231 KMKPLDGSALY pancreas, adenocarcinoma, fibromatosis
232 KPAPAKPVA pancreas, adenocarcinoma, fibromatosis
233 KPVAAKPAA pancreas, adenocarcinoma, fibromatosis
234 KQFGVAPFTI pancreas, adenocarcinoma, fibromatosis
235 QEELVKISL pancreas, adenocarcinoma, fibromatosis
236 RQLGTVQQVI pancreas, adenocarcinoma, fibromatosis
237 RQLINALQI pancreas, adenocarcinoma, fibromatosis
238 RVIGGLLAGQTY pancreas, adenocarcinoma, fibromatosis
239 SENAFYLSP pancreas, adenocarcinoma, fibromatosis
240 SQAPVLDAI pancreas, adenocarcinoma, fibromatosis
241 STRYPPPAV pancreas, adenocarcinoma, fibromatosis
242 TEDTLKVYL pancreas, adenocarcinoma, fibromatosis
243 VAAKPVATK pancreas, adenocarcinoma, fibromatosis
244 VQRVVESL pancreas, adenocarcinoma, fibromatosis
245 VRNPSVVVK pancreas, adenocarcinoma, fibromatosis
246 GESEVAIKI myometrium, leiomyoma
247 LIYSVGLLLA myometrium, leiomyoma
248 SAYPHQLSF myometrium, leiomyoma
249 SVIGVFITK myometrium, leiomyoma
250 AELGNSVQLI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
251 ANMTVTRI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
252 ARISNVEFY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
253 AVFIGNQQF liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
254 DIELQAENI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
255 DSYTVRVSV liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
256 DVKIFVNTI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
257 EIIPKYGSI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
258 EQSKIFIHR liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
259 FVDVGLYQY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
260 GHTSTISTL liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
261 GRIEYVEVF liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
262 GTSIIPFQK liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
263 HPFLRGIGY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
264 IPVEIHTA liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
265 KIFVNTIAY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
266 LPEDKVRIAY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
267 LPFSEGLTV liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
268 LPWANKVTI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
269 PWANKVTI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
270 QAYNRAVTI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
271 RSFPQKMAY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
272 RYPIHWHLL liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
273 SPQNLRLML liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
274 SYFSSPTQR liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
275 VQIKSSLI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
276 VYIGHTSTI liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
277 YHVPGTGESY liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
278 ATNGDLASR pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
279 GLHAEVTGVGY pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
280 HVSSTSSSF pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
281 LQADLQNGL pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
282 SELPVSEVA pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
283 SQTKSVFEI pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
284 THIFTSDGL pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
285 VIYFPPLQK pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
286 YPFSSEQKW pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
287 GQYFGELAL stomach, gastrointestinal stromal tumor (GIST)
288 RIIVKNNAK stomach, gastrointestinal stromal tumor (GIST)
289 RRIIVKNNAK stomach, gastrointestinal stromal tumor (GIST)
290 SFGELALMY stomach, gastrointestinal stromal tumor (GIST)
291 AFNAPVINR stomach, gastrointestinal stromal tumor (GIST)
292 IMKRNIATY stomach, gastrointestinal stromal tumor (GIST)
293 KVVDVIGTK stomach, gastrointestinal stromal tumor (GIST)
294 LPFLKSLEF stomach, gastrointestinal stromal tumor (GIST)
295 RLKVVDVIGTK stomach, gastrointestinal stromal tumor (GIST)
296 TPRAATITA stomach, gastrointestinal stromal tumor (GIST)
297 KPSEKIQVL lipoma
298 VPYPVTTTV lipoma
299 ASFPPFVEK lipoma
300 AFIHISTAY colon or rectum, colon, adenocarcinoma
301 ATFEKIPFER colon or rectum, colon, adenocarcinoma
302 KLFEKVKEV colon or rectum, colon, adenocarcinoma
303 SQMPKLEAF colon or rectum, colon, adenocarcinoma
304 AVLGQHHNY colon or rectum, colon, adenocarcinoma
305 GPPAHKPR spleen, chronic myeloid leukemia
306 RVYDVLVLK colon or rectum, colon, adenocarcinoma
307 LPRPQGITV liver, hepatocellular carcinoma, liver, focal nodular hyperplasia
308 VLYVGSKTK brain, glioblastoma, schwannoma
309 KTKEQVTNV brain, glioblastoma, schwannoma
310 MPVDPDNEAY brain, glioblastoma, schwannoma
311 AEKTKQGVA brain, glioblastoma, schwannoma
312 DIADFFTTR kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical adenoma
313 HSYLQRQSV kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical adenoma
314 KEVTLIEEL kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical adenoma
315 REDGPGVAL kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical adenoma
316 REDPLPPGL kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical adenoma
317 SLFGGSQGLRK kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical adenoma
318 AEFQRLKQA intramuscular lipoma
319 EVIDGVPGKW intramuscular lipoma
320 IPKAPGKII intramuscular lipoma
321 SHNGSAIRY intramuscular lipoma
322 TEVTVVGDKL intramuscular lipoma
323 YASVVVKRY intramuscular lipoma
324 ATDLALYIK stomach, adenocarcinoma, thyroid gland, papillary carcinoma
325 AYHNWRHAF stomach, adenocarcinoma, thyroid gland, papillary carcinoma
326 EPLNIKDAY stomach, adenocarcinoma, thyroid gland, papillary carcinoma
327 KIAATIISF stomach, adenocarcinoma, thyroid gland, papillary carcinoma
328 KIFLHIHGL stomach, adenocarcinoma, thyroid gland, papillary carcinoma
329 LEVILKKI stomach, adenocarcinoma, thyroid gland, papillary carcinoma
330 SEHPLAQLY stomach, adenocarcinoma, thyroid gland, papillary carcinoma
331 VPSAQTLKI stomach, adenocarcinoma, thyroid gland, papillary carcinoma
332 AEYRSYVA stomach, metastatic adrenal gland, adrenal cortical carcinoma
333 ALAPGRGTLY stomach, metastatic adrenal gland, adrenal cortical carcinoma
334 GPRGTQAAL stomach, metastatic adrenal gland, adrenal cortical carcinoma
335 IEDPGTLHI stomach, metastatic adrenal gland, adrenal cortical carcinoma
336 IEDPGTLHIW stomach, metastatic adrenal gland, adrenal cortical carcinoma
337 RPIPIAVKY stomach, metastatic adrenal gland, adrenal cortical carcinoma
338 VEKLLTNW stomach, metastatic, pancreas, adenocarcinoma
339 FLDPDIGGVAV kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
340 HTAPPENKTW kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
341 LLDTPVKTQY kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
342 NAVKDFTSF kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
343 SGLLQIKKL kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
344 YHDKNIVLL kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
345 SVDPKNYPK pancreas, adenocarcinoma, colon, adenocarcinoma
346 AVGLVLPAK liver, hepatocellular carcinoma, cancer, thyroid gland, papillary carcinoma
347 AVGLVLPAKL liver, hepatocellular carcinoma, cancer, thyroid gland, papillary carcinoma
348 ALLEVLSQK stomach, adenocarcinoma, breast, carcinoma
349 HEKQDTLVA kidney, clear cell renal cell carcinoma, spleen, chronic myeloid leukemia
350 KELELQIGM kidney, clear cell renal cell carcinoma, spleen, chronic myeloid leukemia
351 MYSDVWKQL kidney, clear cell renal cell carcinoma, spleen, chronic myeloid leukemia
352 RELQDEKAEL kidney, clear cell renal cell carcinoma, spleen, chronic myeloid leukemia
353 RITDVLDQK kidney, clear cell renal cell carcinoma, spleen, chronic myeloid leukemia
354 EVIKITGLK stomach, adenocarcinoma
355 HHVDITKKL stomach, adenocarcinoma, kidney, carcinoma
356 LPFNVKVSV stomach, adenocarcinoma, stomach, gastrointestinal stromal tumor (GIST)
357 TLPRVLEI stomach, adenocarcinoma, bone, giant cell tumor of bone
358 TVDLPKSPK stomach, adenocarcinoma, thyroid gland, nodular hyperplasia
359 AEHGLLLTA stomach, metastatic, uterin cervix, adenocarcinoma
360 AQAGALLQV stomach, metastatic, uterin cervix, adenocarcinoma
361 DGGFVLKV stomach, metastatic, uterin cervix, adenocarcinoma
362 IVYPSGKVY stomach, metastatic, uterin cervix, adenocarcinoma
363 KLDNQVSKV colon or rectum, prostate, benign nodular hyperplasia
364 SENVKLFSA colon or rectum, prostate, benign nodular hyperplasia
365 VQKLQNII colon or rectum, prostate, benign nodular hyperplasia
366 FSTPHGLEV pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
367 KRFHQKSDM pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
368 KTFGHAVSL pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
369 SSNLITHSR pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
370 GVIDGHIYAV stomach, metastatic, leiomyosarcoma
371 IEPAKETTTNV pancreas, adenocarcinoma, lung, adenocarcinoma
372 NAPPSEVLL pancreas, adenocarcinoma, lung, adenocarcinoma
373 SIEPAKETTTNV pancreas, adenocarcinoma, lung, adenocarcinoma
374 AQSQHNQSL spleen, extramedullary hematopoiesis
375 AQSRTNPQV spleen, extramedullary hematopoiesis
376 KMHDKVFAY spleen, extramedullary hematopoiesis
377 TAKAPLSTV spleen, extramedullary hematopoiesis
378 IPTRTVAI liver, hepatocellular carcinoma, lipoma
379 NHDRKHAV liver, hepatocellular carcinoma, lipoma
380 NNHDRKHAV liver, hepatocellular carcinoma, lipoma
381 TPGGTRIIY liver, hepatocellular carcinoma, breast, carcinoma
382 EHWPSPETF bone, non-ossifying fibroma
383 EIITNTLSF bone, non-ossifying fibroma
384 EVRGALMSAF bone, non-ossifying fibroma
385 IPRPILVLL bone, non-ossifying fibroma
386 LPNKNRDEL bone, non-ossifying fibroma
387 QRIPAGAVL bone, non-ossifying fibroma
388 AEGPAGGFMVV pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
389 AYYRDAEAY pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
390 QVNRPLTMR pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
391 RHSPVFQVY pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
392 SLPVPNSAY pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
393 TLGPPGTAHLY pancreas, adenocarcinoma, spleen, chronic myeloid leukemia
394 IEPAKETTTNV pancreas, adenocarcinoma, lung, adenocarcinoma
395 NAPPSEVLL pancreas, adenocarcinoma, lung, adenocarcinoma
396 SIEPAKETTTNV pancreas, adenocarcinoma, lung, adenocarcinoma
397 DLYSGLNQR lymph node, Hodgkin's disease
398 KAKAKPVTR lymph node, Hodgkin's disease
399 AVLDKAMKAK liver, hepatocellular carcinoma, liver, hepatic adenoma
400 LELSTPLKI liver, hepatocellular carcinoma, liver, hepatic adenoma
401 LPLNLDTKY liver, hepatocellular carcinoma, liver, hepatic adenoma
402 TVIYRIQAL liver, hepatocellular carcinoma, liver, hepatic adenoma
403 DAHIYLNHI stomach, adenocarcinoma, pancreas, microcystic adenoma
404 NHIEPLKIQL stomach, adenocarcinoma, pancreas, microcystic adenoma
405 AYRPAVHPR thyroid gland, nodular hyperplasia
406 LRAPLEHEL thyroid gland, nodular hyperplasia
407 RLFMVLLLK thyroid gland, nodular hyperplasia
408 RSPDVLKDF thyroid gland, nodular hyperplasia
409 ETAPGVHKR stomach, metastatic, non-Hodgkin's lymphoma
410 LYHGYIYTY stomach, metastatic, non-Hodgkin's lymphoma
415 VVFDSPRNR liver, hepatocellular carcinoma, pancreas, adenocarcinoma
416 YPLGRILI lung, non-small cell lung carcinoma, pancreas, adenocarcinoma
417 KEFAEFVTS pancreas, adenocarcinoma, pancreas, adenocarcinoma
418 VMLDVPIRL pancreas, adenocarcinoma, pancreas, adenocarcinoma
419 VPMTPLRTV liver, hepatocellular carcinoma, cancer, rectum, adenocarcinoma
420 QIDYKTLVL stomach, metastatic, leiomyosarcoma
421 VEDPTIVRI stomach, metastatic, leiomyosarcoma
422 IPYQDLPHL kidney, clear cell renal cell carcinoma, lipoma
423 DTPFLTGHGR stomach, adenocarcinoma, bone, non-ossifying fibroma
424 EFYRALYI stomach, adenocarcinoma, bone, non-ossifying fibroma
425 RYYPQILTNK stomach, adenocarcinoma, bone, non-ossifying fibroma
426 KAYERHVL intestines, malignant carcinoid tumor
427 LPSPEFHDY intestines, malignant carcinoid tumor
428 SLYAHPIEH intestines, malignant carcinoid tumor
429 LVREPGSQA kidney, clear cell renal cell carcinoma, lymph node, Hodgkin's disease
430 RLAGPGSEKY kidney, clear cell renal cell carcinoma, lymph node, Hodgkin's disease
431 SPGAGRNSVL kidney, clear cell renal cell carcinoma, lymph node, Hodgkin's disease
432 SVQSDQGYISR kidney, clear cell renal cell carcinoma, lymph node, Hodgkin's disease
433 GVRPPAPSL liver, hepatocellular carcinoma, kidney, carcinoma
434 IFSEKPVFV liver, hepatocellular carcinoma, kidney, carcinoma
435 KASNLLLGF liver, hepatocellular carcinoma, kidney, carcinoma
436 KRYIFADAY liver, hepatocellular carcinoma, kidney, carcinoma
437 RNLQLSLPR liver, hepatocellular carcinoma, kidney, carcinoma
438 EASEPVALR brain, glioblastoma, liver, hepatic adenoma
439 RPKVPDQSV brain, glioblastoma, liver, hepatic adenoma
440 VLYENALKL spleen, extramedullary hematopoiesis
441 EVLDKSQTNY liver, hepatocellular carcinoma, endometrium, hyperplasia
442 MPSPIPAKY liver, hepatocellular carcinoma, endometrium, hyperplasia
443 YGIENFTSV liver, hepatocellular carcinoma, endometrium, hyperplasia
444 ARAAQVFFL colon or rectum, kidney, renal cell carcinoma
445 EHIVPNAEL colon or rectum, kidney, renal cell carcinoma
446 EAFEFVKQR stomach, adenocarcinoma, breast, carcinoma
447 NHFEGHYQY stomach, adenocarcinoma, breast, carcinoma
448 DAYPKNPHL stomach, adenocarcinoma, liver, hepatocellular carcinoma
449 DVNIKSTER stomach, adenocarcinoma, liver, hepatocellular carcinoma
450 HINSIKSVF stomach, adenocarcinoma, liver, hepatocellular carcinoma
451 YESEKVGVA stomach, adenocarcinoma, liver, hepatocellular carcinoma
452 ENAPTTVSR stomach, adenocarcinoma, adrenal gland, adrenal cortical adenoma
453 RFPHLLAHTY stomach, adenocarcinoma, adrenal gland, adrenal cortical adenoma
454 TLDGSLHAV stomach, adenocarcinoma, adrenal gland, adrenal cortical adenoma
455 RTVLKNLSLLK liver, hepatocellular carcinoma, pancreas, microcystic adenoma
456 FEAKVQAI stomach, adenocarcinoma, metastatic adenocarcinoma of stomach
457 FFEAKVQAI stomach, adenocarcinoma, metastatic adenocarcinoma of stomach
458 KELQSTFK stomach, adenocarcinoma, metastatic adenocarcinoma of stomach
459 NVSSRFEEEI stomach, adenocarcinoma, metastatic adenocarcinoma of stomach
460 EVWNNLGTTK brain, cancer, lymph node, malignant melanoma
461 MIFRSGSLI brain, cancer, lymph node, malignant melanoma
462 NHALPLPGF brain, cancer, lymph node, malignant melanoma
463 ASVFGTMPLK kidney, polycystic kidney disease
464 REFPDRLVGY kidney, polycystic kidney disease
465 SVFGTMPLK kidney, polycystic kidney disease
466 DEMRFVTQI lung, non-small cell lung carcinoma, testis, mixed germ cell tumor
467 ETVHFATTQW lung, non-small cell lung carcinoma, testis, mixed germ cell tumor
468 LPPPATQI lung, non-small cell lung carcinoma, testis, mixed germ cell tumor
469 LARDLYAF liver, hepatocellular carcinoma, neuroblastoma
470 LPGIGLSTSL liver, hepatocellular carcinoma, neuroblastoma
471 MEVILPML liver, hepatocellular carcinoma, neuroblastoma
472 AILDYILAK stomach, metastatic, lung, neuroendocrine carcinoma (non-small cell type)
473 KIASQLSKL stomach, metastatic, lung, neuroendocrine carcinoma (non-small cell type)
474 KVTSTTTVK stomach, metastatic, lung, neuroendocrine carcinoma (non-small cell type)
475 YNTLLPYTF stomach, metastatic, lung, neuroendocrine carcinoma (non-small cell type)
476 FLDPRPLTV pancreas, adenocarcinoma, myometrium, leiomyoma
477 SAFADRPAF pancreas, adenocarcinoma, myometrium, leiomyoma
478 AAVPVIISR lymph node, papillary carcinoma of thyroid
479 EEIGKVAAA lymph node, papillary carcinoma of thyroid
480 FLKDLVASV lymph node, papillary carcinoma of thyroid
481 VIISRALEL lymph node, papillary carcinoma of thyroid
482 APRTTGTPRTSL kidney, oncocytoma
483 ESVGGSPQTK kidney, oncocytoma
484 IPKDKAIL kidney, oncocytoma
485 LPAYGRTTL kidney, oncocytoma
486 HQAAIVSKI stomach, adenocarcinoma, kidney, angiomyolipoma
487 QAAIVSKI stomach, adenocarcinoma, kidney, angiomyolipoma
488 RQKMPEDGL stomach, adenocarcinoma, kidney, angiomyolipoma
489 SVQKSSGVK stomach, adenocarcinoma, kidney, angiomyolipoma
490 DSIGSTVSSER stomach, adenocarcinoma
491 LPYNNKDRDAL stomach, adenocarcinoma
492 IYDEIQQEM colon or rectum, colon, adenoma
493 AQAKGLIQV thymus, thymoma, benign
494 EVSSEIYQW thymus, thymoma, benign
495 KWNPVPLSY thymus, thymoma, benign
496 NRLLAQQSL thymus, thymoma, benign
497 APRPVAVAV stomach, adenocarcinoma
498 FYRETVQVGR stomach, adenocarcinoma
499 LLAPRPVAV stomach, adenocarcinoma
500 GLAALVILK stomach, adenocarcinoma, neurofibroma
501 KIQEVFSSY stomach, adenocarcinoma, neurofibroma
502 ASLDKFLSH spleen, chronic myeloid leukemia
503 ALYATKTLR colon or rectum, pancreas, microcystic adenoma
504 MEYVISRI colon or rectum, pancreas, microcystic adenoma
505 VPVGRQPII colon or rectum, pancreas, microcystic adenoma
506 KLLIGVIAAV stomach, metastatic, colon, adenocarcinoma
507 LPSLIKLD stomach, metastatic, colon, adenocarcinoma
508 PSLIKLDL stomach, metastatic, colon, adenocarcinoma
509 ARNKELIGK stomach, adenocarcinoma
510 AVKSNAAAY stomach, adenocarcinoma
511 EVIIPHSGW stomach, adenocarcinoma
512 SVKEQEAQF stomach, adenocarcinoma
513 APRGLEPIAI liver, hepatocellular carcinoma, liver, focal nodular hyperplasia
514 GRFGGVITI liver, hepatocellular carcinoma, liver, focal nodular hyperplasia
518 AEHIESRTL kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
519 DQYPYLKSV kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
520 IARNLTQQL kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
521 IESRTLAIA kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
522 MTSALPIIQK kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
523 SLLTSSKGQLQK kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
524 TSALPIIQK kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
525 VRLGSLSTK kidney, clear cell renal cell carcinoma, liver, focal nodular hyperplasia
526 RINEFSISSF chondrosarcoma
527 DEKQQHIVY liver, hepatocellular carcinoma, synovial sarcoma
528 DEVYQVTVY liver, hepatocellular carcinoma, synovial sarcoma
529 GEISEKAKL liver, hepatocellular carcinoma, synovial sarcoma
530 YTMKEVLFY liver, hepatocellular carcinoma, synovial sarcoma
531 SQLTTLSFY lung, non-small cell lung carcinoma, omentum, adenocarcinoma
532 LEKQLIEL stomach, adenocarcinoma, rectum, adenocarcinoma
533 ELTLGEFLK stomach, metastatic, ovary, Mullerian mixed tumor
534 LTLGEFLK stomach, metastatic, ovary, Mullerian mixed tumor
535 LTLGEFLKL stomach, metastatic, ovary, Mullerian mixed tumor
536 TLGEFLKL stomach, metastatic, ovary, Mullerian mixed tumor
537 ITARPVLW non-Hodgkin's lymphoma
538 KLMSPKLYVW non-Hodgkin's lymphoma
539 KVSAVTLAY non-Hodgkin's lymphoma
540 VEGSGELFRW non-Hodgkin's lymphoma
541 RPKSNIVL non-Hodgkin's lymphoma
542 RPKSNIVLL non-Hodgkin's lymphoma
543 GEPLSYTRFSLARQ lung, non-small cell lung carcinoma, lung, adenocarcinoma
544 GEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
545 GEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
546 GGEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
547 GGEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
548 NPGGYVAYSKAATVTG lung, non-small cell lung carcinoma, lung, adenocarcinoma
549 NPGGYVAYSKAATVTGK lung, non-small cell lung carcinoma, lung, adenocarcinoma
550 NPGGYVAYSKAATVTGKL lung, non-small cell lung carcinoma, lung, adenocarcinoma
551 NSVIIVDKNGRL lung, non-small cell lung carcinoma, lung, adenocarcinoma
552 NSVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
553 NSVIIVDKNGRLVY lung, non-small cell lung carcinoma, lung, adenocarcinoma
554 RVEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
555 RVEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
556 RVEYHFLSPYVSPKESPF lung, non-small cell lung carcinoma, lung, adenocarcinoma
557 SPFRHVFWGSGSHTL lung, non-small cell lung carcinoma, lung, adenocarcinoma
558 SVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
559 VEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
560 VEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
561 LPSQAFEYILYNKG lung, non-small cell lung carcinoma, lung, adenocarcinoma
562 LPSQAFEYILYNKGI lung, non-small cell lung carcinoma, lung, adenocarcinoma
563 LPSQAFEYILYNKGIM lung, non-small cell lung carcinoma, lung, adenocarcinoma
564 LPSQAFEYILYNKGIMG lung, non-small cell lung carcinoma, lung, adenocarcinoma
565 MNGYFLIERGKNM lung, non-small cell lung carcinoma, lung, adenocarcinoma
566 NGYFLIERGKNm lung, non-small cell lung carcinoma, lung, adenocarcinoma
567 PSQAFEYILYNKG lung, non-small cell lung carcinoma, lung, adenocarcinoma
568 PSQAFEYILYNKGI lung, non-small cell lung carcinoma, lung, adenocarcinoma
569 PSQAFEYILYNKGIM lung, non-small cell lung carcinoma, lung, adenocarcinoma
570 EGVQYSYSLFHLM stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
571 EGVQYSYSLFHLML stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
572 GVQYSYSLFHLM stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
573 GVQYSYSLFHLML stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
574 SIISIHPKIQEHQPR stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
575 SSIRTSTNSQVDK stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
576 VLVGYKAVYRIS stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
577 KSSIRTSTNSQVDK stomach, metastatic, stomach, gastrointestinal stromal tumor (GIST)
578

 
colon or rectum, thymus, thymoma, malignant
579 GGSFGGRSSGSP colon or rectum, thymus, thymoma, malignant
580 KGGSFGGRSSGSP colon or rectum, thymus, thymoma, malignant
581

 
colon or rectum, thymus, thymoma, malignant
582

 
colon or rectum, thymus, thymoma, malignant
583

 
colon or rectum, thymus, thymoma, malignant
584

 
colon or rectum, thymus, thymoma, malignant
585 GNRINEFSISSF chondrosarcoma
586 HGNQITSDKVGRKV chondrosarcoma
587 IPPVNTNLENLYLQ chondrosarcoma
588 LQVLRLDGNEIKR chondrosarcoma
589 LQVLRLDGNEIKRS chondrosarcoma
590 LQVLRLDGNEIKRSA chondrosarcoma
591 LRELHLDHNQISRVPN chondrosarcoma
592 LYVRLSHNSLTNNG chondrosarcoma
593 VPSRMKYVYFQNNQ chondrosarcoma
594 VPSRMKYVYFQNNQIT chondrosarcoma
595 VPSRMKYVYFQNNQITS chondrosarcoma
596 WIALHGNQITSD chondrosarcoma
597 WIALHGNQITSDK chondrosarcoma
598 ADDNVSFRWEALGNT chondrosarcoma
599 ADDNVSFRWEALGNTL colon or rectum
600 DADDNVSFRWEALGNTL colon or rectum
601 DDNVSFRWEALGNT colon or rectum
602 DDNVSFRWEALGNTL colon or rectum
603 DNVSFRWEALGNT colon or rectum
604 DNVSFRWEALGNTL colon or rectum
605 DNVSFRWEALGNTLS colon or rectum
606 DTGSYRAQISTKTSAK colon or rectum
607 DTGSYRAQISTKTSAKL colon or rectum
608 DTITIYSTINHSK colon or rectum
609 EDTGSYRAQISTKTSAK colon or rectum
610 ENDTITIYSTINHSK colon or rectum
611 ENDTITIYSTINHSKESKPT colon or rectum
612 GSYRAQISTKTSAK colon or rectum
613 NDTITIYSTINH colon or rectum
614 NDTITIYSTINHS colon or rectum
615 NDTITIYSTINHSK colon or rectum
616 NVSFRWEALGNTL colon or rectum
617 SPTNNTVYASVTHSNRET colon or rectum
618 TGSYRAQISTKTSAK colon or rectum
619   colon or rectum
620

 
colon or rectum
621 VSFRWEALGNTL colon or rectum
622 APIHFTIEKLELNEK lipoma
623 DAQFEVIKGQTIE lipoma
624 DAQFEVIKGQTIEVR lipoma
625 ESYFIPEVRIYDSGT lipoma
626 IPEVRIYDSGTY lipoma
627 KDKAIVAHNRHGNK lipoma
628 KDKAIVAHNRHGNKA lipoma
629 NFVILEFPVEEQDR lipoma
630 SQPRISYDAQFEVIK lipoma
631 SQPRISYDAQFEVIKG lipoma
632 YDAQFEVIKGQTIE lipoma
633 GNPAYRSFSNSLSQ colon or rectum, kidney, angiomyolipoma
634 GPPGEAGYKAFSSLLA colon or rectum, kidney, angiomyolipoma
635 GPPGEAGYKAFSSLLASS colon or rectum, kidney, angiomyolipoma
636 GPPGEAGYKAFSSLLASSA colon or rectum, kidney, angiomyolipoma
637

 
colon or rectum, kidney, angiomyolipoma
638

 
colon or rectum, kidney, angiomyolipoma
639 GYKAFSSLLASSAVSP colon or rectum, kidney, angiomyolipoma
640 GYKAFSSLLASSAVSPE colon or rectum, kidney, angiomyolipoma
641 KAFSSLLASSAVSPE colon or rectum, kidney, angiomyolipoma
642 NPAYRSFSNSLSQ colon or rectum, kidney, angiomyolipoma
643 SRDDFQEGREGIVAR colon or rectum, kidney, angiomyolipoma
644 SSSSFHPAPGNAQ colon or rectum, kidney, angiomyolipoma
645 VARLTESLFLDL colon or rectum, kidney, angiomyolipoma
646 VARLTESLFLDLLG colon or rectum, kidney, angiomyolipoma
647 VIAGNPAYRSFSN colon or rectum, kidney, angiomyolipoma
648 VPQPEPETWEQILRRNVLQ colon or rectum, kidney, angiomyolipoma
649 YKAFSSLLASSAVS colon or rectum, kidney, angiomyolipoma
650 YKAFSSLLASSAVSP colon or rectum, kidney, angiomyolipoma
651 YKAFSSLLASSAVSPE colon or rectum, kidney, angiomyolipoma,
652 GNQVFSYTANKEIRTDD colon or rectum, urinary bladder, transitional cell carcinoma
653 IEEIVLVDDASERD colon or rectum, urinary bladder, transitional cell carcinoma
654 IEEIVLVDDASERDF colon or rectum, urinary bladder, transitional cell carcinoma
655 LENIYPDSQIPRH colon or rectum, urinary bladder, transitional cell carcinoma
656 LENIYPDSQIPRHY colon or rectum, urinary bladder, transitional cell carcinoma
657 NQVFSYTANKEIR colon or rectum, urinary bladder, transitional cell carcinoma
658 NQVFSYTANKEIRT colon or rectum, urinary bladder, transitional cell carcinoma
659 NQVFSYTANKEIRTDD colon or rectum, urinary bladder, transitional cell carcinoma
660 VHSVINRSPRHMIEE colon or rectum, urinary bladder, transitional cell carcinoma
661 EYVSLYHQPAAM non-Hodgkin's lymphoma
662 IKAEYKGRVTLKQYPR non-Hodgkin's lymphoma
663 LNVHSEYEPSWEEQP non-Hodgkin's lymphoma
664 LPYLFQmPAYASSS non-Hodgkin's lymphoma
665 LPYLFQmPAYASSSK non-Hodgkin's lymphoma
666 NFIKAEYKGRVT non-Hodgkin's lymphoma
667 TNFIKAEYKGRVT non-Hodgkin's lymphoma
668 TTNFIKAEYKGRVT non-Hodgkin's lymphoma
669 VTLNVHSEYEPSWEEQP non-Hodgkin's lymphoma
670   non-Hodgkin's lymphoma
671

 
non-Hodgkin's lymphoma
672 ADLSSFKSQELN lymph node, papillary carcinoma of thyroid
673 ADLSSFKSQELNER lymph node, papillary carcinoma of thyroid
674 ADLSSFKSQELNERN lymph node, papillary carcinoma of thyroid
675 ADLSSFKSQELNERNE lymph node, papillary carcinoma of thyroid
676   lymph node, papillary carcinoma of thyroid
677

 
lymph node, papillary carcinoma of thyroid, metastatic
678 EQQRLKSQDLELSWN lymph node, papillary carcinoma of thyroid
679 ISQELEELRAEQQR lymph node, papillary carcinoma of thyroid
680 ISQELEELRAEQQRLK lymph node, papillary carcinoma of thyroid
681 KGTKQWVHARYA lymph node, papillary carcinoma of thyroid
682 QADLSSFKSQELNER lymph node, papillary carcinoma of thyroid, metastatic
683 SWNLNGLQADLSSFK lymph node, papillary carcinoma of thyroid
684 TGSWIGLRNLDLKG lymph node, papillary carcinoma of thyroid
685

 
pancreas, adenocarcinoma, thymus, thymoma, malignant
686

 
pancreas, adenocarcinoma, thymus, thymoma, malignant
687 GPMKGGNFGGRSSGP pancreas, adenocarcinoma, thymus, thymoma, malignant
688 GPYGGGGQYFAKP pancreas, adenocarcinoma, thymus, thymoma, malignant
689 KGGNFGGRSSGP pancreas, adenocarcinoma, thymus, thymoma, malignant
690 NDFGNYNNQSSNFGP pancreas, adenocarcinoma, thymus, thymoma, malignant
691 SGPYGGGGQYFAKP pancreas, adenocarcinoma, thymus, thymoma, malignant
692 DAGSYKAQINQRNFE lung, non-small cell lung carcinoma, lymph node, non-Hodgkin's lymphoma
693 DAGSYKAQINQRNFEVT lung, non-small cell lung carcinoma, lymph node, non-Hodgkin's lymphoma
694 DGELIRTQPQRLPQ pancreas, adenocarcinoma, intramuscular lipoma
695 GELIRTQPQRLPQ pancreas, adenocarcinoma, intramuscular lipoma
696 NPSDGELIRTQPQRLP pancreas, adenocarcinoma, intramuscular lipoma
697 NPSDGELIRTQPQRLPQ pancreas, adenocarcinoma, intramuscular lipoma
698 NPSDGELIRTQPQRLPQL pancreas, adenocarcinoma, intramuscular lipoma
699 ASNDMYHSRALQVVR colon or rectum, bone, giant cell tumor of bone
700 ASNDMYHSRALQVVRA colon or rectum, bone, giant cell tumor of bone
701 EGVRRALDFAVGEYN colon or rectum, bone, giant cell tumor of bone
702 EGVRRALDFAVGEYNK colon or rectum, bone, giant cell tumor of bone
703 SNDMYHSRALQVVR colon or rectum, bone, giant cell tumor of bone
704 VGEYNKASNDMYH colon or rectum, bone, giant cell tumor of bone
705 VRARKQIVAGVNY colon or rectum, bone, giant cell tumor of bone
706 VRRALDFAVGEYNKASND colon or rectum, bone, giant cell tumor of bone
707 VVRARKQIVAGVN colon or rectum, bone, giant cell tumor of bone
708 WRARKQIVAGVNY colon or rectum, bone, giant cell tumor of bone
709 APLEGARFALVRED liver, hepatocellular carcinoma
710 APVELILSDETLPAPE liver, hepatocellular carcinoma
711 ELILSDETLPAPE liver, hepatocellular carcinoma
712 LAPLEGARFALVRE liver, hepatocellular carcinoma
713 LAPLEGARFALVRED liver, hepatocellular carcinoma
714 RGEKELLVPRSSTSPD liver, hepatocellular carcinoma
715 ASKTFTTQETITNAET kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
716 DQHFRTTPLEKNAPV kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
717 NTPILVDGKDVMPE kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
718 NTPILVDGKDVMPEV kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
719 NTPILVDGKDVMPEVN kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
720 SNTPILVDGKDVMPE kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
721 SNTPILVDGKDVMPEVN kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
722 TPILVDGKDVMP kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
723 TPILVDGKDVMPE kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
724 TPILVDGKDVMPEV kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
725 TPILVDGKDVMPEVN kidney, clear cell renal cell carcinoma, kidney, angiomyolipoma
726 GPLKFLHQDIDSGQG kidney, renal cell carcinoma
727 GPLKFLHQDIDSGQGIR kidney, renal cell carcinoma
728 LGDIYFKLFRASG kidney, renal cell carcinoma
729 TGHLFDLSSLSGRAG kidney, renal cell carcinoma
730 VPSPVDCQVTDLAGNE kidney, renal cell carcinoma
731 DGLNSLTYQVLDVQRYPL kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
732 HPVLQRQQLDYGIY kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
733 LNSLTYQVLDVQR kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
734 LNSLTYQVLDVQRYP kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
735 LNSLTYQVLDVQRYPL kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
736 LPQLVGVSTPLQG kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
737 LPQLVGVSTPLQGG kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
738 LPQLVGVSTPLQGGS kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
739 RLPQLVGVSTPLQGGS kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
740 SPHKVAIIIPFRNR kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
741 SPHKVAIIIPFRNRQE kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
742 SPHKVAIIIPFRNRQEH kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
743 AIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
744 ARNFERNKAIKVI non-Hodgkin's lymphoma, peripheral T cell type
745 ARNFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
746 NFERNKAIKVII non-Hodgkin's lymphoma, peripheral T cell type
747 NFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
748 VAIVQAVSAHRH non-Hodgkin's lymphoma, peripheral T cell type
749 VAIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
750 VAIVQAVSAHRHRA non-Hodgkin's lymphoma, peripheral T cell type
751 VAIVQAVSAHRHRAR non-Hodgkin's lymphoma, peripheral T cell type
752 EEVITLIRSNQQLE lung, non-small cell lung carcinoma, pancreas, adenocarcinoma
753 EEVITLIRSNQQLEN lung, non-small cell lung carcinoma, pancreas, adenocarcinoma
754 IPADTFAALKNPNAML lung, non-small cell lung carcinoma, pancreas, adenocarcinoma
755 LKQLLSDKQQKRQSG lung, non-small cell lung carcinoma, pancreas, adenocarcinoma
756 LKQLLSDKQQKRQSGQ lung, non-small cell lung carcinoma, pancreas, adenocarcinoma
757 TPSYVAFTDTER pancreas, adenocarcinoma, rectum, adenocarcinoma
758 TPSYVAFTDTERL pancreas, adenocarcinoma, rectum, adenocarcinoma
759 EGLYSRTLAGSIT liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
760 EGLYSRTLAGSITTPP liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
761 EKWYIPDPTGKFN liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
762 GAIAAINSIQHNTR liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
763 LPILVPSAKKAI liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
764 LPILVPSAKKAIY liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
765 LPILVPSAKKAIYM liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
766 LPILVPSAKKAIYMD liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
767 LPILVPSAKKAIYMDD liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
768 VEEGLYSRTLAGSIT liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
769 WEKWYIPDPTGKFN liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
770 YKIVNFDPKLLE liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
771 YKIVNFDPKLLEG liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
772 YKIVNFDPKLLEGKV liver, hepatocellular carcinoma, cancer, thyroid gland, nodular hyperplasia
773 LPEFYKTVSPAL colon or rectum, endometrium, adenocarcinoma, endometrioid type
774 VGQFIQDVKNSRST colon or rectum, endometrium, adenocarcinoma, endometrioid type
775 VGQFIQDVKNSRSTD colon or rectum, endometrium, adenocarcinoma, endometrioid type
776 VVGQFIQDVKNSRS colon or rectum, endometrium, adenocarcinoma, endometrioid type
777 VVGQFIQDVKNSRST colon or rectum, endometrium, adenocarcinoma, endometrioid type
778 VVGQFIQDVKNSRSTD colon or rectum, endometrium, adenocarcinoma, endometrioid type
779 VVGQFIQDVKNSRSTDS colon or rectum, endometrium, adenocarcinoma, endometrioid type
780 DNGHLYREDQTSPAPG pancreas, adenocarcinoma, kidney, angiomyolipoma
781 DNGHLYREDQTSPAPGLR pancreas, adenocarcinoma, kidney, angiomyolipoma
782 EVQVFAPANALPARSE pancreas, adenocarcinoma, kidney, angiomyolipoma
783 GHLYREDQTSPAPG pancreas, adenocarcinoma, kidney, angiomyolipoma
784 LPARSEAAAVQPVIG pancreas, adenocarcinoma, kidney, angiomyolipoma
785 NGHLYREDQTSPAPG pancreas, adenocarcinoma, kidney, angiomyolipoma
786 NGHLYREDQTSPAPGL pancreas, adenocarcinoma, kidney, angiomyolipoma
787 NGHLYREDQTSPAPGLR pancreas, adenocarcinoma, kidney, angiomyolipoma
788 VFAPANALPARSEAA pancreas, adenocarcinoma, kidney, angiomyolipoma
789 VQVFAPANALPARSE pancreas, adenocarcinoma, kidney, angiomyolipoma
790 AIVVSDRDGVPVIK stomach, adenocarcinoma, parathyroid gland, adenoma
791 GLHAIVVSDRDGVPV stomach, adenocarcinoma, parathyroid gland, adenoma
792 GLHAIVVSDRDGVPVIK stomach, adenocarcinoma, parathyroid gland, adenoma
793 HAIVVSDRDGVPV stomach, adenocarcinoma, parathyroid gland, adenoma
794 KLPSVEGLHAIVVSDRDG stomach, adenocarcinoma, parathyroid gland, adenoma
795 LHAIVVSDRDGVPV stomach, adenocarcinoma, parathyroid gland, adenoma
796 LHAIVVSDRDGVPVI stomach, adenocarcinoma, parathyroid gland, adenoma
797 LHAIVVSDRDGVPVIK stomach, adenocarcinoma, parathyroid gland, adenoma
798 LPSVEGLHAIVVSDR stomach, adenocarcinoma, parathyroid gland, adenoma
799 VPVIKVANDNAPE stomach, adenocarcinoma, parathyroid gland, adenoma
800 YNTYQVVQFNRLP stomach, adenocarcinoma, parathyroid gland, adenoma
801 YNTYQVVQFNRLPL stomach, adenocarcinoma, parathyroid gland, adenoma
802 YNTYQVVQFNRLPLV stomach, adenocarcinoma, parathyroid gland, adenoma
803 YNTYQVVQFNRLPLVV stomach, adenocarcinoma, parathyroid gland, adenoma
804 YYNTYQVVQFNRLP stomach, adenocarcinoma, parathyroid gland, adenoma
805 YYNTYQVVQFNRLPL stomach, adenocarcinoma, parathyroid gland, adenoma
806 YYNTYQVVQFNRLPLV stomach, adenocarcinoma, parathyroid gland, adenoma
807 DKIYFmAGSSRKE liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
808

 
liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
809 EVTFKSILFVPTSAP liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
810 KSEKFAFQAEVNR liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
811 LPEFDGKRFQNVAK liver, hepatocellular carcinoma, thyroid gland, nodular hyperplasia
812 DGSYRIFSKGASE colon or rectum, liposarcoma
813 GSYRIFSKGASE colon or rectum, liposarcoma
814 SDGSYRIFSKGASE colon or rectum, liposarcoma
815 SVKKMMKDNNLVRH colon or rectum, liver, hepatocellular carcinoma
816 VKKMMKDNNLVRH colon or rectum, liver, hepatocellular carcinoma
817 NNmRIFGEAAEKN stomach, adenocarcinoma, thyroid gland, papillary carcinoma
818 VDKVLERDQKLSE lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
819 VDKVLERDQKLSELD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
820 VDKVLERDQKLSELDD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
821 VDKVLERDQKLSELDDR stomach, adenocarcinoma, lymph node, papillary carcinoma of thyroid
822 VLERDQKLSELDDR lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
823 ATRSIQVDGKTIKAQ stomach, adenocarcinoma, kidney, angiomyolipoma
824 ATRSIQVDGKTIKAQI stomach, adenocarcinoma, kidney, angiomyolipoma
825 IGVEFATRSIQVDGK stomach, adenocarcinoma, kidney, angiomyolipoma
826 RSIQVDGKTIKA stomach, adenocarcinoma, kidney, angiomyolipoma
827 RSIQVDGKTIKAQ stomach, adenocarcinoma, kidney, angiomyolipoma
828 RSIQVDGKTIKAQI stomach, adenocarcinoma, kidney, angiomyolipoma
829 TRSIQVDGKTIKAQ stomach, adenocarcinoma, kidney, angiomyolipoma
830 DIMRVNVDKVLERDQK stomach, adenocarcinoma, medullary carcinoma of thyroid origin
831 DIMRVNVDKVLERDQKL stomach, adenocarcinoma, medullary carcinoma of thyroid origin
832 IMRVNVDKVLERDQK lung, non-small cell lung carcinoma, lymph node, Hodgkin's disease
833 VDKVLERDQKLSE lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
834 VDKVLERDQKLSELD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
835 VDKVLERDQKLSELDD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
836 VDKVLERDQKLSELDDR stomach, adenocarcinoma, lymph node, papillary carcinoma of thyroid
837 VLERDQKLSELDDR lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid
838 ATRSIQVDGKTIKAQ stomach, adenocarcinoma
839 ATRSIQVDGKTIKAQI stomach, adenocarcinoma, kidney, angiomyolipoma
840 IGVEFATRSIQVDGK stomach, adenocarcinoma, kidney, angiomyolipoma
841 RSIQVDGKTIKA stomach, adenocarcinoma, kidney, angiomyolipoma
842 RSIQVDGKTIKAQ stomach, adenocarcinoma, kidney, angiomyolipoma
843 RSIQVDGKTIKAQI stomach, adenocarcinoma, kidney, angiomyolipoma
844 TRSIQVDGKTIKAQ stomach, adenocarcinoma, kidney, angiomyolipoma
845 GIRVAPVPLYNS lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
846 GIRVAPVPLYNSFH lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
847 NPNGIRVAPVPLYNSFH lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
848 DDPAIDVCKKLLGKYPN kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
849 DKQPYSKLPGVSLLKP kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
850 DKQPYSKLPGVSLLKPL kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
851 HPRYYISANVTGFK kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
852 SHPRYYISANVTG kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
853 SHPRYYISANVTGFK kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
854 TSHPRYYISANVTG kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
855 TSHPRYYISANVTGFK kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
856 ADIFVDPVLHTA kidney, renal cell carcinoma
857 ADIFVDPVLHTACA kidney, renal cell carcinoma
858 DPGADYRIDRALNEA kidney, renal cell carcinoma
859 IAQDYKVSYSLA kidney, renal cell carcinoma
860 IAQDYKVSYSLAK kidney, renal cell carcinoma
861 ISRDWKLDPVLYRK kidney, renal cell carcinoma
862 LIAQDYKVSYSLA kidney, renal cell carcinoma
863 RQKLIAQDYKVSYS kidney, renal cell carcinoma
864 RQKLIAQDYKVSYSL kidney, renal cell carcinoma
865 RQKLIAQDYKVSYSLA kidney, renal cell carcinoma
866 RQKLIAQDYKVSYSLAK kidney, renal cell carcinoma
867 SALDYRLDPQLQLH kidney, renal cell carcinoma
868 SKADIFVDPVLHTA kidney, renal cell carcinoma
869 SPSKNYILSVISGSI kidney, renal cell carcinoma
870 ETTQLTADSHPSYHTDG stomach, metastatic, skin, squamous cell carcinoma
871 SGESLYHVLGLDKNATSDD stomach, metastatic, skin, squamous cell carcinoma
872 TTQLTADSHPSYHT stomach, metastatic, skin, squamous cell carcinoma
873 TTQLTADSHPSYHTD stomach, metastatic, skin, squamous cell carcinoma
874 TTQLTADSHPSYHTDG stomach, metastatic, skin, squamous cell carcinoma
875 SVEEFLSEKLERI pancreas, adenocarcinoma, liver, hepatic adenoma
876 VEEFLSEKLERI pancreas, adenocarcinoma, liver, hepatic adenoma
877 DLSSSILAQSRERVA pancreas, adenocarcinoma, bone, giant cell tumor of bone
878 EKGVRTLTAAAVSGAQ pancreas, adenocarcinoma, bone, giant cell tumor of bone
879 EKGVRTLTAAAVSGAQP pancreas, adenocarcinoma, bone, giant cell tumor of bone
880 EKGVRTLTAAAVSGAQPI pancreas, adenocarcinoma, bone, giant cell tumor of bone
881 KGVRTLTAAAVSGA pancreas, adenocarcinoma, bone, giant cell tumor of bone
882 KGVRTLTAAAVSGAQ pancreas, adenocarcinoma, bone, giant cell tumor of bone
883 VGPFAPGITEKAPEEKK pancreas, adenocarcinoma, bone, giant cell tumor of bone
884 DPPLIALDKDAPLR brain, glioblastoma, parotid gland, pleomorphic adenoma
885 EIITPDVPFTVDKDG brain, glioblastoma, parotid gland, pleomorphic adenoma
886 IITPDVPFTVDKDG brain, glioblastoma, parotid gland, pleomorphic adenoma
887 PPLIALDKDAPLR brain, glioblastoma, parotid gland, pleomorphic adenoma
888 TNVKKSHKATVHIQ brain, glioblastoma, parotid gland, pleomorphic adenoma
889 DDNIKTYSDHPE kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
890 DDNIKTYSDHPEK kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
891 DSAVFFEQGTTRIG kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
892 GDKVYVHLKNLASRPY kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
893 GDKVYVHLKNLASRPYT kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
894 VHLKNLASRPYT kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
895 VYVHLKNLASRPY kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
896 VYVHLKNLASRPYT kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
897 VYVHLKNLASRPYTFH kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
898 YVHLKNLASRPY kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
899 YVHLKNLASRPYT kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
900 YVHLKNLASRPYTFH kidney, clear cell renal cell carcinoma, liver, hepatocellular carcinoma
901 SNLIKLAQKVPTAD liver, hepatocellular carcinom
902 YDTRTSALSAKS liver, hepatocellular carcinoma
903 ALMTDPKLITWSPV bone, non-ossifying fibroma
904 NDVAWNFEKFLVGPDG bone, non-ossifying fibroma
905 QSVYAFSARPLAG bone, non-ossifying fibroma
906 QSVYAFSARPLAGGEPV bone, non-ossifying fibroma
907 WNFEKFLVGPDG colon or rectum, bone, non-ossifying fibroma
908 DVGMFVALTKLGQPD stomach, adenocarcinoma, uterin cervix, squamous cell carcinoma
909 VGMFVALTKLGQPD stomach, adenocarcinoma, uterin cervix, squamous cell carcinoma
910 AGVFHVEKNGRY stomach, adenocarcinoma, colon, adenocarcinoma
911 FAGVFHVEKNGRYS stomach, adenocarcinoma, colon, adenocarcinoma
912 GPITITIVNRDGTR stomach, adenocarcinoma, colon, adenocarcinoma
913 NGRYSISRTEAADL stomach, adenocarcinoma, colon, adenocarcinoma
914 RKSRQGSLAMEELK rectum, adenocarcinoma
915 RRKSRQGSLAMEELK rectum, adenocarcinoma
916 EEFKKLTSIKIQNDK brain, glioblastoma, small Intestine, gastrointestinal stromal tumor (GIST)
917 INRRMADDNKLFR brain, glioblastoma, small Intestine, gastrointestinal stromal tumor (GIST)
918 TATIVMVTNLKERKE brain, glioblastoma, small Intestine, gastrointestinal stromal tumor (GIST)
919 ELFYKGIRPAINVG liver, hepatocellular carcinoma, kidney, oncocytoma
920 GQKRSTVAQLVKR liver, hepatocellular carcinoma, kidney, oncocytoma
921 SDLDAATQQLLSRGV liver, hepatocellular carcinoma, kidney, oncocytoma
922 FDFSQNTRVPRLPE kidney, clear cell renal cell carcinoma, non-Hodgkin's lymphoma
923 GDAPAILFDKEF kidney, clear cell renal cell carcinoma, non-Hodgkin's lymphoma
924 VTHEIDRYTAIAY kidney, clear cell renal cell carcinoma, non-Hodgkin's lymphoma
929 AAKYQLDPTASISA kidney, oncocytoma
930 IAAKYQLDPTASISA kidney, oncocytoma
931 IAAKYQLDPTASISAK kidney, oncocytoma
932 AGLGRAYALAFAERG liver, hepatocellular carcinoma, hepatic adenoma
933 DAFGRIDVVVNNAG liver, hepatocellular carcinoma, hepatic adenoma
934 GLGRAYALAFAER liver, hepatocellular carcinoma, hepatic adenoma
935 GLGRAYALAFAERG liver, hepatocellular carcinoma, hepatic adenoma
936 AKFALNGEEFMNFDL liver, hepatocellular carcinoma, liposarcoma
937 AKFALNGEEFMNFDLK liver, hepatocellular carcinoma, liposarcoma
938 ALNGEEFMNFDLK liver, hepatocellular carcinoma, liposarcoma
939 KFALNGEEFMNFDL liver, hepatocellular carcinoma, liposarcoma
940 SDGSFHASSSLTVK liver, hepatocellular carcinoma, liposarcoma
941 EERNLLSVAYKNVVGAR colon or rectum, esophagus, adenocarcinoma
942 ERNLLSVAYKNVVGAR colon or rectum, esophagus, adenocarcinoma
943 IAELDTLSEESYKD colon or rectum, Vulva, squamous cell carcinoma
944 IAELDTLSEESYKDS colon or rectum, Vulva, squamous cell carcinoma
945 ADSYLDEGFLLDKKIG lung, non-small cell lung carcinoma, ovary, Mullerian mixed tumor
946 DSYLDEGFLLDKK lung, non-small cell lung carcinoma, ovary, Mullerian mixed tumor
947 DSYLDEGFLLDKKIG lung, non-small cell lung carcinoma, ovary, Mullerian mixed tumor
948 VDNIIKAAPRKRVPD lung, non-small cell lung carcinoma, ovary, Mullerian mixed tumor
949 SPPQFRVNGAISN colon or rectum, ovary, granulosa cell tumor
950 SPPQFRVNGAISNFE colon or rectum, ovary, granulosa cell tumor
951 SPPQFRVNGAISNFEE colon or rectum, ovary, granulosa cell tumor
952 SPPQFRVNGAISNFEEF colon or rectum, ovary, granulosa cell tumor
953 VGKMFVDVYFQEDKK colon or rectum, ovary, granulosa cell tumor
954 VGKMFVDVYFQEDKKE colon or rectum, ovary, granulosa cell tumor
955 DPKRTIAQDYGVLKADE lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
956 DPKRTIAQDYGVLKADEG lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
957 PKRTIAQDYGVLKADEG lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
958 GLFIIDDKGILRQ lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
959 GLFIIDDKGILRQIT lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
960 RGLFIIDDKGILR lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
961 RGLFIIDDKGILRQ lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
962 RGLFIIDDKGILRQIT lung, non-small cell lung carcinoma, thyroid gland, nodular hyperplasia
963 GNTVIHLDQALARMR brain, glioblastoma, lung, small cell carcinoma
964 NTVIHLDQALARMR brain, glioblastoma, lung, small cell carcinoma
965 NTVIHLDQALARMRE brain, glioblastoma, lung, small cell carcinoma
966 ENNEIISNIRDSVIN stomach, adenocarcinoma, kidney, oncocytoma
967 NNEIISNIRDSVIN stomach, adenocarcinoma, kidney, oncocytoma
968 SPTVQVFSASGKPV stomach, adenocarcinoma, kidney, oncocytoma
969 SSPTVQVFSASGKPVE stomach, adenocarcinoma, kidney, oncocytoma
970 AEPNYHSLPSARTDEQ thyroid gland, follicular adenoma
971 SSILAKTASNIIDVS thyroid gland, follicular adenoma
973 ADDLEGEAFLPL stomach, adenocarcinoma, spleen, chronic myeloid leukemia
974 ADDLEGEAFLPLR stomach, adenocarcinoma, spleen, chronic myeloid leukemia
975 ADDLEGEAFLPLRE stomach, adenocarcinoma, spleen, chronic myeloid leukemia
976 GADDLEGEAFLPLR stomach, adenocarcinoma, spleen, chronic myeloid leukemia
977 AGREINLVDAHLKSE lymph node, Hodgkin's disease
978 AGREINLVDAHLKSEQT lymph node, Hodgkin's disease
979 GREINLVDAHLKSE lymph node, Hodgkin's disease
980 KPGIVYASLNHSVIG lymph node, Hodgkin's disease
981 NKPGIVYASLNHSVIG lymph node, Hodgkin's disease
982 TTLYVTDVKSASERPS lymph node, Hodgkin's disease
983 APSTYAHLSPAKTPPP stomach, adenocarcinoma, pancreas, adenocarcinoma
984 APSTYAHLSPAKTPPPP stomach, adenocarcinoma, pancreas, adenocarcinoma
985 APSTYAHLSPAKTPPPPA stomach, adenocarcinoma, pancreas, adenocarcinoma
986 RDDLYDQDDSRDFPR stomach, adenocarcinoma, pancreas, adenocarcinoma
987 TRPYHSLPSEAVFA adrenal gland, adrenal cortical adenoma
988 TRPYHSLPSEAVFAN adrenal gland, adrenal cortical adenoma
989 VAVFTFHNHGRT adrenal gland, adrenal cortical adenoma
990 VAVFTFHNHGRTA adrenal gland, adrenal cortical adenoma
991 VAVFTFHNHGRTANL adrenal gland, adrenal cortical adenoma
992 EDDYIKSWEDNQQGDE brain, glioblastoma, pleura, malignant mesothel ioma
993 ELERIQIQEAAKKKPG brain, glioblastoma, pleura, malignant mesothel ioma
994 ERIQIQEAAKKKP brain, glioblastoma, pleura, malignant mesothel ioma
995 ERIQIQEAAKKKPG brain, glioblastoma, pleura, malignant mesothel ioma
996 ERIQIQEAAKKKPGI brain, glioblastoma, pleura, malignant mesothelioma
997 LERIQIQEAAKKKPG brain, glioblastoma, pleura, malignant mesothelioma
998 LSSISQYSGKIK brain, glioblastoma, pleura, malignant mesothelioma
999 SPAKDSLSFEDF rectum, adenocarcinoma
1000 SPAKDSLSFEDFLDL rectum, adenocarcinoma
1001 INSRFPIPSATDPD brain, glioblastoma, brain, oligodendroglioma
1002 VQHYELLNGQSVFG brain, glioblastoma, brain, oligodendroglioma
1003 DNQYAVLENQKSSH colon or rectum, pleura, malignant mesothelioma
1004 GPPEIYSDTQFPS colon or rectum, pleura, malignant mesothelioma
1005 GPPEIYSDTQFPSLQ colon or rectum, pleura, malignant mesothelioma
1006 TPQGPPEIYSDTQFPS colon or rectum, pleura, malignant mesothelioma
1007 TPQGPPEIYSDTQFPSLQ colon or rectum, pleura, malignant mesothelioma
1008

 
colon or rectum, pleura, malignant mesothelioma
1009 ANLQRAYSLAKEQR kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical carcinoma
1010 NLQRAYSLAKEQR kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical carcinoma
1011 TPSGITYDRKDIEEH kidney, clear cell renal cell carcinoma, adrenal gland, adrenal cortical carcinoma
1012 VSTLNSEDFVLVSR brain, glioblastoma, kidney, angiomyolipoma
1013 VSTLNSEDFVLVSRQ brain, glioblastoma, kidney, angiomyolipoma
1014 VSTLNSEDFVLVSRQG brain, glioblastoma, kidney, angiomyolipoma
1015 GSSFFGELFNQNPE brain, glioblastoma, thyroid gland, papillary carcinoma
1016 SGSSFFGELFNQNPE brain, glioblastoma, thyroid gland, papillary carcinoma


[0012] Thus, disclosed is the use of the peptides as disclosed for the - preferably combined - treatment of a proliferative disease selected from the group of adrenal cortical adenoma; non-ossifying fibroma; brain cancer and a proliferative disease selected from kidney oncocytoma, kidney Wilm's tumor, lymph node malignant melanoma, and omentum leiomyosarcoma; glioblastoma and a proliferative disease selected from oligodendroglioma, kidney angiomyolipoma, liver hepatic adenoma, liver hepatocellular carcinoma, lung small cell carcinoma, parotid gland pleomorphic adenoma, pleura malignant mesothelioma, schwannoma, small intestine gastrointestinal stromal tumor (GIST), and thyroid gland papillary carcinoma; breast carcinoma; chondrosarcoma; colonal or rectal cancer and a proliferative disease selected from bone giant cell tumor of bone, bone, non-ossifying fibroma, breast mucinous carcinoma, colon adenocarcinoma, colon adenoma, endometrium adenocarcinoma endometrioid type, esophagus adenocarcinoma, kidney angiomyolipoma, kidney renal cell carcinoma, liposarcoma, liver hepatocellular carcinoma, ovary granulosa cell tumor, pancreas microcystic adenoma, pleura malignant mesothelioma, prostate benign nodular hyperplasia, spleen non-Hodgkin's lymphoma, stomach mucinous adenocarcinoma, thymus thymoma, malignant, thyroid gland nodular hyperplasia, urinary bladder, transitional cell carcinoma, and vulva squamous cell carcinoma; colon adenoma; esophagus adenocarcinoma; intestines malignant carcinoid tumor; intramuscular lipoma; kidney clear cell renal cell carcinoma and a proliferative disease selected from adrenal gland, adrenal cortical carcinoma, endometrium adenocarcinoma endometrioid type, endometrium adenocarcinoma endometrioid type, kidney angiomyolipoma leiomyosarcoma, lipoma liver hepatocellular carcinoma, lymph node Hodgkin's disease, non-Hodgkin's lymphoma, pancreas adenocarcinoma, parotid gland pleomorphic adenoma, prostate adenocarcinoma, rectum adenocarcinoma, spleen chronic myeloid leukemia, spleen non-Hodgkin's lymphoma, and thyroid gland follicular adenoma; kidney oncocytoma; kidney polycystic kidney disease; kidney renal cell carcinoma; lipoma; liver hepatocellular carcinoma and a proliferative disease selected from, adrenal gland adrenal cortical adenoma, breast carcinoma, liver focal nodular hyperplasia, cancer rectum adenocarcinoma, cancer thyroid gland, nodular hyperplasia, cancer thyroid gland, papillary carcinoma, colon non-Hodgkin's lymphoma, endometrium hyperplasia, hepatic adenoma, kidney carcinoma, kidney oncocytoma, lipoma, liposarcoma, liver focal nodular hyperplasia, liver hepatic adenoma, pleura malignant mesothelioma, neuroblastoma, pancreas adenocarcinoma, pancreas microcystic adenoma, parotid gland pleomorphic adenoma, pleura malignant mesothelioma, synovial sarcoma, thyroid gland nodular hyperplasia, and uterine cervix squamous cell carcinoma; lung, non-small cell lung carcinoma, and a proliferative disease selected from breast carcinoma, chondrosarcoma, kidney oncocytoma, liver hepatocellular carcinoma, lung adenocarcinoma, lymph node Hodgkin's disease, lymph node non-Hodgkin's lymphoma, lymph node papillary carcinoma of thyroid, omentum adenocarcinoma, ovary Mullerian mixed tumor, pancreas adenocarcinoma, testis mixed germ cell tumor, thymus thymoma benign, and thyroid gland, nodular hyperplasia; lymph node Hodgkin's disease; lymph node papillary carcinoma of thyroid; lymph node papillary carcinoma of thyroid metastatic; myometrium leiomyoma; non-Hodgkin's lymphoma; non-Hodgkin's lymphoma, peripheral T cell type or small lymphocytic type; pancreas adenocarcinoma and a proliferative disease selected from bone giant cell tumor of bone, colon adenocarcinoma, fibromatosis, intramuscular lipoma, kidney angiomyolipoma, kidney renal cell carcinoma, liver hepatic adenoma, lung adenocarcinoma, myometrium leiomyoma, non-Hodgkin's lymphoma small lymphocytic type, pancreas adenocarcinoma, prostate benign nodular hyperplasia, rectum adenocarcinoma, spleen chronic myeloid leukemia, and thymus, thymoma, malignant; rectum adenocarcinoma; spleen chronic myeloid leukemia; spleen extramedullary hematopoiesis; stomach, adenocarcinoma and a proliferative disease selected from, adrenal gland adrenal cortical adenoma, bone giant cell tumor of bone, bone non-ossifying fibroma, breast carcinoma, colon adenocarcinoma, colon non-Hodgkin's lymphoma, endometrium adenocarcinoma endometrioid, kidney angiomyolipoma, kidney carcinoma, kidney oncocytoma, liver, focal nodular hyperplasia, liver hepatocellular carcinoma, lymph node Hodgkin's disease, lymph node papillary carcinoma of thyroid, medullary carcinoma of thyroid origin, metastatic adenocarcinoma of stomach, neurofibroma, ovary thecoma-fibroma, pancreas adenocarcinoma, pancreas microcystic adenoma, parathyroid gland adenoma, rectum adenocarcinoma, skin squamous cell carcinoma, spleen chronic myeloid leukemia, stomach gastrointestinal stromal tumor (GIST), thyroid gland nodular hyperplasia, thyroid gland papillary carcinoma, uterin cervix squamous cell carcinoma, and white blood cells chronic lymphocytic leukemia; stomach gastrointestinal stromal tumor (GIST); stomach cancer metastatic and a proliferative disease selected from adrenal gland adrenal cortical carcinoma, thyroid gland papillary carcinoma, skin, squamous cell carcinoma, breast carcinoma, colon adenocarcinoma , endometrium Mullerian mixed tumor, kidney carcinoma, leiomyosarcoma, lung neuroendocrine carcinoma (non-small cell type), lymph node non-Hodgkin's lymphoma, non-Hodgkin's lymphoma, ovary Mullerian mixed tumor, pancreas adenocarcinoma, rectum adenocarcinoma, skin basal cell carcinoma, stomach gastrointestinal stromal tumor (GIST), and uterine cervix adenocarcinoma; testis seminoma; thymus benign thymoma; thyroid gland follicular adenoma; and thyroid gland nodular hyperplasia.

[0013] Disclosed is the use of the peptides as disclosed for the - preferably combined - preferred immunotherapy of diseases according to the following table 4.
Table 4: Preferred peptides and diseases to be treated. SEQ ID NO: 167 is according to the invention.
Seq IDSequenceTissue and disease
22 LEVEERTKPV lung, non-small cell lung carcinoma, breast, carcinoma
23 RDSPINANLRY lung, non-small cell lung carcinoma, breast, carcinoma
24 RPFVIVTA lung, non-small cell lung carcinoma, breast, carcinoma
25 RPIINTPMV lung, non-small cell lung carcinoma, breast, carcinoma
26 SPTSSRTSSL lung, non-small cell lung carcinoma, breast, carcinoma
27 ATSAPLVSR stomach, metastatic, lung, neuroendocrine carcinoma
114 YGNPRTNGM stomach, metastatic, breast, carcinoma
102 FSITKSVEL non-Hodgkin's lymphoma, small lymphocytic type
103 GQTKNDLVV non-Hodgkin's lymphoma, small lymphocytic type
104 LSQEVCRD non-Hodgkin's lymphoma, small lymphocytic type
105 RDIQSPEQI non-Hodgkin's lymphoma, small lymphocytic type
106 REDNSSNSL non-Hodgkin's lymphoma, small lymphocytic type
107 TEHQEPGL non-Hodgkin's lymphoma, small lymphocytic type
108 TKNDLVVSL non-Hodgkin's lymphoma, small lymphocytic type
977 AGREINLVDAHLKSE lymph node, Hodgkin's disease
979 GREINLVDAHLKSE lymph node, Hodgkin's disease
980 KPGIVYASLNHSVIG lymph node, Hodgkin's disease
220 RIHTGEKPYK colon or rectum, thyroid gland, nodular hyperplasia
53 APGSVLPRAL lymph node, Hodgkin's disease
54 DIKEHPLL lymph node, Hodgkin's disease
55 DSAGPQDAR lymph node, Hodgkin's disease
56 FQYAKESYI lymph node, Hodgkin's disease
57 KVLSWPFLM lymph node, Hodgkin's disease
58 LENDQSLSF lymph node, Hodgkin's disease
59 SPSRQPQV lymph node, Hodgkin's disease
60 SRHQSFTTK lymph node, Hodgkin's disease
61 SSHNASKTL lymph node, Hodgkin's disease
1003 DNQYAVLENQKSSH colon or rectum, pleura, malignant mesothelioma,
1004 GPPEIYSDTQFPS colon or rectum, pleura, malignant mesothelioma,
1005 GPPEIYSDTQFPSLQ colon or rectum, pleura, malignant mesothelioma,
1006 TPQGPPEIYSDTQFPS colon or rectum, pleura, malignant mesothelioma,
1007 TPQGPPEIYSDTQFPSLQ colon or rectum, pleura, malignant mesothelioma,
1008 TPQGPPEIYSDTQFPSLQST colon or rectum, pleura, malignant mesothelioma,
91 EHADDDPSL kidney, Wilm's tumor
92 SEESVKSTTL kidney, Wilm's tumor
93 SPRPPLGSSL kidney, Wilm's tumor
94 SPWWRSSL kidney, Wilm's tumor
95 VYTPVDSLVF kidney, Wilm's tumor
18 DALLKRTM stomach, metastatic, skin, basal cell carcinoma
19 GEDVRSALL stomach, metastatic, skin, basal cell carcinoma
20 KFAEEFYSF stomach, metastatic, skin, basal cell carcinoma
21 YGYDNVKEY stomach, metastatic, skin, basal cell carcinoma
661 EYVSLYHQPAAM non-Hodgkin's lymphoma, peripheral T cell type
664 LPYLFQMPAYASSS non-Hodgkin's lymphoma, peripheral T cell type
665 LPYLFQMPAYASSSK non-Hodgkin's lymphoma, peripheral T cell type
666 NFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
667 TNFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
668 TTNFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
780 DNGHLYREDQTSPAPG kidney, angiomyolipoma
781 DNGHLYREDQTSPAPGLR kidney, angiomyolipoma
782 EVQVFAPANALPARSE kidney, angiomyolipoma
783 GHLYREDQTSPAPG kidney, angiomyolipoma
784 LPARSEAAAVQPVIG kidney, angiomyolipoma
785 NGHLYREDQTSPAPG kidney, angiomyolipoma
786 NGHLYREDQTSPAPGL kidney, angiomyolipoma
787 NGHLYREDQTSPAPGLR kidney, angiomyolipoma
788 VFAPANALPARSEAA kidney, angiomyolipoma
789 VQVFAPANALPARSE kidney, angiomyolipoma
178 HEIDRYTAI non-Hodgkin's lymphoma, follicular type,
179 VFTLKPLEF non-Hodgkin's lymphoma, follicular type,
180 YWVPRNAL non-Hodgkin's lymphoma, follicular type,
694 DGELIRTQPQRLPQ pancreas, adenocarcinoma, intramuscular lipoma
695 GELIRTQPQRLPQ pancreas, adenocarcinoma, intramuscular lipoma
696 NPSDGELIRTQPQRLP pancreas, adenocarcinoma, intramuscular lipoma
697 NPSDGELIRTQPQRLPQ pancreas, adenocarcinoma, intramuscular lipoma
698 NPSDGELIRTQPQRLPQL pancreas, adenocarcinoma, intramuscular lipoma
922 FDFSQNTRVPRLPE non-Hodgkin's lymphoma, follicular type
923 GDAPAILFDKEF non-Hodgkin's lymphoma, follicular type
924 VTHEIDRYTAIAY non-Hodgkin's lymphoma, follicular type
692 DAGSYKAQINQRNFE lymph node, non-Hodgkin's lymphoma
693 DAGSYKAQINQRNFEVT lymph node, non-Hodgkin's lymphoma
1 AEHPNVTLTI spleen, non-Hodgkin's lymphoma
2 FLAEHPNVTL spleen, non-Hodgkin's lymphoma
4 EVAEFLARH spleen, non-Hodgkin's lymphoma
5 RHSNVNLTI spleen, non-Hodgkin's lymphoma
222 QSTQRSLAL uterine cervix, squamous cell carcinoma
223 RDLQMNQALRF uterine cervix, squamous cell carcinoma
224 RELESQLHVL uterine cervix, squamous cell carcinoma
225 SEAEKLTLV uterine cervix, squamous cell carcinoma
6 HPDNVKLFL pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
7 ISDTGELKL pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
8 KVNGKLVALK pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
9 NRLSAQAAL pancreas, pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
10 TPFTAIREA pancreas, pancreas, adenocarcinoma, non-Hodgkin's lymphoma, small lymphocytic type
11 FGLARAKSV kidney, clear cell renal cell carcinoma, kidney, renal cell carcinoma, clear cell type
12 KIADFGLAR brain, glioblastoma, liver, hepatocellular carcinoma
812 DGSYRIFSKGASE colon or rectum, liposarcoma
813 GSYRIFSKGASE colon or rectum, liposarcoma
814 SDGSYRIFSKGASE colon or rectum, liposarcoma
815 SVKKMMKDNNLVRH colon or rectum, liver, hepatocellular carcinoma
816 VKKMMKDNNLVRH colon or rectum, liver, hepatocellular carcinoma
145 KITVPASQK colon, non-Hodgkin's lymphoma
146 KITVPASQKL colon, non-Hodgkin's lymphoma
147 VPASQKLRQL colon, non-Hodgkin's lymphoma
537 ITARPVLW non-Hodgkin's lymphoma, diffuse large B-cell type
538 KLMSPKLYVW non-Hodgkin's lymphoma, diffuse large B-cell type
539 KVSAVTLAY non-Hodgkin's lymphoma, diffuse large B-cell type
540 VEGSGELFRW non-Hodgkin's lymphoma, diffuse large B-cell type
672 ADLSSFKSQELN lymph node, papillary carcinoma of thyroid, metastatic
673 ADLSSFKSQELNER lymph node, papillary carcinoma of thyroid, metastatic
674 ADLSSFKSQELNERN lymph node, papillary carcinoma of thyroid, metastatic
679 ISQELEELRAEQQR lymph node, papillary carcinoma of thyroid, metastatic
680 ISQELEELRAEQQRLK lymph node, papillary carcinoma of thyroid, metastatic
681 KGTKQWVHARYA lymph node, papillary carcinoma of thyroid, metastatic
682 QADLSSFKSQELNER lymph node, papillary carcinoma of thyroid, metastatic
684 TGSWIGLRNLDLKG lymph node, papillary carcinoma of thyroid, metastatic
743 AIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
744 ARNFERNKAIKVI non-Hodgkin's lymphoma, peripheral T cell type
745 ARNFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
746 NFERNKAIKVII non-Hodgkin's lymphoma, peripheral T cell type
747 NFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
748 VAIVQAVSAHRH non-Hodgkin's lymphoma, peripheral T cell type
749 VAIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
750 VAIVQAVSAHRHRA non-Hodgkin's lymphoma, peripheral T cell type
818 VDKVLERDQKLSE lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
819 VDKVLERDQKLSELD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
820 VDKVLERDQKLSELDD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
821 VDKVLERDQKLSELDDR stomach, diffuse subtype adenocarcinoma, lymph node, papillary carcinoma of thyroid, metastatic
822 VLERDQKLSELDDR lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
833 VDKVLERDQKLSE lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
834 VDKVLERDQKLSELD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, etastatic
835 VDKVLERDQKLSELDD lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
836 VDKVLERDQKLSELDDR stomach, diffuse subtype adenocarcinoma, lymph node, papillary carcinoma of thyroid, metastatic
837 VLERDQKLSELDDR lung, non-small cell lung carcinoma, lymph node, papillary carcinoma of thyroid, metastatic
848 DDPAIDVCKKLLGKYPN kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
849 DKQPYSKLPGVSLLKP kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
850 DKQPYSKLPGVSLLKPL kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
851 HPRYYISANVTGFK kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
852 SHPRYYISANVTG kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
853 SHPRYYISANVTGFK kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
854 TSHPRYYISANVTG kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
855 TSHPRYYISANVTGFK kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
908 DVGMFVALTKLGQPD stomach, differentiated subtype adenocarcinoma,
    uterine cervix, squamous cell carcinoma,
909 VGMFVALTKLGQPD stomach, differentiated subtype adenocarcinoma, uterine cervix, squamous cell carcinoma
1015 GSSFFGELFNQNPE brain, glioblastoma, thyroid gland, papillary carcinoma
1016 SGSSFFGELFNQNPE brain, glioblastoma, thyroid gland, papillary carcinoma
466 DEMRFVTQI testis, mixed germ cell tumor
467 ETVHFATTQW testis, mixed germ cell tumor
468 LPPPATQI testis, mixed germ cell tumor
633 GNPAYRSFSNSLSQ kidney, angiomyolipoma
634 GPPGEAGYKAFSSLLA kidney, angiomyolipoma
635 GPPGEAGYKAFSSLLASS kidney, angiomyolipoma
636 GPPGEAGYKAFSSLLASSA kidney, angiomyolipoma
637

 
kidney, angiomyolipoma
638

 
kidney, angiomyolipoma
639 GYKAFSSLLASSAVSP kidney, angiomyolipoma
640 GYKAFSSLLASSAVSPE kidney, angiomyolipoma
641 KAFSSLLASSAVSPE kidney, angiomyolipoma
642 NPAYRSFSNSLSQ kidney, angiomyolipoma
643 SRDDFQEGREGIVAR kidney, angiomyolipoma
644 SSSSFHPAPGNAQ kidney, angiomyolipoma
645 VARLTESLFLDL kidney, angiomyolipoma
646 VARLTESLFLDLLG kidney, angiomyolipoma
647 VIAGNPAYRSFSN kidney, angiomyolipoma
648 VPQPEPETWEQILRRNVLQ kidney, angiomyolipoma
649 YKAFSSLLASSAVS kidney, angiomyolipoma
650 YKAFSSLLASSAVSP kidney, angiomyolipoma
651 YKAFSSLLASSAVSPE kidney, angiomyolipoma
992 EDDYIKSWEDNQQGDE pleura, malignant mesothelioma
993 ELERIQIQEAAKKKPG pleura, malignant mesothelioma
994 ERIQIQEAAKKKP pleura, malignant mesothelioma
995 ERIQIQEAAKKKPG pleura, malignant mesothelioma
996 ERIQIQEAAKKKPGI pleura, malignant mesothelioma
997 LERIQIQEAAKKKPG pleura, malignant mesothelioma
998 LSSISQYSGKIK pleura, malignant mesothelioma
941 EERNLLSVAYKNVVGAR colon or rectum,
    esophagus, adenocarcinoma,
942 ERNLLSVAYKNVVGAR colon or rectum,
    esophagus, adenocarcinoma,
943 IAELDTLSEESYKD colon or rectum, vulva, squamous cell carcinoma,
944 IAELDTLSEESYKDS colon or rectum, vulva, squamous cell carcinoma,
218 GDYGRAFNL stomach, metastatic, lymph node, non-Hodgkin's lymphoma, small lymphocytic type
219 TRHKIVHTK stomach, metastatic, lymph node, non-Hodgkin's lymphoma, small lymphocytic type
221 KAFNWFSTL stomach, metastatic, lymph node, non-Hodgkin's lymphoma, small lymphocytic type
541 RPKSNIVL non-Hodgkin's lymphoma, diffuse large B-cell type
542 RPKSNIVLL non-Hodgkin's lymphoma, diffuse large B-cell type
1001 INSRFPIPSATDPD brain, glioblastoma, brain, oligodendroglioma,
1002 VQHYELLNGQSVFG brain, glioblastoma, brain, oligodendroglioma,
910 AGVFHVEKNGRY stomach, diffuse subtype adenocarcinoma, colon, adenocarcinoma
911 FAGVFHVEKNGRYS stomach, diffuse subtype adenocarcinoma, colon, adenocarcinoma
912 GPITITIVNRDGTR stomach, diffuse subtype adenocarcinoma, colon, adenocarcinoma
913 NGRYSISRTEAADL stomach, diffuse subtype adenocarcinoma, colon, adenocarcinoma
45 DELPKFHQY stomach, adenocarcinoma, white blood cells, chronic lymphocytic leukemia
46 DVTGQFPSSF white blood cells, chronic lymphocytic leukemia
47 EHSRVLQQL white blood cells, chronic lymphocytic leukemia
48 IKVSKQLL white blood cells, chronic lymphocytic leukemia
49 KPRQSSPQL white blood cells, chronic lymphocytic leukemia
50 KQLLAALEI white blood cells, chronic lymphocytic leukemia
51 RRKDLVLKY liver, focalnodular hyperplasia
52 RTRDYASLPPK white blood cells, chronic lymphocytic leukemia
124 GQKEALLKY liver, hepatocellular carcinoma, synovial sarcoma
125 KPSEERKTI liver, hepatocellular carcinoma, synovial sarcoma
126 KQTPKVLVV liver, hepatocellular carcinoma, synovial sarcoma
127 SVIQHVQSF liver, hepatocellular carcinoma, synovial sarcoma
128 TPIERIPYL liver, hepatocellular carcinoma, synovial sarcoma
773 LPEFYKTVSPAL colon or rectum, endometrium, adenocarcinoma, endometrioid type
774 VGQFIQDVKNSRST colon or rectum, endometrium, adenocarcinoma, endometrioid type
775 VGQFIQDVKNSRSTD colon or rectum, endometrium, adenocarcinoma, endometrioid type
776 WGQFIQDVKNSRS colon or rectum, endometrium, adenocarcinoma, endometrioid type
777 WGQFIQDVKNSRST colon or rectum, endometrium, adenocarcinoma, endometrioid type
778 WGQFIQDVKNSRSTD colon or rectum, endometrium, adenocarcinoma, endometrioid type
779 WGQFIQDVKNSRSTDS colon or rectum, endometrium, adenocarcinoma, endometrioid type
685

 
pancreas, adenocarcinoma, thymus, thymoma, malignant
686

 
pancreas, adenocarcinoma, thymus, thymoma, malignant
687 GPMKGGNFGGRSSGP pancreas, adenocarcinoma, thymus, thymoma, malignant
688 GPYGGGGQYFAKP pancreas, adenocarcinoma, thymus, thymoma, malignant
689 KGGNFGGRSSGP pancreas, adenocarcinoma, thymus, thymoma, malignant
690 NDFGNYNNQSSNFGP pancreas, adenocarcinoma, thymus, thymoma, malignant
691 SGPYGGGGQYFAKP pancreas, adenocarcinoma, thymus, thymoma, malignant
13 AAANIIRTL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma
14 GRFKNLREAL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma,
15 MSPFSKATL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma,
16 QEDPGDNQITL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma,
17 SPFSKATL liver, hepatocellular carcinoma, adrenal gland, adrenal cortical carcinoma,
129 AEVEKNETV kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
130 EVKEEIPLV kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
131 KPTSARSGL kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
132 KYIETTPLTI kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
133 SEIKTSIEV kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
134 SVKPTSATK kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
135 YPNKGVGQA kidney, clear cell renal cell carcinoma, spleen, non-Hodgkin's lymphoma, follicular type
966 ENNEIISNIRDSVIN stomach, adenocarcinoma, kidney, oncocytoma
967 NNEIISNIRDSVIN stomach, adenocarcinoma, kidney, oncocytoma
968 SPTVQVFSASGKPV stomach, adenocarcinoma, kidney, oncocytoma
969 SSPTVQVFSASGKPVE stomach, adenocarcinoma, kidney, oncocytoma
830 DIMRVNVDKVLERDQK stomach, diffuse subtype adenocarcinoma, Medullary carcinoma of thyroid Origin
831 DIMRVNVDKVLERDQKL stomach, diffuse subtype adenocarcinoma, medullary carcinoma
832 IMRVNVDKVLERDQK lung, non-small cell lung carcinoma, lymph node, Hodgkin's disease
752 EEVITLIRSNQQLE pancreas, adenocarcinoma
753 EEVITLIRSNQQLEN pancreas, adenocarcinoma
754 IPADTFAALKNPNAML pancreas, adenocarcinoma
755 LKQLLSDKQQKRQSG pancreas, adenocarcinoma
756 LKQLLSDKQQKRQSGQ pancreas, adenocarcinoma
118 DEHLLIQHY parotid gland, pleomorphic adenoma
119 KQVASSTGF parotid gland, pleomorphic adenoma
120 RDFGPASQHFL parotid gland, pleomorphic adenoma
121 RQLGEVASF parotid gland, pleomorphic adenoma
122 TEAETTANVL parotid gland, pleomorphic adenoma
123 GYLPVQTVL kidney, clear cell renal cell carcinoma, parotid gland, pleomorphic adenoma
987 TRPYHSLPSEAVFA adrenal gland, adrenal cortical adenoma
988 TRPYHSLPSEAVFAN adrenal gland, adrenal cortical adenoma
989 VAVFTFHNHGRT adrenal gland, adrenal cortical adenoma
990 VAVFTFHNHGRTA adrenal gland, adrenal cortical adenoma
991 VAVFTFHNHGRTANL adrenal gland, adrenal cortical adenoma
339 FLDPDIGGVAV kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
340 HTAPPENKTW kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
341 LLDTPVKTQY kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
342 NAVKDFTSF kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
343 SGLLQIKKL kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
344 YHDKNIVLL kidney, clear cell renal cell carcinoma, pancreas, adenocarcinoma
71 HLKSIPVSL kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
72 KVWYNVENW kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
73 LPAYRAQLL kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
74 LSEQTSVPL kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
75 SLNQWLVSF kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
76 SMTSLAQKI kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
77 SSSGLHPPK kidney, clear cell renal cell carcinoma, prostate, adenocarcinoma
578 GGGYGSGGGSGGYGSRRF colon or rectum, thymus, thymoma, malignant,
579 GGSFGGRSSGSP colon or rectum, thymus, thymoma, malignant
580 KGGSFGGRSSGSP colon or rectum, thymus, thymoma, malignant
581

 
colon or rectum, thymus, thymoma, malignant
582

 
colon or rectum, thymus, thymoma, malignant
583

 
colon or rectum, thymus, thymoma, malignant
584

 
colon or rectum, thymus, thymoma, malignant
84 VPVPHTTAL kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
85 YQVLDVQRY kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
731 DGLNSLTYQVLDVQRYPL kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
732 HPVLQRQQLDYGIY kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
733 LNSLTYQVLDVQR kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
734 LNSLTYQVLDVQRYP kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
735 LNSLTYQVLDVQRYPL kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
736 LPQLVGVSTPLQG kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
737 LPQLVGVSTPLQGG kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
738 LPQLVGVSTPLQGGS kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
739 RLPQLVGVSTPLQGGS kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
740 SPHKVAIIIPFRNR kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
741 SPHKVAIIIPFRNRQE kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
742 SPHKVAIIIPFRNRQEH kidney, clear cell renal cell carcinoma, endometrium, adenocarcinoma, endometrioid type
527 DEKQQHIVY liver, hepatocellular carcinoma, synovial sarcoma
528 DEVYQVTVY liver, hepatocellular carcinoma, synovial sarcoma
529 GEISEKAKL liver, hepatocellular carcinoma, synovial sarcoma
530 YTMKEVLFY liver, hepatocellular carcinoma, synovial sarcoma
203 GPRPITQSEL lymph node, non-Hodgkin's lymphoma, marginal zone B-cell type
204 KPEPVDKVA lymph node, non-Hodgkin's lymphoma
205 TPSSRPASL lymph node, non-Hodgkin's lymphoma
949 SPPQFRVNGAISN ovary, granulosa cell tumor
950 SPPQFRVNGAISNFE ovary, granulosa cell tumor
951 SPPQFRVNGAISNFEE ovary, granulosa cell tumor
952 SPPQFRVNGAISNFEEF ovary, granulosa cell tumor
953 VGKMFVDVYFQEDKK ovary, granulosa cell tumor
954 VGKmFVDVYFQEDKKE ovary, granulosa cell tumor
916 EEFKKLTSIKIQNDK brain, glioblastoma, small intestine, gastrointestinal stromal tumor (GIST)
917 INRRMADDNKLFR brain, glioblastoma, small intestine, gastrointestinal stromal tumor (GIST)
918 TATIVMVTNLKERKE brain, glioblastoma, small intestine, gastrointestinal stromal tumor (GIST)
526 RINEFSISSF chondrosarcoma
585 GNRINEFSISSF chondrosarcoma
586 HGNQITSDKVGRKV chondrosarcoma
587 IPPVNTNLENLYLQ chondrosarcoma
588 LQVLRLDGNEIKR chondrosarcoma
589 LQVLRLDGNEIKRS chondrosarcoma
590 LQVLRLDGNEIKRSA chondrosarcoma
592 LYVRLSHNSLTNNG chondrosarcoma
596 WIALHGNQITSD chondrosarcoma
597 WIALHGNQITSDK chondrosarcoma
165 ELNKLLEEI ovary, adenocarcinoma
166 IPFSNPRVL ovary, adenocarcinoma
167 LLDEGAKLLY ovary, adenocarcinoma
168 SPADAHRNL ovary, adenocarcinoma
96 APLQRSQSL kidney, renal cell carcinoma, clear cell type
97 DEVHQDTY kidney, renal cell carcinoma, clear cell type
98 LPHSATVTL kidney, renal cell carcinoma, clear cell type
152 APSEYRYTL stomach, mucinous adenocarcinoma
153 APSEYRYTLL stomach, mucinous adenocarcinoma
154 EIFQNEVAR stomach, mucinous adenocarcinoma
155 KDVLIPGKL stomach, mucinous adenocarcinoma
156 VPLVREITF stomach, mucinous adenocarcinoma
62 EEIDTTMRW liver, hepatocellular carcinoma, lipoma
63 ILDEKPVII liver, hepatocellular carcinoma, lipoma
64 LPQEPRTSL liver, hepatocellular carcinoma, lipoma
65 LTYKLPVA liver, hepatocellular carcinoma, lipoma
66 NEMELAHSSF liver, hepatocellular carcinoma, lipoma
67 REFPEANFEL liver, hepatocellular carcinoma, lipoma
68 THHIPDAKL liver, hepatocellular carcinoma, lipoma
69 TVKENLSLF liver, hepatocellular carcinoma, lipoma
70 VLLKKAVL liver, hepatocellular carcinoma, lipoma
136 ISMKILNSL lung, non-small cell lung carcinoma, thymus, thymoma
137 KTIAFLLPMF lung, non-small cell lung carcinoma, thymus, thymoma
138 RDSIINDF lung, non-small cell lung carcinoma, thymus, thymoma
139 SVKGGGGNEK lung, non-small cell lung carcinoma, thymus, thymoma
140 GIAKTGSGK lung, non-small cell lung carcinoma, thymus, thymoma
503 ALYATKTLR pancreas, microcystic adenoma
504 MEYVISRI pancreas, microcystic adenoma
505 VPVGRQPII pancreas, microcystic adenoma
278 ATNGDLASR pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
279 GLHAEVTGVGY pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
280 HVSSTSSSF pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
281 LQADLQNGL pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
282 SELPVSEVA pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
283 SQTKSVFEI pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
284 THIFTSDGL pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
285 VIYFPPLQK pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
286 YPFSSEQKW pancreas, adenocarcinoma, prostate, benign nodular hyperplasia
78 DLDVKKMPL kidney, carcinoma
79 FYTVIPHNF kidney, carcinoma
80 HHINTDNPSL kidney, carcinoma
81 RVGEVGQSK kidney, carcinoma
28 AELRSTASLL lipoma
29 APASSHERASM lipoma
30 ASRQAPPHI lipoma
31 AVKKNPGIAA lipoma
32 EEHLESHKKY lipoma
33 GEFTSARAV lipoma
34 GQSTPRLFSI lipoma
35 LVDDPLEY lipoma
36 RPKNLMQTL lipoma
37 RQAPPHIEL lipoma
38 SEAAELRSTA lipoma
490 DSIGSTVSSER stomach, adenocarcinoma, signet ring cell type,
491 LPYNNKDRDAL stomach, adenocarcinoma, signet ring cell type,
215 DAMKRVEEI ovary, thecoma-fibroma
216 DIKEVKQNI ovary, thecoma-fibroma
217 GPIYPGHGM ovary, thecoma-fibroma
963 GNTVIHLDQALARMR lung, small cell carcinoma
964 NTVIHLDQALARMR lung, small cell carcinoma
965 NTVIHLDQALARMRE lung, small cell carcinoma
187 AADTERLAL chondrosarcoma
188 DMKAKVASL chondrosarcoma
189 HVLEEVQQV chondrosarcoma
190 KEAADTERL chondrosarcoma
191 RISEVLQKL chondrosarcoma
192 TEVRELVSL chondrosarcoma
875 SVEEFLSEKLERI liver, hepatic adenoma
876 VEEFLSEKLERI liver, hepatic adenoma
973 ADDLEGEAFLPL spleen, chronic myeloid leukemia
974 ADDLEGEAFLPLR spleen, chronic myeloid leukemia
975 ADDLEGEAFLPLRE spleen, chronic myeloid leukemia
976 GADDLEGEAFLPLR spleen, chronic myeloid leukemia
141 AETTDNVFTL kidney, clear cell renal cell carcinoma, thyroid gland, follicular adenoma
142 SEYQRFAVM kidney, clear cell renal cell carcinoma, thyroid gland, follicular adenoma
143 TFGERWAF kidney, clear cell renal cell carcinoma, thyroid gland, follicular adenoma
144 NENLVERF stomach, colon, adenocarcinoma, mucinous type
117 QLFSYAILGF liver, hepatocellular carcinoma, colon, non-Hodgkin's lymphoma
845 GIRVAPVPLYNS lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
846 GIRVAPVPLYNSFH lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
847 NPNGIRVAPVPLYNSFH lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
478 AAVPVIISR lymph node, papillary carcinoma of thyroid, metastatic
479 EEIGKVAAA lymph node, papillary carcinoma of thyroid, metastatic
480 FLKDLVASV lymph node, papillary carcinoma of thyroid, metastatic
481 VIISRALEL lymph node, papillary carcinoma of thyroid, metastatic
420 QIDYKTLVL stomach, metastatic, leiomyosarcoma
421 VEDPTIVRI stomach, metastatic, leiomyosarcoma
543 GEPLSYTRFSLARQ lung, non-small cell lung carcinoma, lung, adenocarcinoma
544 GEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
545 GEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
546 GGEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
547 GGEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
548 NPGGYVAYSKAATVTG lung, non-small cell lung carcinoma, lung, adenocarcinoma
549 NPGGYVAYSKAATVTGK lung, non-small cell lung carcinoma, lung, adenocarcinoma
550 NPGGYVAYSKAATVTGKL lung, non-small cell lung carcinoma, lung, adenocarcinoma
551 NSVIIVDKNGRL lung, non-small cell lung carcinoma, lung, adenocarcinoma
552 NSVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
553 NSVIIVDKNGRLVY lung, non-small cell lung carcinoma, lung, adenocarcinoma
554 RVEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
555 RVEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
556 RVEYHFLSPYVSPKESPF lung, non-small cell lung carcinoma, lung, adenocarcinoma
557 SPFRHVFWGSGSHTL lung, non-small cell lung carcinoma, lung, adenocarcinoma
558 SVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
559 VEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
560 VEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
388 AEGPAGGFMW spleen, chronic myeloid leukemia
389 AYYRDAEAY spleen, chronic myeloid leukemia
390 QVNRPLTMR spleen, chronic myeloid leukemia
391 RHSPVFQVY spleen, chronic myeloid leukemia
392 SLPVPNSAY spleen, chronic myeloid leukemia
393 TLGPPGTAHLY spleen, chronic myeloid leukemia
308 VLYVGSKTK schwannoma
309 KTKEQVTNV schwannoma
310 MPVDPDNEAY schwannoma
311 AEKTKQGVA schwannoma
446 EAFEFVKQR stomach, adenocarcinoma, breast, carcinoma
447 NHFEGHYQY stomach, adenocarcinoma, breast, carcinoma


[0014] Disclosed is the use of the peptides as disclosed for the - preferably combined - more preferred immunotherapy of diseases according to the following table 5.
Table 5: More preferred peptides and diseases to be treated. SEQ ID NO: 167 is according to the invention.
Seq IDSequenceTissue and disease
22 LEVEERTKPV breast, carcinoma
23 RDSPINANLRY breast, carcinoma
24 RPFVIVTA breast, carcinoma
25 RPIINTPMV breast, carcinoma
26 SPTSSRTSSL breast, carcinoma
27 ATSAPLVSR lung, neuroendocrine carcinoma
114 YGNPRTNGM breast, carcinoma
102 FSITKSVEL non-Hodgkin's lymphoma, small lymphocytic type
103 GQTKNDLVV non-Hodgkin's lymphoma, small lymphocytic type
104 LSQEVCRD non-Hodgkin's lymphoma, small lymphocytic type
105 RDIQSPEQI non-Hodgkin's lymphoma, small lymphocytic type
106 REDNSSNSL non-Hodgkin's lymphoma, small lymphocytic type
107 TEHQEPGL non-Hodgkin's lymphoma, small lymphocytic type
108 TKNDLVVSL non-Hodgkin's lymphoma, small lymphocytic type
977 AGREINLVDAHLKSE lymph node, Hodgkin's disease
978 AGREINLVDAHLKSEQT lymph node, Hodgkin's disease
979 GREINLVDAHLKSE lymph node, Hodgkin's disease
980 KPGIVYASLNHSVIG lymph node, Hodgkin's disease
981 NKPGIVYASLNHSVIG lymph node, Hodgkin's disease
982 TTLYVTDVKSASERPS lymph node, Hodgkin's disease
220 RIHTGEKPYK thyroid gland, nodular hyperplasia
53 APGSVLPRAL lymph node, Hodgkin's disease
54 DIKEHPLL lymph node, Hodgkin's disease
55 DSAGPQDAR lymph node, Hodgkin's disease
56 FQYAKESYI lymph node, Hodgkin's disease
57 KVLSWPFLM lymph node, Hodgkin's disease
58 LENDQSLSF lymph node, Hodgkin's disease
59 SPSRQPQV lymph node, Hodgkin's disease
60 SRHQSFTTK lymph node, Hodgkin's disease
61 SSHNASKTL lymph node, Hodgkin's disease
1003 DNQYAVLENQKSSH pleura, malignant mesothelioma
1004 GPPEIYSDTQFPS pleura, malignant mesothelioma
1005 GPPEIYSDTQFPSLQ pleura, malignant mesothelioma
1006 TPQGPPEIYSDTQFPS pleura, malignant mesothelioma
1007 TPQGPPEIYSDTQFPSLQ pleura, malignant mesothelioma
1008

 
pleura, malignant mesothelioma
91 EHADDDPSL kidney, Wilm's tumor
92 SEESVKSTTL kidney, Wilm's tumor
93 SPRPPLGSSL kidney, Wilm's tumor
94 SPWWRSSL kidney, Wilm's tumor
95 VYTPVDSLVF kidney, Wilm's tumor
18 DALLKRTM skin, basal cell carcinoma
19 GEDVRSALL skin, basal cell carcinoma
20 KFAEEFYSF skin, basal cell carcinoma
21 YGYDNVKEY skin, basal cell carcinoma
661 EYVSLYHQPAAM non-Hodgkin's lymphoma, peripheral T cell type,
662 IKAEYKGRVTLKQYPR non-Hodgkin's lymphoma, peripheral T cell type
663 LNVHSEYEPSWEEQP non-Hodgkin's lymphoma, peripheral T cell type
664 LPYLFQmPAYASSS non-Hodgkin's lymphoma, peripheral T cell type
665 LPYLFQmPAYASSSK non-Hodgkin's lymphoma, peripheral T cell type
666 NFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
667 TNFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
668 TTNFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
669 VTLNVHSEYEPSWEEQP non-Hodgkin's lymphoma, peripheral T cell type
670 YPRKNLFLVEVTQLTESDS non-Hodgkin's lymphoma, peripheral T cell type
671

 
non-Hodgkin's lymphoma, peripheral T cell type
780 DNGHLYREDQTSPAPG kidney, angiomyolipoma
781 DNGHLYREDQTSPAPGLR kidney, angiomyolipoma
782 EVQVFAPANALPARSE kidney, angiomyolipoma
783 GHLYREDQTSPAPG kidney, angiomyolipoma
784 LPARSEAAAVQPVIG kidney, angiomyolipoma
785 NGHLYREDQTSPAPG kidney, angiomyolipoma
786 NGHLYREDQTSPAPGL kidney, angiomyolipoma
787 NGHLYREDQTSPAPGLR kidney, angiomyolipoma
788 VFAPANALPARSEAA kidney, angiomyolipoma
789 VQVFAPANALPARSE kidney, angiomyolipoma
178 HEIDRYTAI non-Hodgkin's lymphoma
179 VFTLKPLEF non-Hodgkin's lymphoma
180 YWVPRNAL non-Hodgkin's lymphoma
694 DGELIRTQPQRLPQ intramuscular lipoma
695 GELIRTQPQRLPQ intramuscular lipoma
696 NPSDGELIRTQPQRLP intramuscular lipoma
697 NPSDGELIRTQPQRLPQ intramuscular lipoma
698 NPSDGELIRTQPQRLPQL intramuscular lipoma
922 FDFSQNTRVPRLPE non-Hodgkin's lymphoma
923 GDAPAILFDKEF non-Hodgkin's lymphoma
924 VTHEIDRYTAIAY non-Hodgkin's lymphoma
692 DAGSYKAQINQRNFE lymph node, non-Hodgkin's lymphoma
693 DAGSYKAQINQRNFEVT lymph node, non-Hodgkin's lymphoma
1 AEHPNVTLTI spleen, non-Hodgkin's lymphoma
2 FLAEHPNVTL spleen, non-Hodgkin's lymphoma
4 EVAEFLARH spleen, non-Hodgkin's lymphoma
5 RHSNVNLTI spleen, non-Hodgkin's lymphoma
222 QSTQRSLAL uterine cervix, squamous cell carcinoma
223 RDLQMNQALRF uterine cervix, squamous cell carcinoma
224 RELESQLHVL uterine cervix, squamous cell carcinoma
225 SEAEKLTLV uterine cervix, squamous cell carcinoma
6 HPDNVKLFL non-Hodgkin's lymphoma, small lymphocytic type
7 ISDTGELKL non-Hodgkin's lymphoma, small lymphocytic type
8 KVNGKLVALK non-Hodgkin's lymphoma, small lymphocytic type
9 NRLSAQAAL non-Hodgkin's lymphoma, small lymphocytic type
10 TPFTAIREA non-Hodgkin's lymphoma, small lymphocytic type
11 FGLARAKSV kidney, renal cell carcinoma, clear cell type
12 KIADFGLAR liver, hepatocellular carcinoma
812 DGSYRIFSKGASE liposarcoma
813 GSYRIFSKGASE liposarcoma
814 SDGSYRIFSKGASE liposarcoma
815 SVKKMMKDNNLVRH liver, hepatocellular carcinoma
816 VKKMMKDNNLVRH liver, hepatocellular carcinoma
145 KITVPASQK colon, non-Hodgkin's lymphoma
146 KITVPASQKL colon, non-Hodgkin's lymphoma
147 VPASQKLRQL colon, non-Hodgkin's lymphoma
537 ITARPVLW non-Hodgkin's lymphoma, diffuse large B-cell type
538 KLMSPKLYVW non-Hodgkin's lymphoma, diffuse large B-cell type
539 KVSAVTLAY non-Hodgkin's lymphoma, diffuse large B-cell type
540 VEGSGELFRW non-Hodgkin's lymphoma, diffuse large B-cell type
672 ADLSSFKSQELN lymph node, papillary carcinoma of thyroid, metastatic
673 ADLSSFKSQELNER lymph node, papillary carcinoma of thyroid, metastatic
674 ADLSSFKSQELNERN lymph node, papillary carcinoma of thyroid, metastatic
675 ADLSSFKSQELNERNE lymph node, papillary carcinoma of thyroid, metastatic
676 ADLSSFKSQELNERNEA lymph node, papillary carcinoma of thyroid, metastatic
677

 
lymph node, papillary carcinoma of thyroid, metastatic
678 EQQRLKSQDLELSWN lymph node, papillary carcinoma of thyroid, metastatic
679 ISQELEELRAEQQR lymph node, papillary carcinoma of thyroid, metastatic
680 ISQELEELRAEQQRLK lymph node, papillary carcinoma of thyroid, metastatic
681 KGTKQWVHARYA lymph node, papillary carcinoma of thyroid, metastatic
682 QADLSSFKSQELNER lymph node, papillary carcinoma of thyroid, metastatic
683 SWNLNGLQADLSSFK lymph node, papillary carcinoma of thyroid, metastatic
684 TGSWIGLRNLDLKG lymph node, papillary carcinoma of thyroid, metastatic
743 AIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
744 ARNFERNKAIKVI non-Hodgkin's lymphoma, peripheral T cell type
745 ARNFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
746 NFERNKAIKVII non-Hodgkin's lymphoma, peripheral T cell type
747 NFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
748 VAIVQAVSAHRH non-Hodgkin's lymphoma, peripheral T cell type
749 VAIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
750 VAIVQAVSAHRHRA non-Hodgkin's lymphoma, peripheral T cell type
751 VAIVQAVSAHRHRAR non-Hodgkin's lymphoma, peripheral T cell type
818 VDKVLERDQKLSE lymph node, papillary carcinoma of thyroid, metastatic
819 VDKVLERDQKLSELD lymph node, papillary carcinoma of thyroid, metastatic
820 VDKVLERDQKLSELDD lymph node, papillary carcinoma of thyroid, metastatic
821 VDKVLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
822 VLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
833 VDKVLERDQKLSE lymph node, papillary carcinoma of thyroid, metastatic
834 VDKVLERDQKLSELD lymph node, papillary carcinoma of thyroid, metastatic
835 VDKVLERDQKLSELDD lymph node, papillary carcinoma of thyroid, metastatic
836 VDKVLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
837 VLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
848 DDPAIDVCKKLLGKYPN pancreas, adenocarcinoma
849 DKQPYSKLPGVSLLKP pancreas, adenocarcinoma
850 DKQPYSKLPGVSLLKPL pancreas, adenocarcinoma
851 HPRYYISANVTGFK pancreas, adenocarcinoma
852 SHPRYYISANVTG pancreas, adenocarcinoma
853 SHPRYYISANVTGFK pancreas, adenocarcinoma
854 TSHPRYYISANVTG pancreas, adenocarcinoma
855 TSHPRYYISANVTGFK pancreas, adenocarcinoma
908 DVGMFVALTKLGQPD uterine cervix, squamous cell carcinoma
909 VGmFVALTKLGQPD uterine cervix, squamous cell carcinoma
1015 GSSFFGELFNQNPE thyroid gland, papillary carcinoma
1016 SGSSFFGELFNQNPE thyroid gland, papillary carcinoma
466 DEMRFVTQI testis, mixed germ cell tumor
467 ETVHFATTQW testis, mixed germ cell tumor
468 LPPPATQI testis, mixed germ cell tumor
633 GNPAYRSFSNSLSQ kidney, angiomyolipoma
634 GPPGEAGYKAFSSLLA kidney, angiomyolipoma
635 GPPGEAGYKAFSSLLASS kidney, angiomyolipoma
636

 
kidney, angiomyolipoma
637

 
kidney, angiomyolipoma
639 GYKAFSSLLASSAVSP kidney, angiomyolipoma
640 GYKAFSSLLASSAVSPE kidney, angiomyolipoma
641 KAFSSLLASSAVSPE kidney, angiomyolipoma
642 NPAYRSFSNSLSQ kidney, angiomyolipoma
643 SRDDFQEGREGIVAR kidney, angiomyolipoma
644 SSSSFHPAPGNAQ kidney, angiomyolipoma
645 VARLTESLFLDL kidney, angiomyolipoma
646 VARLTESLFLDLLG kidney, angiomyolipoma
647 VIAGNPAYRSFSN kidney, angiomyolipoma
648

 
kidney, angiomyolipoma
649 YKAFSSLLASSAVS kidney, angiomyolipoma
650 YKAFSSLLASSAVSP kidney, angiomyolipoma
651 YKAFSSLLASSAVSPE kidney, angiomyolipoma
992 EDDYIKSWEDNQQGDE pleura, malignant mesothelioma
993 ELERIQIQEAAKKKPG pleura, malignant mesothelioma
994 ERIQIQEAAKKKP pleura, malignant mesothelioma
995 ERIQIQEAAKKKPG pleura, malignant mesothelioma
996 ERIQIQEAAKKKPGI pleura, malignant mesothelioma
997 LERIQIQEAAKKKPG pleura, malignant mesothelioma
998 LSSISQYSGKIK pleura, malignant mesothelioma,
941 EERNLLSVAYKNVVGAR esophagus, adenocarcinoma
942 ERNLLSVAYKNVVGAR esophagus, adenocarcinoma
943 IAELDTLSEESYKD vulva, squamous cell carcinoma
944 IAELDTLSEESYKDS vulva, squamous cell carcinoma
218 GDYGRAFNL stomach, metastatic, lymph node, non-Hodgkin's lymphoma, small lymphocytic type
219 TRHKIVHTK stomach, metastatic, lymph node, non-Hodgkin's lymphoma, small lymphocytic type
221 KAFNWFSTL stomach, metastatic, lymph node, non-Hodgkin's lymphoma, small lymphocytic type
541 RPKSNIVL non-Hodgkin's lymphoma, diffuse large B-cell type
542 RPKSNIVLL non-Hodgkin's lymphoma, diffuse large B-cell type
1001 INSRFPIPSATDPD brain, glioblastoma, brain, oligodendroglioma,
1002 VQHYELLNGQSVFG brain, glioblastoma, brain, oligodendroglioma,
910 AGVFHVEKNGRY colon, adenocarcinoma, mucinous type
911 FAGVFHVEKNGRYS colon, adenocarcinoma, mucinous type
912 GPITITIVNRDGTR colon, adenocarcinoma, mucinous type
913 NGRYSISRTEAADL colon, adenocarcinoma, mucinous type
45 DELPKFHQY white blood cells, chronic lymphocytic leukemia
46 DVTGQFPSSF white blood cells, chronic lymphocytic leukemia
47 EHSRVLQQL white blood cells, chronic lymphocytic leukemia
48 IKVSKQLL white blood cells, chronic lymphocytic leukemia
49 KPRQSSPQL white blood cells, chronic lymphocytic leukemia
50 KQLLAALEI white blood cells, chronic lymphocytic leukemia
51 RRKDLVLKY liver, focalnodular hyperplasia
52 RTRDYASLPPK white blood cells, chronic lymphocytic leukemia
124 GQKEALLKY synovial sarcoma
125 KPSEERKTI synovial sarcoma
126 KQTPKVLVV synovial sarcoma
127 SVIQHVQSF synovial sarcoma
128 TPIERIPYL synovial sarcoma
773 LPEFYKTVSPAL endometrium, adenocarcinoma, endometrioid type
774 VGQFIQDVKNSRST endometrium, adenocarcinoma, endometrioid type
775 VGQFIQDVKNSRSTD endometrium, adenocarcinoma, endometrioid type
776 WGQFIQDVKNSRS endometrium, adenocarcinoma, endometrioid type
777 WGQFIQDVKNSRST endometrium, adenocarcinoma, endometrioid type
778 WGQFIQDVKNSRSTD endometrium, adenocarcinoma, endometrioid type
779 WGQFIQDVKNSRSTDS endometrium, adenocarcinoma, endometrioid type
687 GPMKGGNFGGRSSGP thymus, thymoma, malignant
688 GPYGGGGQYFAKP thymus, thymoma, malignant
689 KGGNFGGRSSGP thymus, thymoma, malignant
690 NDFGNYNNQSSNFGP thymus, thymoma, malignant
691 SGPYGGGGQYFAKP thymus, thymoma, malignant
13 AAANIIRTL adrenal gland, adrenal cortical carcinoma
14 GRFKNLREAL adrenal gland, adrenal cortical carcinoma
15 MSPFSKATL adrenal gland, adrenal cortical carcinoma
16 QEDPGDNQITL adrenal gland, adrenal cortical carcinoma
17 SPFSKATL adrenal gland, adrenal cortical carcinoma
129 AEVEKNETV spleen, non-Hodgkin's lymphoma
130 EVKEEIPLV spleen, non-Hodgkin's lymphoma
131 KPTSARSGL spleen, non-Hodgkin's lymphoma
132 KYIETTPLTI spleen, non-Hodgkin's lymphoma
133 SEIKTSIEV spleen, non-Hodgkin's lymphoma
134 SVKPTSATK spleen, non-Hodgkin's lymphoma
135 YPNKGVGQA spleen, non-Hodgkin's lymphoma
966 ENNEIISNIRDSVIN kidney, oncocytoma
967 NNEIISNIRDSVIN kidney, oncocytoma
968 SPTVQVFSASGKPV kidney, oncocytoma
969 SSPTVQVFSASGKPVE kidney, oncocytoma
830 DIMRVNVDKVLERDQK Medullary carcinoma of thyroid origin
831 DIMRVNVDKVLERDQKL Medullary carcinoma of thyroid origin
832 IMRVNVDKVLERDQK lymph node, Hodgkin's disease
752 EEVITLIRSNQQLE pancreas, adenocarcinoma,
753 EEVITLIRSNQQLEN pancreas, adenocarcinoma,
754 IPADTFAALKNPNAML pancreas, adenocarcinoma
755 LKQLLSDKQQKRQSG pancreas, adenocarcinoma
756 LKQLLSDKQQKRQSGQ pancreas, adenocarcinoma
339 FLDPDIGGVAV pancreas, adenocarcinoma
340 HTAPPENKTW pancreas, adenocarcinoma
341 LLDTPVKTQY pancreas, adenocarcinoma
342 NAVKDFTSF pancreas, adenocarcinoma
343 SGLLQIKKL pancreas, adenocarcinoma
344 YHDKNIVLL pancreas, adenocarcinoma
71 HLKSIPVSL prostate, adenocarcinoma
72 KVWYNVENW prostate, adenocarcinoma
73 LPAYRAQLL prostate, adenocarcinoma
74 LSEQTSVPL prostate, adenocarcinoma
75 SLNQWLVSF prostate, adenocarcinoma
76 SMTSLAQKI prostate, adenocarcinoma
77 SSSGLHPPK prostate, adenocarcinoma
578

 
thymus, thymoma, malignant
579 GGSFGGRSSGSP thymus, thymoma, malignant
580 KGGSFGGRSSGSP thymus, thymoma, malignant
583

 
thymus, thymoma, malignant
584

 
thymus, thymoma, malignant
84 VPVPHTTAL endometrium, adenocarcinoma
85 YQVLDVQRY endometrium, adenocarcinoma
731 DGLNSLTYQVLDVQRYPL endometrium, adenocarcinoma
732 HPVLQRQQLDYGIY endometrium, adenocarcinoma
733 LNSLTYQVLDVQR endometrium, adenocarcinoma
734 LNSLTYQVLDVQRYP endometrium, adenocarcinoma
735 LNSLTYQVLDVQRYPL endometrium, adenocarcinoma
736 LPQLVGVSTPLQG endometrium, adenocarcinoma
737 LPQLVGVSTPLQGG endometrium, adenocarcinoma
738 LPQLVGVSTPLQGGS endometrium, adenocarcinoma
739 RLPQLVGVSTPLQGGS endometrium, adenocarcinoma
740 SPHKVAIIIPFRNR endometrium, adenocarcinoma
741 SPHKVAIIIPFRNRQE endometrium, adenocarcinoma
742 SPHKVAIIIPFRNRQEH endometrium, adenocarcinoma
527 DEKQQHIVY synovial sarcoma
528 DEVYQVTVY synovial sarcoma
529 GEISEKAKL synovial sarcoma
530 YTMKEVLFY synovial sarcoma
203 GPRPITQSEL lymph node, non-Hodgkin's lymphoma, marginal Zone B-cell type
204 KPEPVDKVA lymph node, non-Hodgkin's lymphoma, marginal Zone B-cell type
205 TPSSRPASL lymph node, non-Hodgkin's lymphoma, marginal Zone B-cell type
949 SPPQFRVNGAISN ovary, granulosa cell tumor
950 SPPQFRVNGAISNFE ovary, granulosa cell tumor
951 SPPQFRVNGAISNFEE ovary, granulosa cell tumor
952 SPPQFRVNGAISNFEEF ovary, granulosa cell tumor
953 VGKMFVDVYFQEDKK ovary, granulosa cell tumor
954 VGKmFVDVYFQEDKKE ovary, granulosa cell tumor
916 EEFKKLTSIKIQNDK small intestine, gastrointestinal stromal tumor (GIST)
917 INRRMADDNKLFR small intestine, gastrointestinal stromal tumor (GIST)
918 TATIVMVTNLKERKE small intestine, gastrointestinal stromal tumor (GIST)
526 RINEFSISSF connective tissues, chondrosarcoma
585 GNRINEFSISSF connective tissues, chondrosarcoma
586 HGNQITSDKVGRKV connective tissues, chondrosarcoma
587 IPPVNTNLENLYLQ connective tissues, chondrosarcoma
588 LQVLRLDGNEIKR connective tissues, chondrosarcoma
589 LQVLRLDGNEIKRS connective tissues, chondrosarcoma
590 LQVLRLDGNEIKRSA connective tissues, chondrosarcoma
591 LRELHLDHNQISRVPN connective tissues, chondrosarcoma
592 LYVRLSHNSLTNNG connective tissues, chondrosarcoma,
593 VPSRMKYVYFQNNQ connective tissues, chondrosarcoma
594 VPSRMKYVYFQNNQIT connective tissues, chondrosarcoma
595 VPSRMKYVYFQNNQITS connective tissues, chondrosarcoma
596 WIALHGNQITSD connective tissues, chondrosarcoma
597 WIALHGNQITSDK connective tissues, chondrosarcoma
165 ELNKLLEEI ovary, adenocarcinoma, endometrioid type
166 IPFSNPRVL ovary, adenocarcinoma, endometrioid type
167 LLDEGAKLLY ovary, adenocarcinoma, endometrioid type
168 SPADAHRNL ovary, adenocarcinoma, endometrioid type
96 APLQRSQSL kidney, renal cell carcinoma, clear cell type
97 DEVHQDTY kidney, renal cell carcinoma, clear cell type
98 LPHSATVTL kidney, renal cell carcinoma, clear cell type
152 APSEYRYTL stomach, mucinous adenocarcinoma
153 APSEYRYTLL stomach, mucinous adenocarcinoma
154 EIFQNEVAR stomach, mucinous adenocarcinoma
155 KDVLIPGKL stomach, mucinous adenocarcinoma
156 VPLVREITF stomach, mucinous adenocarcinoma
136 ISMKILNSL thymus, thymoma, benign
137 KTIAFLLPMF thymus, thymoma, benign
138 RDSIINDF thymus, thymoma, benign
139 SVKGGGGNEK thymus, thymoma, benign
140 GIAKTGSGK thymus, thymoma, benign
503 ALYATKTLR pancreas, microcystic adenoma
504 MEYVISRI pancreas, microcystic adenoma
505 VPVGRQPII pancreas, microcystic adenoma
278 ATNGDLASR prostate, benign nodular hyperplasia
279 GLHAEVTGVGY prostate, benign nodular hyperplasia
280 HVSSTSSSF prostate, benign nodular hyperplasia
281 LQADLQNGL prostate, benign nodular hyperplasia
282 SELPVSEVA prostate, benign nodular hyperplasia
283 SQTKSVFEI prostate, benign nodular hyperplasia
284 THIFTSDGL prostate, benign nodular hyperplasia
285 VIYFPPLQK prostate, benign nodular hyperplasia
286 YPFSSEQKW prostate, benign nodular hyperplasia
963 GNTVIHLDQALARMR lung, small cell carcinoma
964 NTVIHLDQALARMR lung, small cell carcinoma
965 NTVIHLDQALARMRE lung, small cell carcinoma
187 AADTERLAL connective tissues, chondrosarcoma
188 DMKAKVASL connective tissues, chondrosarcoma
189 HVLEEVQQV connective tissues, chondrosarcoma
190 KEAADTERL connective tissues, chondrosarcoma
191 RISEVLQKL connective tissues, chondrosarcoma
192 TEVRELVSL  
973 ADDLEGEAFLPL spleen, chronic myeloid leukemia
974 ADDLEGEAFLPLR spleen, chronic myeloid leukemia
975 ADDLEGEAFLPLRE spleen, chronic myeloid leukemia
976 GADDLEGEAFLPLR spleen, chronic myeloid leukemia
141 AETTDNVFTL thyroid gland, follicular adenoma
142 SEYQRFAVM thyroid gland, follicular adenoma
143 TFGERWAF thyroid gland, follicular adenoma
144 NENLVERF stomach, colon, adenocarcinoma, mucinous type
117 QLFSYAILGF colon, non-Hodgkin's lymphoma
845 GIRVAPVPLYNS lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
846 GIRVAPVPLYNSFH lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
847 NPNGIRVAPVPLYNSFH lung, non-small cell lung carcinoma, liver, hepatocellular carcinoma
478 AAVPVIISR lymph node, papillary carcinoma of thyroid, metastatic
479 EEIGKVAAA lymph node, papillary carcinoma of thyroid, metastatic
480 FLKDLVASV lymph node, papillary carcinoma of thyroid, metastatic
481 VIISRALEL lymph node, papillary carcinoma of thyroid, metastatic
420 QIDYKTLVL leiomyosarcoma
421 VEDPTIVRI leiomyosarcoma
543 GEPLSYTRFSLARQ lung, non-small cell lung carcinoma, lung, adenocarcinoma
544 GEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
545 GEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
546 GGEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
547 GGEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
548 NPGGYVAYSKAATVTG lung, non-small cell lung carcinoma, lung, adenocarcinoma
549 NPGGYVAYSKAATVTGK lung, non-small cell lung carcinoma, lung, adenocarcinoma
550 NPGGYVAYSKAATVTGKL lung, non-small cell lung carcinoma, lung, adenocarcinoma
551 NSVIIVDKNGRL lung, non-small cell lung carcinoma, lung, adenocarcinoma
552 NSVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
553 NSVIIVDKNGRLVY lung, non-small cell lung carcinoma, lung, adenocarcinoma
554 RVEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
555 RVEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
556 RVEYHFLSPYVSPKESPF lung, non-small cell lung carcinoma, lung, adenocarcinoma
557 SPFRHVFWGSGSHTL lung, non-small cell lung carcinoma, lung, adenocarcinoma
558 SVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
559 VEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
560 VEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
388 AEGPAGGFmW spleen, chronic myeloid leukemia
389 AYYRDAEAY spleen, chronic myeloid leukemia
390 QVNRPLTMR spleen, chronic myeloid leukemia
391 RHSPVFQVY spleen, chronic myeloid leukemia
392 SLPVPNSAY spleen, chronic myeloid leukemia
393 TLGPPGTAHLY spleen, chronic myeloid leukemia
308 VLYVGSKTK schwannoma
309 KTKEQVTNV schwannoma
310 MPVDPDNEAY schwannoma
311 AEKTKQGVA schwannoma
446 EAFEFVKQR stomach, diffuse subtype adenocarcinoma, breast, carcinoma
447 NHFEGHYQY stomach, diffuse subtype adenocarcinoma, breast, carcinoma


[0015] Finally a most preferred aspect as disclosed relates to the use of the peptides as disclosed for the - preferably combined - most preferred immunotherapy of diseases according to the following table 6.
Table 6: Most preferred peptides as disclosed and diseases to be treated. SEQ ID No. 167 is according to the invention.
Seq IDSequenceTissue and disease
22 LEVEERTKPV breast, carcinoma
23 RDSPINANLRY breast, carcinoma
24 RPFVIVTA breast, carcinoma
25 RPIINTPMV breast, carcinoma
26 SPTSSRTSSL breast, carcinoma
27 ATSAPLVSR lung, neuroendocrine carcinoma (non-small cell type)
114 YGNPRTNGM breast, carcinoma
102 FSITKSVEL non-Hodgkin's lymphoma, small lymphocytic type
103 GQTKNDLVV non-Hodgkin's lymphoma, small lymphocytic type
104 LSQEVCRD non-Hodgkin's lymphoma, small lymphocytic type
105 RDIQSPEQI non-Hodgkin's lymphoma, small lymphocytic t type
106 REDNSSNSL non-Hodgkin's lymphoma, small lymphocytic type
107 TEHQEPGL non-Hodgkin's lymphoma, small lymphocytic type
108 TKNDLVVSL non-Hodgkin's lymphoma, small lymphocytic type
977 AGREINLVDAHLKSE lymph node, Hodgkin's disease
978 AGREINLVDAHLKSEQT lymph node, Hodgkin's disease
979 GREINLVDAHLKSE lymph node, Hodgkin's disease
980 KPGIVYASLNHSVIG lymph node, Hodgkin's disease
981 NKPGIVYASLNHSVIG lymph node, Hodgkin's disease
982 TTLYVTDVKSASERPS lymph node, Hodgkin's disease colon or rectum, thyroid gland, nodular
220 RIHTGEKPYK hyperplasia
53 APGSVLPRAL lymph node, Hodgkin's disease
54 DIKEHPLL lymph node, Hodgkin's disease
55 DSAGPQDAR lymph node, Hodgkin's disease
56 FQYAKESYI lymph node, Hodgkin's disease
57 KVLSWPFLM lymph node, Hodgkin's disease
58 LENDQSLSF lymph node, Hodgkin's disease
59 SPSRQPQV lymph node, Hodgkin's disease
60 SRHQSFTTK lymph node, Hodgkin's disease
61 SSHNASKTL lymph node, Hodgkin's disease
100 3 DNQYAVLENQKSSH pleura, malignant mesothelioma
100 4 GPPEIYSDTQFPS pleura, malignant mesothelioma
100 5 GPPEIYSDTQFPSLQ pleura, malignant mesothelioma
100 6 TPQGPPEIYSDTQFPS pleura, malignant mesothelioma
100 7 TPQGPPEIYSDTQFPSLQ pleura, malignant mesothelioma
100 8 TPQGPPEIYSDTQFPSLQS T pleura, malignant mesothelioma
661 EYVSLYHQPAAM non-Hodgkin's lymphoma, peripheral T cell type
662 IKAEYKGRVTLKQYPR non-Hodgkin's lymphoma, peripheral T cell type
663 LNVHSEYEPSWEEQP non-Hodgkin's lymphoma, peripheral T cell type
664 LPYLFQMPAYASSS non-Hodgkin's lymphoma, peripheral T cell type
665 LPYLFQMPAYASSSK non-Hodgkin's lymphoma, peripheral T cell type
666 NFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
667 TNFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
668 TTNFIKAEYKGRVT non-Hodgkin's lymphoma, peripheral T cell type
669 VTLNVHSEYEPSWEEQP non-Hodgkin's lymphoma, peripheral T cell type
670 YPRKNLFLVEVTQLTESDS non-Hodgkin's lymphoma, peripheral T cell type
671

 
non-Hodgkin's lymphoma, peripheral T cell type
780 DNGHLYREDQTSPAPG kidney, angiomyolipoma
781 DNGHLYREDQTSPAPGLR kidney, angiomyolipoma
782 EVQVFAPANALPARSE kidney, angiomyolipoma
783 GHLYREDQTSPAPG kidney, angiomyolipoma
784 LPARSEAAAVQPVIG kidney, angiomyolipoma
785 NGHLYREDQTSPAPG kidney, angiomyolipoma
786 NGHLYREDQTSPAPGL kidney, angiomyolipoma
787 NGHLYREDQTSPAPGLR kidney, angiomyolipoma
788 VFAPANALPARSEAA kidney, angiomyolipoma
789 VQVFAPANALPARSE kidney, angiomyolipoma
222 QSTQRSLAL uterine cervix, squamous cell carcinoma
223 RDLQMNQALRF uterine cervix, squamous cell carcinoma
224 RELESQLHVL uterine cervix, squamous cell carcinoma
225 SEAEKLTLV uterine cervix, squamous cell carcinoma
12 KIADFGLAR liver, hepatocellular carcinoma
812 DGSYRIFSKGASE colon or rectum
813 GSYRIFSKGASE colon or rectum
814 SDGSYRIFSKGASE colon or rectum
815 SVKKMMKDNNLVRH colon or rectum, liver, hepatocellular carcinoma
816 VKKMMKDNNLVRH colon or rectum, liver, hepatocellular carcinoma
743 AIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
744 ARNFERNKAIKVI non-Hodgkin's lymphoma, peripheral T cell type
745 ARNFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
746 NFERNKAIKVII non-Hodgkin's lymphoma, peripheral T cell type
747 NFERNKAIKVIIA non-Hodgkin's lymphoma, peripheral T cell type
748 VAIVQAVSAHRH non-Hodgkin's lymphoma, peripheral T cell type
749 VAIVQAVSAHRHR non-Hodgkin's lymphoma, peripheral T cell type
750 VAIVQAVSAHRHRA non-Hodgkin's lymphoma, peripheral T cell type
751 VAIVQAVSAHRHRAR non-Hodgkin's lymphoma, peripheral T cell type
818 VDKVLERDQKLSE lymph node, papillary carcinoma of thyroid, metastatic
819 VDKVLERDQKLSELD lymph node, papillary carcinoma of thyroid, metastatic
820 VDKVLERDQKLSELDD lymph node, papillary carcinoma of thyroid, metastatic
821 VDKVLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
822 VLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
833 VDKVLERDQKLSE lymph node, papillary carcinoma of thyroid, metastatic
834 VDKVLERDQKLSELD lymph node, papillary carcinoma of thyroid, metastatic
835 VDKVLERDQKLSELDD lymph node, papillary carcinoma of thyroid, metastatic
836 VDKVLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
837 VLERDQKLSELDDR lymph node, papillary carcinoma of thyroid, metastatic
908 DVGMFVALTKLGQPD uterine cervix, squamous cell carcinoma
909 VGmFVALTKLGQPD uterine cervix, squamous cell carcinoma
218 GDYGRAFNL lymph node, non-Hodgkin's lymphoma, small lymphocytic type
219 TRHKIVHTK lymph node, non-Hodgkin's lymphoma, small lymphocytic type
221 KAFNWFSTL lymph node, non-Hodgkin's lymphoma, small lymphocytic type
541 RPKSNIVL non-Hodgkin's lymphoma, diffuse large B-cell type
542 RPKSNIVLL non-Hodgkin's lymphoma, diffuse large B-cell type
752 EEVITLIRSNQQLE pancreas, adenocarcinoma
753 EEVITLIRSNQQLEN pancreas, adenocarcinoma
754 IPADTFAALKNPNAML pancreas, adenocarcinoma
755 LKQLLSDKQQKRQSG pancreas, adenocarcinoma
756 LKQLLSDKQQKRQSGQ pancreas, adenocarcinoma
71 HLKSIPVSL prostate, adenocarcinoma
72 KVWYNVENW prostate, adenocarcinoma
73 LPAYRAQLL prostate, adenocarcinoma
74 LSEQTSVPL prostate, adenocarcinoma
75 SLNQWLVSF prostate, adenocarcinoma
76 SMTSLAQKI prostate, adenocarcinoma
77 SSSGLHPPK prostate, adenocarcinoma
527 DEKQQHIVY synovial sarcoma
528 DEVYQVTVY synovial sarcoma
529 GEISEKAKL synovial sarcoma
530 YTMKEVLFY synovial sarcoma
165 ELNKLLEEI ovary, adenocarcinoma, endometrioid type
166 IPFSNPRVL ovary, adenocarcinoma, endometrioid type
167 LLDEGAKLLY ovary, adenocarcinoma, endometrioid type
168 SPADAHRNL ovary, adenocarcinoma, endometrioid type
96 APLQRSQSL kidney, renal cell carcinoma, clear cell type
97 DEVHQDTY kidney, renal cell carcinoma, clear cell type
98 LPHSATVTL kidney, renal cell carcinoma, clear cell type
278 ATNGDLASR prostate, benign nodular hyperplasia
279 GLHAEVTGVGY prostate, benign nodular hyperplasia
280 HVSSTSSSF prostate, benign nodular hyperplasia
281 LQADLQNGL prostate, benign nodular hyperplasia
282 SELPVSEVA prostate, benign nodular hyperplasia
283 SQTKSVFEI prostate, benign nodular hyperplasia
284 THIFTSDGL prostate, benign nodular hyperplasia
285 VIYFPPLQK prostate, benign nodular hyperplasia
286 YPFSSEQKW prostate, benign nodular hyperplasia
973 ADDLEGEAFLPL spleen, chronic myeloid leukemia
974 ADDLEGEAFLPLR spleen, chronic myeloid leukemia
975 ADDLEGEAFLPLRE spleen, chronic myeloid leukemia
976 GADDLEGEAFLPLR spleen, chronic myeloid leukemia
141 AETTDNVFTL thyroid gland, follicular adenoma
142 SEYQRFAVM thyroid gland, follicular adenoma
143 TFGERWAF thyroid gland, follicular adenoma
144 NENLVERF colon, adenocarcinoma, mucinous type
845 GIRVAPVPLYNS liver, hepatocellular carcinoma
846 GIRVAPVPLYNSFH liver, hepatocellular carcinoma
847 NPNGIRVAPVPLYNSFH liver, hepatocellular carcinoma
478 AAVPVIISR lymph node, papillary carcinoma of thyroid, metastatic
479 EEIGKVAAA lymph node, papillary carcinoma of thyroid, metastatic
480 FLKDLVASV lymph node, papillary carcinoma of thyroid, metastatic
481 VIISRALEL lymph node, papillary carcinoma of thyroid, metastatic
420 QIDYKTLVL leiomyosarcoma
421 VEDPTIVRI leiomyosarcoma
543 GEPLSYTRFSLARQ lung, non-small cell lung carcinoma, lung, adenocarcinoma
544 GEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
545 GEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
546 GGEPLSYTRFSLARQVD lung, non-small cell lung carcinoma, lung, adenocarcinoma
547 GGEPLSYTRFSLARQVDG lung, non-small cell lung carcinoma, lung, adenocarcinoma
548 NPGGYVAYSKAATVTG lung, non-small cell lung carcinoma, lung, adenocarcinoma
549 NPGGYVAYSKAATVTGK lung, non-small cell lung carcinoma, lung, adenocarcinoma
550 NPGGYVAYSKAATVTGKL lung, non-small cell lung carcinoma, lung, adenocarcinoma
551 NSVIIVDKNGRL lung, non-small cell lung carcinoma, lung, adenocarcinoma
552 NSVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
553 NSVIIVDKNGRLVY lung, non-small cell lung carcinoma, lung, adenocarcinoma
554 RVEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
555 RVEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma
556 RVEYHFLSPYVSPKESPF lung, non-small cell lung carcinoma, lung, adenocarcinoma
557 SPFRHVFWGSGSHTL lung, non-small cell lung carcinoma, lung, adenocarcinoma
558 SVIIVDKNGRLV lung, non-small cell lung carcinoma, lung, adenocarcinoma
559 VEYHFLSPYVSPK lung, non-small cell lung carcinoma, lung, adenocarcinoma
560 VEYHFLSPYVSPKE lung, non-small cell lung carcinoma, lung, adenocarcinoma


[0016] The present invention furthermore relates to the peptides according to the present invention that have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I.

[0017] The present invention further relates to the peptides according to the present invention, wherein said peptide includes non-peptide bonds.

[0018] The present invention further relates to a fusion protein comprising (a) an amino acid sequence consisting of SEQ ID NO: 167; and (b) N-terminal amino acids 1-80 of HLA-DR antigen-associated invariant chain (Ii).

[0019] The present invention further relates to a nucleic acid, encoding the peptides according to the present invention.

[0020] The present invention further relates to the nucleic acid according to the present invention that is DNA, cDNA, PNA, RNA or combinations thereof.

[0021] The present invention further relates to an expression vector expressing and/or presenting a nucleic acid according to the present invention.

[0022] The present invention further relates An antibody that specifically binds to a human major histocompatibility complex (MHC) class I being complexed with the peptide according according to SEQ ID NO: 167, and methods of making them.

[0023] The present invention further relates to a T-cell receptor that binds to a human major histocompatibility complex (MHC) class I being complexed with the peptide according according to SEQ ID NO: 167, and methods of making them.

[0024] The present invention further relates to a host cell comprising a nucleic acid according to the present invention or an expression vector as described before.

[0025] The present invention further relates to the host cell according to the present invention that is an antigen presenting cell.

[0026] The present invention further relates to the host cell according to the present invention wherein the antigen presenting cell is a dendritic cell.

[0027] The present invention further relates to a method of producing a peptide according to the present invention, the method comprising culturing the host cell according to the present invention, and isolating the peptide from the host cell or its culture medium.

[0028] The present invention further relates to an in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide according to the present invention.

[0029] The present invention further relates to the method according to the present invention, wherein the antigen is loaded onto class I MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.

[0030] The present invention further relates to the method according to the present invention, wherein the antigen-presenting cell comprises an expression vector expressing said peptide containing SEQ ID NO: 167.

[0031] The present invention further relates to activated cytotoxic T lymphocytes (CTL), produced by the method according to the present invention, which selectively recognize a cell which aberrantly expresses a polypeptide comprising an amino acid sequence according to the present invention.

[0032] The present invention further discloses a method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising any amino acid sequence according to the present invention, the method comprising administering to the patient an effective number of cytotoxic T lymphocytes (CTL) as according to the present invention.

[0033] The present invention further discloses the use of any peptide described, a nucleic acid according to the present invention, an expression vector according to the present invention, a cell according to the present invention, or an activated cytotoxic T lymphocyte according to the present invention as a medicament or in the manufacture of a medicament.

[0034] The present invention further relates to a use according to the present invention, wherein said medicament is a vaccine.

[0035] The present invention further relates to a use according to the present invention, wherein the medicament is active against cancer.

[0036] The present invention further relates to a use according to the present invention, wherein said cancer cells are cells of haematological malignancies, such as, CLL or AML cells.

[0037] The present invention further discloses particular marker proteins and biomarkers based on the peptides according to the present invention that can be used in the diagnosis and/or prognosis of haematological malignancies, in particular chronic lymphoid leukemia (CLL) cells.

[0038] Further, the present invention discloses the use of these novel targets for cancer treatment.

[0039] Further, the present invention discloses a method for producing a personalized anticancer vaccine for an individual patient using a database ("warehouse") of prescreened tumour associated peptides.

[0040] Stimulation of an immune response is dependent upon the presence of antigens recognised as foreign by the host immune system. The discovery of the existence of tumor associated antigens has raised the possibility of using a host's immune system to intervene in tumor growth. Various mechanisms of harnessing both the humoral and cellular arms of the immune system are currently being explored for cancer immunotherapy.

[0041] Specific elements of the cellular immune response are capable of specifically recognising and destroying tumor cells. The isolation of cytotoxic T-cells (CTL) from tumor-infiltrating cell populations or from peripheral blood suggests that such cells play an important role in natural immune defences against cancer. CD8-positive T-cells in particular, which recognise Class I molecules of the major histocompatibility complex (MHC)-bearing peptides of usually 8 to 10 amino acid residues derived from proteins or defect ribosomal products (DRIPS) located in the cytosol, play an important role in this response. The MHC-molecules of the human are also designated as human leukocyte-antigens (HLA).

[0042] There are two classes of MHC-molecules: MHC class I molecules that can be found on most cells having a nucleus. MHC molecules are composed of an alpha heavy chain and beta-2-microglobulin (MHC class I receptors) or an alpha and a beta chain (MHC class II receptors), respectively. Their three-dimensional conformation results in a binding groove, which is used for non-covalent interaction with peptides. MHC class I present peptides that result from proteolytic cleavage of predominantly endogenous proteins, DRIPs and larger peptides. MHC class II molecules can be found predominantly on professional antigen presenting cells (APCs), and primarily present peptides of exogenous or transmembrane proteins that are taken up by APCs during the course of endocytosis, and are subsequently processed. Complexes of peptide and MHC class I molecules are recognized by CD8-positive cytotoxic T-lymphocytes bearing the appropriate TCR (T-cell receptor), whereas complexes of peptide and MHC class II molecules are recognized by CD4-positive-helper-T cells bearing the appropriate TCR. It is well known that the TCR, the peptide and the MHC are thereby present in a stoichiometric amount of 1:1:1.

[0043] CD4-positive helper T cells play an important role in inducing and sustaining effective responses by CD8-positive cytotoxic T cells. The identification of CD4-positive T-cell epitopes derived from tumor associated antigens (TAA) is of great importance for the development of pharmaceutical products for triggering anti-tumor immune responses (Gnjatic S, et al. Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses. Proc Natl Acad Sci U S A. 2003 Jul 22;100(15):8862-7). At the tumor site, T helper cells, support a CTL friendly cytokine milieu Mortara L, et al. CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3435-43) and attract effector cells, e.g. CTLs, NK cells, macrophages, granulocytes (Hwang ML, et al. Cognate memory CD4+ T cells generated with dendritic cell priming influence the expansion, trafficking, and differentiation of secondary CD8+ T cells and enhance tumor control. J Immunol. 2007 Nov 1;179(9):5829-38).

[0044] In the absence of inflammation, expression of MHC class II molecules is mainly restricted to cells of the immune system, especially professional antigen-presenting cells (APC), e.g., monocytes, monocyte-derived cells, macrophages, dendritic cells. In cancer patients, cells of the tumor have surprisingly been found to express MHC class II molecules (Dengjel J, et al. Unexpected abundance of HLA class II presented peptides in primary renal cell carcinomas. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4163-70).

[0045] It was shown in mammalian animal models, e.g., mice, that even in the absence of CTL effector cells (i.e., CD8-positive T lymphocytes), CD4-positive T cells are sufficient for inhibiting manifestation of tumors via inhibition of angiogenesis by secretion of interferon-gamma (IFNy).

[0046] Additionally, it was shown that CD4-positive T cells recognizing peptides from tumor-associated antigens presented by HLA class II molecules can counteract tumor progression via the induction of antibody (Ab) responses.

[0047] In contrast to tumor-associated peptides binding to HLA class I molecules, only a small number of class II ligands of tumor associated antigens (TAA) have been described to date.

[0048] Since the constitutive expression of HLA class II molecules is usually limited to cells of the immune system, the possibility of isolating class II peptides directly from primary tumors was not considered possible. However, Dengjel et al. were successful in identifying a number of MHC Class II epitopes directly from tumors (WO 2007/028574, EP 1 760 088 B1; (Dengjel et al., 2006).

[0049] The antigens that are recognized by the tumor specific cytotoxic T lymphocytes, that is, their epitopes, can be molecules derived from all protein classes, such as enzymes, receptors, transcription factors, etc. which are expressed and, as compared to unaltered cells of the same origin, up-regulated in cells of the respective tumor.

[0050] Since both types of response, CD8 and CD4 dependent, contribute jointly and synergistically to the anti-tumor effect, the identification and characterization of tumor-associated antigens recognized by either CD8+ CTLs (ligand: MHC class I molecule + peptide epitope) or by CD4-positive T-helper cells (ligand: MHC class II molecule + peptide epitope) is important in the development of tumor vaccines.

[0051] The length variants are generally N- and/or C-terminally extended (between 1 and 5, preferably 1 to 10 amino acids) or N- and/or C-terminally shortened (between 1 and 5 amino acids) peptides, which still can bind to MHC, and elicit a cellular immune response as described herein.

[0052] For a peptide to trigger (elicit) a cellular immune response, it must bind to an MHC-molecule. This process is dependent on the allele of the MHC-molecule and specific polymorphisms of the amino acid sequence of the peptide. MHC-class-I-binding peptides are usually 8-12 amino acid residues in length and usually contain two conserved residues ("anchors") in their sequence that interact with the corresponding binding groove of the MHC-molecule. In this way each MHC allele has a "binding motif" determining which peptides can bind specifically to the binding groove.

[0053] In the MHC class I dependent immune reaction, peptides not only have to be able to bind to certain MHC class I molecules being expressed by tumor cells, they also have to be recognized by T cells bearing specific T cell receptors (TCR).

[0054] The antigens that are recognized by the tumor specific cytotoxic T lymphocytes, that is, their epitopes, can be molecules derived from all protein classes, such as enzymes, receptors, transcription factors, etc. which are expressed and, as compared to unaltered cells of the same origin, up-regulated in cells of the respective tumor.

[0055] The current classification of tumor associated antigens comprises the following major groups:
  1. a) Cancer-testis antigens: The first TAAs ever identified that can be recognized by T cells belong to this class, which was originally called cancer-testis (CT) antigens because of the expression of its members in histologically different human tumors and, among normal tissues, only in spermatocytes/spermatogonia of testis and, occasionally, in placenta. Since the cells of testis do not express class I and II HLA molecules, these antigens cannot be recognized by T cells in normal tissues and can therefore be considered as immunologically tumor-specific. Well-known examples for CT antigens are the MAGE family members or NY-ESO-1.
  2. b) Differentiation antigens: These TAAs are shared between tumors and the normal tissue from which the tumor arose; most are found in melanomas and normal melanocytes. Many of these melanocyte lineage-related proteins are involved in the biosynthesis of melanin and are therefore not tumor specific but nevertheless are widely used for cancer immunotherapy. Examples include, but are not limited to, tyrosinase and Melan-A/MART-1 for melanoma or PSA for prostate cancer.
  3. c) Overexpressed TAAs: Genes encoding widely expressed TAAs have been detected in histologically different types of tumors as well as in many normal tissues, generally with lower expression levels. It is possible that many of the epitopes processed and potentially presented by normal tissues are below the threshold level for T-cell recognition, while their overexpression in tumor cells can trigger an anticancer response by breaking previously established tolerance. Prominent examples for this class of TAAs are Her-2/neu, Survivin, Telomerase or WT1.
  4. d) Tumor specific antigens: These unique TAAs arise from mutations of normal genes (such as β-catenin, CDK4, etc.). Some of these molecular changes are associated with neoplastic transformation and/or progression. Tumor specific antigens are generally able to induce strong immune responses without bearing the risk for autoimmune reactions against normal tissues. On the other hand, these TAAs are in most cases only relevant to the exact tumor on which they were identified and are usually not shared between many individual tumors.
  5. e) TAAs arising from abnormal post-translational modifications: Such TAAs may arise from proteins which are neither specific nor overexpressed in tumors but nevertheless become tumor associated by posttranslational processes primarily active in tumors. Examples for this class arise from altered glycosylation patterns leading to novel epitopes in tumors as for MUC1 or events like protein splicing during degradation which may or may not be tumor specific.
  6. f) Oncoviral proteins: These TAAs are viral proteins that may play a critical role in the oncogenic process and, because they are foreign (not of human origin), they can evoke a T-cell response. Examples of such proteins are the human papilloma type 16 virus proteins, E6 and E7, which are expressed in cervical carcinoma.


[0056] For proteins to be recognized by cytotoxic T-lymphocytes as tumor-specific or - associated antigens, and to be used in a therapy, particular prerequisites must be fulfilled. The antigen should be expressed mainly by tumor cells and not or in comparably small amounts by normal healthy tissues or in another preferred embodiment the peptide should be over-presented by tumor cells as compared to normal healthy tissues. It is furthermore desirable, that the respective antigen is not only present in a type of tumor, but also in high concentrations (i.e. copy numbers of the respective peptide per cell). Tumor-specific and tumor-associated antigens are often derived from proteins directly involved in transformation of a normal cell to a tumor cell due to a function e.g. in cell cycle control or suppression of apoptosis. Additionally, downstream targets of the proteins directly causative for a transformation may be upregulated und thus may be indirectly tumor-associated. Such indirect tumor-associated antigens may also be targets of a vaccination approach (Singh-Jasuja et al., 2004). In both cases it is essential that epitopes are present in the amino acid sequence of the antigen, since such a peptide ("immunogenic peptide") that is derived from a tumor associated antigen should lead to an in vitro or in vivo T-cell-response.

[0057] Basically, any peptide able to bind a MHC molecule may function as a T-cell epitope. A prerequisite for the induction of an in vitro or in vivo T-cell-response is the presence of a T cell with a corresponding TCR and the absence of immunological tolerance for this particular epitope.

[0058] Therefore, TAAs are a starting point for the development of a tumor vaccine. The methods for identifying and characterizing the TAAs are based on the use of CTL that can be isolated from patients or healthy subjects, or they are based on the generation of differential transcription profiles or differential peptide expression patterns between tumors and normal tissues.

[0059] However, the identification of genes over-expressed in tumor tissues or human tumor cell lines, or selectively expressed in such tissues or cell lines, does not provide precise information as to the use of the antigens being transcribed from these genes in an immune therapy. This is because only an individual subpopulation of epitopes of these antigens are suitable for such an application since a T cell with a corresponding TCR has to be present and immunological tolerance for this particular epitope needs to be absent or minimal. In a very preferred embodiment of the invention it is therefore important to select only those over- or selectively presented peptides against which a functional and/or a proliferating T cell can be found. Such a functional T cell is defined as a T cell, which upon stimulation with a specific antigen can be clonally expanded and is able to execute effector functions ("effector T cell").

[0060] In case of TCRs and antibodies according to the invention the immunogenicity of the underlying peptides is secondary. For TCRs and antibodies according to the invention the presentation is the determining factor.

[0061] T-helper cells play an important role in orchestrating the effector function of CTLs in anti-tumor immunity. T-helper cell epitopes that trigger a T-helper cell response of the TH1 type support effector functions of CD8-positive killer T cells, which include cytotoxic functions directed against tumor cells displaying tumor-associated peptide/MHC complexes on their cell surfaces. In this way tumor-associated T-helper cell peptide epitopes, alone or in combination with other tumor-associated peptides, can serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses.

[0062] The inventors identified a novel category of ligandome-derived tumor-associated antigens (LiTAAs), which were frequently and exclusively detected in CLL patients. Specific immune recognition of the corresponding HLA ligands (LiTAPs) was observed exclusively in CLL patients, remarkably showing a direct correlation with the frequency of HLA restricted presentation. Furthermore, retrospective survival analysis of 33 CLL patients indicated a potential association of LiTAP-specific immune responses with improved overall survival in CLL patients.

[0063] Uses against further cancers are disclosed in the following description of the proteins of the peptides according to the invention.

Detailed description of the invention



[0064] As used herein and except as noted otherwise all terms are defined as given below.

[0065] The term "peptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The peptides are preferably 9 amino acids in length, but can be as short as 8 amino acids in length, and as long as 10, 11, 12, 13 or 14 and in case of MHC class II peptides they can be as long as 15, 16, 17, 18, 19 or 20 amino acids in length.

[0066] Furthermore, the term "peptide" shall include salts of a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. Preferably, the salts are pharmaceutical acceptable salts of the peptides, such as, for example, the chloride or acetate (trifluoroacetate) salts.

[0067] The term "peptide" shall include "oligopeptide". The term "oligopeptide" is used herein to designate a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the oligopeptide is not critical to the invention, as long as the correct epitope or epitopes are maintained therein. The oligopeptides are typically less than about 30 amino acid residues in length, and greater than about 15 amino acids in length.

[0068] The term "the peptides of the present invention" shall include the peptides consisting of or comprising a peptide as defined above according to SEQ ID NO: 167.

[0069] The term "polypeptide" designates a series of amino acid residues, connected one to the other typically by peptide bonds between the alpha-amino and carbonyl groups of the adjacent amino acids. The length of the polypeptide is not critical to the invention as long as the correct epitopes are maintained. In contrast to the terms peptide or oligopeptide, the term polypeptide is meant to refer to molecules containing more than about 30 amino acid residues.

[0070] A peptide, oligopeptide, protein or polynucleotide coding for such a molecule is "immunogenic" (and thus is an "immunogen" within the present invention), if it is capable of inducing an immune response. In the case of the present invention, immunogenicity is more specifically defined as the ability to induce a T-cell response. Thus, an "immunogen" would be a molecule that is capable of inducing an immune response, and in the case of the present invention, a molecule capable of inducing a T-cell response. In another aspect, the immunogen can be the peptide, the complex of the peptide with MHC, oligopeptide, and/or protein that is used to raise specific antibodies or TCRs against it.

[0071] A class I T cell "epitope" requires a short peptide that is bound to a class I MHC receptor, forming a ternary complex (MHC class I alpha chain, beta-2-microglobulin, and peptide) that can be recognized by a T cell bearing a matching T-cell receptor binding to the MHC/peptide complex with appropriate affinity. Peptides binding to MHC class I molecules are typically 8-14 amino acids in length, and most typically 9 amino acids in length.

[0072] In humans there are three different genetic loci that encode MHC class I molecules (the MHC-molecules of the human are also designated human leukocyte antigens (HLA)): HLA-A, HLA-B, and HLA-C. HLA-A*01, HLA-A*02, and HLA-B*07 are examples of different MHC class I alleles that can be expressed from these loci.
Table 7: Expression frequencies F of HLA*A02 and the most frequent HLA-DR serotypes. Frequencies are deduced from haplotype frequencies Gf within the American population adapted from Mori et al. (Mori M, et al. HLA gene and haplotype frequencies in the North American population: the National Marrow Donor Program Donor Registry. Transplantation. 1997 Oct 15;64(7):1017-27) employing the Hardy-Weinberg formula F=1-(1-Gf)2. Combinations of A*02 with certain HLA-DR alleles might be enriched or less frequent than expected from their single frequencies due to linkage disequilibrium. For details refer to Chanock et al. (S.J. Chanock, et al (2004) HLA-A, -B, -Cw, -DQA1 and DRB1 in an African American population from Bethesda, USA Human Immunology, 65: 1223-1235).
 Expression frequencies of HLA*02 and HLA-DR serotypes within North American subpopulations
HLA AlleleCaucasian AmericanAfrican AmericanAsian AmericanLatin American
A*02 49.1% 34.1% 43.2% 48.3%
DR1 19.4% 13.2% 6.8% 15.3%
DR2 28.2% 29.8% 33.8% 21.2%
DR3 20.6% 24.8% 9.2% 15.2%
DR4 30.7% 11.1% 28.6% 36.8%
DR5 23.3% 31.1% 30.0% 20.0%
DR6 26.7% 33.7% 25.1% 31.1%
DR7 24.8% 19.2% 13.4% 20.2%
DR8 5.7% 12.1% 12.7% 18.6%
DR9 2.1% 5.8% 18.6% 2.1%


[0073] Therefore, for therapeutic and diagnostic purposes a peptide that binds with appropriate affinity to several different HLA class II receptors is highly desirable. A peptide binding to several different HLA class II molecules is called a promiscuous binder.

[0074] As used herein, reference to a DNA sequence includes both single stranded and double stranded DNA. Thus, the specific sequence, unless the context indicates otherwise, refers to the single strand DNA of such sequence, the duplex of such sequence with its complement (double stranded DNA) and the complement of such sequence. The term "coding region" refers to that portion of a gene which either naturally or normally codes for the expression product of that gene in its natural genomic environment, i.e., the region coding in vivo for the native expression product of the gene.

[0075] The coding region can be from a non-mutated ("normal"), mutated or altered gene, or can even be from a DNA sequence, or gene, wholly synthesized in the laboratory using methods well known to those of skill in the art of DNA synthesis.

[0076] The term "nucleotide sequence" refers to a heteropolymer of deoxyribonucleotides.

[0077] The nucleotide sequence coding for a particular peptide, oligopeptide, or polypeptide may be naturally occurring or they may be synthetically constructed. Generally, DNA segments encoding the peptides, polypeptides, and proteins of this invention are assembled from cDNA fragments and short oligonucleotide linkers, or from a series of oligonucleotides, to provide a synthetic gene that is capable of being expressed in a recombinant transcriptional unit comprising regulatory elements derived from a microbial or viral operon.

[0078] As used herein the term "a nucleotide coding (or encoding) for a peptide" refers to a nucleotide sequence coding for the peptide including artificial (man-made) start and stop codons compatible for the biological system the sequence is going to be expressed by.

[0079] The term "expression product" means the polypeptide or protein that is the natural translation product of the gene and any nucleic acid sequence coding equivalents resulting from genetic code degeneracy and thus coding for the same amino acid(s).

[0080] The term "fragment", when referring to a coding sequence, means a portion of DNA comprising less than the complete coding region, whose expression product retains essentially the same biological function or activity as the expression product of the complete coding region.

[0081] The term "DNA segment" refers to a DNA polymer, in the form of a separate fragment or as a component of a larger DNA construct, which has been derived from DNA isolated at least once in substantially pure form, i.e., free of contaminating endogenous materials and in a quantity or concentration enabling identification, manipulation, and recovery of the segment and its component nucleotide sequences by standard biochemical methods, for example, by using a cloning vector. Such segments are provided in the form of an open reading frame uninterrupted by internal non-translated sequences, or introns, which are typically present in eukaryotic genes. Sequences of non-translated DNA may be present downstream from the open reading frame, where the same do not interfere with manipulation or expression of the coding regions.

[0082] The term "primer" means a short nucleic acid sequence that can be paired with one strand of DNA and provides a free 3'-OH end at which a DNA polymerase starts synthesis of a deoxyribonucleotide chain.

[0083] The term "promoter" means a region of DNA involved in binding of RNA polymerase to initiate transcription.

[0084] The term "isolated" means that the material is removed from its original environment (e.g., the natural environment if it is naturally occurring). For example, a naturally-occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide, separated from some or all of the coexisting materials in the natural system, is isolated. Such polynucleotides could be part of a vector and/or such polynucleotides or polypeptides could be part of a composition, and still be isolated in that such vector or composition is not part of its natural environment.

[0085] The polynucleotides, and recombinant or immunogenic polypeptides, disclosed in accordance with the present invention may also be in "purified" form. The term "purified" does not require absolute purity; rather, it is intended as a relative definition, and can include preparations that are highly purified or preparations that are only partially purified, as those terms are understood by those of skill in the relevant art. For example, individual clones isolated from a cDNA library have been conventionally purified to electrophoretic homogeneity. Purification of starting material or natural material to at least one order of magnitude, preferably two or three orders, and more preferably four or five orders of magnitude is expressly contemplated. Furthermore, a claimed polypeptide which has a purity of preferably 99.999%, or at least 99.99% or 99.9%; and even desirably 99% by weight or greater is expressly contemplated.

[0086] The nucleic acids and polypeptide expression products disclosed according to the present invention, as well as expression vectors containing such nucleic acids and/or such polypeptides, may be in "enriched form". As used herein, the term "enriched" means that the concentration of the material is at least about 2, 5, 10, 100, or 1000 times its natural concentration (for example), advantageously 0.01 %, by weight, preferably at least about 0.1% by weight. Enriched preparations of about 0.5%, 1%, 5%, 10%, and 20% by weight are also contemplated. The sequences, constructs, vectors, clones, and other materials comprising the present invention can advantageously be in enriched or isolated form.

[0087] The term "active fragment" means a fragment that generates an immune response (i.e., has immunogenic activity) when administered, alone or optionally with a suitable adjuvant, to an animal, such as a mammal, for example, a rabbit or a mouse, and also including a human, such immune response taking the form of stimulating a T-cell response within the recipient animal, such as a human. Alternatively, the "active fragment" may also be used to induce a T-cell response in vitro.

[0088] As used herein, the terms "portion", "segment" and "fragment," when used in relation to polypeptides, refer to a continuous sequence of residues, such as amino acid residues, which sequence forms a subset of a larger sequence. For example, if a polypeptide were subjected to treatment with any of the common endopeptidases, such as trypsin or chymotrypsin, the oligopeptides resulting from such treatment would represent portions, segments or fragments of the starting polypeptide. When used in relation to polynucleotides, these terms refer to the products produced by treatment of said polynucleotides with any of the endonucleases.

[0089] In accordance with the present invention, the term "percent identity" or "percent identical", when referring to a sequence, means that a sequence is compared to a claimed or described sequence after alignment of the sequence to be compared (the "Compared Sequence") with the described or claimed sequence (the "Reference Sequence"). The Percent Identity is then determined according to the following formula:

wherein C is the number of differences between the Reference Sequence and the Compared Sequence over the length of alignment between the Reference Sequence and the Compared Sequence, wherein

(i) each base or amino acid in the Reference Sequence that does not have a corresponding aligned base or amino acid in the Compared Sequence and

(ii) each gap in the Reference Sequence and

(iii) each aligned base or amino acid in the Reference Sequence that is different from an aligned base or amino acid in the Compared Sequence, constitutes a difference and

(iiii) the alignment has to start at position 1 of the aligned sequences;

and R is the number of bases or amino acids in the Reference Sequence over the length of the alignment with the Compared Sequence with any gap created in the Reference Sequence also being counted as a base or amino acid.

[0090] If an alignment exists between the Compared Sequence and the Reference Sequence for which the Percent Identity as calculated above is about equal to or greater than a specified minimum Percent Identity then the Compared Sequence has the specified minimum Percent Identity to the Reference Sequence even though alignments may exist in which the herein above calculated Percent Identity is less than the specified Percent Identity.

[0091] The peptides of the invention can be elongated by up to four amino acids, that is 1, 2, 3 or 4 amino acids can be added to either end in any combination between 4:0 and 0:4.

[0092] Combinations of the elongations according to the invention can be depicted from table 8:
C-terminusN-terminus
4 0
3 0 or 1
2 0 or 1 or 2
1 0 or 1 or 2 or 3
0 0 or 1 or 2 or 3 or 4
N-terminusC-terminus
4 0
3 0 or 1
2 0 or 1 or 2
1 0 or 1 or 2 or 3
0 0 or 1 or 2 or 3 or 4


[0093] The amino acids for the elongation can be the peptides of the original sequence of the protein or any other amino acid. The elongation can be used to enhance the stability or solubility of the peptides.

[0094] The term "T-cell response" means the specific proliferation and activation of effector functions induced by a peptide in vitro or in vivo. For MHC class I restricted CTLs, effector functions may be lysis of peptide-pulsed, peptide-precursor pulsed or naturally peptide-presenting target cells, secretion of cytokines, preferably Interferon-gamma, TNF-alpha, or IL-2 induced by peptide, secretion of effector molecules, preferably granzymes or perforins induced by peptide, or degranulation.

[0095] Preferably, when the CTLs specific for a peptide according to the present invention are tested against the substituted peptides, the peptide concentration at which the substituted peptides achieve half the maximal increase in lysis relative to background is no more than about 1 mM, preferably no more than about 1 µM, more preferably no more than about 1 nM, and still more preferably no more than about 100 pM, and most preferably no more than about 10 pM. It is also preferred that the substituted peptide be recognized by CTLs from more than one individual, at least two, and more preferably three individuals.

[0096] Stimulation of an immune response is dependent upon the presence of antigens recognized as foreign by the host immune system. The discovery of the existence of tumor associated antigens has now raised the possibility of using a host's immune system to intervene in tumor growth. Various mechanisms of harnessing both the humoral and cellular arms of the immune system are currently explored for cancer immunotherapy.

[0097] Specific elements of the cellular immune response are capable of specifically recognizing and destroying tumor cells. The isolation of cytotoxic T-cells (CTL) from tumor-infiltrating cell populations or from peripheral blood suggests that such cells play an important role in natural immune defences against cancer. CD8-positive T-cells in particular, which recognize class I molecules of the major histocompatibility complex (MHC)-bearing peptides of usually 8 to 12 residues derived from proteins or defect ribosomal products (DRIPS) located in the cytosols, play an important role in this response. The MHC-molecules of the human are also designated as human leukocyte-antigens (HLA).

[0098] MHC class I molecules can be found on most cells having a nucleus which present peptides that result from proteolytic cleavage of mainly endogenous, cytosolic or nuclear proteins, DRIPS, and larger peptides. However, peptides derived from endosomal compartments or exogenous sources are also frequently found on MHC class I molecules. This non-classical way of class I presentation is referred to as cross-presentation in literature.

[0099] Since both types of response, CD8 and CD4 dependent, contribute jointly and synergistically to the anti-tumor effect, the identification and characterization of tumor-associated antigens recognized by either CD8-positive CTLs (MHC class I molecule) or by CD4-positive CTLs (MHC class II molecule) is important in the development of tumor vaccines. It is therefore an object of the present invention, to provide compositions of peptides that contain peptides binding to MHC complexes of either class.

[0100] Considering the severe side-effects and expense associated with treating cancer better prognosis and diagnostic methods are desperately needed. Therefore, there is a need to identify other factors representing biomarkers for cancer in general and CLL in particular. Furthermore, there is a need to identify factors that can be used in the treatment of cancer in general and CLL in particular.

[0101] The present invention provides peptides that are useful in treating cancers / tumors, preferably CLL that over- or exclusively present the peptides of the invention. These peptides were shown by mass spectrometry to be naturally presented by HLA molecules on primary human CLL samples.

[0102] The source gene/protein (also designated "full-length protein" or "underlying protein") from which the peptides are derived were shown to be highly overexpressed in diseased (e.g. cancerous) compared with normal tissues. "Normal tissues" in relation to this invention shall particularly mean a blood sample from a healthy donor and sub-populations of blood cells,especially white blood cells, (see example 2, and figure 2) demonstrating a high degree of tumor association of the source genes. Moreover, the peptides themselves are strongly over-presented on tumor tissue - "tumor tissue" in relation to this invention shall mean a blood sample from a patient suffering from CLL and sub-populations of blood cells,especially white blood cells, but not on normal tissues (see example 3 and Figure 3).

[0103] HLA-bound peptides can be recognized by the immune system, specifically T lymphocytes/T cells. T cells can destroy the cells presenting the recognized HLA/peptide complex, e.g. cells presenting the peptides of the present invention that are derived from their underlying proteins.

[0104] The peptides as disclosed have been shown to be capable of stimulating T cell responses and/or are over-presented and thus can be used for the production of antibodies and/or TCRs, in particular sTCRs, according to the present invention (see example 4 and figure 4). Furthermore, the peptides when complexed with the respective MHC can be used for the production of antibodies and / or TCRs, in particular sTCRs, according to the present invention, as well. Respective methods are well known to the person of skill, and can be found in the respective literature as well. Thus, the peptides of the present invention are useful for generating an immune response in a patient by which tumor cells can be destroyed. An immune response in a patient can be induced by direct administration of the described peptides or suitable precursor substances (e.g. elongated peptides, proteins, or nucleic acids encoding these peptides) to the patient, ideally in combination with an agent enhancing the immunogenicity (i.e. an adjuvant). The immune response originating from such a therapeutic vaccination can be expected to be highly specific against tumor cells because the target peptides of the present invention are not presented on normal tissues in comparable copy numbers, preventing the risk of undesired autoimmune reactions against normal cells in the patient.

[0105] A "pharmaceutical composition" is a composition suitable for administration to a human being in a medical setting. Preferably, said pharmaceutical composition is sterile and produced according to the GMP guidelines.

[0106] The pharmaceutical compositions comprise the peptides either in the free form or in the form of a pharmaceutically acceptable salt (see also above). As used herein, "a pharmaceutically acceptable salt" refers to a derivative of the disclosed peptides wherein the peptide is modified by making acid or base salts of the agent. For example, acid salts are prepared from the free base (typically wherein the neutral form of the drug has a neutral -NH2 group) involving reaction with a suitable acid. Suitable acids for preparing acid salts include both organic acids, e.g., acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methane sulfonic acid, ethane sulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like, as well as inorganic acids, e.g., hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid phosphoric acid and the like. Conversely, preparation of basic salts of acid moieties which may be present on a peptide are prepared using a pharmaceutically acceptable base such as sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, trimethylamine or the like.

[0107] In an especially preferred embodiment, the pharmaceutical compositions comprise the peptides as salts of acetic acid (acetates), trifluoro acetates or hydrochloric acid (chlorides).

[0108] The peptides of the present invention can be used to generate and develop specific antibodies against MHC/peptide complexes. These can be used for therapy, targeting toxins or radioactive substances to the diseased tissue. Another use of these antibodies can be targeting radionuclides to the diseased tissue for imaging purposes such as PET. This use can help to detect small metastases or to determine the size and precise localization of diseased tissues.

[0109] Therefore, it is a further aspect of the invention to provide a method for producing a recombinant antibody specifically binding to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen, the method comprising: immunizing a genetically engineered non-human mammal comprising cells expressing said human major histocompatibility complex (MHC) class I with a soluble form of a MHC class I molecule being complexed with said HLA-restricted antigen; isolating mRNA molecules from antibody producing cells of said non-human mammal; producing a phage display library displaying protein molecules encoded by said mRNA molecules; and isolating at least one phage from said phage display library, said at least one phage displaying said antibody specifically binding to said human major histocompatibility complex (MHC) class I being complexed with said HLA-restricted antigen.

[0110] It is a further aspect of the invention to provide an antibody that specifically binds to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen, wherein the antibody preferably is a polyclonal antibody, monoclonal antibody, bi-specific antibody and/or a chimeric antibody.

[0111] Yet another aspect of the present invention then relates to a method of producing said antibody specifically binding to a human major histocompatibility complex (MHC) class I being complexed with a HLA-restricted antigen, the method comprising: immunizing a genetically engineered non-human mammal comprising cells expressing said human major histocompatibility complex (MHC) class I with a soluble form of a MHC class I molecule being complexed with said HLA-restricted antigen; isolating mRNA molecules from antibody producing cells of said non-human mammal; producing a phage display library displaying protein molecules encoded by said mRNA molecules; and isolating at least one phage from said phage display library, said at least one phage displaying said antibody specifically bindable to said human major histocompatibility complex (MHC) class I being complexed with said HLA-restricted antigen. Respective methods for producing such antibodies and single chain class I major histocompatibility complexes, as well as other tools for the production of these antibodies are disclosed in WO 03/068201, WO 2004/084798, WO 01/72768, WO 03/070752, and Cohen CJ, et al. Recombinant antibodies with MHC-restricted, peptide-specific, T-cell receptor-like specificity: new tools to study antigen presentation and TCR-peptide-MHC interactions. J Mol Recognit. 2003 Sep-Oct;16(5):324-32.; Denkberg G, et al. Selective targeting of melanoma and APCs using a recombinant antibody with TCR-like specificity directed toward a melanoma differentiation antigen. J Immunol. 2003 Sep 1;171(5):2197-207; and Cohen CJ, et al. Direct phenotypic analysis of human MHC class I antigen presentation: visualization, quantitation, and in situ detection of human viral epitopes using peptide-specific, MHC-restricted human recombinant antibodies. J Immunol. 2003 Apr 15; 170(8):4349-61.

[0112] Preferably, the antibody is binding with a binding affinity of below 20 nanomolar, preferably of below 10 nanomolar, to the complex, which is regarded as "specific" in the context of the present invention.

[0113] It is a further aspect of the invention to provide a method for producing a soluble T-cell receptor recognizing a specific peptide-MHC complex. Such soluble T-cell receptors can be generated from specific T-cell clones, and their affinity can be increased by mutagenesis targeting the complementarity-determining regions. For the purpose of T-cell receptor selection, phage display can be used (US 2010/0113300, Liddy N, et al. Monoclonal TCR-redirected tumor cell killing. Nat Med 2012 Jun;18(6):980-987). For the purpose of stabilization of T-cell receptors during phage display and in case of practical use as drug, alpha and beta chain can be linked e.g. by non-native disulfide bonds, other covalent bonds (single-chain T-cell receptor), or by dimerization domains (see Boulter JM, et al. Stable, soluble T-cell receptor molecules for crystallization and therapeutics. Protein Eng 2003 Sep;16(9):707-711.; Card KF, et al. A soluble single-chain T-cell receptor IL-2 fusion protein retains MHC-restricted peptide specificity and IL-2 bioactivity. Cancer Immunol Immunother 2004 Apr;53(4):345-357; and Willcox BE, et al. Production of soluble alphabeta T-cell receptor heterodimers suitable for biophysical analysis of ligand binding. Protein Sci 1999 Nov; 8 (11):2418-2423). The T-cell receptor can be linked to toxins, drugs, cytokines (see US 2013/0115191), domains recruiting effector cells such as an anti-CD3 domain, etc., in order to execute particular functions on target cells. Moreover, it could be expressed in T cells used for adoptive transfer.

[0114] Further information can be found in WO 2004/033685A1 and WO 2004/074322A1. A combination of sTCRs is described in WO 2012/056407A1. Further methods for the production are disclosed in WO 2013/057586A1.

[0115] In addition, they can be used to verify a pathologist's diagnosis of a cancer based on a biopsied sample.

[0116] In order to select over-presented peptides, a presentation profile is calculated showing the median sample presentation as well as replicate variation. The profile juxtaposes samples of the tumor entity of interest to a baseline of normal tissue samples. Each of these profiles can then be consolidated into an over-presentation score by calculating the p-value of a Linear Mixed-Effects Model (J. Pinheiro, et al. The nlme Package: Linear and Nonlinear Mixed Effects Models. 2007) adjusting for multiple testing by False Discovery Rate (Y. Benjamini and Y. Hochberg. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. Journal of the Royal Statistical Society. Series B (Methodological), Vol.57 (No.1):289-300, 1995).

[0117] For the identification and relative quantitation of HLA ligands by mass spectrometry, HLA molecules from shock-frozen tissue samples were purified and HLA-associated peptides were isolated. The isolated peptides were separated and sequences were identified by online nano-electrospray-ionization (nanoESI) liquid chromatography-mass spectrometry (LC-MS) experiments. The resulting peptide sequences were verified by comparison of the fragmentation pattern of natural TUMAPs recorded from CLL samples with the fragmentation patterns of corresponding synthetic reference peptides of identical sequences. Since the peptides were directly identified as ligands of HLA molecules of primary tumors, these results provide direct evidence for the natural processing and presentation of the identified peptides on primary cancer tissue obtained from CLL patients.

[0118] The discovery pipeline XPRESIDENT® v2.1 (see, for example, US 2013-0096016,) allows the identification and selection of relevant over-presented peptide vaccine candidates based on direct relative quantitation of HLA-restricted peptide levels on cancer tissues in comparison to several different non-cancerous tissues and organs. This was achieved by the development of label-free differential quantitation using the acquired LC-MS data processed by a proprietary data analysis pipeline, combining algorithms for sequence identification, spectral clustering, ion counting, retention time alignment, charge state deconvolution and normalization.

[0119] Presentation levels including error estimates for each peptide and sample were established. Peptides exclusively presented on tumor tissue and peptides over-presented in tumor versus non-cancerous tissues and organs have been identified.

[0120] HLA-peptide complexes from CLL tissue samples were purified and HLA-associated peptides were isolated and analysed by LC-MS (see examples). All TUMAPs contained in the present application were identified with this approach on primary CLL samples confirming their presentation on primary CLL.

[0121] All TUMAPs contained in the application at hand were identified with this approach on primary CLL samples confirming their presentation on primary CLL.

[0122] TUMAPs identified on multiple CLL tumor and normal tissues were quantified using ion-counting of label-free LC-MS data. The method assumes that LC-MS signal areas of a peptide correlate with its abundance in the sample. All quantitative signals of a peptide in various LC-MS experiments were normalized based on central tendency, averaged per sample and merged into a bar plot, called presentation profile. The presentation profile consolidates different analysis methods like protein database search, spectral clustering, charge state deconvolution (decharging) and retention time alignment and normalization.

[0123] The present invention therefore relates to a peptide of between 10 and 30 amino acids in length, comprising an amino acid sequence consisting of SEQ ID NO: 167, or a pharmaceutically acceptable salt thereof.

[0124] The present invention further relates to the peptides according to the invention that have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I.

[0125] The present invention further relates to the peptides according to the invention wherein the peptide consists of an amino acid sequence according to SEQ ID NO: 167.

[0126] The present invention further relates to the peptides according to the invention, wherein the peptide includes non-peptide bonds.

[0127] The present invention further relates to the peptides according to the invention, wherein the peptide is a fusion protein, comprising (a) an amino acid sequence consisting of SEQ ID NO: 167; and (b) N-terminal amino acids 1-80 of HLA-DR antigen-associated invariant chain (Ii).

[0128] The present invention further relates to a nucleic acid, encoding the peptides according to the invention.

[0129] The present invention further relates to the nucleic acid according to the invention that is DNA, cDNA, PNA, RNA or combinations thereof.

[0130] The present invention further relates to an expression vector expressing a nucleic acid according to the invention.

[0131] The present invention further relates to a host cell comprising a nucleic acid according to the invention or an expression vector according to the invention.

[0132] The present invention further relates to the host cell according to the invention that is an antigen presenting cell.

[0133] The present invention further relates to the host cell according to the invention wherein the antigen presenting cell is a dendritic cell.

[0134] The present invention further relates to a method for producing a peptide according to the invention, the method comprising culturing the host cell described, and isolating the peptide from the host cell or its culture medium.

[0135] The present invention further relates to an in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is any peptide according to the invention.

[0136] The present invention further relates to the method as described, wherein said antigen is loaded onto class I MHC molecules expressed on the surface of a suitable antigen-presenting cell by contacting a sufficient amount of the antigen with an antigen-presenting cell.

[0137] The present invention further relates to the method according to the invention, wherein the antigen-presenting cell comprises an expression vector expressing said peptide containing SEQ ID NO: 167.

[0138] The present invention further relates to activated cytotoxic T lymphocytes (CTL), produced by the method according to the invention, which selectively recognise a cell which aberrantly expresses a polypeptide comprising an amino acid sequence described.

[0139] The present invention further discloses a method of killing target cells in a patient which target cells aberrantly express a polypeptide comprising any amino acid sequence according to the invention, the method comprising administering to the patient an effective number of cytotoxic T lymphocytes (CTL) according to the invention.

[0140] The present invention further relates to any peptide according to the invention, a nucleic acid according to the invention, an expression vector according to the invention, a cell according to the invention, or an activated cytotoxic T lymphocyte according to the invention for use as a medicament against cancer.

[0141] The present invention further relates to a use according to the invention, wherein the medicament is a vaccine.

[0142] The present invention further relates to a use according to the invention, wherein said cancer cells are CLL cells or other non solid tumor cells.

[0143] The term "antibody" or "antibodies" is used herein in a broad sense and includes both polyclonal and monoclonal antibodies. In addition to intact or "full" immunoglobulin molecules, also included in the term "antibodies" are fragments or polymers of those immunoglobulin molecules and humanized versions of immunoglobulin molecules, so long as they exhibit any of the desired properties (e.g., specific binding of an CLL marker polypeptide, delivery of a toxin to an CLL (leukimea) cells expressing a CLL marker gene at an increased level, and/or inhibiting the activity of a CLL marker polypeptide) according to the invention.

[0144] Whenever possible, the antibodies of the invention may be purchased from commercial sources. The antibodies of the invention may also be generated using well-known methods. The skilled artisan will understand that either full length CLL marker polypeptides or fragments thereof may be used to generate the antibodies of the invention. A polypeptide to be used for generating an antibody of the invention may be partially or fully purified from a natural source, or may be produced using recombinant DNA techniques.

[0145] For example, a cDNA encoding a peptide according to the present invention, such as a peptide according to SEQ ID NO: 167 polypeptide, or a variant or fragment thereof, can be expressed in prokaryotic cells (e.g., bacteria) or eukaryotic cells (e.g., yeast, insect, or mammalian cells), after which the recombinant protein can be purified and used to generate a monoclonal or polyclonal antibody preparation that specifically bind the CLL marker polypeptide used to generate the antibody according to the invention.

[0146] One of skill in the art will realize that the generation of two or more different sets of monoclonal or polyclonal antibodies maximizes the likelihood of obtaining an antibody with the specificity and affinity required for its intended use (e.g., ELISA, immunohistochemistry, in vivo imaging, immunotoxin therapy). The antibodies are tested for their desired activity by known methods, in accordance with the purpose for which the antibodies are to be used (e.g., ELISA, immunohistochemistry, immunotherapy, etc.; for further guidance on the generation and testing of antibodies, see, e.g., Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1988, new 2nd edition 2013). For example, the antibodies may be tested in ELISA assays or Western blots. After their initial in vitro characterization, antibodies intended for therapeutic or in vivo diagnostic use are tested according to known clinical testing methods.

[0147] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e.; the individual antibodies comprising the population are identical except for possible naturally occurring mutations that may be present in minor amounts. The monoclonal antibodies herein specifically include "chimeric" antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, so long as they exhibit the desired antagonistic activity (U.S. Pat. No. 4,816,567).

[0148] Monoclonal antibodies of the invention may be prepared using hybridoma methods. In a hybridoma method, a mouse or other appropriate host animal is typically immunized with an immunizing agent to elicit lymphocytes that produce or are capable of producing antibodies that will specifically bind to the immunizing agent. Alternatively, the lymphocytes may be immunized in vitro.

[0149] The monoclonal antibodies may also be made by recombinant DNA methods, such as those described in U.S. Pat. No. 4,816,567. DNA encoding the monoclonal antibodies of the invention can be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of murine antibodies).

[0150] In vitro methods are also suitable for preparing monovalent antibodies. Digestion of antibodies to produce fragments thereof, particularly, Fab fragments, can be accomplished using routine techniques known in the art. For instance, digestion can be performed using papain. Examples of papain digestion are described in WO 94/29348 and U.S. Pat. No. 4,342,566. Papain digestion of antibodies typically produces two identical antigen binding fragments, called Fab fragments, each with a single antigen binding site, and a residual Fc fragment. Pepsin treatment yields a a F(ab')2 fragment and a pFc' fragment.

[0151] The antibody fragments, whether attached to other sequences or not, can also include insertions, deletions, substitutions, or other selected modifications of particular regions or specific amino acids residues, provided the activity of the fragment is not significantly altered or impaired compared to the non-modified antibody or antibody fragment. These modifications can provide for some additional property, such as to remove/add amino acids capable of disulfide bonding, to increase its bio-longevity, to alter its secretory characteristics, etc. In any case, the antibody fragment must possess a bioactive property, such as binding activity, regulation of binding at the binding domain, etc. Functional or active regions of the antibody may be identified by mutagenesis of a specific region of the protein, followed by expression and testing of the expressed polypeptide. Such methods are readily apparent to a skilled practitioner in the art and can include site-specific mutagenesis of the nucleic acid encoding the antibody fragment.

[0152] The antibodies of the invention may further comprise humanized antibodies or human antibodies. Humanized forms of non-human (e.g., murine) antibodies are chimeric immunoglobulins, immunoglobulin chains or fragments thereof (such as Fv, Fab, Fab' or other antigen-binding subsequences of antibodies) which contain minimal sequence derived from non-human immunoglobulin. Humanized antibodies include human immunoglobulins (recipient antibody) in which residues from a complementary determining region (CDR) of the recipient are replaced by residues from a CDR of a non-human species (donor antibody) such as mouse, rat or rabbit having the desired specificity, affinity and capacity. In some instances, Fv framework (FR) residues of the human immunoglobulin are replaced by corresponding non-human residues. Humanized antibodies may also comprise residues which are found neither in the recipient antibody nor in the imported CDR or framework sequences. In general, the humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the CDR regions correspond to those of a non-human immunoglobulin and all or substantially all of the FR regions are those of a human immunoglobulin consensus sequence. The humanized antibody optimally also will comprise at least a portion of an immunoglobulin constant region (Fc), typically that of a human immunoglobulin.

[0153] Methods for humanizing non-human antibodies are well known in the art. Generally, a humanized antibody has one or more amino acid residues introduced into it from a source which is non-human. These non-human amino acid residues are often referred to as "import" residues, which are typically taken from an "import" variable domain. Humanization can be essentially performed by substituting rodent CDRs or CDR sequences for the corresponding sequences of a human antibody. Accordingly, such "humanized" antibodies are chimeric antibodies (U.S. Pat. No. 4,816,567), wherein substantially less than an intact human variable domain has been substituted by the corresponding sequence from a non-human species. In practice, humanized antibodies are typically human antibodies in which some CDR residues and possibly some FR residues are substituted by residues from analogous sites in rodent antibodies.

[0154] Transgenic animals (e.g., mice) that are capable, upon immunization, of producing a full repertoire of human antibodies in the absence of endogenous immunoglobulin production can be employed. For example, it has been described that the homozygous deletion of the antibody heavy chain joining region gene in chimeric and germ-line mutant mice results in complete inhibition of endogenous antibody production. Transfer of the human germ-line immunoglobulin gene array in such germ-line mutant mice will result in the production of human antibodies upon antigen challenge. Human antibodies can also be produced in phage display libraries.

[0155] Antibodies of the invention are preferably administered to a subject in a pharmaceutically acceptable carrier. Typically, an appropriate amount of a pharmaceutically-acceptable salt is used in the formulation to render the formulation isotonic. Examples of the pharmaceutically-acceptable carrier include saline, Ringer's solution and dextrose solution. The pH of the solution is preferably from about 5 to about 8, and more preferably from about 7 to about 7.5. Further carriers include sustained release preparations such as semipermeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, e.g., films, liposomes or microparticles. It will be apparent to those persons skilled in the art that certain carriers may be more preferable depending upon, for instance, the route of administration and concentration of antibody being administered.

[0156] The antibodies can be administered to the subject, patient, or cell by injection (e.g., intravenous, intraperitoneal, subcutaneous, intramuscular), or by other methods such as infusion that ensure its delivery to the bloodstream in an effective form. The antibodies may also be administered by intratumoral or peritumoral routes, to exert local as well as systemic therapeutic effects. Local or intravenous injection is preferred.

[0157] Effective dosages and schedules for administering the antibodies may be determined empirically, and making such determinations is within the skill in the art. Those skilled in the art will understand that the dosage of antibodies that must be administered will vary depending on, for example, the subject that will receive the antibody, the route of administration, the particular type of antibody used and other drugs being administered. A typical daily dosage of the antibody used alone might range from about 1 (µg/kg to up to 100 mg/kg of body weight or more per day, depending on the factors mentioned above. Following administration of an antibody for treating CLL, the efficacy of the therapeutic antibody can be assessed in various ways well known to the skilled practitioner.

[0158] The antibodies may also be used for in vivo diagnostic assays. Generally, the antibody is labeled with a radionucleotide (such as 111In, 99Tc, 14C, 131I, 3H, 32P or 35 S) so that the tumor can be localized using immunoscintiography.

[0159] Antibodies for diagnostic use may be labeled with probes suitable for detection by various imaging methods. Methods for detection of probes include, but are not limited to, fluorescence, light, confocal and electron microscopy; magnetic resonance imaging and spectroscopy; fluoroscopy, computed tomography and positron emission tomography. Suitable probes include, but are not limited to, fluorescein, rhodamine, eosin and other fluorophores, radioisotopes, gold, gadolinium and other lanthanides, paramagnetic iron, fluorine-18 and other positron-emitting radionuclides. Additionally, probes may be bi- or multi-functional and be detectable by more than one of the methods listed. These antibodies may be directly or indirectly labeled with said probes. Attachment of probes to the antibodies includes covalent attachment of the probe, incorporation of the probe into the antibody, and the covalent attachment of a chelating compound for binding of probe, amongst others well recognized in the art. For immunohistochemistry, the disease tissue sample may be fresh or frozen or may be embedded in paraffin and fixed with a preservative such as formalin. The fixed or embedded section contains the sample are contacted with a labeled primary antibody and secondary antibody, wherein the antibody is used to detect the expression of the proteins in situ.

[0160] The present invention thus provides a peptide of between 10 and 30 amino acids in length, comprising an amino acid sequence consisting of SEQ ID NO: 167, or a pharmaceutically acceptable salt thereof.

[0161] The peptides of the invention have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class-I.

[0162] In the present invention, the term "homologous" refers to the degree of identity (see Percent Identity above) between sequences of two amino acid sequences, i.e. peptide or polypeptide sequences. The aforementioned "homology" is determined by comparing two sequences aligned under optimal conditions over the sequences to be compared. Such a sequence homology can be calculated by creating an alignment using, for example, the ClustalW algorithm. Commonly available sequence analysis software, more specifically, Vector NTI, GENETYX or other analysis tools are provided by public databases.

[0163] A person skilled in the art will be able to assess, whether T cells induced by a variant of a specific peptide will be able to cross-react with the peptide itself (Fong L, et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy. Proc Natl Acad Sci USA. 2001 Jul 17;98(15):8809-14; Zaremba S, et al. Identification of an enhancer agonist cytotoxic T lymphocyte peptide from human carcinoembryonic antigen. Cancer Res. 1997 Oct 15;57(20):4570-7; Colombetti S, et al. Impact of orthologous melan-A peptide immunizations on the anti-self melan-A/HLA-A2 T cell cross-reactivity. J Immunol. 2006 Jun 1;176(11):6560-7; Appay V, et al. Decreased specific CD8+ T cell cross-reactivity of antigen recognition following vaccination with Melan-A peptide. Eur J Immunol. 2006 Jul;36(7):1805-14).

[0164] CTL can subsequently cross-react with cells and kill cells that express a polypeptide that contains the natural amino acid sequence of the cognate peptide as defined in the aspects of the invention. As can be derived from the scientific literature (Godkin A, et al. Use of eluted peptide sequence data to identify the binding characteristics of peptides to the insulin-dependent diabetes susceptibility allele HLA-DQ8 (DQ 3.2). Int Immunol. 1997 Jun;9(6):905-11) and databases (Rammensee H. et al. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999 Nov;50(3-4):213-9), certain positions of HLA binding peptides are typically anchor residues forming a core sequence fitting to the binding motif of the HLA receptor, which is defined by polar, electrophysical, hydrophobic and spatial properties of the polypeptide chains constituting the binding groove.

[0165] Longer peptides may also be suitable. It is also possible, that MHC class I epitopes, although usually between 8 and 11 amino acids long, are generated by peptide processing from longer peptides or proteins that include the actual epitope. It is preferred that the residues that flank the actual epitope are residues that do not substantially affect proteolytic cleavage necessary to expose the actual epitope during processing.

[0166] Accordingly, the present invention also provides peptides of MHC class I epitopes wherein the peptide has an overall length of between 10 and 30 amino acids.

[0167] Of course, the peptide according to the present invention will have the ability to bind to a molecule of the human major histocompatibility complex (MHC) class I. Binding of a peptide to a MHC complex may be tested by methods known in the art.

[0168] In a particularly preferred embodiment of the invention the peptide consists of an amino acid sequence according to SEQ ID NO: 167.

[0169] In one embodiment of the present invention, the peptide is a fusion protein which comprises, for example, the 80 N-terminal amino acids of the HLA-DR antigen-associated invariant chain (p33, in the following "Ii") as derived from the NCBI, GenBank Accession number X00497. In other fusions, the peptides of the present invention can be fused to an antibody as described herein, or a functional part thereof, in particular into a sequence of an antibody, so as to be specifically targeted by said antibody, or, for example, to or into an antibody that is specific for dendritic cells.

[0170] In a reverse peptide bond amino acid residues are not joined by peptide (-CO-NH-) linkages but the peptide bond is reversed. Such retro-inverso peptidomimetics may be made using methods known in the art, for example such as those described in Meziere et al (1997) J. Immunol. 159, 3230-3237. This approach involves making pseudopeptides containing changes involving the backbone, and not the orientation of side chains. Meziere et al (1997) show that for MHC binding and T helper cell responses, these pseudopeptides are useful. Retro-inverse peptides, which contain NH-CO bonds instead of CO-NH peptide bonds, are much more resistant to proteolysis.

[0171] A non-peptide bond is, for example, -CH2-NH, -CH2S-, -CH2CH2-, -CH=CH-, -COCH2-, -CH(OH)CH2-, and -CH2SO-. United States Patent 4,897,445 provides a method for the solid phase synthesis of non-peptide bonds (-CH2-NH) in polypeptide chains which involves polypeptides synthesized by standard procedures and the non-peptide bond synthesized by reacting an amino aldehyde and an amino acid in the presence of NaCNBH3.

[0172] Peptides comprising the sequences described above may be synthesized with additional chemical groups present at their amino and/or carboxy termini, to enhance the stability, bioavailability, and/or affinity of the peptides. For example, hydrophobic groups such as carbobenzoxyl, dansyl, or t-butyloxycarbonyl groups may be added to the peptides' amino termini. Likewise, an acetyl group or a 9-fluorenylmethoxycarbonyl group may be placed at the peptides' amino termini. Additionally, the hydrophobic group, t-butyloxycarbonyl, or an amido group may be added to the peptides' carboxy termini.

[0173] A peptide, wherein the peptide includes non-peptide bonds is a preferred embodiment of the invention. Generally, peptides (at least those containing peptide linkages between amino acid residues) may be synthesized by the Fmoc-polyamide mode of solid-phase peptide synthesis as disclosed by Lukas et al. (Solid-phase peptide synthesis under continuous-flow conditions. Proc Natl Acad Sci U S A. May 1981; 78(5): 2791-2795) and references therein. Temporary N-amino group protection is afforded by the 9-fluorenylmethyloxycarbonyl (Fmoc) group. Repetitive cleavage of this highly base-labile protecting group is done using 20% piperidine in N, N-dimethylformamide. Side-chain functionalities may be protected as their butyl ethers (in the case of serine threonine and tyrosine), butyl esters (in the case of glutamic acid and aspartic acid), butyloxycarbonyl derivative (in the case of lysine and histidine), trityl derivative (in the case of cysteine) and 4-methoxy-2,3,6-trimethylbenzenesulphonyl derivative (in the case of arginine). Where glutamine or asparagine are C-terminal residues, use is made of the 4,4'-dimethoxybenzhydryl group for protection of the side chain amido functionalities. The solid-phase support is based on a polydimethyl-acrylamide polymer constituted from the three monomers dimethylacrylamide (backbone-monomer), bisacryloylethylene diamine (cross linker) and acryloylsarcosine methyl ester (functionalizing agent). The peptide-to-resin cleavable linked agent used is the acid-labile 4-hydroxymethyl-phenoxyacetic acid derivative. All amino acid derivatives are added as their preformed symmetrical anhydride derivatives with the exception of asparagine and glutamine, which are added using a reversed N, N-dicyclohexylcarbodiimide/lhydroxybenzotriazole mediated coupling procedure. All coupling and deprotection reactions are monitored using ninhydrin, trinitrobenzene sulphonic acid or isotin test procedures. Upon completion of synthesis, peptides are cleaved from the resin support with concomitant removal of side-chain protecting groups by treatment with 95% trifluoroacetic acid containing a 50 % scavenger mix. Scavengers commonly used include ethandithiol, phenol, anisole and water, the exact choice depending on the constituent amino acids of the peptide being synthesized. Also a combination of solid phase and solution phase methodologies for the synthesis of peptides is possible (see, for example, Bruckdorfer et al., 2004, and the references as cited therein).

[0174] Trifluoroacetic acid is removed by evaporation in vacuo, with subsequent trituration with diethyl ether affording the crude peptide. Any scavengers present are removed by a simple extraction procedure which on lyophilisation of the aqueous phase affords the crude peptide free of scavengers. Reagents for peptide synthesis are generally available from e.g. Calbiochem-Novabiochem (UK) Ltd, Nottingham NG7 2QJ, UK.

[0175] Purification may be performed by any one, or a combination of, techniques such as re-crystallization, size exclusion chromatography, ion-exchange chromatography, hydrophobic interaction chromatography and (usually) reverse-phase high performance liquid chromatography using e.g. acetonitril/water gradient separation.

[0176] Analysis of peptides may be carried out using thin layer chromatography, electrophoresis, in particular capillary electrophoresis, solid phase extraction (CSPE), reverse-phase high performance liquid chromatography, amino-acid analysis after acid hydrolysis and by fast atom bombardment (FAB) mass spectrometric analysis, as well as MALDI and ESI-Q-TOF mass spectrometric analysis.

[0177] A further aspect of the invention provides a nucleic acid (for example a polynucleotide) encoding a peptide of the invention. The polynucleotide may be, for example, DNA, cDNA, PNA, RNA or combinations thereof, either single- and/or double-stranded, or native or stabilized forms of polynucleotides, such as, for example, polynucleotides with a phosphorothioate backbone and it may or may not contain introns so long as it codes for the peptide. Of course, only peptides that contain naturally occurring amino acid residues joined by naturally occurring peptide bonds are encodable by a polynucleotide. A still further aspect of the invention provides an expression vector capable of expressing a polypeptide according to the invention.

[0178] A variety of methods have been developed to link polynucleotides, especially DNA, to vectors for example via complementary cohesive termini. For instance, complementary homopolymer tracts can be added to the DNA segment to be inserted to the vector DNA. The vector and DNA segment are then joined by hydrogen bonding between the complementary homopolymeric tails to form recombinant DNA molecules.

[0179] Synthetic linkers containing one or more restriction sites provide an alternative method of joining the DNA segment to vectors. Synthetic linkers containing a variety of restriction endonuclease sites are commercially available from a number of sources including International Biotechnologies Inc. New Haven, CN, USA.

[0180] A desirable method of modifying the DNA encoding the polypeptide of the invention employs the polymerase chain reaction as disclosed by Saiki RK, et al. (Diagnosis of sickle cell anemia and beta-thalassemia with enzymatically amplified DNA and nonradioactive allele-specific oligonucleotide probes. N Engl J Med. 1988 Sep 1;319(9):537-41). This method may be used for introducing the DNA into a suitable vector, for example by engineering in suitable restriction sites, or it may be used to modify the DNA in other useful ways as is known in the art. If viral vectors are used, pox- or adenovirus vectors are preferred.

[0181] The DNA (or in the case of retroviral vectors, RNA) may then be expressed in a suitable host to produce a polypeptide comprising the peptide of the invention. Thus, the DNA encoding the peptide or variant of the invention may be used in accordance with known techniques, appropriately modified in view of the teachings contained herein, to construct an expression vector, which is then used to transform an appropriate host cell for the expression and production of the polypeptide of the invention. Such techniques include those disclosed in US Patent Nos. 4,440,859, 4,530,901, 4,582,800, 4,677,063, 4,678,751, 4,704,362, 4,710,463, 4,757,006, 4,766,075, and 4,810,648.

[0182] The DNA (or in the case of retroviral vectors, RNA) encoding the polypeptide constituting the compound of the invention may be joined to a wide variety of other DNA sequences for introduction into an appropriate host. The companion DNA will depend upon the nature of the host, the manner of the introduction of the DNA into the host, and whether episomal maintenance or integration is desired.

[0183] Generally, the DNA is inserted into an expression vector, such as a plasmid, in proper orientation and correct reading frame for expression. If necessary, the DNA may be linked to the appropriate transcriptional and translational regulatory control nucleotide sequences recognized by the desired host, although such controls are generally available in the expression vector. The vector is then introduced into the host through standard techniques. Generally, not all of the hosts will be transformed by the vector. Therefore, it will be necessary to select for transformed host cells. One selection technique involves incorporating into the expression vector a DNA sequence, with any necessary control elements, that codes for a selectable trait in the transformed cell, such as antibiotic resistance.

[0184] Alternatively, the gene for such selectable trait can be on another vector, which is used to co-transform the desired host cell.

[0185] Host cells that have been transformed by the recombinant DNA of the invention are then cultured for a sufficient time and under appropriate conditions known to those skilled in the art in view of the teachings disclosed herein to permit the expression of the polypeptide, which can then be recovered.

[0186] Many expression systems are known, including bacteria (for example E. coli and Bacillus subtilis), yeasts (for example Saccharomyces cerevisiae), filamentous fungi (for example Aspergillus spec.), plant cells, animal cells and insect cells. Preferably, the system can be mammalian cells such as CHO cells available from the ATCC Cell Biology Collection.

[0187] A typical mammalian cell vector plasmid for constitutive expression comprises the CMV or SV40 promoter with a suitable poly A tail and a resistance marker, such as neomycin. One example is pSVL available from Pharmacia, Piscataway, NJ, USA. An example of an inducible mammalian expression vector is pMSG, also available from Pharmacia. Useful yeast plasmid vectors are pRS403-406 and pRS413-416 and are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Plasmids pRS403, pRS404, pRS405 and pRS406 are Yeast Integrating plasmids (Yips) and incorporate the yeast selectable markers HIS3, TRP1, LEU2 and URA3. Plasmids pRS413-416 are Yeast Centromere plasmids (Ycps). CMV promoter-based vectors (for example from Sigma-Aldrich) provide transient or stable expression, cytoplasmic expression or secretion, and N-terminal or C-terminal tagging in various combinations of FLAG, 3xFLAG, c-myc or MAT. These fusion proteins allow for detection, purification and analysis of recombinant protein. Dual-tagged fusions provide flexibility in detection.

[0188] The strong human cytomegalovirus (CMV) promoter regulatory region drives constitutive protein expression levels as high as 1 mg/L in COS cells. For less potent cell lines, protein levels are typically ∼0.1 mg/L. The presence of the SV40 replication origin will result in high levels of DNA replication in SV40 replication permissive COS cells. CMV vectors, for example, can contain the pMB1 (derivative of pBR322) origin for replication in bacterial cells, the b-lactamase gene for ampicillin resistance selection in bacteria, hGH polyA, and the f1 origin. Vectors containing the preprotrypsin leader (PPT) sequence can direct the secretion of FLAG fusion proteins into the culture medium for purification using ANTI-FLAG antibodies, resins, and plates. Other vectors and expression systems are well known in the art for use with a variety of host cells.

[0189] In another embodiment two or more peptides of the invention are encoded and thus expressed in a successive order (similar to "beads on a string" constructs). In doing so, the peptides may be linked or fused together by stretches of linker amino acids, such as for example LLLLLL, or may be linked without any additional peptide(s) between them.

[0190] The present invention also relates to a host cell transformed with a polynucleotide vector construct of the present invention. The host cell can be either prokaryotic or eukaryotic. Bacterial cells may be preferred prokaryotic host cells in some circumstances and typically are a strain of E. coli such as, for example, the E. coli strains DH5 available from Bethesda Research Laboratories Inc., Bethesda, MD, USA, and RR1 available from the American Type Culture Collection (ATCC) of Rockville, MD, USA (No ATCC 31343). Preferred eukaryotic host cells include yeast, insect and mammalian cells, preferably vertebrate cells such as those from a mouse, rat, monkey or human fibroblastic and colon cell lines. Yeast host cells include YPH499, YPH500 and YPH501, which are generally available from Stratagene Cloning Systems, La Jolla, CA 92037, USA. Preferred mammalian host cells include Chinese hamster ovary (CHO) cells available from the ATCC as CCL61, NIH Swiss mouse embryo cells NIH/3T3 available from the ATCC as CRL 1658, monkey kidney-derived COS-1 cells available from the ATCC as CRL 1650 and 293 cells which are human embryonic kidney cells. Preferred insect cells are Sf9 cells which can be transfected with baculovirus expression vectors. An overview regarding the choice of suitable host cells for expression can be found in, for example, the textbook of Paulina Balbás and Argelia Lorence "Methods in Molecular Biology Recombinant Gene Expression, Reviews and Protocols," Part One, Second Edition, ISBN 978-1-58829-262-9, and other literature known to the person of skill.

[0191] Transformation of appropriate cell hosts with a DNA construct of the present invention is accomplished by well-known methods that typically depend on the type of vector used. With regard to transformation of prokaryotic host cells, see, for example, Cohen et al (1972) Proc. Natl. Acad. Sci. USA 69, 2110, and Sambrook et al (1989) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. Transformation of yeast cells is described in Sherman et al (1986) Methods In Yeast Genetics, A Laboratory Manual, Cold Spring Harbor, NY. The method of Beggs (1978) Nature 275,104-109 is also useful. With regard to vertebrate cells, reagents useful in transfecting such cells, for example calcium phosphate and DEAE-dextran or liposome formulations, are available from Stratagene Cloning Systems, or Life Technologies Inc., Gaithersburg, MD 20877, USA. Electroporation is also useful for transforming and/or transfecting cells and is well known in the art for transforming yeast cell, bacterial cells, insect cells and vertebrate cells.

[0192] Successfully transformed cells, i.e. cells that contain a DNA construct of the present invention, can be identified by well-known techniques such as PCR. Alternatively, the presence of the protein in the supernatant can be detected using antibodies.

[0193] It will be appreciated that certain host cells of the invention are useful in the preparation of the peptides of the invention, for example bacterial, yeast and insect cells. However, other host cells may be useful in certain therapeutic methods. For example, antigen-presenting cells, such as dendritic cells, may usefully be used to express the peptides of the invention such that they may be loaded into appropriate MHC molecules. Thus, the current invention provides a host cell comprising a nucleic acid or an expression vector according to the invention.

[0194] In a preferred embodiment the host cell is an antigen presenting cell, in particular a dendritic cell or antigen presenting cell. APCs loaded with a recombinant fusion protein containing prostatic acid phosphatase (PAP) were approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010, to treat asymptomatic or minimally symptomatic metastatic HRPC (Sipuleucel-T) (Small EJ, et al. Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006 Jul 1;24(19):3089-94. Rini et al. Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy. Cancer. 2006 Jul 1:107(1):67-74).

[0195] A further aspect of the invention provides a method of producing a peptide, the method comprising culturing a host cell and isolating the peptide from the host cell or its culture medium.

[0196] In another embodiment the peptide, the nucleic acid or the expression vector of the invention are used in medicine. For example, the peptide may be prepared for intravenous (i.v.) injection, sub-cutaneous (s.c.) injection, intradermal (i.d.) injection, intraperitoneal (i.p.) injection, intramuscular (i.m.) injection. Preferred methods of peptide injection include s.c., i.d., i.p., i.m., and i.v. Preferred methods of DNA injection include i.d., i.m., s.c., i.p. and i.v. Doses of e.g. between 50 µg and 1.5 mg, preferably 125 µg to 500 µg, of peptide or DNA may be given and will depend on the respective peptide or DNA. Dosages of this range were successfully used in previous trials (Walter et al Nature Medicine 18, 1254-1261 (2012)).

[0197] Another aspect of the present invention includes an in vitro method for producing activated T cells, the method comprising contacting in vitro T cells with antigen loaded human MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate the T cell in an antigen specific manner, wherein the antigen is a peptide according to the invention. Preferably a sufficient amount of the antigen is used with an antigen-presenting cell.

[0198] Preferably the mammalian cell lacks or has a reduced level or function of the TAP peptide transporter. Suitable cells that lack the TAP peptide transporter include T2, RMA-S and Drosophila cells. TAP is the transporter associated with antigen processing.

[0199] The human peptide loading deficient cell line T2 is available from the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Maryland 20852, USA under Catalogue No CRL 1992; the Drosophila cell line Schneider line 2 is available from the ATCC under Catalogue No CRL 19863; the mouse RMA-S cell line is described in Karre et al 1985 (Ljunggren, H.-G., and K. Karre. 1985. J. Exp. Med. 162:1745).

[0200] Preferably, the host cell before transfection expresses substantially no MHC class I molecules. It is also preferred that the stimulator cell expresses a molecule important for providing a co-stimulatory signal for T-cells such as any of B7.1, B7.2, ICAM-1 and LFA 3. The nucleic acid sequences of numerous MHC class I molecules and of the co-stimulator molecules are publicly available from the GenBank and EMBL databases.

[0201] In case of a MHC class I epitope being used as an antigen, the T cells are CD8-positive CTLs.

[0202] If an antigen-presenting cell is transfected to express such an epitope, preferably the cell comprises an expression vector expressing a peptide containing SEQ ID NO: 167.

[0203] A number of other methods may be used for generating CTL in vitro. For example, autologous tumor-infiltrating lymphocytes can be used in the generation of CTL. Plebanski et al (1995) (Induction of peptide-specific primary cytotoxic T lymphocyte responses from human peripheral blood.Eur J Immunol. 1995 Jun;25(6):1783-7) make use of autologous peripheral blood lymphocytes (PLBs) in the preparation of CTL. Furthermore, the production of autologous CTL by pulsing dendritic cells with peptide or polypeptide, or via infection with recombinant virus is possible. Also, B cells can be used in the production of autologous CTL. In addition, macrophages pulsed with peptide or polypeptide, or infected with recombinant virus, may be used in the preparation of autologous CTL. S. Walter et al. 2003 (Cutting edge: predetermined avidity of human CD8 T cells expanded on calibrated MHC/anti-CD28-coated microspheres.J Immunol. 2003 Nov 15;171(10):4974-8) describe the in vitro priming of T cells by using artificial antigen presenting cells (aAPCs), which is also a suitable way for generating T cells against the peptide of choice. In the present invention, aAPCs were generated by the coupling of preformed MHC:peptide complexes to the surface of polystyrene particles (microbeads) by biotin:streptavidin biochemistry. This system permits the exact control of the MHC density on aAPCs, which allows to selectively elicit high- or low-avidity antigen-specific T cell responses with high efficiency from blood samples. Apart from MHC:peptide complexes, aAPCs should carry other proteins with co-stimulatory activity like anti-CD28 antibodies coupled to their surface. Furthermore such aAPC-based systems often require the addition of appropriate soluble factors, e. g. cytokines, like interleukin-12.

[0204] Allogeneic cells may also be used in the preparation of T cells and a method is described in detail in WO 97/26328. For example, in addition to Drosophila cells and T2 cells, other cells may be used to present antigens such as CHO cells, baculovirus-infected insect cells, bacteria, yeast, vaccinia-infected target cells. In addition plant viruses may be used (see, for example, Porta et al. (1994) Development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.Virology. 1994 Aug 1;202(2):949-55) which describes the development of cowpea mosaic virus as a high-yielding system for the presentation of foreign peptides.

[0205] The activated T cells that are directed against the peptides of the invention are useful in therapy. Thus, a further aspect of the invention provides activated T cells obtainable by the foregoing methods of the invention.

[0206] Activated T cells, which are produced by the above method, will selectively recognize a cell that aberrantly expresses a polypeptide that comprises an amino acid sequence of SEQ ID NO: 167.

[0207] Preferably, the T cell recognizes the cell by interacting through its TCR with the HLA/peptide-complex (for example, binding). The T cells are useful in a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention wherein the patient is administered an effective number of the activated T cells. The T cells that are administered to the patient may be derived from the patient and activated as described above (i.e. they are autologous T cells). Alternatively, the T cells are not from the patient but are from another individual. Of course, it is preferred if the individual is a healthy individual. By "healthy individual" the inventors mean that the individual is generally in good health, preferably has a competent immune system and, more preferably, is not suffering from any disease that can be readily tested for, and detected.

[0208] In vivo, the target cells for the CD8-positive T cells according to the present invention can be cells of the tumor (which sometimes express MHC class II) and/or stromal cells surrounding the tumor (tumor cells) (which sometimes also express MHC class II; (Dengjel et al., 2006)).

[0209] The T cells of the present invention may be used as active ingredients of a therapeutic composition. Thus, the invention also provides a method of killing target cells in a patient whose target cells aberrantly express a polypeptide comprising an amino acid sequence of the invention, the method comprising administering to the patient an effective number of T cells as defined above.

[0210] By "aberrantly expressed" the inventors also mean that the polypeptide is over-expressed compared to normal levels of expression or that the gene is silent in the tissue from which the tumor is derived but in the tumor it is expressed. By "over-expressed" the inventors mean that the polypeptide is present at a level at least 1.2-fold of that present in normal tissue; preferably at least 2-fold, and more preferably at least 5-fold or 10-fold the level present in normal tissue.

[0211] T cells may be obtained by methods known in the art, e.g. those described above.

[0212] Protocols for this so-called adoptive transfer of T cells are well known in the art. Reviews can be found in: Gattinoni L, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006 May;6(5):383-93. Review, and Morgan RA, et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science. 2006 Oct 6;314(5796):126-9).

[0213] Any molecule of the invention, i.e. the peptide, nucleic acid, antibody, expression vector, cell, activated CTL, T-cell receptor or the nucleic acid encoding it is useful for the treatment of disorders, characterized by cells escaping an immune response.

[0214] Therefore any molecule of the present invention may be used as medicament or in the manufacture of a medicament. The molecule may be used by itself or combined with other molecule(s) of the invention or (a) known molecule(s).

[0215] Preferably, the medicament of the present invention is a vaccine. It may be administered directly into the patient, into the affected organ or systemically i.d., i.m., s.c., i.p. and i.v., or applied ex vivo to cells derived from the patient or a human cell line which are subsequently administered to the patient, or used in vitro to select a subpopulation of immune cells derived from the patient, which are then re-administered to the patient. If the nucleic acid is administered to cells in vitro, it may be useful for the cells to be transfected so as to co-express immune-stimulating cytokines, such as interleukin-2. The peptide may be substantially pure, or combined with an immune-stimulating adjuvant (see below) or used in combination with immune-stimulatory cytokines, or be administered with a suitable delivery system, for example liposomes. The peptide may also be conjugated to a suitable carrier such as keyhole limpet haemocyanin (KLH) or mannan (see WO 95/18145 and Longenecker, 1993). The peptide may also be tagged, may be a fusion protein, or may be a hybrid molecule. The peptides whose sequence is given in the present invention are expected to stimulate CD4 or CD8 T cells. However, stimulation of CD8 CTLs is more efficient in the presence of help provided by CD4 T-helper cells. Thus, for MHC Class I epitopes that stimulate CD8 CTL the fusion partner or sections of a hybrid molecule suitably provide epitopes which stimulate CD4-positive T cells. CD4- and CD8-stimulating epitopes are well known in the art and include those identified in the present invention.

[0216] In one aspect, the vaccine comprises at least one peptide having the amino acid sequence set forth SEQ ID No. 167, and at least one additional peptide, preferably two to 50, more preferably two to 25, even more preferably two to 20 and most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen or eighteen peptides. The peptide(s) may be derived from one or more specific TAAs and may bind to MHC class I molecules.

[0217] In another aspect, the vaccine comprises at least one peptide having the amino acid sequence set forth in SEQ ID NO: 167, and at least one additional peptide, preferably two to 50, more preferably two to 25, even more preferably two to 20 and most preferably two, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen or eighteen peptides. The peptide(s) may be derived from one or more specific TAAs and may bind to MHC class I molecules.

[0218] The polynucleotide may be substantially pure, or contained in a suitable vector or delivery system. The nucleic acid may be DNA, cDNA, PNA, RNA or a combination thereof. Methods for designing and introducing such a nucleic acid are well known in the art. An overview is provided by e.g. (Pascolo et al., Human peripheral blood mononuclear cells transfected with messenger RNA stimulate antigen-specific cytotoxic T-lymphocytes in vitro.Cell Mol Life Sci. 2005 Aug;62(15):1755-62). Polynucleotide vaccines are easy to prepare, but the mode of action of these vectors in inducing an immune response is not fully understood. Suitable vectors and delivery systems include viral DNA and/or RNA, such as systems based on adenovirus, vaccinia virus, retroviruses, herpes virus, adeno-associated virus or hybrids containing elements of more than one virus. Non-viral delivery systems include cationic lipids and cationic polymers and are well known in the art of DNA delivery. Physical delivery, such as via a "gene-gun" may also be used. The peptide or peptides encoded by the nucleic acid may be a fusion protein, for example with an epitope that stimulates T cells for the respective opposite CDR as noted above.

[0219] The medicament of the invention may also include one or more adjuvants. Adjuvants are substances that non-specifically enhance or potentiate the immune response (e.g., immune responses mediated by CTLs and helper-T (TH) cells to an antigen, and would thus be considered useful in the medicament of the present invention. Suitable adjuvants include, but are not limited to, 1018 ISS, aluminium salts, AMPLIVAX®, AS15, BCG, CP-870,893, CpG7909, CyaA, dSLIM, flagellin or TLR5 ligands derived from flagellin, FLT3 ligand, GM-CSF, IC30, IC31, Imiquimod (ALDARA®), resiquimod, ImuFact IMP321, Interleukins as IL-2, IL-13, IL-21, Interferon-alpha or -beta, or pegylated derivatives thereof, IS Patch, ISS, ISCOMATRIX, ISCOMs, JuvImmune®, LipoVac, MALP2, MF59, monophosphoryl lipid A, Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, water-in-oil and oil-in-water emulsions, OK-432, OM-174, OM-197-MP-EC, ONTAK, OspA, PepTel® vector system, poly(lactid co-glycolid) [PLG]-based and dextran microparticles, talactoferrin SRL172, Virosomes and other Virus-like particles, YF-17D, VEGF trap, R848, beta-glucan, Pam3Cys, Aquila's QS21 stimulon, which is derived from saponin, mycobacterial extracts and synthetic bacterial cell wall mimics, and other proprietary adjuvants such as Ribi's Detox, Quil, or Superfos. Adjuvants such as Freund's or GM-CSF are preferred. Several immunological adjuvants (e.g., MF59) specific for dendritic cells and their preparation have been described previously (Allison and Krummel, 1995 The Yin and Yang of T cell costimulation.Science. 1995 Nov 10;270(5238):932-3. Review). Also cytokines may be used. Several cytokines have been directly linked to influencing dendritic cell migration to lymphoid tissues (e.g., TNF-), accelerating the maturation of dendritic cells into efficient antigen-presenting cells for T-lymphocytes (e.g., GM-CSF, IL-1 and IL-4) (U.S. Pat. No. 5,849,589) and acting as immunoadjuvants (e.g., IL-12, IL-15, IL-23, IL-7, IFN-alpha. IFN-beta) (Gabrilovich, 1996 Production of vascular endothelial growth factor by human tumors inhibits the functional maturation of dendritic cells Nat Med. 1996 Oct;2(10):1096-103).

[0220] CpG immunostimulatory oligonucleotides have also been reported to enhance the effects of adjuvants in a vaccine setting. Without being bound by theory, CpG oligonucleotides act by activating the innate (non-adaptive) immune system via Toll-like receptors (TLR), mainly TLR9. CpG triggered TLR9 activation enhances antigen-specific humoral and cellular responses to a wide variety of antigens, including peptide or protein antigens, live or killed viruses, dendritic cell vaccines, autologous cellular vaccines and polysaccharide conjugates in both prophylactic and therapeutic vaccines. More importantly it enhances dendritic cell maturation and differentiation, resulting in enhanced activation of TH1 cells and strong cytotoxic T-lymphocyte (CTL) generation, even in the absence of CD4 T cell help. The TH1 bias induced by TLR9 stimulation is maintained even in the presence of vaccine adjuvants such as alum or incomplete Freund's adjuvant (IFA) that normally promote a TH2 bias. CpG oligonucleotides show even greater adjuvant activity when formulated or co-administered with other adjuvants or in formulations such as microparticles, nanoparticles, lipid emulsions or similar formulations, which are especially necessary for inducing a strong response when the antigen is relatively weak. They also accelerate the immune response and enable the antigen doses to be reduced by approximately two orders of magnitude, with comparable antibody responses to the full-dose vaccine without CpG in some experiments (Krieg, 2006). US Pat. No. 6,406,705 B1 describes the combined use of CpG oligonucleotides, non-nucleic acid adjuvants and an antigen to induce an antigen-specific immune response. A CpG TLR9 antagonist is dSLIM (double Stem Loop Immunomodulator) by Mologen (Berlin, Germany) which is a preferred component of the pharmaceutical composition of the present invention. Other TLR binding molecules such as RNA binding TLR 7, TLR 8 and/or TLR 9 may also be used.

[0221] Other examples for useful adjuvants include, but are not limited to chemically modified CpGs (e.g. CpR, Idera), dsRNA analogues such as Poly(I:C) and derivates thereof (e.g. AmpliGen®, Hiltonol®, poly-(ICLC), poly(IC-R), poly(I:C12U), non-CpG bacterial DNA or RNA as well as immunoactive small molecules and antibodies such as cyclophosphamide, sunitinib, Bevacizumab®, celebrex, NCX-4016, sildenafil, tadalafil, vardenafil, sorafenib, temozolomide, temsirolimus, XL-999, CP-547632, pazopanib, VEGF Trap, ZD2171, AZD2171, anti-CTLA4, other antibodies targeting key structures of the immune system (e.g. anti-CD40, anti-TGFbeta, anti-TNFalpha receptor) and SC58175, which may act therapeutically and/or as an adjuvant. The amounts and concentrations of adjuvants and additives useful in the context of the present invention can readily be determined by the skilled artisan without undue experimentation.

[0222] Preferred adjuvants are imiquimod, resiquimod, GM-CSF, cyclophosphamide, sunitinib, bevacizumab, interferon-alpha, CpG oligonucleotides and derivates, poly-(I:C) and derivates, RNA, sildenafil, and particulate formulations with PLG or virosomes.

[0223] In a preferred embodiment, the pharmaceutical composition according to the invention the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), cyclophosphamide, imiquimod, resiquimod, and interferon-alpha.

[0224] In a preferred embodiment, the pharmaceutical composition according to the invention the adjuvant is selected from the group consisting of colony-stimulating factors, such as Granulocyte Macrophage Colony Stimulating Factor (GM-CSF, sargramostim), cyclophosphamide, immiquimod and resiquimod.

[0225] In a preferred embodiment of the pharmaceutical composition according to the invention, the adjuvant is cyclophosphamide, imiquimod or resiquimod.

[0226] Even more preferred adjuvants are Montanide IMS 1312, Montanide ISA 206, Montanide ISA 50V, Montanide ISA-51, poly-ICLC (Hiltonol®) and anti-CD40 mAB or combinations thereof.

[0227] This composition is used for parenteral administration, such as subcutaneous, intradermal, intramuscular or oral administration. For this, the peptides and optionally other molecules are dissolved or suspended in a pharmaceutically acceptable, preferably aqueous carrier. In addition, the composition can contain excipients, such as buffers, binding agents, blasting agents, diluents, flavours, lubricants, etc. The peptides can also be administered together with immune stimulating substances, such as cytokines. An extensive listing of excipients that can be used in such a composition, can be, for example, taken from A. Kibbe, Handbook of Pharmaceutical Excipients, 3rd Ed., 2000, American Pharmaceutical Association and pharmaceutical press. The composition can be used for a prevention, prophylaxis and/or therapy of adenomateous or cancerous diseases. Exemplary formulations can be found in, for example, EP2112253.

[0228] Nevertheless depending on the number and the physico-chemical characteristics of the peptides of the invention further research is needed to provide formulations for specific combinations of peptides, especially combinations with more than 20 peptides that are stable for more than 12 to 18 months.

[0229] The present invention provides a medicament that useful in treating cancer, in particular AML, Chronic lymphoid leukemia (CLL) and other hematological malignancies.

[0230] The present invention further discloses a kit comprising:
  1. (a) a container containing a pharmaceutical composition as described above, in solution or in lyophilized form;
  2. (b) optionally a second container containing a diluent or reconstituting solution for the lyophilized formulation; and
  3. (c) optionally, instructions for (i) use of the solution or (ii) reconstitution and/or use of the lyophilized formulation.


[0231] The kit may further comprise one or more of (iii) a buffer, (iv) a diluent, (v) a filter, (vi) a needle, or (v) a syringe. The container is preferably a bottle, a vial, a syringe or test tube; and it may be a multi-use container. The pharmaceutical composition is preferably lyophilized.

[0232] Kits as disclosed preferably comprise a lyophilized formulation of the present invention in a suitable container and instructions for its reconstitution and/or use. Suitable containers include, for example, bottles, vials (e.g. dual chamber vials), syringes (such as dual chamber syringes) and test tubes. The container may be formed from a variety of materials such as glass or plastic. Preferably the kit and/or container contain/s instructions on or associated with the container that indicates directions for reconstitution and/or use. For example, the label may indicate that the lyophilized formulation is to be reconstituted to peptide concentrations as described above. The label may further indicate that the formulation is useful or intended for subcutaneous administration.

[0233] The container holding the formulation may be a multi-use vial, which allows for repeat administrations (e.g., from 2-6 administrations) of the reconstituted formulation. The kit may further comprise a second container comprising a suitable diluent (e.g., sodium bicarbonate solution).

[0234] Upon mixing of the diluent and the lyophilized formulation, the final peptide concentration in the reconstituted formulation is preferably at least 0.15 mg/mL/peptide (=75 µg) and preferably not more than 3 mg/mL/peptide (=1500 µg). The kit may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.

[0235] Kits as disclosed may have a single container that contains the formulation of the pharmaceutical compositions according to the present invention with or without other components (e.g., other compounds or pharmaceutical compositions of these other compounds) or may have distinct container for each component.

[0236] Preferably, kits as disclosed include a formulation of the invention packaged for use in combination with the co-administration of a second compound (such as adjuvants (e.g. GM-CSF), a chemotherapeutic agent, a natural product, a hormone or antagonist, an anti-angiogenesis agent or inhibitor, a apoptosis-inducing agent or a chelator) or a pharmaceutical composition thereof. The components of the kit may be pre-complexed or each component may be in a separate distinct container prior to administration to a patient. The components of the kit may be provided in one or more liquid solutions, preferably, an aqueous solution, more preferably, a sterile aqueous solution. The components of the kit may also be provided as solids, which may be converted into liquids by addition of suitable solvents, which are preferably provided in another distinct container.

[0237] The container of a therapeutic kit may be a vial, test tube, flask, bottle, syringe, or any other means of enclosing a solid or liquid. Usually, when there is more than one component, the kit will contain a second vial or other container, which allows for separate dosing. The kit may also contain another container for a pharmaceutically acceptable liquid. Preferably, a therapeutic kit will contain an apparatus (e.g., one or more needles, syringes, eye droppers, pipette, etc.), which enables administration of the agents of the invention that are components of the present kit.

[0238] The present formulation is one that is suitable for administration of the peptides by any acceptable route such as oral (enteral), nasal, ophthal, subcutaneous, intradermal, intramuscular, intravenous or transdermal. Preferably the administration is s.c., and most preferably i.d. Administration may be by infusion pump.

[0239] Since the peptides of the invention were isolated from CLL, the medicament of the invention is preferably used to treat CLL.

[0240] The present invention further discloses a method for producing a personalized pharmaceutical for an individual patient comprising manufacturing a pharmaceutical composition comprising at least one peptide selected from a warehouse of pre-screened TUMAPs, wherein the at least one peptide used in the pharmaceutical composition is selected for suitability in the individual patient. Preferably, the pharmaceutical composition is a vaccine. The method could also be adapted to produce T cell clones for down-stream applications such as TCR isolations.

[0241] A "personalized pharmaceutical" shall mean specifically tailored therapies for one individual patient that will only be used for therapy in such individual patient, including actively personalized cancer vaccines and adoptive cellular therapies using autologous patient tissue.

[0242] As used herein, the term "warehouse" shall refer to a group of peptides that have been pre-screened for immunogenicity and over-presentation in a particular tumour type. The term "warehouse" is not intended to imply that the particular peptides included in the vaccine have been pre-manufactured and stored in a physical facility, although that possibility is contemplated. It is expressly contemplated that the peptides may be manufactured de novo for each individualized vaccine produced, or may be pre-manufactured and stored.

[0243] The warehouse (e.g. in the form of a database) is composed of tumour-associated peptides which were highly overexpressed in the tumour tissue of several HLA-A, HLA-B and HLA-C positive CLL patients analyzed (see tables above). It contains MHC class I and MHC class II peptides. In addition to the tumor associated peptides collected from several GBM tissues, the warehouse may contain an HLA-A02 and an HLA-A24 marker peptide. These peptides allow comparison of the magnitude of T-cell immunity induced by TUMAPS in a quantitative manner and hence allow important conclusion to be drawn on the capacity of the vaccine to elicit anti-tumor responses. Secondly, it functions as an important positive control peptide derived from a "non-self' antigen in the case that any vaccine-induced T-cell responses to TUMAPs derived from "self antigens in a patient are not observed. And thirdly, it may allow conclusions to be drawn, regarding the status of immunocompetence of the patient population.

[0244] HLA class I and II TUMAPs for the warehouse are identified by using an integrated functional genomics approach combining gene expression analysis, mass spectrometry, and T-cell immunology. The approach assures that only TUMAPs truly present on a high percentage of tumours but not or only minimally expressed on normal tissue, are chosen for further analysis. For peptide selection, CLL samples from patients and blood from healthy donors were analyzed in a stepwise approach:
  1. 1. HLA ligands from the malignant material were identified by mass spectrometry
  2. 2. Genome-wide messenger ribonucleic acid (mRNA) expression analysis by microarrays was used to identify genes over-expressed in the malignant tissue (CLL) compared with a range of normal organs and tissues
  3. 3. Identified HLA ligands were compared to gene expression data. Peptides encoded by selectively expressed or over-expressed genes as detected in step 2 were considered suitable TUMAP candidates for a multi-peptide vaccine.
  4. 4. Literature research was performed in order to identify additional evidence supporting the relevance of the identified peptides as TUMAPs
  5. 5. The relevance of over-expression at the mRNA level was confirmed by redetection of selected TUMAPs from step 3 on tumor tissue and lack of (or infrequent) detection on healthy tissues
  6. 6. To assess whether an induction of in vivo T-cell responses by the selected peptides may be feasible, in vitro immunogenicity assays were performed using human T cells from healthy donors as well as from CLL patients.


[0245] In an aspect, the peptides are pre-screened for immunogenicity before being included in the warehouse. By way of example, and not limitation, the immunogenicity of the peptides included in the warehouse is determined by a method comprising in vitro T-cell priming through repeated stimulations of CD8+ T cells from healthy donors with artificial antigen presenting cells loaded with peptide/MHC complexes and anti-CD28 antibody.

[0246] This method is preferred for rare cancers and patients with a rare expression profile. In contrast to multi-peptide cocktails with a fixed composition as currently developed the warehouse allows a significantly higher matching of the actual expression of antigens in the tumour with the vaccine. Selected single or combinations of several "off-the-shelf" peptides will be used for each patient in a multitarget approach. In theory an approach based on selection of e.g. 5 different antigenic peptides from a library of 50 would already lead to approximately 17 million possible drug product (DP) compositions.

[0247] In an aspect, the peptides are selected for inclusion in the vaccine based on their suitability for the individual patient based on the method as disclosed, and as follows.

[0248] The HLA phenotype, transcriptomic and peptidomic data will be gathered from the patient's tumour material and blood samples to identify the most suitable peptides for each patient containing warehouse and patient-unique (ie. mutated) TUMAPs. Those peptides will be chosen, which are selectively or over-expressed in the patients tumor and, where possible, showed strong in vitro immunogenicity if tested with the patients individual PBMCs.

[0249] Preferably, the peptides included in the vaccine are identified by a method comprising: (a) identifying tumour-associated peptides (TUMAPs) presented by a tumor sample from the individual patient; (b) comparing the peptides identified in (a) with a warehouse (database) of peptides as described above; and (c) selecting at least one peptide from the warehouse (database) that correlates with a tumour-associated peptide identified in the patient. For example, the TUMAPs presented by the tumor sample are identified by: (a1) comparing expression data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or aberrantly expressed in the tumor sample; and (a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumor. Preferably, the sequences of MHC ligands are identified by eluting bound peptides from MHC molecules isolated from the tumor sample, and sequencing the eluted ligands. Preferably, the tumor sample and the normal tissue are obtained from the same patient.

[0250] In addition to, or as an alternative to, selecting peptides using a warehousing (database) model, TUMAPs may be identified in the patient de novo and then included in the vaccine. As one example, candidate TUMAPs may be identified in the patient by (a1) comparing expression data from the tumor sample to expression data from a sample of normal tissue corresponding to the tissue type of the tumor sample to identify proteins that are over-expressed or aberrantly expressed in the tumor sample; and (a2) correlating the expression data with sequences of MHC ligands bound to MHC class I and/or class II molecules in the tumor sample to identify MHC ligands derived from proteins over-expressed or aberrantly expressed by the tumor. As another example, proteins may be identified containing mutations that are unique to the tumor sample relative to normal corresponding tissue from the individual patient, and TUMAPs can be identified that specifically target the mutation. For example, the genome of the tumour and of corresponding normal tissue can be sequenced by whole genome sequencing: For discovery of non-synonymous mutations in the protein-coding regions of genes, genomic DNA and RNA are extracted from tumour tissues and normal non-mutated genomic germline DNA is extracted from peripheral blood mononuclear cells (PBMCs). The applied NGS approach is confined to the re-sequencing of protein coding regions (exome re-sequencing). For this purpose, exonic DNA from human samples is captured using vendor-supplied target enrichment kits, followed by sequencing with e.g. a HiSeq2000 (Illumina). Additionally, tumour mRNA is sequenced for direct quantification of gene expression and validation that mutated genes are expressed in the patients' tumours. The resultant millions of sequence reads are processed through software algorithms. The output list contains mutations and gene expression. Tumour-specific somatic mutations are determined by comparison with the PBMC-derived germline variations and prioritized.. The de novo identified peptides may then be tested for immunogenicity as described above for the warehouse, and candidate TUMAPs possessing suitable immunogenicity are selected for inclusion in the vaccine.

[0251] In one exemplary embodiment, the peptides included in the vaccine are identified by: (a) identifying tumour-associated peptides (TUMAPs) presented by a tumor sample from the individual patient by the methdos described above; (b) comparing the peptides identified in a) with a warehouse of peptides that have been prescreened for immunogenicity and overpresentation in tumors as compared to corresponding normal tissue; (c) selecting at least one peptide from the warehouse that correlates with a tumour-associated peptide identified in the patient; and (d) optionally, selecting at least one peptide identified de novo in (a) confirming its immunogenicity.

[0252] In one exemplary embodiment, the peptides included in the vaccine are identified by: (a) identifying tumour-associated peptides (TUMAPs) presented by a tumor sample from the individual patient; and (b) selecting at least one peptide identified de novo in (a) and confirming its immunogenicity.

[0253] Once the peptides are selected, the vaccine is manufactured.

[0254] The vaccine preferably is a liquid formulation consisting of the individual peptides dissolved in 33% DMSO.
Each peptide to be included into a product is dissolved in DMSO. The concentration of the single peptide solutions has to be chosen depending on the number of peptides to be included into the product. The single peptide-DMSO solutions are mixed in equal parts to achieve a solution containing all peptides to be included in the product with a concentration of ∼2.5 mg/ml per peptide. The mixed solution is then diluted 1:3 with water for injection to achieve a concentration of 0.826 mg/ml per peptide in 33% DMSO. The diluted solution is filtered through a 0.22 µm sterile filter. The final bulk solution is obtained.

[0255] Final bulk solution is filled into vials and stored at -20°C until use. One vial contains 700 µL solution containing 0.578 mg of each peptide. Of this, 500 µL (approx. 400 µg per peptide) will be applied for intradermal injection.

[0256] The present invention will now be described in the following examples that describe preferred embodiments thereof, nevertheless, without being limited thereto.

Figure 1 shows the HLA surface expression of primary CLL samples. (a) HLA class I and (b) HLA class II expression of CD5+CD19+ CLL cells compared to autologous CD5-CD19+ B cells in 7 primary CLL samples. Data are expressed as mean ± s.d. of triplicate experiments. (c) Mean HLA class I and (d) HLA class II expression CD5+CD19+ CLL cells compared to autologous CD5-CD19+ B cells (n=7). * P<0.01 Abbreviations: UPN, uniform patient number

Figure 2 shows the identification of a novel category of tumor-associated antigens by HLA ligandome profiling. (a) Overlap of HLA class I ligand source proteins of primary CLL samples (n=30) and HV PBMC (n=30). (b) Comparative profiling of HLA class I ligand source proteins based on the frequency of HLA restricted representation in CLL and HV PBMC ligandomes. Frequencies [%] of CLL patients/HVs positive for HLA restricted presentation of the respective source protein (x-axis) are indicated on the y-axis. The box on the left-hand side highlights the subset of source proteins showing CLL-exclusive representation in >20% of patients (LiTAAs: ligandome-derived tumor-associated antigens). (c) Representation of published CLL-associated antigens in HLA class I ligandomes. Bars indicate relative representation [%] of respective antigens by HLA class I ligands in CLL and HV PBMC. Dashed lines separate the antigens into three groups according to their degree of CLL-association. (d) Source protein overlaps of CLL samples from different stages of disease (Binet A (n=9), Binet B (n=7), Binet C (n=14)). (e) Heatmap analysis of the representation frequencies [%] of LiTAAs across different disease stages (Binet A-C, as in (d)) (f) Heatmap analysis of LiTAA representation [%] on primary CLL samples with del17p (n=5) and without del17p (n=25). Abbreviations: CLL, chronic lymphocytic leukemia; HV, healthy volunteer

Figure 3 shows that LiTAAs are specifically recognized by CLL patient immune responses. (a) HLA class I LiTAAs and corresponding LiTAPs (3 HLA-A03, 5 HLA-A02, 5 HLA-B07) functionally evaluated in IFNy ELISPOT assays. Absolute numbers and frequencies of peptide-specific immune recognition by CLL patient PBMC are summarized in the right hand column. (b) Example of A03 LiTAPs evaluated in ELISPOT using HV PBMC as a control. An EBV epitope mix containing 4 frequently recognized peptides (....) was used as positive control, HIV GAG18-26 A03 peptide served as negative control. (c) Example of ELISPOT assays using HLA-A03 LiTAPs (n=3) on PBMC of 3 different CLL patients. Results are shown for immunoreactive LiTAPs. EBV epitope mix served as positive control, HIV GAG18-26 A03 peptide as negative control. (d) Example of HLA-A03 benign tissue-derived LiBAPs (n=3) tested on CLL patient PBMC as internal control for the target selection strategy. EBV epitope mix served as positive control, HIV GAG18-26 A03 peptide as negative control. (e) Scatterplot of the allele-adjusted frequencies of LiTAP presentation in CLL ligandomes (as detected by MS) and the corresponding allele-adjusted frequencies of immune recognition by CLL patient PBMC in IFNy ELISPOT. Data points are shown for the 14/15 LiTAPs showing immune recognition. Abbreviations: LiTAP, ligandome-derived tumor-associated peptide; HV, healthy volunteer; neg., negative; pos., positive; UPN, uniform patient number; LiBAP, ligandome-derived benign tissue-associated peptide; MS, mass spectrometry .

Figure 4 shows the identification of additional/synergistic HLA class II LiTAAs and LiTAPs. (a) Overlap of HLA class II ligand source proteins of primary CLL samples (n=20) and HV PBMC (n=13). (b) Comparative profiling of HLA class II ligand source proteins based on the frequency of HLA restricted representation in CLL and HV PBMC ligandomes. Frequencies [%] of CLL patients/HVs positive for HLA restricted presentation of the respective source protein (x-axis) are indicated on the y-axis. The box on the left-hand side highlights the subset of source proteins showing CLL-exclusive representation in >20% of patients (LiTAAs: ligandome-derived tumor-associated antigens). (c) HLA class II LiTAAs and corresponding LiTAPs (n=6) functionally evaluated in IFNγ ELISPOT assays. Absolute numbers and frequencies of peptide-specific immune recognition by CLL patient PBMC are summarized in the right hand column. (d) Example of HLA class II LiTAPs evaluated in ELISPOT using HV PBMC as a control. PHA was used as positive control. FLNA1669-1683 HLA-DR peptide served as negative control. (e) Example of ELISPOT assays using HLA class II LiTAPs (n=6) on PBMC of 3 different CLL patients. Results are shown for immunoreactive LiTAPs. PHA was used as positive control, FLNA1669-1683 HLA-DR peptide served as negative control. (f) Overlap analysis of CLL-exclusive HLA class I and HLA class II ligand source proteins for shared/synergistic vaccine targets. (g) Heatmap analysis of the 132 shared HLA class I/II LiTAAs (identified in (d)). The two source proteins showing representation in ≥20% of both, HLA class I and II CLL patient ligandomes are specified.

Figure 5 shows the longitudinal HLA class I ligandome analysis of CLL patients undergoing chemo-/immunotherapy. Volcano-Plots of the relative abundances of ligands in the HLA class I ligandomes of patients after treatment compared to their respective abundance prior to therapy (ratio post therapy/pre therapy). Dashed lines indicate the thresholds for significant changes in abundance (>2-fold ratio, p<0.05), with significantly up-regulated ligands in the upper-right and significantly downregulated ligands in the upper-left. Frequencies of significantly regulated ligands are specified in the respective quadrants. LiTAPs showing significant regulation over the course of therapy are marked in red and their sequences are specified. (a) Analysis of a CLL patient ligandome prior to therapy and 48h/24h after treatment with rituximab/bendamustin (375mg/m2 / 90mg/m2). 1/28 (3.6%) of detectable LiTAPs showed significant changes in abundance. (b) Analysis of a CLL patient ligandome prior to therapy and after the first 7 days of treatment with alemtuzumab (3 doses of alemtuzumab, 10 mg, 20 mg and 30mg on day 1, 3 and 5; ligandome analysis on day 7). 3/24 (12.5%) of detectable LiTAPs showed significant changes in abundance. (c) Analysis of a CLL patient ligandome prior to therapy and 24h after treatment with 300 mg ofatumumab. 2/10 (20.0%) of detectable LiTAPs showed significant changes in abundance.

Figure 6 shows the retrospective survival analysis of CLL patients with respect to their immune recognition of LiTAPs. (a) Kaplan Meier plot of the overall survival of 44 CLL patients. (b) Overall survival of subjects evaluated for LiTAP-specific immune responses grouped as follows: black, CLL patients showing immune responses to >1 LiTAPs (n=10). Red, CLL patients showing immune reactions to 0-1 LiTAPs (n=34).

Figure 7 shows the saturation analysis of HLA class I ligand source protein identifications in CLL patients. Number of unique HLA ligand source protein identifications as a function of total HLA ligand source protein identifications in 30 CLL patients. Exponential regression allowed for the robust calculation (R2=0.9912) of the maximum attainable number of different source protein identifications (dashed line). The dotted line depicts the source proteome coverage achieved in our CLL patient cohort.

Figure 8 shows that HLA-A02 and B07 LiTAPs are specifically recognized by CLL patient immune responses. (a) Example of HLA-A02 (n=3) and (d) HLA-B07 (n=3) benign tissue-derived LiBAPs tested on CLL patient PBMC as internal control for the target selection strategy. EBV epitope mix served as positive control, HIV XXxx-xx A02 and HIV XXxx-xx HLA-B07 peptide served as negative control, respectively. (b) Example of HLA-A02 (n=6) and (e) HLA-B07 (n=5) LiTAPs evaluated in ELISPOT assays using HV PBMC as a control. Positive and negative controls as described in (a). (c) Example of ELISPOT assays using HLA-A02 (n=6) and (f) HLA-B07 (n=5) LiTAPs on PBMC of 3 different HLA-matched CLL patients, each. Results are shown for immunoreactive LiTAPs. Positive and negative controls as described in (a). Abbreviations: LiBAP, ligandome-derived benign tissue-associated peptide; LiTAP, ligandome-derived tumor-associated peptide; HV, healthy volunteer; neg., negative; pos., positive; UPN, uniform patient number.

Figure 9 shows the intracellular cytokine and tetramer staining of HLA-A03 LiTAP specific CLL patient T cells. (a) Intracellular staining for IFNy and TNFa of PA*033 (DMXL11271-1279 SSSGLHPPK (SEQ ID NO: 77) stimulated CLL patient PBMC. PMA/ionomycin served as positive control, HIV GAG18-26 A03 peptide as negative control. (b) Tetramer staining of CLL patient CD8+ T cells with PA*033 (DMXL11271-1279 SSSGLHPPK (SEQ ID NO: 77)) tetramers. As control, tetramer staining with the non-recognized PA*021 (ABCA61270-1278 ILDEKPVII (SEQ ID NO: 63) in the same patient is shown.

Figure 10 shows the quantification of HLA surface expression on primary CLL cells from patients undergoing chemo-/immunotherapy. HLA surface expression on CD5+CD19+ CLL cells was quantified by flow cytometry, before and after therapy. Data are expressed as mean ± s.d. of triplicate experiments. (a) HLA class I and (b) HLA class II surface expression on primary CLL cells of 4 patients prior to therapy and 24h after treatment with rituximab. (c) HLA class I and (d) HLA class II surface expression on primary CLL cells of a patient prior to therapy, 72h (10mg) and 7d (60mg) after treatment with alemtuzumab. *P<0.01 Abbreviations: UPN, uniform patient number; h, hour; d, day.

Figure 11 shows the over-presentation of peptide ILDEKPVII in normal tissues as compared to CLL samples. Shown are only samples on which the peptide was detected. The test panel included 12 CLL samples and the following normal samples: 1 x adipose tissue, 3 x adrenal gland, 6 x artery, 5 x bone marrow, 7 x brain, 3 x breast, 5 x nerve, 13 x colon, 7 x esophagus, 2 x gallbladder, 5 x heart, 12 x kidney, 20 x liver, 44 x lung, 3 x lymph node, 4 x peripheral blood mononuclear cells, 2 x ovary, 6 x pancreas, 1 x peritoneum, 3 x pituitary, 2 x placenta, 3 x pleura, 3 x prostate, 6 x rectum, 7 x salivary gland, 4 x skeletal muscle, 5 x skin, 3 x small intestine, 4 x spleen, 5 x stomach, 4 x testis, 3 x thymus, 3 x thyroid gland, 3 x trachea, 2 x ureter, 5 x urinary bladder, 2 x uterus, 2 x vein.


EXAMPLES


EXAMPLE 1:


Identification and quantitation of tumor associated peptides presented on the cell surface


Tissue samples



[0257] Patients' tumor samples were provided by University of Tübingen, Tübingen, Germany. Written informed consents of all patients had been given. For ligandome analysis, PBMC from CLL patients (>80% CLL cell frequency) as well as PBMC from healthy volunteers (HVs) were isolated by density gradient centrifugation. Informed consent was obtained in accordance with the Helsinki protocol. This study was performed according to the guidelines of the local ethics committee. HLA typing was carried out by the Department of Hematology and Oncology, Tübingen. Samples were stored at -80°C until further use.

Quantification of HLA surface expression



[0258] For comparison with healthy autologous B lymphocytes, quantification of HLA surface expression was performed in patient samples containing at least 0.5% CD5- CD19+ normal B cells. HLA surface expression was analyzed using the QIFIKIT® quantitative flow cytometric assay (Dako) according to the manufacturer's instructions. In brief, triplicates of each sample were stained with the pan-HLA class I specific monoclonal antibody (mAb) W6/32, HLA-DR specific mAb L243 (both produced in house) or IgG isotype control (BioLegend), respectively. Surface marker staining was carried out with directly labeled CD3 (BD), CD5 (BD) and CD19 (BD) antibodies. 7-AAD (BioLegend) was added as viability marker immediately prior to flow cytometric analysis on a FACSCanto Analyzer (BD).

Isolation of HLA peptides from tissue samples



[0259] HLA class I and II molecules were isolated employing standard immunoaffinity purification as described previously. In brief, snap-frozen cell pellets were lysed in 10 mM CHAPS/PBS (AppliChem, St. Louis, MO, USA/Gibco, Carlsbad, CA, USA) containing 1x protease inhibitor (Complete, Roche, Basel, Switzerland). HLA molecules were single-step purified using the pan-HLA class I specific mAb W6/32 and the pan-HLA class II specific mAb Tü39 respectively, covalently linked to CNBr-activated sepharose (GE Healthcare, Chalfont St Giles, UK). HLA:peptide complexes were eluted by repeated addition of 0.2% trifluoroacetic acid (TFA, Merck, Whitehouse Station, NJ, USA). Elution fractions E1-E8 were pooled and free HLA ligands were isolated by ultrafiltration using centrifugal filter units (Amicon, Millipore, Billerica, MA, USA). HLA ligands were extracted and desalted from the filtrate using ZipTip C18 pipette tips (Millipore). Extracted peptides were eluted in 35 µl of 80% acetonitrile (ACN, Merck)/0.2% TFA, centrifuged to complete dryness and resuspended in 25 µl of 1% ACN/0.05% TFA. Samples were stored at -20 °C until analysis by LC-MS/MS.

Analysis of HLA ligands by LC-MS/MS



[0260] Peptide samples were separated by reversed-phase liquid chromatography (nanoUHPLC, UltiMate 3000 RSLCnano,ThermoFisher, Waltham, MA, USA) and subsequently analyzed in an on-line coupled LTQ Orbitrap XL hybrid mass spectrometer (ThermoFisher). Samples were analyzed in 5 technical replicates. Sample volumes of 5 µl (sample shares of 20%) were injected onto a 75 µm x 2 cm trapping column (Acclaim PepMap RSLC, ThermoFisher) at 4 µl/min for 5.75 min. Peptide separation was subsequently performed at 50°C and a flow rate of 175 nl/min on a 50 µm x 50 cm separation column (Acclaim PepMap RSLC, ThermoFisher) applying a gradient ranging from 2.4-32.0% of ACN over the course of 140 min. Eluting peptides were ionized by nanospray ionization and analyzed in the mass spectrometer implementing a top 5 CID (collision induced dissociation) method generating fragment spectra for the 5 most abundant precursor ions in the survey scans. Resolution was set to 60,000. For HLA class I ligands, the mass range was limited to 400-650 m/z with charge states 2 and 3 permitted for fragmentation. For HLA class II, a mass range of 300-1,500 m/z was analyzed with charge states ≥2 allowed for fragmentation.

Database Search and Spectral Annotation



[0261] For data processing, the software Proteome Discoverer (v1.3, ThermoFisher) was used to integrate the search results of the Mascot search engine (Mascot 2.2.04, Matrix Science) against the human proteome as comprised in the Swiss-Prot database (www.uniprot.org, release: September 27th 2013; 20,279 reviewed protein sequences contained). The search combined data of technical replicates and was not restricted by enzymatic specificity. Precursor mass tolerance was set to 5 ppm, fragment mass tolerance to 0.5 Da. Oxidized methionine was allowed as a dynamic modification. False discovery rates (FDR) were determined by the Percolator algorithm based on processing against a decoy database consisting of the shuffled target database. FDR was set at a target value of q≤0.05 (5% FDR). Peptide-spectrum matches (PSMs) with q≤0.05 were filtered according to additional, orthogonal parameters, to ensure spectral quality and validity. Mascot scores were filtered to ≥20. For HLA class I, peptide lengths were limited to 8-12 amino acids (aa) of length. For HLA class II, peptides were limited to 12-25 aa length. Protein grouping was disabled, allowing for multiple annotations of peptides (e.g. conserved sequences mapping into multiple proteins). For quality control, yield thresholds of ≥300 unique HLA class I ligands and ≥100 unique HLA class II ligands per sample were applied. HLA annotation was performed using SYFPEITHI (www.syfpeithi.de) or an extended in-house database.

Longitudinal analysis of CLL patient ligandomes over the course of therapy



[0262] For label-free quantification (LFQ) of the relative HLA ligand abundances over the course of therapy, the injected peptide amounts of paired samples were normalized and LC-MS/MS analysis was performed in 5 technical replicates for each sample.

[0263] In brief, relative amounts of substance of paired samples were calculated from average precursor ion intensities determined in dose-finding mass spectrometry runs and adjusted accordingly by dilution. Relative quantification of HLA ligands was performed by calculating the area under the curve of the corresponding precursor extracted ion chromatograms (XIC) using Proteome Discoverer 1.3. The ratios of the mean areas of the individual peptides in the 5 LFQ-MS runs of each sample were calculated and two-tailed t-tests were performed using an in-house Matlab script (v8.2, Mathworks).

Peptide synthesis



[0264] The automated peptide synthesizer EPS221 (Abimed) was used to synthesize peptides using the 9-fluorenylmethyl-oxycarbonyl/tert-butyl (Fmoc/tBu) strategy as described. Synthetic peptides were used for validation of LC-MS/MS identifications as well as for functional experiments.

Amplification of peptide-specific T cells



[0265] PBMC from CLL patients and healthy volunteers were cultured in RPMI1640 medium (Gibco) supplemented with 10% pooled human serum (PHS, produced in-house), 100 mM β-mercaptoethanol (Roth, Karlsruhe, Germany) and 1% penicillin/streptomycin (GE). For CD8+ T cell stimulation, PBMC were thawed and pulsed with 1 µg/ml per peptide. Peptide-pulsed PBMC (5-6 x 106 cells/ml) were cultured at 37°C and 5% CO2 for 12 days. On day 0 and day 1.5 ng/ml IL-4 (R&D Systems, Minneapolis, MN, USA) and 5 ng/ml IL-7 (Promokine, Heidelberg, Germany) were added to the culture medium. On days 3, 5, 7 and 9, 2 ng/ml IL-2 (R&D Systems) were added to the culture medium. Peptide-stimulated PBMC were functionally characterized by ELISPOT assays on day 12 and by intracellular cytokine staining on day 13 respectively. For CD4+ T-cell stimulation, culture was performed as described for CD8+T cells with 2 modifications: pulsing was carried out with 10 µg/ml of HLA class II peptide and no IL-4 and IL-7 was added.

IFN-γ ELISPOT assay



[0266] IFN-γ ELISPOT assays were carried out as described previously (33). In brief, 96-well nitrocellulose plates (Millipore) were coated with 1 mg/ml IFN-γ mAb (Mabtech, Cincinnati, OH, USA) and incubated over night at 4 °C. Plates were blocked with 10% PHS for 2 h at 37 °C. 5 x 105 cells/well of pre-stimulated PBMC were pulsed with 1 µg/ml (HLA class I) or 2.5 µg/ml (HLA class II) peptide and incubated for 24-26 h. Readout was performed according to manufacturer's instructions. Spots were counted using an ImmunoSpot S5 analyzer (CTL, Shaker Heights, OH, USA). T cell responses were considered to be positive when >15 spots/well were counted and the mean spot count per well was at least 3-fold higher than the mean number of spots in the negative control wells (according to the cancer immunoguiding program (CIP) guidelines).

Intracellular IFN-γ and TNF-α staining



[0267] The frequency and functionality of peptide-specific CD8+ T cells was analyzed by intracellular IFN-γ and TNF-α staining. PBMC were pulsed with 1 µg/ml of individual peptide and incubated in the presence of 10 µg/ml Brefeldin A (Sigma, St. Louis, MO, USA) and 10 µg/ml GolgiStop (BD) for 6-8 h. Cells were labeled using Cytofix/Cytoperm (BD), CD8-PECy7 (Beckman Coulter, Fullerton, CA, USA), CD4-APC (BD Bioscience), TNF-α-PE (Beckman Coulter) and IFN-γ-FITC (BD). Samples were analyzed on a FACS Canto II.
The frequency of peptide-specific CD8+ T cells was determined by staining with anti-CD8 and HLA:peptide-tetramer-PE

Results


Primary CLL cells display no loss or down-regulation of HLA expression compared to autologous normal B cells



[0268] HLA loss or down-regulation in malignancies may pose a major limitation for T cell based immunotherapy. Therefore, as a first step, the inventors determined the HLA expression levels on CD19+CD5+ CLL cells compared to autologous CD19+CD5- B lymphocytes. HLA surface levels were quantified by flow cytometry in a panel of 7 CLL patients. HLA surface expression levels revealed patient-individual heterogeneity with total HLA class I molecule counts ranging from ∼42,500-288,500 molecules/cell on CLL cells and ∼32,000-256,500 molecules/cell on normal B cells. Patient individual analysis of HLA surface expression in triplicates revealed small, albeit significant differences in expression levels (P<0.01) for 4/7 patients (Fig. 1a). HLA-DR expression ranged from ∼29,000-100,500 on CLL cells and ∼19,500-79,500 on B cells. Minor differences in HLA-DR levels (P<0.01) were detected for 5/7 patients. Statistical analysis of mean HLA surface expression on CLL cells compared to normal B cells showed no significant differences in HLA class I and II expression (Fig. 1c, d). Taken together, these data demonstrate high levels of HLA class I and II expression on CLL cells without evidence of HLA loss or down-regulation compared to normal B cells.

LC-MS/MS identifies a vast array of naturally presented HLA class I & II ligands



[0269] Mapping the HLA class I ligandomes of 30 CLL patients, the inventors were able to identify a total of 18,844 different peptides representing 7,377 source proteins, attaining >95% of maximum attainable coverage (Figure 7). The numbers of different peptides identified per patient ranged from 345-2,497 (mean 1,131). Overall, peptides restricted by more than 30 different HLA-A and -B alleles (covering >99% of the Caucasian population_ENREF_27) were identified in this study. In the HV cohort of 30 PBMC donors, a total of 17,322 unique peptides representing 7,180 different source proteins were identified (>90% coverage). The HLA allele distribution in the HV cohort covered 100% of HLA-A and >80% of HLA-B alleles in the CLL patient cohort.

[0270] Analysis of the HLA class II ligandomes was performed for 20 CLL patients. A total of 5,059 unique peptides representing 1,486 source proteins was identified. The HLA class II HV cohort of 13 PBMC donors yielded 2,046 different peptides representing 756 source proteins.

Comparative profiling of HLA class I ligandomes reveals a multitude of CLL-associated antigens



[0271] In order to identify novel CLL-associated antigens, the inventors compared the HLA ligand source proteomes of the CLL and HV cohorts. Overlap analysis of HLA source proteins revealed 2,148 proteins (29.1% of the mapped CLL source proteome) to be exclusively represented in the HLA ligandome of CLL (Fig. 2a). With the aim of designing a broadly applicable off-the-shelf peptide vaccine, the inventors subsequently prioritized the selection of potential targets according to the following criteria:
CLL-exclusivity was defined as paramount criterion, followed by ranking of antigens according to frequency of representation in CLL ligandomes (Fig. 2b). Our platform highlighted 49 source proteins (0.7% of the CLL source proteome) represented by 225 different HLA ligands showing CLL-exclusive representation in ≥20% of CLL patients. Applying the same antigen ranking strategy to HV PBMC exclusive antigens, a set of 71 ligandome-derived benign tissue-associated antigens (LiBAAs) and the 298 corresponding ligands (LiBAPs) were identified for use as internal control in immunological assays.

[0272] Apart from broadly represented CLL-LiTAAs suited for the design of off-the-shelf vaccines, a second panel of 2,099 CLL-exclusive antigens with representation frequencies <20% was identified by our platform. These targets lend themselves as repositories for more individualized therapeutic approaches.

Detection of naturally presented HLA class I ligands derived from established CLL-associated antigens by LC-MS/MS



[0273] Alongside the identification of novel CLL-associated antigens, a secondary approach focused on the ranking of the few established CLL-antigens within the present dataset of naturally presented HLA ligands. The inventors were able to identify 28 different HLA ligands representing 8 described CLL-associated antigens. Of note, only Fibromodulin (FMOD324-333, RINEFSISSF, HLA-A23 (SEQ ID NO: 526) showed CLL-exclusive representation, ranking at #437 of CLL-antigens in the present dataset, due to low frequency of representation in the CLL patient cohort. The remaining seven antigens showed representation, both on CLL and HV PBMC, thus failing to fulfill the paramount criterion of CLL-exclusivity. However, for CD19, CD20, RHAMM and PRAME, CLL-associated overrepresentation of varying degrees was detected (Fig. 2c).

Comparative ligandome profiling identifies LiTAAs shared among different disease stages and risk strata



[0274] In order to assess the applicability of the novel targets across different stages of disease, the inventors performed subset-specific ligandome profiling comparing patients in disease stages Binet A (n=9), B (n=7) and C (n=14). Overlap analysis of the 2,148 CLL-exclusive source proteins found 550 (25.6%) of them shared among at least two stages, with a core group of 137 proteins (6.1%) represented in patients of all three stages of disease (Fig. 2d). Of note, 45/49 (91.8%) of LiTAAs belong to the core group of shared source proteins represented in all three subsets. Heatmap analysis of the representation frequencies of all 49 LiTAAs across Binet stages A, B and C is shown in Fig. 2e.

[0275] Another focus was placed on determining the representation of LiTAAs in the subsets of high-risk patients carrying the 17p13 deletion (del17p, n=5) as compared to patients without this genetic aberration (no del17p, n=25). The inventors found 77.7% of the identified LiTAAs to be represented in both subsets (Fig. 2f). Together, these data support the devised strategy of cohort-comprising analysis of HLA ligandomes for selection of broadly applicable targets.

Functional characterization of HLA class I LiTAPs reveals CLL-associated immunoreactivity



[0276] In order to evaluate the immunogenicity and specificity of our HLA class I LiTAPs, the inventors next performed 12-day recall IFNγ ELISPOT assays. A panel of 15 LiTAPs (6 A02, 4 A03 and 5 B07 LiTAPs) was implemented for stimulation of HLA-matched PBMC obtained from CLL patients and healthy volunteers (Fig. 3a). The inventors observed IFNy secretion for 14/15 (93.3%) of tested LiTAPs in CLL patients (3/4 A03 (Fig. 3c), 6/6 A02 and 5/5 B07 LiTAPs (Fig. 8 c,f)), but not in healthy controls (0/10, Fig. 3b, Fig. 8 b,e). These findings were confirmed exemplarily for PA*033 (DMXL11271-1279 SSSGLHPPK) by tetramer staining of CD8+ T cells and intracellular cytokine staining for IFNγ and TNFα (Fig. 9 a,b). ELISPOT assays using HLA-matched benign tissue-derived LiBAPs were performed to control for the CLL-specificity of the observed LiTAP-directed immune recognition in CLL patients. The inventors tested a panel of 9 LiBAPs (3 A02, 3 A03, 3B07) and observed no significant IFNγ secretion in any of the tested CLL patients (0/7 A03 (Fig. 3d), 0/10 A02+ and 0/5 B07 (Fig. 8 a,d)).

[0277] For the 14/15 LiTAPs showing immune recognition in 1 or more patients, the inventors calculated the allele-adjusted frequencies of HLA restricted presentation (as detected by LC-MS/MS) and the frequencies of immunoreactivity (as detected by ELISPOT) in CLL patients. Strikingly, a linear correlation of these two parameters was observed (Pearson's r=0.77, R2=0.59, Fig. 3 e). These findings suggest two main points: First, tumor-exclusive representation is prerequisite for immune recognition. Secondly, frequency of immune recognition can be directly deduced from the frequency of HLA restricted presentation for immunoreactive LiTAPs. Together, these data demonstrate the efficacy of our approach identifying immunologically relevant targets for CLL-specific peptide vaccines.

HLA class II ligandome analysis identifies additional CD4+ T cell epitopes for synergistic vaccine design



[0278] Because of the important indirect and direct roles CD4+ T cells play in anti-cancer immune responses, optimal vaccine design calls for the inclusion of additional HLA class II epitopes. The inventors performed overlap analysis of CLL and HV PBMC ligandomes and identified 937 proteins (63.0% of the identified CLL source proteins) to be exclusively represented in the ligandomes of CLL patients (Fig. 4 a). Applying the same antigen-ranking strategy as described for HLA class I, the inventors identified 73 HLA class II LiTAAs represented by 460 corresponding LiTAPs (Fig. 4 b). Functional characterization of a panel of 7 HLA class II LiTAPs (Fig. 4c) in IFNy ELISPOT assays revealed significant IFNy secretion for 6/7 (85.7%) LiTAPs in CLL patients (Fig. 4e), but not in healthy controls (0/10, Fig. 4d). Next, the inventors performed combined analysis of HLA class I and II ligandomes in order to identify shared, synergistic targets. Overlap analysis of CLL-exclusive source proteins revealed 132 proteins to be represented both in HLA class I and II ligandomes (Fig. 4f). Heatmap analysis identified 2 proteins displaying representation frequencies ≥20% in both ligandomes (B4GALT1 (26.7% class 1/30.0% class II), HLA-DMA (20.0% class I/20% class II), Fig. 4g). Strikingly, one of the class I LiTAPs (HLA-DMA206-214, HEIDRYTAI, B18) was revealed to be completely embedded in the corresponding HLA class II LiTAP (VTHEIDRYTAIAY (SEQ ID No. 924)). Together, the inventors identified a panel of class II LiTAPs, which could be verified as T cell epitopes, as well as an array of potentially synergistic HLA class II ligands covering class I LiTAAs.

Longitudinal analysis of CLL patient ligandomes under different therapeutic regimens



[0279] The scope of peptide based immunotherapy is maintenance therapy and eradication of MRD. As a consequence, peptide vaccination in CLL would take place after standard chemo-/immunotherapy. Therefore, the inventors analyzed HLA expression and performed ligandome profiling across different time points of CLL patients undergoing different therapeutic regimens.

[0280] The inventors quantified HLA class I and II surface expression in 4 patients undergoing rituximab treatment (Rt0h, Rt24h) and 1 patient receiving alemtuzumab (At0h, At72h, At7d, Fig. 10 a-d). HLA surface expression showed patient-individual heterogeneity with no significant changes in mean HLA class I (Rt0h=50,500, Rt24h=48,000; At0h=42,500, At7d=61,500) and HLA class II (Rt0h=36,500, Rt24h=27,500; At0h=47,000, At7d=55,500) expression over the course of either therapeutic regimen.

[0281] Longitudinal HLA class I ligandome profiling was performed in single patients undergoing rituximab-bendamustin, alemtuzumab or ofatumumab treatment, respectively (Fig. 5a-c). Differential presentation (≥2-fold change, p≤0.05) was observed for 11.1% of HLA class I ligands under rituximab-bendamustin treatment, for 21.6% of ligands under ofatumumab treatment and for 33.6% of ligands under alemtuzumab treatment. Overall, LiTAPs representing 8/49 (16.3%) LiTAAs were revealed to be differentially presented over the course of therapy. Taken together, these data demonstrate stable expression of surface HLA and robust presentation of LiTAPs over the course of different therapies.

Immune responses against LiTAPs might be associated with improved overall survival of CLL patients



[0282] As a last step, the inventors performed retrospective survival analysis of 33 CLL patients (Fig. 6a) analyzed by ELISPOT assays comparing cases with 0-1 LiTAP-specific (n=23) versus >1 LiTAP-specific (n=10) T cell responses (Fig. 6 b). In the low-responding cohort 6/23 (26.1%) of patients, in the high-responding cohort 0/11 of patients died. Overall survival seems to be prolonged in the cohort showing >1 immune reactions.

EXAMPLE 2


Synthesis of peptides



[0283] All peptides were synthesized using standard and well-established solid phase peptide synthesis using the Fmoc-strategy. After purification by preparative RP-HPLC, ion-exchange procedure was performed to incorporate physiological compatible counter ions (for example trifluoro-acetate, acetate, ammonium or chloride).

[0284] Identity and purity of each individual peptide have been determined by mass spectrometry and analytical RP-HPLC. After ion-exchange procedure the peptides were obtained as white to off-white lyophilizates in purities of 90% to 99.7%.

[0285] All TUMAPs are preferably administered as trifluoro-acetate salts or acetate salts, other salt-forms are also possible. For the measurements of example 4, trifluoro-acetate salts of the peptides were used.

EXAMPLE 3


MHC Binding Assays



[0286] Candidate peptides for T cell based therapies as disclosed were further tested for their MHC binding capacity (affinity). The individual peptide-MHC complexes were produced by peptide-ligand exchange, where a cleavage-sensitive peptide is cleaved, and exchanged with the peptide of interest as analyzed. Only peptide candidates that can effectively bind and stabilize the peptide-receptive MHC molecules prevent dissociation of the MHC complexes. To determine the yield of the exchange reaction, an ELISA was performed based on the detection of the light chain (β2m) of stabilized MHC complexes. The assay was performed as generally described in Rodenko et al. (Rodenko et al., Nat Protoc. 1 (2006): 1120-1132).

[0287] 96 well MAXISorp plates (NUNC) were coated over night with 2ug/ml streptavidin in PBS at room temperature, washed 4x and blocked for 1h at 37°C in 2% BSA containing blocking buffer. Refolded HLA-A0201/MLA-001 monomers served as standards, covering the range of 15-500 ng/ml. Peptide-MHC monomers of the UV-exchange reaction were diluted 100 fold in blocking buffer. Samples were incubated for 1h at 37°C, washed four times, incubated with 2ug/ml HRP conjugated anti-β2m for 1h at 37°C, washed again and detected with TMB solution that is stopped with NH2SO4. Absorption was measured at 450nm. Candidate peptides that show a high exchange yield (preferably higher than 50%, most preferred higher than 75%) are generally preferred for a generation and production of antibodies or fragments thereof, and/or T cell receptors or fragments thereof, as they show sufficient avidity to the MHC molecules and prevent dissociation of the MHC complexes.

[0288] MHC class I binding scores for the peptides as tested were; <20 % = +; 20 % - 49 % = ++; 50 % - 75 %= +++; >= 75 % = ++++
Seq ID NO.sequencePeptide exchange
229 FRVGNVQEL ++++
239 SENAFYLSP ++++

EXAMPLE 4


In vitro immunogenicity for MHC class I presented peptides



[0289] In order to obtain information regarding the immunogenicity of the TUMAPs as disclosed, the inventors performed investigations using an in vitro T-cell priming assay based on repeated stimulations of CD8+ T cells with artificial antigen presenting cells (aAPCs) loaded with peptide/MHC complexes and anti-CD28 antibody. This way the inventors could show immunogenicity for HLA-A0201 restricted TUMAPs as disclosed, demonstrating that these peptides are T-cell epitopes against which CD8+ precursor T cells exist in humans.

In vitro priming of CD8+ T cells



[0290] In order to perform in vitro stimulations by artificial antigen presenting cells loaded with peptide-MHC complex (pMHC) and anti-CD28 antibody, the inventors first isolated CD8+ T cells from fresh HLA-A02 leukapheresis products via positive selection using CD8 microbeads (Miltenyi Biotec, Bergisch-Gladbach, Germany) of healthy donors obtained from the University clinics Mannheim, Germany, after informed consent.

[0291] PBMCs and isolated CD8+ lymphocytes were incubated in T-cell medium (TCM) until use consisting of RPMI-Glutamax (Invitrogen, Karlsruhe, Germany) supplemented with 10% heat inactivated human AB serum (PAN-Biotech, Aidenbach, Germany), 100 U/ml Penicillin/100 µg/ml Streptomycin (Cambrex, Cologne, Germany), 1 mM sodium pyruvate (CC Pro, Oberdorla, Germany), 20 µg/ml Gentamycin (Cambrex). 2.5 ng/ml IL-7 (PromoCell, Heidelberg, Germany) and 10 U/ml IL-2 (Novartis Pharma, Nürnberg, Germany) were also added to the TCM at this step.

[0292] Generation of pMHC/anti-CD28 coated beads, T-cell stimulations and readout was performed in a highly defined in vitro system using four different pMHC molecules per stimulation condition and 8 different pMHC molecules per readout condition.

[0293] The purified co-stimulatory mouse IgG2a anti human CD28 Ab 9.3 (Jung et al., Proc Natl Acad Sci USA 84 (1987): 4611-4615) was chemically biotinylated using Sulfo-N-hydroxysuccinimidobiotin as recommended by the manufacturer (Perbio, Bonn, Germany). Beads used were 5.6 µm diameter streptavidin coated polystyrene particles (Bangs Laboratories, Illinois, USA).

[0294] pMHC used for positive and negative control stimulations were A0201/MLA-001 (peptide ELAGIGILTV (SEQ ID NO. 1017) from modified Melan-A/MART-1) and A0201/DDX5-001 (YLLPAIVHI from DDX5, SEQ ID NO. 1018), respectively.

[0295] 800.000 beads / 200 µl were coated in 96-well plates in the presence of 4 x 12.5 ng different biotin-pMHC, washed and 600 ng biotin anti-CD28 were added subsequently in a volume of 200 µl. Stimulations were initiated in 96-well plates by co-incubating 1x106 CD8+ T cells with 2x105 washed coated beads in 200 µl TCM supplemented with 5 ng/ml IL-12 (PromoCell) for 3 days at 37°C. Half of the medium was then exchanged by fresh TCM supplemented with 80 U/ml IL-2 and incubating was continued for 4 days at 37°C. This stimulation cycle was performed for a total of three times. For the pMHC multimer readout using 8 different pMHC molecules per condition, a two-dimensional combinatorial coding approach was used as previously described (Andersen et al., Nat.Protoc. 7 (2012): 891-902) with minor modifications encompassing coupling to 5 different fluorochromes. Finally, multimeric analyses were performed by staining the cells with Live/dead near IR dye (Invitrogen, Karlsruhe, Germany), CD8-FITC antibody clone SK1 (BD, Heidelberg, Germany) and fluorescent pMHC multimers. For analysis, a BD LSRII SORP cytometer equipped with appropriate lasers and filters was used. Peptide specific cells were calculated as percentage of total CD8+ cells. Evaluation of multimeric analysis was done using the FlowJo software (Tree Star, Oregon, USA). In vitro priming of specific multimer+ CD8+ lymphocytes was detected by by comparing to negative control stimulations. Immunogenicity for a given antigen was detected if at least one evaluable in vitro stimulated well of one healthy donor was found to contain a specific CD8+ T-cell line after in vitro stimulation (i.e. this well contained at least 1% of specific multimer+ among CD8+ T-cells and the percentage of specific multimer+ cells was at least 10x the median of the negative control stimulations).

In vitro immunogenicity for CLL peptides



[0296] For tested HLA class I peptides, in vitro immunogenicity could be demonstrated by generation of peptide specific T-cell lines. As an exemplary result, peptide KFAEEFYSF (SEQ ID NO. 20) led to in vitro T-cell responses in 2 of 5 tested donors.

EXAMPLE 5


Identification and quantitation of tumor associated peptides presented on the cell surface


Tissue samples:



[0297] In addition to the samples used for identification of peptides, an independent sample set comprising both normal and tumor (CLL) tissues was used for analysis / confirmation of HLA-A02-associated as disclosed. Written informed consents of all patients had been given before surgery or autopsy. Tissues were shock-frozen immediately after excision and stored until isolation of TUMAPs at -70°C or below.

Isolation of HLA peptides from tissue samples



[0298] HLA peptide pools from shock-frozen tissue samples were obtained by immune precipitation from solid tissues according to a slightly modified protocol (Falk et al., Nature 351 (1991): 290-296; Seeger et al., Immunogenetics 49 (1999): 571-576) using the HLA-A02-specific antibody BB7.2, the HLA-A, -B, C-specific antibody W6/32, CNBr-activated sepharose, acid treatment, and ultrafiltration.

Mass spectrometry analyses



[0299] The HLA peptide pools as obtained were separated according to their hydrophobicity by reversed-phase chromatography (nanoAcquity UPLC system, Waters) and the eluting peptides were analyzed in LTQ- velos and fusion hybrid mass spectrometers (ThermoElectron) equipped with an ESI source. Peptide pools were loaded directly onto the analytical fused-silica micro-capillary column (75 µm i.d. x 250 mm) packed with 1.7 µm C18 reversed-phase material (Waters) applying a flow rate of 400 nL per minute. Subsequently, the peptides were separated using a two-step 180 minute-binary gradient from 10% to 33% B at a flow rate of 300 nL per minute. The gradient was composed of Solvent A (0.1% formic acid in water) and solvent B (0.1% formic acid in acetonitrile). A gold coated glass capillary (PicoTip, New Objective) was used for introduction into the nanoESI source. The LTQ-Orbitrap mass spectrometers were operated in the data-dependent mode using a TOP5 strategy. In brief, a scan cycle was initiated with a full scan of high mass accuracy in the orbitrap (R = 30 000), which was followed by MS/MS scans also in the orbitrap (R = 7500) on the 5 most abundant precursor ions with dynamic exclusion of previously selected ions. Tandem mass spectra were interpreted by SEQUEST and additional manual control. The identified peptide sequence was assured by comparison of the generated natural peptide fragmentation pattern with the fragmentation pattern of a synthetic sequence-identical reference peptide.

[0300] Label-free relative LC-MS quantitation was performed by ion counting i.e. by extraction and analysis of LC-MS features (Mueller et al., Proteomics. 7 (2007): 3470-3480). The method assumes that the peptide's LC-MS signal area correlates with its abundance in the sample. Extracted features were further processed by charge state deconvolution and retention time alignment (Mueller et al., J Proteome.Res 7 (2008): 51-61; Sturm et al., BMC.Bioinformatics. 9 (2008): 163). Finally, all LC-MS features were cross-referenced with the sequence identification results to combine quantitative data of different samples and tissues to peptide presentation profiles. The quantitative data were normalized in a two-tier fashion according to central tendency to account for variation within technical and biological replicates. Thus each identified peptide can be associated with quantitative data allowing relative quantification between samples and tissues. In addition, all quantitative data acquired for peptide candidates was inspected manually to assure data consistency and to verify the accuracy of the automated analysis. For each peptide a presentation profile was calculated showing the mean sample presentation as well as replicate variations. The profiles juxtapose CLL samples to a baseline of normal tissue samples. The presentation profile of an exemplary over-presented peptide is shown in Figure 11.

Cited references



[0301] 

Ding, M. X. et al., Asian Pac.J Cancer Prev. 13 (2012): 5653-5657

Gallardo-Perez, J. C. et al., Biochim.Biophys.Acta 1843 (2014): 1043-1053

Jardim, B. V. et al., Oncol Rep. 30 (2013): 1119-1128

Jevnikar, Z. et al., J Biol.Chem 288 (2013): 2201-2209

Liu, Y. Y. et al., Mol.Cancer 9 (2010): 145

Mayr, C. et al., Blood 105 (2005): 1566-1573

Men, T. et al., Tumour.Biol. 35 (2014): 269-275

Nagai, K. et al., Cancer Med. 3 (2014): 1085-1099

Pallasch, C. P. et al., Blood 112 (2008): 4213-4219

Poeta, M. L. et al., Genes Chromosomes.Cancer 51 (2012): 1133-1143

Teh, M. T. et al., PLoS.One. 7 (2012): e34329

Yi, S. et al., Leuk.Lymphoma 52 (2011): 72-78

Yoon, D. Y. et al., Biochem.Biophys.Res.Commun. 288 (2001): 882-886

Yu, Z. et al., Zhonghua Yi.Xue.Za Zhi. 91 (2011): 1371-1374

Zhang, K. et al., Chin Med.J (Engl.) 126 (2013): 4660-4664

Zhou, H. et al., IUBMB.Life 64 (2012): 889-900


SEQUENCE LISTING



[0302] 

<110> immatics biotechnologies GmbH

<120> Novel immunotherapy against several tumors of the blood, in
particular chronic lymphoid leukemia (CLL)

<130> I32605WO

<150> GB 1411037.3
<151> 2014-06-20

<150> US 62/014,849
<151> 2014-06-20

<160> 1018

<170> PatentIn version 3.5

<210> 1
<211> 10
<212> PRT
<213> Homo sapiens

<400> 1

<210> 2
<211> 10
<212> PRT
<213> Homo sapiens

<400> 2

<210> 3
<211> 9
<212> PRT
<213> Homo sapiens

<400> 3

<210> 4
<211> 9
<212> PRT
<213> Homo sapiens

<400> 4

<210> 5
<211> 9
<212> PRT
<213> Homo sapiens

<400> 5

<210> 6
<211> 9
<212> PRT
<213> Homo sapiens

<400> 6

<210> 7
<211> 9
<212> PRT
<213> Homo sapiens

<400> 7

<210> 8
<211> 10
<212> PRT
<213> Homo sapiens

<400> 8

<210> 9
<211> 9
<212> PRT
<213> Homo sapiens

<400> 9

<210> 10
<211> 9
<212> PRT
<213> Homo sapiens

<400> 10

<210> 11
<211> 9
<212> PRT
<213> Homo sapiens

<400> 11

<210> 12
<211> 9
<212> PRT
<213> Homo sapiens

<400> 12

<210> 13
<211> 9
<212> PRT
<213> Homo sapiens

<400> 13

<210> 14
<211> 10
<212> PRT
<213> Homo sapiens

<400> 14

<210> 15
<211> 9
<212> PRT
<213> Homo sapiens

<400> 15

<210> 16
<211> 11
<212> PRT
<213> Homo sapiens

<400> 16

<210> 17
<211> 8
<212> PRT
<213> Homo sapiens

<400> 17

<210> 18
<211> 8
<212> PRT
<213> Homo sapiens

<400> 18

<210> 19
<211> 9
<212> PRT
<213> Homo sapiens

<400> 19

<210> 20
<211> 9
<212> PRT
<213> Homo sapiens

<400> 20

<210> 21
<211> 9
<212> PRT
<213> Homo sapiens

<400> 21

<210> 22
<211> 10
<212> PRT
<213> Homo sapiens

<400> 22

<210> 23
<211> 11
<212> PRT
<213> Homo sapiens

<400> 23

<210> 24
<211> 8
<212> PRT
<213> Homo sapiens

<400> 24

<210> 25
<211> 9
<212> PRT
<213> Homo sapiens

<400> 25

<210> 26
<211> 10
<212> PRT
<213> Homo sapiens

<400> 26

<210> 27
<211> 9
<212> PRT
<213> Homo sapiens

<400> 27



<210> 28
<211> 10
<212> PRT
<213> Homo sapiens

<400> 28

<210> 29
<211> 11
<212> PRT
<213> Homo sapiens

<400> 29

<210> 30
<211> 9
<212> PRT
<213> Homo sapiens

<400> 30

<210> 31
<211> 10
<212> PRT
<213> Homo sapiens

<400> 31

<210> 32
<211> 10
<212> PRT
<213> Homo sapiens

<400> 32

<210> 33
<211> 9
<212> PRT
<213> Homo sapiens

<400> 33

<210> 34
<211> 10
<212> PRT
<213> Homo sapiens

<400> 34

<210> 35
<211> 8
<212> PRT
<213> Homo sapiens

<400> 35

<210> 36
<211> 9
<212> PRT
<213> Homo sapiens

<400> 36

<210> 37
<211> 9
<212> PRT
<213> Homo sapiens

<400> 37

<210> 38
<211> 10
<212> PRT
<213> Homo sapiens

<400> 38

<210> 39
<211> 9
<212> PRT
<213> Homo sapiens

<400> 39

<210> 40
<211> 9
<212> PRT
<213> Homo sapiens

<400> 40

<210> 41
<211> 10
<212> PRT
<213> Homo sapiens

<400> 41

<210> 42
<211> 10
<212> PRT
<213> Homo sapiens

<400> 42

<210> 43
<211> 9
<212> PRT
<213> Homo sapiens

<400> 43

<210> 44
<211> 9
<212> PRT
<213> Homo sapiens

<400> 44

<210> 45
<211> 9
<212> PRT
<213> Homo sapiens

<400> 45

<210> 46
<211> 10
<212> PRT
<213> Homo sapiens

<400> 46

<210> 47
<211> 9
<212> PRT
<213> Homo sapiens

<400> 47

<210> 48
<211> 8
<212> PRT
<213> Homo sapiens

<400> 48

<210> 49
<211> 9
<212> PRT
<213> Homo sapiens

<400> 49

<210> 50
<211> 9
<212> PRT
<213> Homo sapiens

<400> 50

<210> 51
<211> 9
<212> PRT
<213> Homo sapiens

<400> 51

<210> 52
<211> 11
<212> PRT
<213> Homo sapiens

<400> 52

<210> 53
<211> 10
<212> PRT
<213> Homo sapiens

<400> 53

<210> 54
<211> 8
<212> PRT
<213> Homo sapiens

<400> 54

<210> 55
<211> 9
<212> PRT
<213> Homo sapiens

<400> 55

<210> 56
<211> 9
<212> PRT
<213> Homo sapiens

<400> 56

<210> 57
<211> 9
<212> PRT
<213> Homo sapiens

<400> 57

<210> 58
<211> 9
<212> PRT
<213> Homo sapiens

<400> 58

<210> 59
<211> 8
<212> PRT
<213> Homo sapiens

<400> 59

<210> 60
<211> 9
<212> PRT
<213> Homo sapiens

<400> 60

<210> 61
<211> 9
<212> PRT
<213> Homo sapiens

<400> 61

<210> 62
<211> 9
<212> PRT
<213> Homo sapiens

<400> 62

<210> 63
<211> 9
<212> PRT
<213> Homo sapiens

<400> 63

<210> 64
<211> 9
<212> PRT
<213> Homo sapiens

<400> 64

<210> 65
<211> 8
<212> PRT
<213> Homo sapiens

<400> 65

<210> 66
<211> 10
<212> PRT
<213> Homo sapiens

<400> 66

<210> 67
<211> 10
<212> PRT
<213> Homo sapiens

<400> 67

<210> 68
<211> 9
<212> PRT
<213> Homo sapiens

<400> 68

<210> 69
<211> 9
<212> PRT
<213> Homo sapiens

<400> 69

<210> 70
<211> 8
<212> PRT
<213> Homo sapiens

<400> 70

<210> 71
<211> 9
<212> PRT
<213> Homo sapiens

<400> 71

<210> 72
<211> 9
<212> PRT
<213> Homo sapiens

<400> 72

<210> 73
<211> 9
<212> PRT
<213> Homo sapiens

<400> 73

<210> 74
<211> 9
<212> PRT
<213> Homo sapiens

<400> 74

<210> 75
<211> 9
<212> PRT
<213> Homo sapiens

<400> 75

<210> 76
<211> 9
<212> PRT
<213> Homo sapiens

<400> 76

<210> 77
<211> 9
<212> PRT
<213> Homo sapiens

<400> 77

<210> 78
<211> 9
<212> PRT
<213> Homo sapiens

<400> 78

<210> 79
<211> 9
<212> PRT
<213> Homo sapiens

<400> 79

<210> 80
<211> 10
<212> PRT
<213> Homo sapiens

<400> 80

<210> 81
<211> 9
<212> PRT
<213> Homo sapiens

<400> 81

<210> 82
<211> 11
<212> PRT
<213> Homo sapiens

<400> 82

<210> 83
<211> 9
<212> PRT
<213> Homo sapiens

<400> 83

<210> 84
<211> 9
<212> PRT
<213> Homo sapiens

<400> 84

<210> 85
<211> 9
<212> PRT
<213> Homo sapiens

<400> 85

<210> 86
<211> 10
<212> PRT
<213> Homo sapiens

<400> 86

<210> 87
<211> 9
<212> PRT
<213> Homo sapiens

<400> 87

<210> 88
<211> 10
<212> PRT
<213> Homo sapiens

<400> 88

<210> 89
<211> 9
<212> PRT
<213> Homo sapiens

<400> 89

<210> 90
<211> 9
<212> PRT
<213> Homo sapiens

<400> 90



<210> 91
<211> 9
<212> PRT
<213> Homo sapiens

<400> 91

<210> 92
<211> 10
<212> PRT
<213> Homo sapiens

<400> 92

<210> 93
<211> 10
<212> PRT
<213> Homo sapiens

<400> 93

<210> 94
<211> 8
<212> PRT
<213> Homo sapiens

<400> 94

<210> 95
<211> 10
<212> PRT
<213> Homo sapiens

<400> 95

<210> 96
<211> 9
<212> PRT
<213> Homo sapiens

<400> 96

<210> 97
<211> 8
<212> PRT
<213> Homo sapiens

<400> 97

<210> 98
<211> 9
<212> PRT
<213> Homo sapiens

<400> 98

<210> 99
<211> 9
<212> PRT
<213> Homo sapiens

<400> 99

<210> 100
<211> 9
<212> PRT
<213> Homo sapiens

<400> 100

<210> 101
<211> 9
<212> PRT
<213> Homo sapiens

<400> 101

<210> 102
<211> 9
<212> PRT
<213> Homo sapiens

<400> 102

<210> 103
<211> 9
<212> PRT
<213> Homo sapiens

<400> 103

<210> 104
<211> 8
<212> PRT
<213> Homo sapiens

<400> 104

<210> 105
<211> 9
<212> PRT
<213> Homo sapiens

<400> 105

<210> 106
<211> 9
<212> PRT
<213> Homo sapiens

<400> 106

<210> 107
<211> 8
<212> PRT
<213> Homo sapiens

<400> 107

<210> 108
<211> 9
<212> PRT
<213> Homo sapiens

<400> 108

<210> 109
<211> 9
<212> PRT
<213> Homo sapiens

<400> 109

<210> 110
<211> 8
<212> PRT
<213> Homo sapiens

<400> 110

<210> 111
<211> 10
<212> PRT
<213> Homo sapiens

<400> 111

<210> 112
<211> 12
<212> PRT
<213> Homo sapiens

<400> 112

<210> 113
<211> 11
<212> PRT
<213> Homo sapiens

<400> 113

<210> 114
<211> 9
<212> PRT
<213> Homo sapiens

<400> 114

<210> 115
<211> 9
<212> PRT
<213> Homo sapiens

<400> 115

<210> 116
<211> 11
<212> PRT
<213> Homo sapiens

<400> 116

<210> 117
<211> 10
<212> PRT
<213> Homo sapiens

<400> 117

<210> 118
<211> 9
<212> PRT
<213> Homo sapiens

<400> 118

<210> 119
<211> 9
<212> PRT
<213> Homo sapiens

<400> 119

<210> 120
<211> 11
<212> PRT
<213> Homo sapiens

<400> 120

<210> 121
<211> 9
<212> PRT
<213> Homo sapiens

<400> 121

<210> 122
<211> 10
<212> PRT
<213> Homo sapiens

<400> 122

<210> 123
<211> 9
<212> PRT
<213> Homo sapiens

<400> 123

<210> 124
<211> 9
<212> PRT
<213> Homo sapiens

<400> 124

<210> 125
<211> 9
<212> PRT
<213> Homo sapiens

<400> 125

<210> 126
<211> 9
<212> PRT
<213> Homo sapiens

<400> 126

<210> 127
<211> 9
<212> PRT
<213> Homo sapiens

<400> 127

<210> 128
<211> 9
<212> PRT
<213> Homo sapiens

<400> 128

<210> 129
<211> 9
<212> PRT
<213> Homo sapiens

<400> 129

<210> 130
<211> 9
<212> PRT
<213> Homo sapiens

<400> 130

<210> 131
<211> 9
<212> PRT
<213> Homo sapiens

<400> 131

<210> 132
<211> 10
<212> PRT
<213> Homo sapiens

<400> 132

<210> 133
<211> 9
<212> PRT
<213> Homo sapiens

<400> 133

<210> 134
<211> 9
<212> PRT
<213> Homo sapiens

<400> 134

<210> 135
<211> 9
<212> PRT
<213> Homo sapiens

<400> 135

<210> 136
<211> 9
<212> PRT
<213> Homo sapiens

<400> 136

<210> 137
<211> 10
<212> PRT
<213> Homo sapiens

<400> 137

<210> 138
<211> 8
<212> PRT
<213> Homo sapiens

<400> 138

<210> 139
<211> 10
<212> PRT
<213> Homo sapiens

<400> 139

<210> 140
<211> 9
<212> PRT
<213> Homo sapiens

<400> 140

<210> 141
<211> 10
<212> PRT
<213> Homo sapiens

<400> 141

<210> 142
<211> 9
<212> PRT
<213> Homo sapiens

<400> 142

<210> 143
<211> 9
<212> PRT
<213> Homo sapiens

<400> 143

<210> 144
<211> 8
<212> PRT
<213> Homo sapiens

<400> 144

<210> 145
<211> 9
<212> PRT
<213> Homo sapiens

<400> 145

<210> 146
<211> 10
<212> PRT
<213> Homo sapiens

<400> 146

<210> 147
<211> 10
<212> PRT
<213> Homo sapiens

<400> 147

<210> 148
<211> 9
<212> PRT
<213> Homo sapiens

<400> 148

<210> 149
<211> 10
<212> PRT
<213> Homo sapiens

<400> 149

<210> 150
<211> 9
<212> PRT
<213> Homo sapiens

<400> 150

<210> 151
<211> 9
<212> PRT
<213> Homo sapiens

<400> 151

<210> 152
<211> 9
<212> PRT
<213> Homo sapiens

<400> 152

<210> 153
<211> 10
<212> PRT
<213> Homo sapiens

<400> 153



<210> 154
<211> 9
<212> PRT
<213> Homo sapiens

<400> 154

<210> 155
<211> 9
<212> PRT
<213> Homo sapiens

<400> 155

<210> 156
<211> 9
<212> PRT
<213> Homo sapiens

<400> 156

<210> 157
<211> 9
<212> PRT
<213> Homo sapiens

<400> 157

<210> 158
<211> 9
<212> PRT
<213> Homo sapiens

<400> 158

<210> 159
<211> 10
<212> PRT
<213> Homo sapiens

<400> 159

<210> 160
<211> 9
<212> PRT
<213> Homo sapiens

<400> 160

<210> 161
<211> 9
<212> PRT
<213> Homo sapiens

<400> 161

<210> 162
<211> 9
<212> PRT
<213> Homo sapiens

<400> 162

<210> 163
<211> 9
<212> PRT
<213> Homo sapiens

<400> 163

<210> 164
<211> 9
<212> PRT
<213> Homo sapiens

<400> 164

<210> 165
<211> 9
<212> PRT
<213> Homo sapiens

<400> 165

<210> 166
<211> 9
<212> PRT
<213> Homo sapiens

<400> 166

<210> 167
<211> 10
<212> PRT
<213> Homo sapiens

<400> 167

<210> 168
<211> 9
<212> PRT
<213> Homo sapiens

<400> 168

<210> 169
<211> 9
<212> PRT
<213> Homo sapiens

<400> 169

<210> 170
<211> 9
<212> PRT
<213> Homo sapiens

<400> 170

<210> 171
<211> 9
<212> PRT
<213> Homo sapiens

<400> 171

<210> 172
<211> 9
<212> PRT
<213> Homo sapiens

<400> 172

<210> 173
<211> 8
<212> PRT
<213> Homo sapiens

<400> 173

<210> 174
<211> 10
<212> PRT
<213> Homo sapiens

<400> 174

<210> 175
<211> 8
<212> PRT
<213> Homo sapiens

<400> 175

<210> 176
<211> 10
<212> PRT
<213> Homo sapiens

<400> 176

<210> 177
<211> 9
<212> PRT
<213> Homo sapiens

<400> 177

<210> 178
<211> 9
<212> PRT
<213> Homo sapiens

<400> 178

<210> 179
<211> 9
<212> PRT
<213> Homo sapiens

<400> 179

<210> 180
<211> 8
<212> PRT
<213> Homo sapiens

<400> 180

<210> 181
<211> 9
<212> PRT
<213> Homo sapiens

<400> 181

<210> 182
<211> 8
<212> PRT
<213> Homo sapiens

<400> 182

<210> 183
<211> 9
<212> PRT
<213> Homo sapiens

<400> 183

<210> 184
<211> 8
<212> PRT
<213> Homo sapiens

<400> 184

<210> 185
<211> 9
<212> PRT
<213> Homo sapiens

<400> 185

<210> 186
<211> 11
<212> PRT
<213> Homo sapiens

<400> 186

<210> 187
<211> 9
<212> PRT
<213> Homo sapiens

<400> 187

<210> 188
<211> 9
<212> PRT
<213> Homo sapiens

<400> 188

<210> 189
<211> 9
<212> PRT
<213> Homo sapiens

<400> 189

<210> 190
<211> 9
<212> PRT
<213> Homo sapiens

<400> 190

<210> 191
<211> 9
<212> PRT
<213> Homo sapiens

<400> 191

<210> 192
<211> 9
<212> PRT
<213> Homo sapiens

<400> 192

<210> 193
<211> 10
<212> PRT
<213> Homo sapiens

<400> 193

<210> 194
<211> 9
<212> PRT
<213> Homo sapiens

<400> 194

<210> 195
<211> 8
<212> PRT
<213> Homo sapiens

<400> 195

<210> 196
<211> 9
<212> PRT
<213> Homo sapiens

<400> 196

<210> 197
<211> 9
<212> PRT
<213> Homo sapiens

<400> 197

<210> 198
<211> 9
<212> PRT
<213> Homo sapiens

<400> 198

<210> 199
<211> 9
<212> PRT
<213> Homo sapiens

<400> 199

<210> 200
<211> 9
<212> PRT
<213> Homo sapiens

<400> 200

<210> 201
<211> 11
<212> PRT
<213> Homo sapiens

<400> 201

<210> 202
<211> 8
<212> PRT
<213> Homo sapiens

<400> 202

<210> 203
<211> 10
<212> PRT
<213> Homo sapiens

<400> 203

<210> 204
<211> 9
<212> PRT
<213> Homo sapiens

<400> 204

<210> 205
<211> 9
<212> PRT
<213> Homo sapiens

<400> 205

<210> 206
<211> 9
<212> PRT
<213> Homo sapiens

<400> 206

<210> 207
<211> 11
<212> PRT
<213> Homo sapiens

<400> 207

<210> 208
<211> 9
<212> PRT
<213> Homo sapiens

<400> 208

<210> 209
<211> 11
<212> PRT
<213> Homo sapiens

<400> 209

<210> 210
<211> 8
<212> PRT
<213> Homo sapiens

<400> 210

<210> 211
<211> 11
<212> PRT
<213> Homo sapiens

<400> 211

<210> 212
<211> 9
<212> PRT
<213> Homo sapiens

<400> 212

<210> 213
<211> 9
<212> PRT
<213> Homo sapiens

<400> 213

<210> 214
<211> 9
<212> PRT
<213> Homo sapiens

<400> 214

<210> 215
<211> 9
<212> PRT
<213> Homo sapiens

<400> 215

<210> 216
<211> 9
<212> PRT
<213> Homo sapiens

<400> 216



<210> 217
<211> 9
<212> PRT
<213> Homo sapiens

<400> 217

<210> 218
<211> 9
<212> PRT
<213> Homo sapiens

<400> 218

<210> 219
<211> 9
<212> PRT
<213> Homo sapiens

<400> 219

<210> 220
<211> 10
<212> PRT
<213> Homo sapiens

<400> 220

<210> 221
<211> 9
<212> PRT
<213> Homo sapiens

<400> 221

<210> 222
<211> 9
<212> PRT
<213> Homo sapiens

<400> 222

<210> 223
<211> 11
<212> PRT
<213> Homo sapiens

<400> 223

<210> 224
<211> 10
<212> PRT
<213> Homo sapiens

<400> 224

<210> 225
<211> 9
<212> PRT
<213> Homo sapiens

<400> 225

<210> 226
<211> 9
<212> PRT
<213> Homo sapiens

<400> 226

<210> 227
<211> 10
<212> PRT
<213> Homo sapiens

<400> 227

<210> 228
<211> 9
<212> PRT
<213> Homo sapiens

<400> 228

<210> 229
<211> 9
<212> PRT
<213> Homo sapiens

<400> 229

<210> 230
<211> 9
<212> PRT
<213> Homo sapiens

<400> 230

<210> 231
<211> 11
<212> PRT
<213> Homo sapiens

<400> 231

<210> 232
<211> 9
<212> PRT
<213> Homo sapiens

<400> 232

<210> 233
<211> 9
<212> PRT
<213> Homo sapiens

<400> 233

<210> 234
<211> 10
<212> PRT
<213> Homo sapiens

<400> 234

<210> 235
<211> 9
<212> PRT
<213> Homo sapiens

<400> 235

<210> 236
<211> 10
<212> PRT
<213> Homo sapiens

<400> 236

<210> 237
<211> 9
<212> PRT
<213> Homo sapiens

<400> 237

<210> 238
<211> 12
<212> PRT
<213> Homo sapiens

<400> 238

<210> 239
<211> 9
<212> PRT
<213> Homo sapiens

<400> 239

<210> 240
<211> 9
<212> PRT
<213> Homo sapiens

<400> 240

<210> 241
<211> 9
<212> PRT
<213> Homo sapiens

<400> 241

<210> 242
<211> 9
<212> PRT
<213> Homo sapiens

<400> 242

<210> 243
<211> 9
<212> PRT
<213> Homo sapiens

<400> 243

<210> 244
<211> 8
<212> PRT
<213> Homo sapiens

<400> 244

<210> 245
<211> 9
<212> PRT
<213> Homo sapiens

<400> 245

<210> 246
<211> 9
<212> PRT
<213> Homo sapiens

<400> 246

<210> 247
<211> 10
<212> PRT
<213> Homo sapiens

<400> 247

<210> 248
<211> 9
<212> PRT
<213> Homo sapiens

<400> 248

<210> 249
<211> 9
<212> PRT
<213> Homo sapiens

<400> 249

<210> 250
<211> 10
<212> PRT
<213> Homo sapiens

<400> 250

<210> 251
<211> 8
<212> PRT
<213> Homo sapiens

<400> 251

<210> 252
<211> 9
<212> PRT
<213> Homo sapiens

<400> 252

<210> 253
<211> 9
<212> PRT
<213> Homo sapiens

<400> 253

<210> 254
<211> 9
<212> PRT
<213> Homo sapiens

<400> 254

<210> 255
<211> 9
<212> PRT
<213> Homo sapiens

<400> 255

<210> 256
<211> 9
<212> PRT
<213> Homo sapiens

<400> 256

<210> 257
<211> 9
<212> PRT
<213> Homo sapiens

<400> 257

<210> 258
<211> 9
<212> PRT
<213> Homo sapiens

<400> 258

<210> 259
<211> 9
<212> PRT
<213> Homo sapiens

<400> 259

<210> 260
<211> 9
<212> PRT
<213> Homo sapiens

<400> 260

<210> 261
<211> 9
<212> PRT
<213> Homo sapiens

<400> 261

<210> 262
<211> 9
<212> PRT
<213> Homo sapiens

<400> 262

<210> 263
<211> 9
<212> PRT
<213> Homo sapiens

<400> 263

<210> 264
<211> 8
<212> PRT
<213> Homo sapiens

<400> 264

<210> 265
<211> 9
<212> PRT
<213> Homo sapiens

<400> 265

<210> 266
<211> 10
<212> PRT
<213> Homo sapiens

<400> 266

<210> 267
<211> 9
<212> PRT
<213> Homo sapiens

<400> 267

<210> 268
<211> 9
<212> PRT
<213> Homo sapiens

<400> 268

<210> 269
<211> 8
<212> PRT
<213> Homo sapiens

<400> 269

<210> 270
<211> 9
<212> PRT
<213> Homo sapiens

<400> 270

<210> 271
<211> 9
<212> PRT
<213> Homo sapiens

<400> 271

<210> 272
<211> 9
<212> PRT
<213> Homo sapiens

<400> 272

<210> 273
<211> 9
<212> PRT
<213> Homo sapiens

<400> 273

<210> 274
<211> 9
<212> PRT
<213> Homo sapiens

<400> 274

<210> 275
<211> 8
<212> PRT
<213> Homo sapiens

<400> 275

<210> 276
<211> 9
<212> PRT
<213> Homo sapiens

<400> 276

<210> 277
<211> 10
<212> PRT
<213> Homo sapiens

<400> 277

<210> 278
<211> 9
<212> PRT
<213> Homo sapiens

<400> 278

<210> 279
<211> 11
<212> PRT
<213> Homo sapiens

<400> 279



<210> 280
<211> 9
<212> PRT
<213> Homo sapiens

<400> 280

<210> 281
<211> 9
<212> PRT
<213> Homo sapiens

<400> 281

<210> 282
<211> 9
<212> PRT
<213> Homo sapiens

<400> 282

<210> 283
<211> 9
<212> PRT
<213> Homo sapiens

<400> 283

<210> 284
<211> 9
<212> PRT
<213> Homo sapiens

<400> 284

<210> 285
<211> 9
<212> PRT
<213> Homo sapiens

<400> 285

<210> 286
<211> 9
<212> PRT
<213> Homo sapiens

<400> 286

<210> 287
<211> 9
<212> PRT
<213> Homo sapiens

<400> 287

<210> 288
<211> 9
<212> PRT
<213> Homo sapiens

<400> 288

<210> 289
<211> 10
<212> PRT
<213> Homo sapiens

<400> 289

<210> 290
<211> 9
<212> PRT
<213> Homo sapiens

<400> 290

<210> 291
<211> 9
<212> PRT
<213> Homo sapiens

<400> 291

<210> 292
<211> 9
<212> PRT
<213> Homo sapiens

<400> 292

<210> 293
<211> 9
<212> PRT
<213> Homo sapiens

<400> 293

<210> 294
<211> 9
<212> PRT
<213> Homo sapiens

<400> 294

<210> 295
<211> 11
<212> PRT
<213> Homo sapiens

<400> 295

<210> 296
<211> 9
<212> PRT
<213> Homo sapiens

<400> 296

<210> 297
<211> 9
<212> PRT
<213> Homo sapiens

<400> 297

<210> 298
<211> 9
<212> PRT
<213> Homo sapiens

<400> 298

<210> 299
<211> 9
<212> PRT
<213> Homo sapiens

<400> 299

<210> 300
<211> 9
<212> PRT
<213> Homo sapiens

<400> 300

<210> 301
<211> 10
<212> PRT
<213> Homo sapiens

<400> 301

<210> 302
<211> 9
<212> PRT
<213> Homo sapiens

<400> 302

<210> 303
<211> 9
<212> PRT
<213> Homo sapiens

<400> 303

<210> 304
<211> 9
<212> PRT
<213> Homo sapiens

<400> 304

<210> 305
<211> 8
<212> PRT
<213> Homo sapiens

<400> 305

<210> 306
<211> 9
<212> PRT
<213> Homo sapiens

<400> 306

<210> 307
<211> 9
<212> PRT
<213> Homo sapiens

<400> 307

<210> 308
<211> 9
<212> PRT
<213> Homo sapiens

<400> 308

<210> 309
<211> 9
<212> PRT
<213> Homo sapiens

<400> 309

<210> 310
<211> 10
<212> PRT
<213> Homo sapiens

<400> 310

<210> 311
<211> 9
<212> PRT
<213> Homo sapiens

<400> 311

<210> 312
<211> 9
<212> PRT
<213> Homo sapiens

<400> 312

<210> 313
<211> 9
<212> PRT
<213> Homo sapiens

<400> 313

<210> 314
<211> 9
<212> PRT
<213> Homo sapiens

<400> 314

<210> 315
<211> 9
<212> PRT
<213> Homo sapiens

<400> 315

<210> 316
<211> 9
<212> PRT
<213> Homo sapiens

<400> 316

<210> 317
<211> 11
<212> PRT
<213> Homo sapiens

<400> 317

<210> 318
<211> 9
<212> PRT
<213> Homo sapiens

<400> 318

<210> 319
<211> 10
<212> PRT
<213> Homo sapiens

<400> 319

<210> 320
<211> 9
<212> PRT
<213> Homo sapiens

<400> 320

<210> 321
<211> 9
<212> PRT
<213> Homo sapiens

<400> 321

<210> 322
<211> 10
<212> PRT
<213> Homo sapiens

<400> 322

<210> 323
<211> 9
<212> PRT
<213> Homo sapiens

<400> 323

<210> 324
<211> 9
<212> PRT
<213> Homo sapiens

<400> 324

<210> 325
<211> 9
<212> PRT
<213> Homo sapiens

<400> 325

<210> 326
<211> 9
<212> PRT
<213> Homo sapiens

<400> 326

<210> 327
<211> 9
<212> PRT
<213> Homo sapiens

<400> 327

<210> 328
<211> 9
<212> PRT
<213> Homo sapiens

<400> 328

<210> 329
<211> 8
<212> PRT
<213> Homo sapiens

<400> 329

<210> 330
<211> 9
<212> PRT
<213> Homo sapiens

<400> 330

<210> 331
<211> 9
<212> PRT
<213> Homo sapiens

<400> 331

<210> 332
<211> 8
<212> PRT
<213> Homo sapiens

<400> 332

<210> 333
<211> 10
<212> PRT
<213> Homo sapiens

<400> 333

<210> 334
<211> 9
<212> PRT
<213> Homo sapiens

<400> 334

<210> 335
<211> 9
<212> PRT
<213> Homo sapiens

<400> 335

<210> 336
<211> 10
<212> PRT
<213> Homo sapiens

<400> 336

<210> 337
<211> 9
<212> PRT
<213> Homo sapiens

<400> 337

<210> 338
<211> 8
<212> PRT
<213> Homo sapiens

<400> 338

<210> 339
<211> 11
<212> PRT
<213> Homo sapiens

<400> 339

<210> 340
<211> 10
<212> PRT
<213> Homo sapiens

<400> 340

<210> 341
<211> 10
<212> PRT
<213> Homo sapiens

<400> 341

<210> 342
<211> 9
<212> PRT
<213> Homo sapiens

<400> 342



<210> 343
<211> 9
<212> PRT
<213> Homo sapiens

<400> 343

<210> 344
<211> 9
<212> PRT
<213> Homo sapiens

<400> 344

<210> 345
<211> 9
<212> PRT
<213> Homo sapiens

<400> 345

<210> 346
<211> 9
<212> PRT
<213> Homo sapiens

<400> 346

<210> 347
<211> 10
<212> PRT
<213> Homo sapiens

<400> 347

<210> 348
<211> 9
<212> PRT
<213> Homo sapiens

<400> 348

<210> 349
<211> 9
<212> PRT
<213> Homo sapiens

<400> 349

<210> 350
<211> 9
<212> PRT
<213> Homo sapiens

<400> 350

<210> 351
<211> 9
<212> PRT
<213> Homo sapiens

<400> 351

<210> 352
<211> 10
<212> PRT
<213> Homo sapiens

<400> 352

<210> 353
<211> 9
<212> PRT
<213> Homo sapiens

<400> 353

<210> 354
<211> 9
<212> PRT
<213> Homo sapiens

<400> 354

<210> 355
<211> 9
<212> PRT
<213> Homo sapiens

<400> 355

<210> 356
<211> 9
<212> PRT
<213> Homo sapiens

<400> 356

<210> 357
<211> 8
<212> PRT
<213> Homo sapiens

<400> 357

<210> 358
<211> 9
<212> PRT
<213> Homo sapiens

<400> 358

<210> 359
<211> 9
<212> PRT
<213> Homo sapiens

<400> 359

<210> 360
<211> 9
<212> PRT
<213> Homo sapiens

<400> 360

<210> 361
<211> 8
<212> PRT
<213> Homo sapiens

<400> 361

<210> 362
<211> 9
<212> PRT
<213> Homo sapiens

<400> 362

<210> 363
<211> 9
<212> PRT
<213> Homo sapiens

<400> 363

<210> 364
<211> 9
<212> PRT
<213> Homo sapiens

<400> 364

<210> 365
<211> 8
<212> PRT
<213> Homo sapiens

<400> 365

<210> 366
<211> 9
<212> PRT
<213> Homo sapiens

<400> 366

<210> 367
<211> 9
<212> PRT
<213> Homo sapiens

<400> 367

<210> 368
<211> 9
<212> PRT
<213> Homo sapiens

<400> 368

<210> 369
<211> 9
<212> PRT
<213> Homo sapiens

<400> 369

<210> 370
<211> 10
<212> PRT
<213> Homo sapiens

<400> 370

<210> 371
<211> 11
<212> PRT
<213> Homo sapiens

<400> 371

<210> 372
<211> 9
<212> PRT
<213> Homo sapiens

<400> 372

<210> 373
<211> 12
<212> PRT
<213> Homo sapiens

<400> 373

<210> 374
<211> 9
<212> PRT
<213> Homo sapiens

<400> 374

<210> 375
<211> 9
<212> PRT
<213> Homo sapiens

<400> 375

<210> 376
<211> 9
<212> PRT
<213> Homo sapiens

<400> 376

<210> 377
<211> 9
<212> PRT
<213> Homo sapiens

<400> 377

<210> 378
<211> 8
<212> PRT
<213> Homo sapiens

<400> 378

<210> 379
<211> 8
<212> PRT
<213> Homo sapiens

<400> 379

<210> 380
<211> 9
<212> PRT
<213> Homo sapiens

<400> 380

<210> 381
<211> 9
<212> PRT
<213> Homo sapiens

<400> 381

<210> 382
<211> 9
<212> PRT
<213> Homo sapiens

<400> 382

<210> 383
<211> 9
<212> PRT
<213> Homo sapiens

<400> 383

<210> 384
<211> 10
<212> PRT
<213> Homo sapiens

<400> 384

<210> 385
<211> 9
<212> PRT
<213> Homo sapiens

<400> 385

<210> 386
<211> 9
<212> PRT
<213> Homo sapiens

<400> 386

<210> 387
<211> 9
<212> PRT
<213> Homo sapiens

<400> 387

<210> 388
<211> 11
<212> PRT
<213> Homo sapiens

<400> 388

<210> 389
<211> 9
<212> PRT
<213> Homo sapiens

<400> 389

<210> 390
<211> 9
<212> PRT
<213> Homo sapiens

<400> 390

<210> 391
<211> 9
<212> PRT
<213> Homo sapiens

<400> 391

<210> 392
<211> 9
<212> PRT
<213> Homo sapiens

<400> 392

<210> 393
<211> 11
<212> PRT
<213> Homo sapiens

<400> 393

<210> 394
<211> 11
<212> PRT
<213> Homo sapiens

<400> 394

<210> 395
<211> 9
<212> PRT
<213> Homo sapiens

<400> 395

<210> 396
<211> 12
<212> PRT
<213> Homo sapiens

<400> 396

<210> 397
<211> 9
<212> PRT
<213> Homo sapiens

<400> 397

<210> 398
<211> 9
<212> PRT
<213> Homo sapiens

<400> 398

<210> 399
<211> 10
<212> PRT
<213> Homo sapiens

<400> 399

<210> 400
<211> 9
<212> PRT
<213> Homo sapiens

<400> 400

<210> 401
<211> 9
<212> PRT
<213> Homo sapiens

<400> 401

<210> 402
<211> 9
<212> PRT
<213> Homo sapiens

<400> 402

<210> 403
<211> 9
<212> PRT
<213> Homo sapiens

<400> 403

<210> 404
<211> 10
<212> PRT
<213> Homo sapiens

<400> 404

<210> 405
<211> 9
<212> PRT
<213> Homo sapiens

<400> 405



<210> 406
<211> 9
<212> PRT
<213> Homo sapiens

<400> 406

<210> 407
<211> 9
<212> PRT
<213> Homo sapiens

<400> 407

<210> 408
<211> 9
<212> PRT
<213> Homo sapiens

<400> 408

<210> 409
<211> 9
<212> PRT
<213> Homo sapiens

<400> 409

<210> 410
<211> 9
<212> PRT
<213> Homo sapiens

<400> 410

<210> 411
<211> 9
<212> PRT
<213> Homo sapiens

<400> 411

<210> 412
<211> 8
<212> PRT
<213> Homo sapiens

<400> 412

<210> 413
<211> 11
<212> PRT
<213> Homo sapiens

<400> 413

<210> 414
<211> 9
<212> PRT
<213> Homo sapiens

<400> 414

<210> 415
<211> 9
<212> PRT
<213> Homo sapiens

<400> 415

<210> 416
<211> 8
<212> PRT
<213> Homo sapiens

<400> 416

<210> 417
<211> 9
<212> PRT
<213> Homo sapiens

<400> 417

<210> 418
<211> 9
<212> PRT
<213> Homo sapiens

<400> 418

<210> 419
<211> 9
<212> PRT
<213> Homo sapiens

<400> 419

<210> 420
<211> 9
<212> PRT
<213> Homo sapiens

<400> 420

<210> 421
<211> 9
<212> PRT
<213> Homo sapiens

<400> 421

<210> 422
<211> 9
<212> PRT
<213> Homo sapiens

<400> 422

<210> 423
<211> 10
<212> PRT
<213> Homo sapiens

<400> 423

<210> 424
<211> 8
<212> PRT
<213> Homo sapiens

<400> 424

<210> 425
<211> 10
<212> PRT
<213> Homo sapiens

<400> 425

<210> 426
<211> 8
<212> PRT
<213> Homo sapiens

<400> 426

<210> 427
<211> 9
<212> PRT
<213> Homo sapiens

<400> 427

<210> 428
<211> 9
<212> PRT
<213> Homo sapiens

<400> 428

<210> 429
<211> 9
<212> PRT
<213> Homo sapiens

<400> 429

<210> 430
<211> 10
<212> PRT
<213> Homo sapiens

<400> 430

<210> 431
<211> 10
<212> PRT
<213> Homo sapiens

<400> 431

<210> 432
<211> 11
<212> PRT
<213> Homo sapiens

<400> 432

<210> 433
<211> 9
<212> PRT
<213> Homo sapiens

<400> 433

<210> 434
<211> 9
<212> PRT
<213> Homo sapiens

<400> 434

<210> 435
<211> 9
<212> PRT
<213> Homo sapiens

<400> 435

<210> 436
<211> 9
<212> PRT
<213> Homo sapiens

<400> 436

<210> 437
<211> 9
<212> PRT
<213> Homo sapiens

<400> 437

<210> 438
<211> 9
<212> PRT
<213> Homo sapiens

<400> 438

<210> 439
<211> 9
<212> PRT
<213> Homo sapiens

<400> 439

<210> 440
<211> 9
<212> PRT
<213> Homo sapiens

<400> 440

<210> 441
<211> 10
<212> PRT
<213> Homo sapiens

<400> 441

<210> 442
<211> 9
<212> PRT
<213> Homo sapiens

<400> 442

<210> 443
<211> 9
<212> PRT
<213> Homo sapiens

<400> 443

<210> 444
<211> 9
<212> PRT
<213> Homo sapiens

<400> 444

<210> 445
<211> 9
<212> PRT
<213> Homo sapiens

<400> 445

<210> 446
<211> 9
<212> PRT
<213> Homo sapiens

<400> 446

<210> 447
<211> 9
<212> PRT
<213> Homo sapiens

<400> 447

<210> 448
<211> 9
<212> PRT
<213> Homo sapiens

<400> 448

<210> 449
<211> 9
<212> PRT
<213> Homo sapiens

<400> 449

<210> 450
<211> 9
<212> PRT
<213> Homo sapiens

<400> 450

<210> 451
<211> 9
<212> PRT
<213> Homo sapiens

<400> 451

<210> 452
<211> 9
<212> PRT
<213> Homo sapiens

<400> 452

<210> 453
<211> 10
<212> PRT
<213> Homo sapiens

<400> 453

<210> 454
<211> 9
<212> PRT
<213> Homo sapiens

<400> 454

<210> 455
<211> 11
<212> PRT
<213> Homo sapiens

<400> 455

<210> 456
<211> 8
<212> PRT
<213> Homo sapiens

<400> 456

<210> 457
<211> 9
<212> PRT
<213> Homo sapiens

<400> 457

<210> 458
<211> 8
<212> PRT
<213> Homo sapiens

<400> 458

<210> 459
<211> 10
<212> PRT
<213> Homo sapiens

<400> 459

<210> 460
<211> 10
<212> PRT
<213> Homo sapiens

<400> 460

<210> 461
<211> 9
<212> PRT
<213> Homo sapiens

<400> 461

<210> 462
<211> 9
<212> PRT
<213> Homo sapiens

<400> 462

<210> 463
<211> 10
<212> PRT
<213> Homo sapiens

<400> 463

<210> 464
<211> 10
<212> PRT
<213> Homo sapiens

<400> 464

<210> 465
<211> 9
<212> PRT
<213> Homo sapiens

<400> 465

<210> 466
<211> 9
<212> PRT
<213> Homo sapiens

<400> 466

<210> 467
<211> 10
<212> PRT
<213> Homo sapiens

<400> 467

<210> 468
<211> 8
<212> PRT
<213> Homo sapiens

<400> 468



<210> 469
<211> 8
<212> PRT
<213> Homo sapiens

<400> 469

<210> 470
<211> 10
<212> PRT
<213> Homo sapiens

<400> 470

<210> 471
<211> 8
<212> PRT
<213> Homo sapiens

<400> 471

<210> 472
<211> 9
<212> PRT
<213> Homo sapiens

<400> 472

<210> 473
<211> 9
<212> PRT
<213> Homo sapiens

<400> 473

<210> 474
<211> 9
<212> PRT
<213> Homo sapiens

<400> 474

<210> 475
<211> 9
<212> PRT
<213> Homo sapiens

<400> 475

<210> 476
<211> 9
<212> PRT
<213> Homo sapiens

<400> 476

<210> 477
<211> 9
<212> PRT
<213> Homo sapiens

<400> 477

<210> 478
<211> 9
<212> PRT
<213> Homo sapiens

<400> 478

<210> 479
<211> 9
<212> PRT
<213> Homo sapiens

<400> 479

<210> 480
<211> 9
<212> PRT
<213> Homo sapiens

<400> 480

<210> 481
<211> 9
<212> PRT
<213> Homo sapiens

<400> 481

<210> 482
<211> 12
<212> PRT
<213> Homo sapiens

<400> 482

<210> 483
<211> 10
<212> PRT
<213> Homo sapiens

<400> 483

<210> 484
<211> 8
<212> PRT
<213> Homo sapiens

<400> 484

<210> 485
<211> 9
<212> PRT
<213> Homo sapiens

<400> 485

<210> 486
<211> 9
<212> PRT
<213> Homo sapiens

<400> 486

<210> 487
<211> 8
<212> PRT
<213> Homo sapiens

<400> 487

<210> 488
<211> 9
<212> PRT
<213> Homo sapiens

<400> 488

<210> 489
<211> 9
<212> PRT
<213> Homo sapiens

<400> 489

<210> 490
<211> 11
<212> PRT
<213> Homo sapiens

<400> 490

<210> 491
<211> 11
<212> PRT
<213> Homo sapiens

<400> 491

<210> 492
<211> 9
<212> PRT
<213> Homo sapiens

<400> 492

<210> 493
<211> 9
<212> PRT
<213> Homo sapiens

<400> 493

<210> 494
<211> 9
<212> PRT
<213> Homo sapiens

<400> 494

<210> 495
<211> 9
<212> PRT
<213> Homo sapiens

<400> 495

<210> 496
<211> 9
<212> PRT
<213> Homo sapiens

<400> 496

<210> 497
<211> 9
<212> PRT
<213> Homo sapiens

<400> 497

<210> 498
<211> 10
<212> PRT
<213> Homo sapiens

<400> 498

<210> 499
<211> 9
<212> PRT
<213> Homo sapiens

<400> 499

<210> 500
<211> 9
<212> PRT
<213> Homo sapiens

<400> 500

<210> 501
<211> 9
<212> PRT
<213> Homo sapiens

<400> 501

<210> 502
<211> 9
<212> PRT
<213> Homo sapiens

<400> 502

<210> 503
<211> 9
<212> PRT
<213> Homo sapiens

<400> 503

<210> 504
<211> 8
<212> PRT
<213> Homo sapiens

<400> 504

<210> 505
<211> 9
<212> PRT
<213> Homo sapiens

<400> 505

<210> 506
<211> 10
<212> PRT
<213> Homo sapiens

<400> 506

<210> 507
<211> 8
<212> PRT
<213> Homo sapiens

<400> 507

<210> 508
<211> 8
<212> PRT
<213> Homo sapiens

<400> 508

<210> 509
<211> 9
<212> PRT
<213> Homo sapiens

<400> 509

<210> 510
<211> 9
<212> PRT
<213> Homo sapiens

<400> 510

<210> 511
<211> 9
<212> PRT
<213> Homo sapiens

<400> 511

<210> 512
<211> 9
<212> PRT
<213> Homo sapiens

<400> 512

<210> 513
<211> 10
<212> PRT
<213> Homo sapiens

<400> 513

<210> 514
<211> 9
<212> PRT
<213> Homo sapiens

<400> 514

<210> 515
<211> 9
<212> PRT
<213> Homo sapiens

<400> 515

<210> 516
<211> 9
<212> PRT
<213> Homo sapiens

<400> 516

<210> 517
<211> 10
<212> PRT
<213> Homo sapiens

<400> 517

<210> 518
<211> 9
<212> PRT
<213> Homo sapiens

<400> 518

<210> 519
<211> 9
<212> PRT
<213> Homo sapiens

<400> 519

<210> 520
<211> 9
<212> PRT
<213> Homo sapiens

<400> 520

<210> 521
<211> 9
<212> PRT
<213> Homo sapiens

<400> 521

<210> 522
<211> 10
<212> PRT
<213> Homo sapiens

<400> 522

<210> 523
<211> 12
<212> PRT
<213> Homo sapiens

<400> 523

<210> 524
<211> 9
<212> PRT
<213> Homo sapiens

<400> 524

<210> 525
<211> 9
<212> PRT
<213> Homo sapiens

<400> 525

<210> 526
<211> 10
<212> PRT
<213> Homo sapiens

<400> 526

<210> 527
<211> 9
<212> PRT
<213> Homo sapiens

<400> 527

<210> 528
<211> 9
<212> PRT
<213> Homo sapiens

<400> 528

<210> 529
<211> 9
<212> PRT
<213> Homo sapiens

<400> 529

<210> 530
<211> 9
<212> PRT
<213> Homo sapiens

<400> 530

<210> 531
<211> 9
<212> PRT
<213> Homo sapiens

<400> 531



<210> 532
<211> 8
<212> PRT
<213> Homo sapiens

<400> 532

<210> 533
<211> 9
<212> PRT
<213> Homo sapiens

<400> 533

<210> 534
<211> 8
<212> PRT
<213> Homo sapiens

<400> 534

<210> 535
<211> 9
<212> PRT
<213> Homo sapiens

<400> 535

<210> 536
<211> 8
<212> PRT
<213> Homo sapiens

<400> 536

<210> 537
<211> 8
<212> PRT
<213> Homo sapiens

<400> 537

<210> 538
<211> 10
<212> PRT
<213> Homo sapiens

<400> 538

<210> 539
<211> 9
<212> PRT
<213> Homo sapiens

<400> 539

<210> 540
<211> 10
<212> PRT
<213> Homo sapiens

<400> 540

<210> 541
<211> 8
<212> PRT
<213> Homo sapiens

<400> 541

<210> 542
<211> 9
<212> PRT
<213> Homo sapiens

<400> 542

<210> 543
<211> 14
<212> PRT
<213> Homo sapiens

<400> 543

<210> 544
<211> 16
<212> PRT
<213> Homo sapiens

<400> 544

<210> 545
<211> 17
<212> PRT
<213> Homo sapiens

<400> 545

<210> 546
<211> 17
<212> PRT
<213> Homo sapiens

<400> 546

<210> 547
<211> 18
<212> PRT
<213> Homo sapiens

<400> 547

<210> 548
<211> 16
<212> PRT
<213> Homo sapiens

<400> 548

<210> 549
<211> 17
<212> PRT
<213> Homo sapiens

<400> 549

<210> 550
<211> 18
<212> PRT
<213> Homo sapiens

<400> 550

<210> 551
<211> 12
<212> PRT
<213> Homo sapiens

<400> 551

<210> 552
<211> 13
<212> PRT
<213> Homo sapiens

<400> 552

<210> 553
<211> 14
<212> PRT
<213> Homo sapiens

<400> 553

<210> 554
<211> 14
<212> PRT
<213> Homo sapiens

<400> 554

<210> 555
<211> 15
<212> PRT
<213> Homo sapiens

<400> 555

<210> 556
<211> 18
<212> PRT
<213> Homo sapiens

<400> 556

<210> 557
<211> 15
<212> PRT
<213> Homo sapiens

<400> 557

<210> 558
<211> 12
<212> PRT
<213> Homo sapiens

<400> 558

<210> 559
<211> 13
<212> PRT
<213> Homo sapiens

<400> 559

<210> 560
<211> 14
<212> PRT
<213> Homo sapiens

<400> 560

<210> 561
<211> 14
<212> PRT
<213> Homo sapiens

<400> 561

<210> 562
<211> 15
<212> PRT
<213> Homo sapiens

<400> 562

<210> 563
<211> 16
<212> PRT
<213> Homo sapiens

<400> 563

<210> 564
<211> 17
<212> PRT
<213> Homo sapiens

<400> 564

<210> 565
<211> 13
<212> PRT
<213> Homo sapiens

<400> 565

<210> 566
<211> 12
<212> PRT
<213> Homo sapiens

<400> 566

<210> 567
<211> 13
<212> PRT
<213> Homo sapiens

<400> 567

<210> 568
<211> 14
<212> PRT
<213> Homo sapiens

<400> 568

<210> 569
<211> 15
<212> PRT
<213> Homo sapiens

<400> 569

<210> 570
<211> 13
<212> PRT
<213> Homo sapiens

<400> 570

<210> 571
<211> 14
<212> PRT
<213> Homo sapiens

<400> 571

<210> 572
<211> 12
<212> PRT
<213> Homo sapiens

<400> 572

<210> 573
<211> 13
<212> PRT
<213> Homo sapiens

<400> 573

<210> 574
<211> 15
<212> PRT
<213> Homo sapiens

<400> 574

<210> 575
<211> 13
<212> PRT
<213> Homo sapiens

<400> 575

<210> 576
<211> 12
<212> PRT
<213> Homo sapiens

<400> 576

<210> 577
<211> 14
<212> PRT
<213> Homo sapiens

<400> 577

<210> 578
<211> 18
<212> PRT
<213> Homo sapiens

<400> 578

<210> 579
<211> 12
<212> PRT
<213> Homo sapiens

<400> 579

<210> 580
<211> 13
<212> PRT
<213> Homo sapiens

<400> 580

<210> 581
<211> 25
<212> PRT
<213> Homo sapiens

<400> 581

<210> 582
<211> 23
<212> PRT
<213> Homo sapiens

<400> 582

<210> 583
<211> 21
<212> PRT
<213> Homo sapiens

<400> 583

<210> 584
<211> 19
<212> PRT
<213> Homo sapiens

<400> 584



<210> 585
<211> 12
<212> PRT
<213> Homo sapiens

<400> 585

<210> 586
<211> 14
<212> PRT
<213> Homo sapiens

<400> 586

<210> 587
<211> 14
<212> PRT
<213> Homo sapiens

<400> 587

<210> 588
<211> 13
<212> PRT
<213> Homo sapiens

<400> 588

<210> 589
<211> 14
<212> PRT
<213> Homo sapiens

<400> 589

<210> 590
<211> 15
<212> PRT
<213> Homo sapiens

<400> 590

<210> 591
<211> 16
<212> PRT
<213> Homo sapiens

<400> 591

<210> 592
<211> 14
<212> PRT
<213> Homo sapiens

<400> 592

<210> 593
<211> 14
<212> PRT
<213> Homo sapiens

<400> 593

<210> 594
<211> 16
<212> PRT
<213> Homo sapiens

<400> 594

<210> 595
<211> 17
<212> PRT
<213> Homo sapiens

<400> 595

<210> 596
<211> 12
<212> PRT
<213> Homo sapiens

<400> 596

<210> 597
<211> 13
<212> PRT
<213> Homo sapiens

<400> 597

<210> 598
<211> 15
<212> PRT
<213> Homo sapiens

<400> 598

<210> 599
<211> 16
<212> PRT
<213> Homo sapiens

<400> 599

<210> 600
<211> 17
<212> PRT
<213> Homo sapiens

<400> 600

<210> 601
<211> 14
<212> PRT
<213> Homo sapiens

<400> 601

<210> 602
<211> 15
<212> PRT
<213> Homo sapiens

<400> 602

<210> 603
<211> 13
<212> PRT
<213> Homo sapiens

<400> 603

<210> 604
<211> 14
<212> PRT
<213> Homo sapiens

<400> 604

<210> 605
<211> 15
<212> PRT
<213> Homo sapiens

<400> 605

<210> 606
<211> 16
<212> PRT
<213> Homo sapiens

<400> 606

<210> 607
<211> 17
<212> PRT
<213> Homo sapiens

<400> 607

<210> 608
<211> 13
<212> PRT
<213> Homo sapiens

<400> 608

<210> 609
<211> 17
<212> PRT
<213> Homo sapiens

<400> 609

<210> 610
<211> 15
<212> PRT
<213> Homo sapiens

<400> 610

<210> 611
<211> 20
<212> PRT
<213> Homo sapiens

<400> 611



<210> 612
<211> 14
<212> PRT
<213> Homo sapiens

<400> 612

<210> 613
<211> 12
<212> PRT
<213> Homo sapiens

<400> 613

<210> 614
<211> 13
<212> PRT
<213> Homo sapiens

<400> 614

<210> 615
<211> 14
<212> PRT
<213> Homo sapiens

<400> 615

<210> 616
<211> 13
<212> PRT
<213> Homo sapiens

<400> 616

<210> 617
<211> 18
<212> PRT
<213> Homo sapiens

<400> 617

<210> 618
<211> 15
<212> PRT
<213> Homo sapiens

<400> 618

<210> 619
<211> 18
<212> PRT
<213> Homo sapiens

<400> 619

<210> 620
<211> 23
<212> PRT
<213> Homo sapiens

<400> 620

<210> 621
<211> 12
<212> PRT
<213> Homo sapiens

<400> 621

<210> 622
<211> 15
<212> PRT
<213> Homo sapiens

<400> 622

<210> 623
<211> 13
<212> PRT
<213> Homo sapiens

<400> 623

<210> 624
<211> 15
<212> PRT
<213> Homo sapiens

<400> 624

<210> 625
<211> 15
<212> PRT
<213> Homo sapiens

<400> 625

<210> 626
<211> 12
<212> PRT
<213> Homo sapiens

<400> 626

<210> 627
<211> 14
<212> PRT
<213> Homo sapiens

<400> 627

<210> 628
<211> 15
<212> PRT
<213> Homo sapiens

<400> 628

<210> 629
<211> 14
<212> PRT
<213> Homo sapiens

<400> 629

<210> 630
<211> 15
<212> PRT
<213> Homo sapiens

<400> 630

<210> 631
<211> 16
<212> PRT
<213> Homo sapiens

<400> 631

<210> 632
<211> 14
<212> PRT
<213> Homo sapiens

<400> 632

<210> 633
<211> 14
<212> PRT
<213> Homo sapiens

<400> 633

<210> 634
<211> 16
<212> PRT
<213> Homo sapiens

<400> 634

<210> 635
<211> 18
<212> PRT
<213> Homo sapiens

<400> 635

<210> 636
<211> 19
<212> PRT
<213> Homo sapiens

<400> 636

<210> 637
<211> 23
<212> PRT
<213> Homo sapiens

<400> 637

<210> 638
<211> 24
<212> PRT
<213> Homo sapiens

<400> 638

<210> 639
<211> 16
<212> PRT
<213> Homo sapiens

<400> 639

<210> 640
<211> 17
<212> PRT
<213> Homo sapiens

<400> 640

<210> 641
<211> 15
<212> PRT
<213> Homo sapiens

<400> 641

<210> 642
<211> 13
<212> PRT
<213> Homo sapiens

<400> 642

<210> 643
<211> 15
<212> PRT
<213> Homo sapiens

<400> 643

<210> 644
<211> 13
<212> PRT
<213> Homo sapiens

<400> 644

<210> 645
<211> 12
<212> PRT
<213> Homo sapiens

<400> 645

<210> 646
<211> 14
<212> PRT
<213> Homo sapiens

<400> 646

<210> 647
<211> 13
<212> PRT
<213> Homo sapiens

<400> 647

<210> 648
<211> 19
<212> PRT
<213> Homo sapiens

<400> 648

<210> 649
<211> 14
<212> PRT
<213> Homo sapiens

<400> 649

<210> 650
<211> 15
<212> PRT
<213> Homo sapiens

<400> 650

<210> 651
<211> 16
<212> PRT
<213> Homo sapiens

<400> 651

<210> 652
<211> 17
<212> PRT
<213> Homo sapiens

<400> 652

<210> 653
<211> 14
<212> PRT
<213> Homo sapiens

<400> 653

<210> 654
<211> 15
<212> PRT
<213> Homo sapiens

<400> 654

<210> 655
<211> 13
<212> PRT
<213> Homo sapiens

<400> 655

<210> 656
<211> 14
<212> PRT
<213> Homo sapiens

<400> 656

<210> 657
<211> 13
<212> PRT
<213> Homo sapiens

<400> 657

<210> 658
<211> 14
<212> PRT
<213> Homo sapiens

<400> 658

<210> 659
<211> 16
<212> PRT
<213> Homo sapiens

<400> 659

<210> 660
<211> 15
<212> PRT
<213> Homo sapiens

<400> 660

<210> 661
<211> 12
<212> PRT
<213> Homo sapiens

<400> 661

<210> 662
<211> 16
<212> PRT
<213> Homo sapiens

<400> 662

<210> 663
<211> 15
<212> PRT
<213> Homo sapiens

<400> 663

<210> 664
<211> 14
<212> PRT
<213> Homo sapiens

<400> 664

<210> 665
<211> 15
<212> PRT
<213> Homo sapiens

<400> 665

<210> 666
<211> 12
<212> PRT
<213> Homo sapiens

<400> 666

<210> 667
<211> 13
<212> PRT
<213> Homo sapiens

<400> 667

<210> 668
<211> 14
<212> PRT
<213> Homo sapiens

<400> 668

<210> 669
<211> 17
<212> PRT
<213> Homo sapiens

<400> 669

<210> 670
<211> 19
<212> PRT
<213> Homo sapiens

<400> 670

<210> 671
<211> 20
<212> PRT
<213> Homo sapiens

<400> 671

<210> 672
<211> 12
<212> PRT
<213> Homo sapiens

<400> 672

<210> 673
<211> 14
<212> PRT
<213> Homo sapiens

<400> 673

<210> 674
<211> 15
<212> PRT
<213> Homo sapiens

<400> 674

<210> 675
<211> 16
<212> PRT
<213> Homo sapiens

<400> 675

<210> 676
<211> 17
<212> PRT
<213> Homo sapiens

<400> 676

<210> 677
<211> 19
<212> PRT
<213> Homo sapiens

<400> 677

<210> 678
<211> 15
<212> PRT
<213> Homo sapiens

<400> 678

<210> 679
<211> 14
<212> PRT
<213> Homo sapiens

<400> 679

<210> 680
<211> 16
<212> PRT
<213> Homo sapiens

<400> 680

<210> 681
<211> 12
<212> PRT
<213> Homo sapiens

<400> 681

<210> 682
<211> 15
<212> PRT
<213> Homo sapiens

<400> 682

<210> 683
<211> 15
<212> PRT
<213> Homo sapiens

<400> 683

<210> 684
<211> 14
<212> PRT
<213> Homo sapiens

<400> 684

<210> 685
<211> 23
<212> PRT
<213> Homo sapiens

<400> 685

<210> 686
<211> 23
<212> PRT
<213> Homo sapiens

<400> 686

<210> 687
<211> 15
<212> PRT
<213> Homo sapiens

<400> 687

<210> 688
<211> 13
<212> PRT
<213> Homo sapiens

<400> 688

<210> 689
<211> 12
<212> PRT
<213> Homo sapiens

<400> 689

<210> 690
<211> 15
<212> PRT
<213> Homo sapiens

<400> 690

<210> 691
<211> 14
<212> PRT
<213> Homo sapiens

<400> 691

<210> 692
<211> 15
<212> PRT
<213> Homo sapiens

<400> 692

<210> 693
<211> 17
<212> PRT
<213> Homo sapiens

<400> 693

<210> 694
<211> 14
<212> PRT
<213> Homo sapiens

<400> 694

<210> 695
<211> 13
<212> PRT
<213> Homo sapiens

<400> 695

<210> 696
<211> 16
<212> PRT
<213> Homo sapiens

<400> 696

<210> 697
<211> 17
<212> PRT
<213> Homo sapiens

<400> 697

<210> 698
<211> 18
<212> PRT
<213> Homo sapiens

<400> 698

<210> 699
<211> 15
<212> PRT
<213> Homo sapiens

<400> 699

<210> 700
<211> 16
<212> PRT
<213> Homo sapiens

<400> 700

<210> 701
<211> 15
<212> PRT
<213> Homo sapiens

<400> 701

<210> 702
<211> 16
<212> PRT
<213> Homo sapiens

<400> 702

<210> 703
<211> 14
<212> PRT
<213> Homo sapiens

<400> 703

<210> 704
<211> 13
<212> PRT
<213> Homo sapiens

<400> 704

<210> 705
<211> 13
<212> PRT
<213> Homo sapiens

<400> 705

<210> 706
<211> 18
<212> PRT
<213> Homo sapiens

<400> 706

<210> 707
<211> 13
<212> PRT
<213> Homo sapiens

<400> 707

<210> 708
<211> 14
<212> PRT
<213> Homo sapiens

<400> 708

<210> 709
<211> 14
<212> PRT
<213> Homo sapiens

<400> 709

<210> 710
<211> 16
<212> PRT
<213> Homo sapiens

<400> 710

<210> 711
<211> 13
<212> PRT
<213> Homo sapiens

<400> 711

<210> 712
<211> 14
<212> PRT
<213> Homo sapiens

<400> 712

<210> 713
<211> 15
<212> PRT
<213> Homo sapiens

<400> 713

<210> 714
<211> 16
<212> PRT
<213> Homo sapiens

<400> 714

<210> 715
<211> 16
<212> PRT
<213> Homo sapiens

<400> 715

<210> 716
<211> 15
<212> PRT
<213> Homo sapiens

<400> 716

<210> 717
<211> 14
<212> PRT
<213> Homo sapiens

<400> 717

<210> 718
<211> 15
<212> PRT
<213> Homo sapiens

<400> 718

<210> 719
<211> 16
<212> PRT
<213> Homo sapiens

<400> 719

<210> 720
<211> 15
<212> PRT
<213> Homo sapiens

<400> 720

<210> 721
<211> 17
<212> PRT
<213> Homo sapiens

<400> 721

<210> 722
<211> 12
<212> PRT
<213> Homo sapiens

<400> 722

<210> 723
<211> 13
<212> PRT
<213> Homo sapiens

<400> 723



<210> 724
<211> 14
<212> PRT
<213> Homo sapiens

<400> 724

<210> 725
<211> 15
<212> PRT
<213> Homo sapiens

<400> 725

<210> 726
<211> 15
<212> PRT
<213> Homo sapiens

<400> 726

<210> 727
<211> 17
<212> PRT
<213> Homo sapiens

<400> 727

<210> 728
<211> 13
<212> PRT
<213> Homo sapiens

<400> 728

<210> 729
<211> 15
<212> PRT
<213> Homo sapiens

<400> 729

<210> 730
<211> 16
<212> PRT
<213> Homo sapiens

<400> 730

<210> 731
<211> 18
<212> PRT
<213> Homo sapiens

<400> 731

<210> 732
<211> 14
<212> PRT
<213> Homo sapiens

<400> 732

<210> 733
<211> 13
<212> PRT
<213> Homo sapiens

<400> 733

<210> 734
<211> 15
<212> PRT
<213> Homo sapiens

<400> 734

<210> 735
<211> 16
<212> PRT
<213> Homo sapiens

<400> 735

<210> 736
<211> 13
<212> PRT
<213> Homo sapiens

<400> 736

<210> 737
<211> 14
<212> PRT
<213> Homo sapiens

<400> 737

<210> 738
<211> 15
<212> PRT
<213> Homo sapiens

<400> 738

<210> 739
<211> 16
<212> PRT
<213> Homo sapiens

<400> 739

<210> 740
<211> 14
<212> PRT
<213> Homo sapiens

<400> 740

<210> 741
<211> 16
<212> PRT
<213> Homo sapiens

<400> 741

<210> 742
<211> 17
<212> PRT
<213> Homo sapiens

<400> 742

<210> 743
<211> 12
<212> PRT
<213> Homo sapiens

<400> 743

<210> 744
<211> 13
<212> PRT
<213> Homo sapiens

<400> 744

<210> 745
<211> 15
<212> PRT
<213> Homo sapiens

<400> 745

<210> 746
<211> 12
<212> PRT
<213> Homo sapiens

<400> 746

<210> 747
<211> 13
<212> PRT
<213> Homo sapiens

<400> 747

<210> 748
<211> 12
<212> PRT
<213> Homo sapiens

<400> 748

<210> 749
<211> 13
<212> PRT
<213> Homo sapiens

<400> 749

<210> 750
<211> 14
<212> PRT
<213> Homo sapiens

<400> 750

<210> 751
<211> 15
<212> PRT
<213> Homo sapiens

<400> 751

<210> 752
<211> 14
<212> PRT
<213> Homo sapiens

<400> 752

<210> 753
<211> 15
<212> PRT
<213> Homo sapiens

<400> 753

<210> 754
<211> 16
<212> PRT
<213> Homo sapiens

<400> 754

<210> 755
<211> 15
<212> PRT
<213> Homo sapiens

<400> 755

<210> 756
<211> 16
<212> PRT
<213> Homo sapiens

<400> 756

<210> 757
<211> 12
<212> PRT
<213> Homo sapiens

<400> 757

<210> 758
<211> 13
<212> PRT
<213> Homo sapiens

<400> 758

<210> 759
<211> 13
<212> PRT
<213> Homo sapiens

<400> 759

<210> 760
<211> 16
<212> PRT
<213> Homo sapiens

<400> 760

<210> 761
<211> 13
<212> PRT
<213> Homo sapiens

<400> 761

<210> 762
<211> 14
<212> PRT
<213> Homo sapiens

<400> 762



<210> 763
<211> 12
<212> PRT
<213> Homo sapiens

<400> 763

<210> 764
<211> 13
<212> PRT
<213> Homo sapiens

<400> 764

<210> 765
<211> 14
<212> PRT
<213> Homo sapiens

<400> 765

<210> 766
<211> 15
<212> PRT
<213> Homo sapiens

<400> 766

<210> 767
<211> 16
<212> PRT
<213> Homo sapiens

<400> 767

<210> 768
<211> 15
<212> PRT
<213> Homo sapiens

<400> 768

<210> 769
<211> 14
<212> PRT
<213> Homo sapiens

<400> 769

<210> 770
<211> 12
<212> PRT
<213> Homo sapiens

<400> 770

<210> 771
<211> 13
<212> PRT
<213> Homo sapiens

<400> 771

<210> 772
<211> 15
<212> PRT
<213> Homo sapiens

<400> 772

<210> 773
<211> 12
<212> PRT
<213> Homo sapiens

<400> 773

<210> 774
<211> 14
<212> PRT
<213> Homo sapiens

<400> 774

<210> 775
<211> 15
<212> PRT
<213> Homo sapiens

<400> 775

<210> 776
<211> 14
<212> PRT
<213> Homo sapiens

<400> 776

<210> 777
<211> 15
<212> PRT
<213> Homo sapiens

<400> 777

<210> 778
<211> 16
<212> PRT
<213> Homo sapiens

<400> 778

<210> 779
<211> 17
<212> PRT
<213> Homo sapiens

<400> 779



<210> 780
<211> 16
<212> PRT
<213> Homo sapiens

<400> 780

<210> 781
<211> 18
<212> PRT
<213> Homo sapiens

<400> 781

<210> 782
<211> 16
<212> PRT
<213> Homo sapiens

<400> 782

<210> 783
<211> 14
<212> PRT
<213> Homo sapiens

<400> 783

<210> 784
<211> 15
<212> PRT
<213> Homo sapiens

<400> 784

<210> 785
<211> 15
<212> PRT
<213> Homo sapiens

<400> 785

<210> 786
<211> 16
<212> PRT
<213> Homo sapiens

<400> 786

<210> 787
<211> 17
<212> PRT
<213> Homo sapiens

<400> 787

<210> 788
<211> 15
<212> PRT
<213> Homo sapiens

<400> 788

<210> 789
<211> 15
<212> PRT
<213> Homo sapiens

<400> 789

<210> 790
<211> 14
<212> PRT
<213> Homo sapiens

<400> 790

<210> 791
<211> 15
<212> PRT
<213> Homo sapiens

<400> 791

<210> 792
<211> 17
<212> PRT
<213> Homo sapiens

<400> 792

<210> 793
<211> 13
<212> PRT
<213> Homo sapiens

<400> 793

<210> 794
<211> 18
<212> PRT
<213> Homo sapiens

<400> 794

<210> 795
<211> 14
<212> PRT
<213> Homo sapiens

<400> 795

<210> 796
<211> 15
<212> PRT
<213> Homo sapiens

<400> 796

<210> 797
<211> 16
<212> PRT
<213> Homo sapiens

<400> 797

<210> 798
<211> 15
<212> PRT
<213> Homo sapiens

<400> 798

<210> 799
<211> 13
<212> PRT
<213> Homo sapiens

<400> 799

<210> 800
<211> 13
<212> PRT
<213> Homo sapiens

<400> 800

<210> 801
<211> 14
<212> PRT
<213> Homo sapiens

<400> 801

<210> 802
<211> 15
<212> PRT
<213> Homo sapiens

<400> 802

<210> 803
<211> 16
<212> PRT
<213> Homo sapiens

<400> 803

<210> 804
<211> 14
<212> PRT
<213> Homo sapiens

<400> 804

<210> 805
<211> 15
<212> PRT
<213> Homo sapiens

<400> 805

<210> 806
<211> 16
<212> PRT
<213> Homo sapiens

<400> 806



<210> 807
<211> 13
<212> PRT
<213> Homo sapiens

<400> 807

<210> 808
<211> 20
<212> PRT
<213> Homo sapiens

<400> 808

<210> 809
<211> 15
<212> PRT
<213> Homo sapiens

<400> 809

<210> 810
<211> 13
<212> PRT
<213> Homo sapiens

<400> 810

<210> 811
<211> 14
<212> PRT
<213> Homo sapiens

<400> 811

<210> 812
<211> 13
<212> PRT
<213> Homo sapiens

<400> 812

<210> 813
<211> 12
<212> PRT
<213> Homo sapiens

<400> 813

<210> 814
<211> 14
<212> PRT
<213> Homo sapiens

<400> 814

<210> 815
<211> 14
<212> PRT
<213> Homo sapiens

<400> 815

<210> 816
<211> 13
<212> PRT
<213> Homo sapiens

<400> 816

<210> 817
<211> 13
<212> PRT
<213> Homo sapiens

<400> 817

<210> 818
<211> 13
<212> PRT
<213> Homo sapiens

<400> 818

<210> 819
<211> 15
<212> PRT
<213> Homo sapiens

<400> 819

<210> 820
<211> 16
<212> PRT
<213> Homo sapiens

<400> 820

<210> 821
<211> 17
<212> PRT
<213> Homo sapiens

<400> 821

<210> 822
<211> 14
<212> PRT
<213> Homo sapiens

<400> 822

<210> 823
<211> 15
<212> PRT
<213> Homo sapiens

<400> 823

<210> 824
<211> 16
<212> PRT
<213> Homo sapiens

<400> 824

<210> 825
<211> 15
<212> PRT
<213> Homo sapiens

<400> 825

<210> 826
<211> 12
<212> PRT
<213> Homo sapiens

<400> 826

<210> 827
<211> 13
<212> PRT
<213> Homo sapiens

<400> 827

<210> 828
<211> 14
<212> PRT
<213> Homo sapiens

<400> 828

<210> 829
<211> 14
<212> PRT
<213> Homo sapiens

<400> 829

<210> 830
<211> 16
<212> PRT
<213> Homo sapiens

<400> 830

<210> 831
<211> 17
<212> PRT
<213> Homo sapiens

<400> 831

<210> 832
<211> 15
<212> PRT
<213> Homo sapiens

<400> 832

<210> 833
<211> 13
<212> PRT
<213> Homo sapiens

<400> 833

<210> 834
<211> 15
<212> PRT
<213> Homo sapiens

<400> 834

<210> 835
<211> 16
<212> PRT
<213> Homo sapiens

<400> 835

<210> 836
<211> 17
<212> PRT
<213> Homo sapiens

<400> 836

<210> 837
<211> 14
<212> PRT
<213> Homo sapiens

<400> 837

<210> 838
<211> 15
<212> PRT
<213> Homo sapiens

<400> 838

<210> 839
<211> 16
<212> PRT
<213> Homo sapiens

<400> 839

<210> 840
<211> 15
<212> PRT
<213> Homo sapiens

<400> 840

<210> 841
<211> 12
<212> PRT
<213> Homo sapiens

<400> 841

<210> 842
<211> 13
<212> PRT
<213> Homo sapiens

<400> 842

<210> 843
<211> 14
<212> PRT
<213> Homo sapiens

<400> 843

<210> 844
<211> 14
<212> PRT
<213> Homo sapiens

<400> 844

<210> 845
<211> 12
<212> PRT
<213> Homo sapiens

<400> 845

<210> 846
<211> 14
<212> PRT
<213> Homo sapiens

<400> 846

<210> 847
<211> 17
<212> PRT
<213> Homo sapiens

<400> 847

<210> 848
<211> 17
<212> PRT
<213> Homo sapiens

<400> 848

<210> 849
<211> 16
<212> PRT
<213> Homo sapiens

<400> 849

<210> 850
<211> 17
<212> PRT
<213> Homo sapiens

<400> 850

<210> 851
<211> 14
<212> PRT
<213> Homo sapiens

<400> 851

<210> 852
<211> 13
<212> PRT
<213> Homo sapiens

<400> 852

<210> 853
<211> 15
<212> PRT
<213> Homo sapiens

<400> 853

<210> 854
<211> 14
<212> PRT
<213> Homo sapiens

<400> 854

<210> 855
<211> 16
<212> PRT
<213> Homo sapiens

<400> 855



<210> 856
<211> 12
<212> PRT
<213> Homo sapiens

<400> 856

<210> 857
<211> 14
<212> PRT
<213> Homo sapiens

<400> 857

<210> 858
<211> 15
<212> PRT
<213> Homo sapiens

<400> 858

<210> 859
<211> 12
<212> PRT
<213> Homo sapiens

<400> 859

<210> 860
<211> 13
<212> PRT
<213> Homo sapiens

<400> 860

<210> 861
<211> 14
<212> PRT
<213> Homo sapiens

<400> 861

<210> 862
<211> 13
<212> PRT
<213> Homo sapiens

<400> 862

<210> 863
<211> 14
<212> PRT
<213> Homo sapiens

<400> 863

<210> 864
<211> 15
<212> PRT
<213> Homo sapiens

<400> 864

<210> 865
<211> 16
<212> PRT
<213> Homo sapiens

<400> 865

<210> 866
<211> 17
<212> PRT
<213> Homo sapiens

<400> 866

<210> 867
<211> 14
<212> PRT
<213> Homo sapiens

<400> 867

<210> 868
<211> 14
<212> PRT
<213> Homo sapiens

<400> 868

<210> 869
<211> 15
<212> PRT
<213> Homo sapiens

<400> 869

<210> 870
<211> 17
<212> PRT
<213> Homo sapiens

<400> 870

<210> 871
<211> 19
<212> PRT
<213> Homo sapiens

<400> 871

<210> 872
<211> 14
<212> PRT
<213> Homo sapiens

<400> 872

<210> 873
<211> 15
<212> PRT
<213> Homo sapiens

<400> 873

<210> 874
<211> 16
<212> PRT
<213> Homo sapiens

<400> 874

<210> 875
<211> 13
<212> PRT
<213> Homo sapiens

<400> 875

<210> 876
<211> 12
<212> PRT
<213> Homo sapiens

<400> 876

<210> 877
<211> 15
<212> PRT
<213> Homo sapiens

<400> 877

<210> 878
<211> 16
<212> PRT
<213> Homo sapiens

<400> 878

<210> 879
<211> 17
<212> PRT
<213> Homo sapiens

<400> 879

<210> 880
<211> 18
<212> PRT
<213> Homo sapiens

<400> 880

<210> 881
<211> 14
<212> PRT
<213> Homo sapiens

<400> 881

<210> 882
<211> 15
<212> PRT
<213> Homo sapiens

<400> 882

<210> 883
<211> 17
<212> PRT
<213> Homo sapiens

<400> 883

<210> 884
<211> 14
<212> PRT
<213> Homo sapiens

<400> 884

<210> 885
<211> 15
<212> PRT
<213> Homo sapiens

<400> 885

<210> 886
<211> 14
<212> PRT
<213> Homo sapiens

<400> 886

<210> 887
<211> 13
<212> PRT
<213> Homo sapiens

<400> 887

<210> 888
<211> 14
<212> PRT
<213> Homo sapiens

<400> 888

<210> 889
<211> 12
<212> PRT
<213> Homo sapiens

<400> 889

<210> 890
<211> 13
<212> PRT
<213> Homo sapiens

<400> 890

<210> 891
<211> 14
<212> PRT
<213> Homo sapiens

<400> 891

<210> 892
<211> 16
<212> PRT
<213> Homo sapiens

<400> 892

<210> 893
<211> 17
<212> PRT
<213> Homo sapiens

<400> 893

<210> 894
<211> 12
<212> PRT
<213> Homo sapiens

<400> 894

<210> 895
<211> 13
<212> PRT
<213> Homo sapiens

<400> 895

<210> 896
<211> 14
<212> PRT
<213> Homo sapiens

<400> 896

<210> 897
<211> 16
<212> PRT
<213> Homo sapiens

<400> 897

<210> 898
<211> 12
<212> PRT
<213> Homo sapiens

<400> 898

<210> 899
<211> 13
<212> PRT
<213> Homo sapiens

<400> 899

<210> 900
<211> 15
<212> PRT
<213> Homo sapiens

<400> 900

<210> 901
<211> 14
<212> PRT
<213> Homo sapiens

<400> 901

<210> 902
<211> 12
<212> PRT
<213> Homo sapiens

<400> 902

<210> 903
<211> 14
<212> PRT
<213> Homo sapiens

<400> 903

<210> 904
<211> 16
<212> PRT
<213> Homo sapiens

<400> 904



<210> 905
<211> 13
<212> PRT
<213> Homo sapiens

<400> 905

<210> 906
<211> 17
<212> PRT
<213> Homo sapiens

<400> 906

<210> 907
<211> 12
<212> PRT
<213> Homo sapiens

<400> 907

<210> 908
<211> 15
<212> PRT
<213> Homo sapiens

<400> 908

<210> 909
<211> 14
<212> PRT
<213> Homo sapiens

<400> 909

<210> 910
<211> 12
<212> PRT
<213> Homo sapiens

<400> 910

<210> 911
<211> 14
<212> PRT
<213> Homo sapiens

<400> 911

<210> 912
<211> 14
<212> PRT
<213> Homo sapiens

<400> 912

<210> 913
<211> 14
<212> PRT
<213> Homo sapiens

<400> 913

<210> 914
<211> 14
<212> PRT
<213> Homo sapiens

<400> 914

<210> 915
<211> 15
<212> PRT
<213> Homo sapiens

<400> 915

<210> 916
<211> 15
<212> PRT
<213> Homo sapiens

<400> 916

<210> 917
<211> 13
<212> PRT
<213> Homo sapiens

<400> 917

<210> 918
<211> 15
<212> PRT
<213> Homo sapiens

<400> 918

<210> 919
<211> 14
<212> PRT
<213> Homo sapiens

<400> 919

<210> 920
<211> 13
<212> PRT
<213> Homo sapiens

<400> 920

<210> 921
<211> 15
<212> PRT
<213> Homo sapiens

<400> 921

<210> 922
<211> 14
<212> PRT
<213> Homo sapiens

<400> 922

<210> 923
<211> 12
<212> PRT
<213> Homo sapiens

<400> 923

<210> 924
<211> 13
<212> PRT
<213> Homo sapiens

<400> 924

<210> 925
<211> 16
<212> PRT
<213> Homo sapiens

<400> 925

<210> 926
<211> 15
<212> PRT
<213> Homo sapiens

<400> 926

<210> 927
<211> 19
<212> PRT
<213> Homo sapiens

<400> 927

<210> 928
<211> 15
<212> PRT
<213> Homo sapiens

<400> 928

<210> 929
<211> 14
<212> PRT
<213> Homo sapiens

<400> 929

<210> 930
<211> 15
<212> PRT
<213> Homo sapiens

<400> 930

<210> 931
<211> 16
<212> PRT
<213> Homo sapiens

<400> 931

<210> 932
<211> 15
<212> PRT
<213> Homo sapiens

<400> 932

<210> 933
<211> 14
<212> PRT
<213> Homo sapiens

<400> 933

<210> 934
<211> 13
<212> PRT
<213> Homo sapiens

<400> 934

<210> 935
<211> 14
<212> PRT
<213> Homo sapiens

<400> 935

<210> 936
<211> 15
<212> PRT
<213> Homo sapiens

<400> 936

<210> 937
<211> 16
<212> PRT
<213> Homo sapiens

<400> 937

<210> 938
<211> 13
<212> PRT
<213> Homo sapiens

<400> 938

<210> 939
<211> 14
<212> PRT
<213> Homo sapiens

<400> 939

<210> 940
<211> 14
<212> PRT
<213> Homo sapiens

<400> 940

<210> 941
<211> 17
<212> PRT
<213> Homo sapiens

<400> 941

<210> 942
<211> 16
<212> PRT
<213> Homo sapiens

<400> 942

<210> 943
<211> 14
<212> PRT
<213> Homo sapiens

<400> 943



<210> 944
<211> 15
<212> PRT
<213> Homo sapiens

<400> 944

<210> 945
<211> 16
<212> PRT
<213> Homo sapiens

<400> 945

<210> 946
<211> 13
<212> PRT
<213> Homo sapiens

<400> 946

<210> 947
<211> 15
<212> PRT
<213> Homo sapiens

<400> 947

<210> 948
<211> 15
<212> PRT
<213> Homo sapiens

<400> 948

<210> 949
<211> 13
<212> PRT
<213> Homo sapiens

<400> 949

<210> 950
<211> 15
<212> PRT
<213> Homo sapiens

<400> 950

<210> 951
<211> 16
<212> PRT
<213> Homo sapiens

<400> 951

<210> 952
<211> 17
<212> PRT
<213> Homo sapiens

<400> 952

<210> 953
<211> 15
<212> PRT
<213> Homo sapiens

<400> 953

<210> 954
<211> 16
<212> PRT
<213> Homo sapiens

<400> 954

<210> 955
<211> 17
<212> PRT
<213> Homo sapiens

<400> 955

<210> 956
<211> 18
<212> PRT
<213> Homo sapiens

<400> 956

<210> 957
<211> 17
<212> PRT
<213> Homo sapiens

<400> 957

<210> 958
<211> 13
<212> PRT
<213> Homo sapiens

<400> 958

<210> 959
<211> 15
<212> PRT
<213> Homo sapiens

<400> 959

<210> 960
<211> 13
<212> PRT
<213> Homo sapiens

<400> 960

<210> 961
<211> 14
<212> PRT
<213> Homo sapiens

<400> 961

<210> 962
<211> 16
<212> PRT
<213> Homo sapiens

<400> 962

<210> 963
<211> 15
<212> PRT
<213> Homo sapiens

<400> 963

<210> 964
<211> 14
<212> PRT
<213> Homo sapiens

<400> 964

<210> 965
<211> 15
<212> PRT
<213> Homo sapiens

<400> 965

<210> 966
<211> 15
<212> PRT
<213> Homo sapiens

<400> 966

<210> 967
<211> 14
<212> PRT
<213> Homo sapiens

<400> 967

<210> 968
<211> 14
<212> PRT
<213> Homo sapiens

<400> 968

<210> 969
<211> 16
<212> PRT
<213> Homo sapiens

<400> 969

<210> 970
<211> 16
<212> PRT
<213> Homo sapiens

<400> 970

<210> 971
<211> 15
<212> PRT
<213> Homo sapiens

<400> 971

<210> 972
<211> 15
<212> PRT
<213> Homo sapiens

<400> 972

<210> 973
<211> 12
<212> PRT
<213> Homo sapiens

<400> 973

<210> 974
<211> 13
<212> PRT
<213> Homo sapiens

<400> 974

<210> 975
<211> 14
<212> PRT
<213> Homo sapiens

<400> 975

<210> 976
<211> 14
<212> PRT
<213> Homo sapiens

<400> 976

<210> 977
<211> 15
<212> PRT
<213> Homo sapiens

<400> 977

<210> 978
<211> 17
<212> PRT
<213> Homo sapiens

<400> 978

<210> 979
<211> 14
<212> PRT
<213> Homo sapiens

<400> 979

<210> 980
<211> 15
<212> PRT
<213> Homo sapiens

<400> 980

<210> 981
<211> 16
<212> PRT
<213> Homo sapiens

<400> 981

<210> 982
<211> 16
<212> PRT
<213> Homo sapiens

<400> 982

<210> 983
<211> 16
<212> PRT
<213> Homo sapiens

<400> 983

<210> 984
<211> 17
<212> PRT
<213> Homo sapiens

<400> 984

<210> 985
<211> 18
<212> PRT
<213> Homo sapiens

<400> 985

<210> 986
<211> 15
<212> PRT
<213> Homo sapiens

<400> 986

<210> 987
<211> 14
<212> PRT
<213> Homo sapiens

<400> 987

<210> 988
<211> 15
<212> PRT
<213> Homo sapiens

<400> 988

<210> 989
<211> 12
<212> PRT
<213> Homo sapiens

<400> 989

<210> 990
<211> 13
<212> PRT
<213> Homo sapiens

<400> 990

<210> 991
<211> 15
<212> PRT
<213> Homo sapiens

<400> 991

<210> 992
<211> 16
<212> PRT
<213> Homo sapiens

<400> 992



<210> 993
<211> 16
<212> PRT
<213> Homo sapiens

<400> 993

<210> 994
<211> 13
<212> PRT
<213> Homo sapiens

<400> 994

<210> 995
<211> 14
<212> PRT
<213> Homo sapiens

<400> 995

<210> 996
<211> 15
<212> PRT
<213> Homo sapiens

<400> 996

<210> 997
<211> 15
<212> PRT
<213> Homo sapiens

<400> 997

<210> 998
<211> 12
<212> PRT
<213> Homo sapiens

<400> 998

<210> 999
<211> 12
<212> PRT
<213> Homo sapiens

<400> 999

<210> 1000
<211> 15
<212> PRT
<213> Homo sapiens

<400> 1000

<210> 1001
<211> 14
<212> PRT
<213> Homo sapiens

<400> 1001

<210> 1002
<211> 14
<212> PRT
<213> Homo sapiens

<400> 1002

<210> 1003
<211> 14
<212> PRT
<213> Homo sapiens

<400> 1003

<210> 1004
<211> 13
<212> PRT
<213> Homo sapiens

<400> 1004

<210> 1005
<211> 15
<212> PRT
<213> Homo sapiens

<400> 1005

<210> 1006
<211> 16
<212> PRT
<213> Homo sapiens

<400> 1006

<210> 1007
<211> 18
<212> PRT
<213> Homo sapiens

<400> 1007

<210> 1008
<211> 20
<212> PRT
<213> Homo sapiens

<400> 1008

<210> 1009
<211> 14
<212> PRT
<213> Homo sapiens

<400> 1009

<210> 1010
<211> 13
<212> PRT
<213> Homo sapiens

<400> 1010

<210> 1011
<211> 15
<212> PRT
<213> Homo sapiens

<400> 1011

<210> 1012
<211> 14
<212> PRT
<213> Homo sapiens

<400> 1012

<210> 1013
<211> 15
<212> PRT
<213> Homo sapiens

<400> 1013

<210> 1014
<211> 16
<212> PRT
<213> Homo sapiens

<400> 1014

<210> 1015
<211> 14
<212> PRT
<213> Homo sapiens

<400> 1015

<210> 1016
<211> 15
<212> PRT
<213> Homo sapiens

<400> 1016

<210> 1017
<211> 10
<212> PRT
<213> Homo sapiens

<400> 1016

<210> 1018
<211> 9
<212> PRT
<213> Homo sapiens

<400> 1016




Claims

1. A peptide of between 10 and 30 amino acids in length, comprising an amino acid sequence consisting of SEQ ID NO: 167, or a pharmaceutically acceptable salt thereof.
 
2. The peptide according to claim 1, wherein said peptide has the ability to bind to a human major histocompatibility complex (MHC) class-I molecule.
 
3. The peptide according to claim 1 or 2, consisting of the sequence of SEQ ID NO: 167.
 
4. The peptide according to any of claims 1 to 3, wherein said peptide includes non-peptide bonds.
 
5. A fusion protein, comprising

(a) an amino acid sequence consisting of SEQ ID NO: 167; and

(b) N-terminal amino acids 1-80 of HLA-DR antigen-associated invariant chain (Ii).


 
6. An antibody that specifically binds to a human major histocompatibility complex (MHC) class I being complexed with the peptide according to any one of claims 1 to 3.
 
7. A T-cell receptor that binds to a human major histocompatibility complex (MHC) class I being complexed with the peptide according to any one of claims 1 to 3.
 
8. A nucleic acid, encoding for (a) the peptide according to any one of claims 1 to 3; (b) the T cell receptor according to claim 7; (c) the fusion protein according to claim 5, or (d) the antibody according to claim 6.
 
9. An expression vector comprising a nucleic acid according to claim 8.
 
10. A host cell comprising the nucleic acid according to claim 8, or the expression vector according to claim 9.
 
11. A method for producing the peptide according to any of claims 1 to 3; the T cell receptor according to claim 7; the fusion protein according to claim 5, or the antibody according to claim 6, said method comprising culturing the host cell according to claim 10, and isolating said peptide, said T cell receptor, said fusion protein, or said antibody from said host cell and/or its culture medium.
 
12. An in vitro method for producing activated cytotoxic T lymphocytes (CTL), the method comprising contacting in vitro a CTL with antigen loaded human class I MHC molecules expressed on the surface of a suitable antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is said peptide according to claim 1 or 2.
 
13. An activated cytotoxic T lymphocyte (CTL), produced by the method according to claim 12.
 
14. A pharmaceutical composition comprising at least one active ingredient selected from the group consisting of the peptide according to any of claims 1 to 3, the T cell receptor according to claim 7; the fusion protein according to claim 5, or the antibody according to claim 6, the nucleic acid according to claim 8, the expression vector according to claim 9, the host cell according to claim 10, and the activated cytotoxic T lymphocyte according to claim 13, and a pharmaceutically acceptable carrier.
 
15. The pharmaceutical composition according to claim 14 for use as a medicament that is active against cancer, such as, for example, chronic lymphatic leukemia (CLL), acute myeloid leukemia (AML), adenocarcinoma, and ovary cancer.
 


Ansprüche

1. Peptid mit einer Länge zwischen 10 und 30 Aminosäuren, umfassend eine Aminosäuresequenz bestehend aus SEQ ID No: 167, oder ein pharmazeutisch akzeptables Salz davon.
 
2. Das Peptid gemäß Anspruch 1, wobei das Peptid die Fähigkeit aufweist, an ein Molekül des menschlichen Haupthistokompatibilitätskomplexes (MHC) Klasse-I zu binden.
 
3. Das Peptid nach Anspruch 1 oder 2 bestehend aus der Sequenz mit SEQ ID NO: 167.
 
4. Das Peptid nach einem der Ansprüche 1 bis 3, wobei das Peptid nicht-peptidische Bindungen einschließt.
 
5. Ein Fusionsprotein umfassend

(a) eine Aminosäuresequenz bestehend aus SEQ ID No. 167; und

(b) N-terminale Aminosäuren 1-80 der HLA-DR-Antigen-assoziierten invarianten Kette (Ii).


 
6. Ein Antikörper, der spezifisch an einen menschlichen Haupthistokompatibilitätskomplex (MHC) der Klasse I bindet, der mit dem Peptid nach einem der Ansprüche 1 bis 3 komplexiert ist.
 
7. Ein T-Zell-Rezeptor, der an einen menschlichen Haupthistokompatibilitätskomplex (MHC) der Klasse I bindet, der mit dem Peptid nach einem der Ansprüche 1 bis 3 komplexiert ist.
 
8. Nukleinsäure, die für (a) das Peptid nach einem der Ansprüche 1 bis 3; (b) den T-Zell-Rezeptor nach Anspruch 7; (c) das Fusionsprotein nach Anspruch 5 oder (d) den Antikörper nach Anspruch 6 kodiert.
 
9. Ein Expressionsvektor umfassend eine Nukleinsäure nach Anspruch 8.
 
10. Eine Wirtszelle umfassend die Nukleinsäure nach Anspruch 8 oder den Expressionsvektor nach Anspruch 9.
 
11. Verfahren zur Herstellung des Peptids nach einem der Ansprüche 1 bis 3; des T-Zell-Rezeptors nach Anspruch 7; des Fusionsproteins nach Anspruch 5 oder des Antikörpers nach Anspruch 6, wobei das Verfahren die Kultivierung der Wirtszelle nach Anspruch 10 und die Isolierung des Peptids, des T-Zell-Rezeptors, des Fusionsproteins oder des Antikörpers aus der Wirtszelle und/oder ihrem Kulturmedium umfasst.
 
12. In vitro-Verfahren zur Herstellung von aktivierten cytotoxischen T-Lymphocyten (CTL), wobei das Verfahren ein in Kontakt bringen in vitro von einem CTL mit Antigen beladenen menschlichen Klasse-I MHC-Molekülen umfasst, die auf der Oberfläche einer geeigneten Antigen-präsentierende Zelle für eine Zeitdauer präsentiert werden, die ausreichend ist, um die CTL auf eine Antigen-spezifische Weise zu aktivieren, wobei das Antigen das Peptid nach Anspruch 1 oder 2 ist.
 
13. Aktivierter zytotoxischer T-Lymphozyt (CTL), der nach dem Verfahren gemäß Anspruch 12 hergestellt wurde.
 
14. Pharmazeutische Zusammensetzung, umfassend mindestens einen Wirkstoff, ausgewählt aus der Gruppe, bestehend aus dem Peptid nach einem der Ansprüche 1 bis 3, dem T-Zell-Rezeptor nach Anspruch 7, dem Fusionsprotein nach Anspruch 5, dem Antikörper nach Anspruch 6, der Nukleinsäure nach Anspruch 8, dem Expressionsvektor nach Anspruch 9, der Wirtszelle nach Anspruch 10 und dem aktivierten zytotoxischen T-Lymphozyten nach Anspruch 13, und einen pharmazeutisch akzeptablen Träger.
 
15. Die pharmazeutische Zusammensetzung nach Anspruch 14 zur Verwendung als Medikament, das gegen Krebs, wie z. B. chronische lymphatische Leukämie (CLL), akute myeloische Leukämie (AML), Adenokarzinom und Eierstockkrebs, wirksam ist.
 


Revendications

1. Peptide d'une longueur comprise entre 10 et 30 acides aminés, comprenant une séquence d'acides aminés consistant en SEQ ID n°: 167, ou sel pharmaceutiquement acceptable de ce dernier.
 
2. Peptide conforme à la revendication 1, où ledit peptide a la capacité de se lier à une molécule du complexe majeur d'histocompatibilité (CMH) de classe I.
 
3. Peptide conforme à la revendication 1 ou 2, consistant en la séquence SEQ ID n° 167.
 
4. Peptide conforme à l'une des revendications 1 à 3, où ledit peptide comprend des liaisons non peptidiques.
 
5. Protéine de fusion, comprenant

(a) une séquence d'acides aminés consistant en SEQ ID n° 167 ; et

(b) les acides aminés N-terminaux 1 à 80 de la chaîne invariante (Ii) associée aux antigènes du système HLA-DR.


 
6. Anticorps qui se lie spécifiquement à un complexe majeur d'histocompatibilité (CMH) humain de classe I formant un complexe avec le peptide conforme à l'une des revendications 1 à 3.
 
7. Récepteur de lymphocytes T qui se lie à un complexe majeur d'histocompatibilité (CMH) humain de classe I formant un complexe avec le peptide conforme à l'une des revendications 1 à 3.
 
8. Acide nucléique, codant pour (a) le peptide conforme à l'une des revendications 1 à 3, (b) le récepteur de lymphocytes T conforme à la revendication 7, (c) la protéine de fusion conforme à la revendication 5, ou (d) l'anticorps conforme à la revendication 6.
 
9. Vecteur d'expression comprenant un acide nucléique conforme à la revendication 8.
 
10. Cellule hôte comprenant l'acide nucléique conforme à la revendication 8 ou le vecteur d'expression conforme à la revendication 9.
 
11. Procédé de production du peptide conforme à l'une des revendications 1 à 3, du récepteur de lymphocytes T conforme à la revendication 7, de la protéine de fusion conforme à la revendication 5 ou de l'anticorps conforme à la revendication 6, ledit procédé comprenant la mise en culture de la cellule hôte conforme à la revendication 10, et l'isolement dudit peptide, dudit récepteur de lymphocytes T, de ladite protéine de fusion ou dudit anticorps de ladite cellule hôte et/ou de son milieu de culture.
 
12. Procédé in vitro de production de lymphocytes T cytotoxiques (CTL) activés, ce procédé comprenant la mise en contact in vitro d'un CTL avec des molécules du CMH de classe I humain chargées d'antigènes exprimées à la surface d'une cellule présentatrice d'antigènes appropriée pendant un temps suffisant pour activer, de manière antigène-spécifique, ledit CTL, où ledit antigène est ledit peptide conforme à la revendication 1 ou 2.
 
13. Lymphocyte T cytotoxique (CTL) activé, produit par le procédé conforme à la revendication 12.
 
14. Composition pharmaceutique comprenant au moins un ingrédient actif sélectionné parmi le groupe consistant en : le peptide conforme à l'une des revendications 1 à 3, le récepteur de lymphocytes T conforme à la revendication 7, la protéine de fusion conforme à la revendication 5, l'anticorps conforme à la revendication 6, l'acide nucléique conforme à la revendication 8, le vecteur d'expression conforme à la revendication 9, la cellule hôte conforme à la revendication 10, et le lymphocyte T cytotoxique activé conforme à la revendication 13, et un transporteur pharmaceutiquement acceptable.
 
15. Composition pharmaceutique conforme à la revendication 14 pour une utilisation en tant que médicament actif contre le cancer, notamment, par exemple, la leucémie lymphoïde chronique (LLC), la leucémie aiguë myéloïde (LAM), l'adénocarcinome et le cancer de l'ovaire.
 




Drawing
























































Cited references

REFERENCES CITED IN THE DESCRIPTION



This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.

Patent documents cited in the description




Non-patent literature cited in the description